298749 2A2740346 2A2817922	PKC	C34	[INST]Context: [PMID: 34784647 BACKGROUND AND PURPOSE: Dietary fibre comprises a complex group of polysaccharides that are indigestible but are fermented by gut microbiota, promoting beneficial effects to the intestinal mucosa indirectly through the production of short chain fatty acids. We found that a polysaccharide, rhamnogalacturonan, from the plant Acmella oleracea, has direct effects on intestinal epithelial barrier function. EXPERIMENTAL APPROACH: Monolayers of colonic epithelial cell lines (Caco-2, T84) and of human primary cells from organoids were mounted in Ussing chambers to assess barrier function. The cellular mechanism of rhamnogalacturonan effects on barrier function was determined using inhibitors of TLR-4 and PKC isoforms. KEY RESULTS: Apically applied rhamnogalacturonan (1000___mug___ml-1 ) significantly enhanced barrier function as shown by increased transepithelial electrical resistance and reduced fluorescein isothiocyanate -dextran flux in Caco-2, T84 and human primary cell monolayers, and accelerated tight junction reassembly in Caco-2 cells in a calcium switch assay. Rhamnogalacturonan also reversed the barrier-damaging effects of inflammatory cytokines on FITC-dextran flux and preserved the tight junction distribution of occludin. Rhamnogalacturonan activated TLR4 in TLR4-expressing HEK reporter cells, an effect that was inhibited by the TLR4 inhibitor, C34. The effect of rhamnogalacturonan was also dependent on PKC, specifically the isoforms PKCdelta and PKCzeta. CONCLUSION AND IMPLICATIONS: rhamnogalacturonan enhances intestinal epithelial barrier function through activation of TLR4 and PKC signalling pathways. Elucidation of rhamnogalacturonan mechanisms of action could lead to new, dietary approaches to enhance mucosal healing in inflammatory bowel diseases.] Question: Based on the provided context, do the terms [PKC protein] and [C34 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not indicate a direct interaction between PKC protein and C34 protein. Instead, it describes the effects of rhamnogalacturonan on intestinal epithelial barrier function through the activation of TLR4 and PKC signaling pathways. C34 is mentioned as a TLR4 inhibitor, while PKC is involved in the signaling pathways. There is no direct interaction described between PKC protein and C34 protein.</s>
362832 2A2520685 2A2537764	EGFR	FGFR3	[INST]Context: [PMID: 28776571 Expanded molecular profiling of myxofibrosarcoma reveals potentially actionable targets. Myxofibrosarcomas are morphologically heterogeneous soft tissue sarcomas lacking a specific immunohistochemical expression profile and recurrent genetic changes. The study was designed to gain further insights into the molecular landscape of myxofibrosarcomas by targeted re-sequencing of known cancer driver hotspot mutations and the analysis of genomewide somatic copy number alterations. Mutational analysis demonstrated mutations in TP53, PTEN, FGFR3, CDKN2A, and RB1. TP53 mutations were seen in 11 (44%) of patients and detected in myxofibrosarcomas G1, G3, with heterogeneous morphology and G3 with subsequent metastases in 1 patient (16%), 3 patients (42%), 2 patients (62.5%), and 3 patients (75%), respectively. Focal alterations affected CDKN2A, CCND1, CCNE1, EGFR, EPHA3, EPHB1, FGFR1, JUN, NF1, RB1, RET, TP53, and additional novel amplifications in CCNE1, KIT, EGFR, RET, BRAF, NTRK2 were seen in G3 compared with the G1 tumor areas. TRIO and RICTOR co-amplification was seen in 8 (44%) G3 and 1 (10%) G1 myxofibrosarcomas and RICTOR amplification alone in 4 (40%) G1 myxofibrosarcomas. These findings support the use of expanded molecular profiling in myxofibrosarcomas to detect drug-able targets to allow patients to participate in basket trials.] Question: Based on the provided context, do the terms [EGFR protein] and [FGFR3 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the mutational analysis of myxofibrosarcomas and mentions mutations in various genes, including TP53, PTEN, FGFR3, CDKN2A, and RB1. It also notes the presence of focal alterations affecting genes such as EGFR, EPHA3, EPHB1, FGFR1, JUN, NF1, RB1, RET, TP53, and others. However, there is no direct mention or evidence of an interaction between the EGFR protein and the FGFR3 protein. The context focuses on the individual mutations and alterations in these genes rather than any specific interaction between the proteins they encode.</s>
392861 2A2498850 2A2874087	HP-1	EST	[INST]Context: [PMID: 14968305 The tomato homolog of the gene encoding UV-damaged DNA binding protein 1 underlined as the gene that causes the high pigment-1 mutant phenotype. A tomato EST sequence, highly homologous to the human and Arabidopsis thaliana UV-damaged DNA binding protein 1, was mapped to the centromeric region of the tomato chromosome 2. This region was previously shown to harbor the HP-1 gene, encoding the high pigment-1 ( hp-1) and the high pigment-1(w) ( hp-1(w)) mutant phenotypes. Recent results also show that the A. thaliana damaged dna binding protein 1 protein interacts both genetically and biochemically with the protein encoded by DEETIOLATED1, a gene carrying three tomato mutations that are in many respects isophenotypic to high pigment-1: high pigment-2 ( hp-2), high pigment-2(j) ( hp-2(j)) and dark green ( dg). This transversion results in the substitution of the conserved asparagine at position 311 to a tyrosine residue. In the hp-1(w) mutant, on the other hand, a single G(2392)-to-A(2392) transition was observed, resulting in the substitution of the conserved glutamic acid at position 798 to a lysine residue. From MeSH: Lycopersicon esculentum.] Question: Based on the provided context, do the terms [HP-1 protein] and [EST protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the mapping of a tomato EST sequence homologous to the human and Arabidopsis thaliana UV-damaged DNA binding protein 1 to the centromeric region of tomato chromosome 2, which harbors the HP-1 gene. It also mentions the interaction of the damaged DNA binding protein 1 protein with the protein encoded by DEETIOLATED1, which is related to the high pigment-1 mutant phenotype. However, there is no direct mention of an interaction between the HP-1 protein and the EST protein. Instead, the context focuses on the mapping and phenotypic effects of the EST sequence and the interaction of the damaged DNA binding protein 1 protein with DEETIOLATED1. Therefore, based on the provided information, there is no evidence to suggest that the HP-1 protein and the EST protein interact with each other.</s>
36157 2A2936581 2A2909421	VIM	serotransferrin	[INST]Context: [PMID: 30612956 Endometrial stromal cell proteome mapping in repeated implantation failure and recurrent pregnancy loss cases and fertile women. RESEARCH QUESTION: Are there proteomic differences between endometrial stromal cells of repeated implantation failure, recurrent pregnancy loss and normal fertile women, and is there differential protein expression upon decidualization? DESIGN: This exploratory study investigated the proteome of in-vitro cultured endometrial stromal cells of women with repeated implantation failure (n__^=__^4), women with recurrent pregnancy loss (n__^=__^3) and normal fertile women (n__^=__^4), comparing day 0 with 5 days of decidualization. RESULTS: In the repeated implantation failure group, ANXA6, PSMC5 and FSCN1 were up-regulated (1.9-fold, 2.5-fold and 1.9-fold, respectively), whereas PBXIP1 was down-regulated (7.7-fold) upon decidualization. In the recurrent pregnancy loss group, RPS25 and ACADVL were down-regulated (1.9-fold and 2.4-fold, respectively; false discovery rate 10%) between the non-decidualized and the decidualized samples. In the normal fertile group VIM and RPL23A were down-regulated (1.9-fold and 2.4-fold, respectively). Comparing ratios of expression of decidualized over non-decidualized samples in the different groups revealed six differentially expressed proteins: DUX4L2, CNPY4, PDE7A, CTSK, PCBP2 and PSMD4. Comparison of recurrent pregnancy loss versus normal fertile in the decidualized condition revealed serotransferrin to be differentially expressed. The changes in expression levels for serotransferrin, ANX6, ACDVL and VIM were confirmed by western blot. CONCLUSIONS: Results show a varying response of endometrial stromal cells in distinct clinical groups (RIF, recurrent pregnancy loss and normal fertile) upon in-vitro decidualization. Serotransferrin could serve as a marker for the aberrant decidualization process in recurrent pregnancy loss.] Question: Based on the provided context, do the terms [VIM protein] and [serotransferrin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between VIM protein and serotransferrin protein. Instead, it discusses the differential expression of these proteins in endometrial stromal cells of women with repeated implantation failure, recurrent pregnancy loss, and normal fertile women upon decidualization. The changes in expression levels are noted separately for each protein, without any indication that they interact with each other.</s>
496629 2A2658178 2A2871385	MEK	src	[INST]Context: [PMID: 10336467 Morphological transformation induced by activation of the mitogen-activated protein kinase pathway requires suppression of the T-type Ca2+ channel. Transformation of fibroblasts by various oncogenes, including ras, mos, and src accompanies with characteristic morphological changes from flat to round (or spindle) shapes. Such morphological change is believed to play an important role in establishing malignant characteristics of cancer cells. Activation of the mitogen-activated protein kinase pathway is a converging downstream event of transforming activities of many oncogene products commonly found in human cancers. Intracellular calcium is known to regulate cellular morphology. In fibroblasts, Ca2+ influx is primarily controlled by two types of Ca2+ channels (T- and L-types). Here, we report that the T-type current was specifically inhibited in cells expressing oncogenically activated Ras as well as gain-of-function mutant MEK (MAPK/extracellular signal-regulated kinase (ERK) kinase, a direct activator of MAPK), whereas treatment of ras-transformed cells with a MEK-specific inhibitor restored T-type Ca2+ channel activity. Using a T-type Ca2+ channel antagonist, we further found that suppression of the T-type Ca2+ channel by the activated mitogen-activated protein kinase pathway is a prerequisite event for the induction and/or maintenance of transformation-associated morphological changes. From MeSH: Mice.] Question: Based on the provided context, do the terms [MEK protein] and [src protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the roles of MEK and src proteins in the transformation of fibroblasts and the activation of the mitogen-activated protein kinase pathway. However, there is no direct interaction mentioned between MEK protein and src protein. Instead, both proteins are presented as separate entities that contribute to the transformation process through different mechanisms. MEK is involved in the activation of the mitogen-activated protein kinase pathway, while src is mentioned as one of the oncogenes that can induce morphological changes in fibroblasts. Therefore, based on the given information, there is no evidence of a direct interaction between MEK and src proteins.</s>
102398 2A2704682 2A2459794	p53	CDK4	[INST]Context: [PMID: 9485022 Cancer dormancy: role of cyclin-dependent kinase inhibitors in induction of cell cycle arrest mediated via membrane IgM. Anti-idiotype antibody can induce tumor dormancy in a murine B lymphoma, BCL1, by its ability to induce cell cycle arrest and apoptosis (negative signaling). In human B lymphoma, there is accumulating evidence that the antitumor effect of anti-idiotype or several other B cell-reactive antibodies relates to their ability to act as agonists rather than conventional effector antibodies. In this study, we sought to elucidate the role of cyclins, cyclin-dependent kinases, and their inhibitors in anti-IgM-induced cell cycle arrest to better understand the mechanisms underlying cancer dormancy. To accomplish this, we have performed in vitro studies with a human lymphoma cell line (Daudi) because its response to anti-idiotype (or anti-IgM) is similar to that of a BCL1 cell line, more reagents are available, and the results would be particularly pertinent to therapy of human B cell lymphomas. Our results show that cross-linking of membrane IgM on Daudi cells induces an arrest late in G1 and prevents pRb from becoming phosphorylated. The G1 arrest is correlated with an induction of the CDK inhibitor p21 and reduced CDK2 activity, although the level of CDK2 protein was not changed. Coprecipitation of CDK2 with p21 in anti-IgM-treated cells and the unchanged level of cyclin E suggest that p21 is responsible for the reduction of CDK2 activity and therefore blockade of the cell cycle. The induction of p21 was not accompanied by changes in p53 levels. As a result of the G1 block, cyclin A levels sharply declined by 24 h after anti-IgM treatment. There was no evidence for involvement of CDK4 or CDK6 in the blockade. These results provide evidence that membrane IgM cross-linking on Daudi cells induces expression of p21 and a subsequent inhibition of the cyclin E-CDK2 kinase complex resulting in a block to pRb phosphorylation and cell cycle arrest late in G1.] Question: Based on the provided context, do the terms [p53 protein] and [CDK4 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the p53 protein and the CDK4 protein. The study focuses on the role of p21 and its inhibition of the cyclin E-CDK2 kinase complex in inducing cell cycle arrest. While p53 is mentioned in the context of the induction of p21, there is no indication that p53 interacts directly with CDK4. Instead, the study highlights the involvement of p21 in the inhibition of CDK2 activity, which is responsible for the blockade of the cell cycle.</s>
341387 2A2749952 2A2749676	PTPs	MEG	[INST]Context: [PMID: 11587846 Comparative analysis of the Band 4.1/ezrin-related protein tyrosine phosphatase Pez from two Drosophila species: implications for structure and function. The FERM-PTPs are a group of proteins that have FERM (Band 4.1, ezrin, radixin, moesin homology) domains at or near their N-termini, and protein tyrosine phosphatase domains at their C-termini. Their central regions contain either PSD-95, Dlg, ZO-1 homology domains or putative Src homology 3 domain binding sites. The known FERM-PTPs fall into three distinct classes, which we name BAS, MEG, and PEZ, after representative human PTPs. Here we analyze Pez, a novel gene encoding the single PEZ-class protein present in Drosophila. Pez cDNAs were sequenced from the distantly related flies Drosophila melanogaster and Drosophila silvestris, and found to be highly conserved except in the central region, which contains at least 21 insertions and deletions. Comparison of fly and human Pez reveals several short conserved motifs in the central region that are likely protein binding sites and/or phosphorylation sites. We also identified novel invertebrate members of the BAS and MEG classes using genome data, and generated an alignment of vertebrate and invertebrate FERM domains of each class. 'Specialized' residues were identified that are conserved only within a given class of PTPs. For PEZ, these residues cluster on and near FERM subdomain F1. Finally, the protein tyrosine phosphatase domain of fly Pez was modeled based on known protein tyrosine phosphatase tertiary structures, and we conclude that Pez is likely a functional phosphatase despite some unusual features of the active site cleft sequences. Biochemical confirmation of this hypothesis and genetic analysis of Pez are currently underway. From MeSH: Drosophila melanogaster.] Question: Based on the provided context, do the terms [PTPs protein] and [MEG protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the FERM-PTPs, which are a group of proteins with FERM domains and protein tyrosine phosphatase domains. It mentions three distinct classes of FERM-PTPs: BAS, MEG, and PEZ. While it describes the characteristics and conservation of these classes, it does not mention any direct interaction between PTPs protein and MEG protein. Instead, it focuses on the structural and functional aspects of each class separately. Therefore, based on the given information, there is no evidence to suggest that PTPs protein and MEG protein interact with each other.</s>
37117 2A2936581 2A2865279	vimentin	SMA	[INST]Context: [PMID: 18841827 Ceruminous gland tumours are rare neoplasms. We describe a case of a ceruminous tumour with complex morphology characterised by fibrous hyaline stroma bilayered epithelial ductal structures and nodules of tightly arranged clear cells with abundant Pas-positive cytoplasm. Within nodules among clear cells delicate apocrine ducts were found. Stromal tongues infiltrated with lymphocytes invaginated into nodules producing a lymphadenomatous pattern. Among clear cells, there are also numerous eosinophilic, Pas-positive refractile crystalline inclusions that appeared as floral petals (gerbera) or as a firework-like pattern. By immunohistochemistry, ductal structures were reactive for CK pan, CK7, CK18, CK19, EMA and GCDFP-15. Epithelial ductal basal cells were reactive for CK5, p63, calponin and SMA. Clear cells were weakly positive for CK18 and strongly positive for vimentin; Interestingly clear cells lacked immunostaining for calponin, p63, caldesmone, SMA and MSA. This result supports the myoepithelial nature of clear cells, which have lost some antigenic specificities, and the diagnosis of adenomyoepithelioma of the ceruminous gland. The patient is a 47-year-old woman with no evidence of disease after 3 years of follow-up.] Question: Based on the provided context, do the terms [vimentin protein] and [SMA protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context describes the immunohistochemical staining patterns of various proteins in a ceruminous gland tumor. It mentions that clear cells are strongly positive for vimentin and that they lack immunostaining for SMA. However, there is no indication that vimentin and SMA interact with each other. Instead, they are presented as separate markers used to characterize different cell types within the tumor.</s>
102452 2A2704682 2A2459951	p53 tumor suppressor	Mts2	[INST]Context: [PMID: 8764131 Allelotype analysis of 2',3'-dideoxycytidine- and 1,3-butadiene-induced lymphomas in B6C3F1 mice. To identify potential tumor suppressor genes involved in lymphoma development, we generated allelotypes of 16 2',3'-dideoxycytidine (ddC and 31 1,3-butadiene (BD)-induced lymphomas from C57BL/6 x C3H/He F1 (hereafter called B6C3F1) mice. Two or more anonymous simple sequence length polymorphisms per autosome were examined for loss of heterozygosity . The highest frequency of allelic losses was observed on chromosome 12, with 38 and 39% in ddC and BD-induced lymphomas, respectively. The most prevalent loss of heterozygosity was localized to the distal region bounded by markers D12Mit263 and D12Nds2. Detailed analysis localized a potential tumor suppressor gene residing on the distal region of chromosome 2, between markers D2Mit147 and D2Mit148. One of the regions includes the IFN gene cluster and is syntenic to human chromosome 9p2l-22. Candidate tumor suppressor genes, multiple tumor suppressor 1 and Mts2 have been mapped to this region. The second region is located on the distal part of chromosome 4, which is homologous to human chromosome 1p35-36, a region that is frequently deleted in various types of human tumors. Finally, 19% of ddC-induced and 29% of BD-induced lymphomas revealed loss of heterozygosity on chromosome 11 at the Acrb locus, which lies within 1 cM of p53, suggesting that the p53 tumor suppressor gene also plays a role in lymphomagenesis. These results suggest that multiple potential suppressor loci contribute to lymphoma development in B6C3F1 mice. From MeSH: Mice.] Question: Based on the provided context, do the terms [p53 tumor suppressor protein] and [Mts2 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the roles of various tumor suppressor genes, including p53 and Mts2, in lymphoma development in B6C3F1 mice. However, there is no mention of a direct interaction between the p53 tumor suppressor protein and the Mts2 protein. The context focuses on the allelic losses and potential tumor suppressor loci involved in lymphomagenesis, but it does not describe any interaction between these two specific proteins.</s>
126298 2A2590057 2A2592161	HSP90	HSP70	[INST]Context: [PMID: 16211252 Induction of heat shock protein 72 in C6 glioma cells by methyl jasmonate through ROS-dependent heat shock factor 1 activation. Salicylate and jasmonates are two different types of plant hormone that play critical roles in plant defense responses against insect herbivores and microbial pathogens, through activating defense genes. These two natural products have been shown to have similar activities in animal cells: the compounds are able to induce cell cycle arrest or apoptosis in a variety of human cancer cells including those of colon, prostate, breast, and leukemia, suggesting the chemicals may potentially be a novel class of anti-cancer drugs. Since sodium salicylate can induce the heat shock response in animals, we examined the effects of jasmonates on the heat shock response in C6 glioma cells. Here, we show that brief exposure to methyl jasmonate, but not to jasmonic acid, induces heat shock protein 72, but not HSP73 and HSP90, via heat shock factor I (HSF1) activation in C6 glioma cells without affecting cell viability. Intracellular H2O2 and O2-, and mitochondrial ROS were prominently increased in response to 5 mM methyl jasmonate in C6 cells. MeJA-induced heat shock protein 72 expression, HSF1 DNA binding, and human HSP70 promoter-driven CAT activity were prevented by N-acetyl-L-cysteine (a general antioxidant), catalase (a specific antioxidant for H2O2), and sodium formate (an inhibitor of OH.), but not by Rac1 dominant negative mutant Rac1N17 and diphenyleneiodonium (a NADPH oxidase inhibitor), indicating that methyl jasmonate induces heat shock protein 72 expression though HSF1 that is activated via Rac1-NADPH oxidase-independent ROS production pathway. These results suggest that the plant stress hormones share the ability to induce heat shock response in animal cells. Rats.] Question: Based on the provided context, do the terms [HSP90 protein] and [HSP70 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between HSP90 protein and HSP70 protein. Instead, it focuses on the induction of HSP72 (a member of the HSP70 family) by methyl jasmonate through the activation of heat shock factor 1 (HSF1) and the involvement of reactive oxygen species (ROS). There is no indication that HSP90 protein is involved in this process or interacts with HSP70 protein in the context described.</s>
362600 2A2520685 2A2871148	epidermal growth factor receptor	SQSTM1	[INST]Context: [PMID: 32401642 Autophagy in the physiological endometrium and cancer. Autophagy is a highly conserved catabolic process and a major cellular pathway for the degradation of long-lived proteins and cytoplasmic organelles. An increasing body of evidence has unveiled autophagy as an indispensable biological function that helps to maintain normal tissue homeostasis and metabolic fitness that can also lead to severe consequences for the normal cellular functioning when altered. Recent accumulating data point to autophagy as a key player in a wide variety of physiological and pathophysiological conditions in the human endometrium, one of the most proficient self-regenerating tissues in the human body and an instrumental player in placental species reproductive function. The current review highlights the most recent findings regarding the process of autophagy in the normal and cancerous endometrial tissue. Current research efforts aiming to therapeutically exploit autophagy and the methodological approaches used are discussed.Abbreviations: 3-MA: 3-methyladenine; Acetyl-CoA carboxylase alpha ; AICAR: 5-aminoimidazole-4-carboximide riboside; AMPK: AMP-activated protein kinase; ATG: autophagy related; ATG12: autophagy related 12; ATG16L1: autophagy related 16 like 1; ATG3: autophagy related 3; ATG4C: autophagy related 4C cysteine peptidase; ATG5: autophagy related 5; ATG7: autophagy related 7; Baf A1: bafilomycin A1; BAX: BCL2 associated X, apoptosis regulator; BCL2: BCL2 apoptosis regulator; BECN1: beclin 1; CACNA1D: calcium voltage-gated channel subunit alpha1 D; CASP3: caspase 3; CASP7: caspase 7; CASP8: caspase 8; CASP9: caspase 9; CD44: CD44 molecule (Indian blood group); CDH1: cadherin 1; CDKN1A: cyclin dependent kinase inhibitor 1A; CDKN2A: cyclin dependent kinase inhibitor 2A; CMA: chaperone-mediated autophagy; CQ: chloroquine; CTNNB1: catenin beta 1; DDIT3: DNA damage inducible transcript 3; EC: endometrial cancer; EGFR: epidermal growth factor receptor; EH: endometrial hyperplasia; EIF4E: eukaryotic translation initiation factor 4E; EPHB2/ERK: EPH receptor B2; ER: endoplasmic reticulum; ERBB2: er-b2 receptor tyrosine kinase 2; ERVW-1: endogenous retrovirus group W member 1, envelope; ESR1: estrogen receptor 1; GCG/GLP1: glucagon; GIP: gastric inhibitory polypeptide; GLP1R: glucagon-like peptide-1 receptor; GLS: glutaminase; H2AX: H2A.X variant histone; HIF1A: hypoxia inducible factor 1 alpha; HMGB1: high mobility group box 1; HOTAIR: HOX transcript antisense RNA; HSPA5: heat shock protein family A member 5; HSPA8: heat shock protein family A member 8; IGF1: insulin like growth factor 1; IL27: interleukin 27; INS: insulin; ISL: isoliquiritigenin; KRAS: KRAS proto-oncogene, GTPase; LAMP2: lysosomal-associated membrane protein 2; MAP1LC3A/LC3A: microtubule associated protein 1 light chain 3 alpha; MAP1LC3B/LC3B: microtubule associated protein 1 light chain 3 beta; MAPK8: mitogen-activated protein kinase 8; MAPK9: mitogen-activated protein kinase 9; MPA: medroxyprogesterone acetate; MTOR: mechanistic target of rapamycin kinase; MTORC1: mechanistic target of rapamycin kinase complex 1; MTORC2: mechanistic target of rapamycin kinase complex 2; MYCBP: MYC-binding protein; NFE2L2: nuclear factor, erythroid 2 like 2; NFKBIA: NFKB inhibitor alpha; NR5A1: nuclear receptor subfamily 5 group A member 1; PARP1: poly(ADP-ribose) polymerase 1; PAX2: paired box 2; PDK1: pyruvate dehydrogenase kinase 1; PIK3C3/Vps34: phosphatidylinositol 3-kinase catalytic subunit type 3; PIK3CA: phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; PIK3R1: phosphoinositide-3-kinase regulatory subunit 1; PIKFYVE: phosphoinositide kinase, FYVE-type zinc finger containing; PPD: protopanaxadiol; PRKCD: protein kinase C delta; PROM1/CD133: prominin 1; PtdIns3P: phosphatidylinositol-3-phosphate; PTEN: phosphatase and tensin homolog; RB1CC1/FIP200: RB1 inducible coiled-coil 1; RPS6KB1/S6K1: ribosomal protein S6 kinase B1; RSV: resveratrol; SGK1: serum/glucocorticoid regulated kinase 1; SGK3: serum/glucocorticoid regulated kinase family member 3; SMAD2: SMAD family member 2; SMAD3: SMAD family member 3; SQSTM1: sequestosome 1; TGFBR2: transforming growth factor beta receptor 2; TP53: tumor protein p53; TRIB3: tribbles pseudokinase 3; ULK1: unc-51 like autophagy activating kinase 1; ULK4: unc-51 like kinase 4; VEGFA: vascular endothelial growth factor A; WIPI2: WD repeat domain, phosphoinositide interacting 2; XBP1: X-box binding protein 1; ZFYVE1: zinc finger FYVE domain containing 1.] Question: Based on the provided context, do the terms [epidermal growth factor receptor protein] and [SQSTM1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the epidermal growth factor receptor protein (EGFR) and the SQSTM1 protein. The context discusses various proteins and pathways involved in autophagy and other cellular processes in the endometrium, but it does not specify any interaction between EGFR and SQSTM1. Therefore, based on the given information, there is no evidence to suggest that these two proteins interact with each other.</s>
106690 2A2762817 2A2764443	Rab10	Rab27A	[INST]Context: [PMID: 11773082 Rab27A, which encodes a small GTP-binding protein, was recently identified as a gene in which mutations caused human hemophagocytic syndrome (Griscelli syndrome) and ashen mice, which exhibit defects in melanosome transport as well as in regulated granule exocytosis in cytotoxic T lymphocytes. However, little is known about the molecular mechanism of Rab27A-dependent membrane trafficking or the specific effector molecules of Rab27A. In this study, we discovered that the synaptotagmin-like protein homology domain (SHD) of Slp1--3 and Slac2-a/b specifically and directly binds the GTP-bound form of Rab27A both in vitro and in intact cells but not of the other Rabs tested (Rab1, Rab2, Rab3A, Rab4, Rab5A, Rab6A, Rab7, Rab8, Rab9, Rab10, Rab11A, Rab17, Rab18, Rab20, Rab22, Rab23, Rab25, Rab28, and Rab37). Immunocytochemical analysis revealed that Slp2 (or Slp1) colocalized with Rab27A in the melanosomes of melanoma cells. Slp2 and Rab27A were distributed to the periphery of the cells (especially at the dendritic tips) in the wild-type melanoma cells, whereas they accumulated in the perinuclear region in the melanosome transport-defective cells (S91/Cloudman). From MeSH: Mice. Rabbits.] Question: Based on the provided context, do the terms [Rab10 protein] and [Rab27A protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between Rab10 protein and Rab27A protein. Instead, it focuses on the interaction of Rab27A with other proteins such as Slp1-3 and Slac2-a/b. The context lists various Rabs tested for their interaction with Rab27A, but Rab10 is not among those that were found to interact. Therefore, based on the given information, there is no evidence to suggest that Rab10 protein and Rab27A protein interact with each other.</s>
683319 2A2458091 2A2748379	CCND3	PTEN	[INST]Context: [PMID: 21412932 Pancreatic adenocarcinoma is one of the most aggressive human cancers. By using 244 K high-resolution array-comparative genomic hybridization we studied the genome alterations of 39 fine-needle aspirations from pancreatic adenocarcinoma and eight human adenocarcinoma pancreatic cell lines. Using both visual inspection and GISTIC analysis, recurrent losses were observed on 1p, 3p, 4p, 6, 8p, 9, 10, 11q, 15q, 17, 18, 19p, 20p, 21, and 22 and comprised several known or suspected tumor suppressor genes such as ARHGEF10, ARID1A, CDKN2A/B, FHIT, PTEN, RB1, RUNX1-3, SMAD4, STK11/LKB1, TP53, and TUSC3. Heterozygous deletion of the 1p35-p36 chromosomal region was identified in one-third of the tumors and three of the cell lines. This region, commonly deleted in human cancers, contains several tumor suppressor genes including ARID1A and RUNX3. We identified frequent genetic gains on chromosome arms 1q, 3q, 5p, 6p, 7q, 8q, 12q, 15q, 18q, 19q, and 20q. AKT2, CCND3, CDK4, FOXA2, GATA6, MDM2, MYC, and SMURF1 genes were gained or amplified. The most obvious amplification was located at 18q11.2 and targeted the GATA6 gene, which plays a predominant role in the initial specification of the pancreas and in pancreatic cell type differentiation. In conclusion, we have identified novel biomarkers and potential therapeutic targets in pancreatic adenocarcinoma.] Question: Based on the provided context, do the terms [CCND3 protein] and [PTEN protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the CCND3 protein and the PTEN protein. The context discusses the genetic gains and losses observed in pancreatic adenocarcinoma, including the amplification of CCND3 and the deletion of PTEN. However, it does not describe any interaction between these two proteins. Instead, it lists them as separate entities affected by genetic alterations in the cancer.</s>
454586 2A2537221 2A2411518	alpha-fetoprotein	albumin	[INST]Context: [PMID: 22381903 Influence of tumor thrombus location on the outcome of external-beam radiation therapy in advanced hepatocellular carcinoma with macrovascular invasion. PURPOSE: The present study evaluates the influence of portal vein vs. inferior vena cava tumor thrombosis sites on the effectiveness of external-beam radiation therapy in advanced hepatocellular carcinoma with macrovascular invasion. METHODS AND MATERIALS: We retrospectively reviewed 181 hepatocellular carcinoma patients with portal vein and/or inferior vena cava tumor thrombi who were referred for external-beam radiation therapy at our institution between 2000 and 2009. RESULTS: The median survival was 10.2, 7.4, 17.4, and 8.5 months for patients with portal vein branch, portal vein trunk, inferior vena cava, and portal vein plus inferior vena cava tumor thrombosis, respectively. Unfavorable pretreatment predictors were associated by multivariate analysis with lower albumin and higher alpha-fetoprotein levels, poorer Child-Pugh liver function classification, multiple intrahepatic foci, lymph node metastases, thrombus location, less chance to receive post-external-beam radiation therapy transarterial chemoembolization and the two-dimensional external-beam radiation therapy technique. In comparison to patients with portal vein tumor thrombosis, patients with inferior vena cava thrombi had a higher occurrence of solitary intrahepatic lesions (p = 0.027), well-controlled intrahepatic tumors (p < 0.001), and a better response to external-beam radiation therapy (p < 0.001), and they were more likely to receive post-external-beam radiation therapy transarterial chemoembolization (p = 0.033). CONCLUSIONS: In hepatocellular carcinoma, patients with inferior vena cava thrombus treated with external-beam radiation therapy had a better response rate and longer survival than those with portal vein thrombus.] Question: Based on the provided context, do the terms [alpha-fetoprotein protein] and [albumin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the influence of tumor thrombus location on the outcome of external-beam radiation therapy in advanced hepatocellular carcinoma with macrovascular invasion. It mentions that unfavorable pretreatment predictors include lower albumin and higher alpha-fetoprotein levels, but it does not indicate any direct interaction between albumin protein and alpha-fetoprotein protein. Instead, they are presented as separate biomarkers that are associated with different outcomes in the study.</s>
111101 2A2577116 2A2871385	Hck	Src	[INST]Context: [PMID: 25305536 Embryonic stem cells are characterized by pluripotency, defined as the developmental potential to generate cell lineages derived from all three primary germ layers. In the past decade, great progress has been made on the cell culture conditions, transcription factor programs and intracellular signaling pathways that control both murine and human embryonic stem cell fates. Embryonic stem cells of mouse vs. human origin have distinct culture conditions, responding to some tyrosine kinase signaling pathways in opposite ways. Previous work has implicated the Src family of non-receptor protein-tyrosine kinases in mouse embryonic stem cell self-renewal and differentiation. Both Hck and c-Yes are important in self-renewal, while c-Src activity alone is sufficient to induce differentiation. Of the eleven Src-related kinases in the human genome, Fyn, c-Yes, c-Src, Lyn, Lck and Hck were expressed in H1, H7 and H9 hembryonic stem cells, while Fgr, Blk, Srm, Brk, and Frk transcripts were not detected. Of these, c-Yes, Lyn, and Hck transcript levels remained constant in self-renewing human embryonic stem cells vs. differentiated EBs, while c-Src and Fyn showed a modest increase in expression as a function of differentiation. In contrast, Lck expression levels dropped dramatically as a function of EB differentiation.] Question: Based on the provided context, do the terms [Hck protein] and [Src protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the roles of various Src-related kinases in mouse and human embryonic stem cell self-renewal and differentiation. While it mentions the involvement of Hck and c-Src in these processes, it does not indicate a direct interaction between the Hck protein and the Src protein. Instead, it describes their individual roles and how their activities influence embryonic stem cell fates. Therefore, there is no evidence of a direct interaction between Hck and Src proteins based on the given information.</s>
217651 2A2454115 2A2905922	FLICE	Fas	[INST]Context: [PMID: 12419941 Oxidized low density lipoprotein potentiation of Fas-induced apoptosis through lectin-like oxidized-low density lipoprotein receptor-1 in human umbilical vascular endothelial cells. Under normal conditions, vascular endothelial cells are resistant to Fas-mediated apoptosis, although they express detectable Fas on their cell surface. Because oxidized Low density lipoprotein is thought to promote atherogenesis, the potential role that oxidized low density lipoprotein may play in Fas-mediated apoptosis was investigated in human umbilical vascular endothelial cells, focusing particularly on the involvement of the lectin-like oxidized low density lipoprotein receptor-1 (LOX-1). Human umbilical vascular endothelial cells were treated with agonistic anti-Fas antibody (CH11) and oxidized low density lipoprotein and then the degree of apoptosis was determined by cell death ELISA. Oxidized low density lipoprotein concentration-dependently sensitized Fas-mediated apoptosis. On the other hand, treating human umbilical vascular endothelial cells with oxidized low density lipoprotein did not lead to any significant change in the expression of death mediators, including Fas, Fas ligand, FADD, and FLICE as assessed by multiplex polymerase chain reaction amplification. More importantly, these effects of oxidized low density lipoprotein on Fas-mediated apoptosis were significantly blocked by a neutralizing LOX-1 monoclonal antibody, which can block LOX-1-mediated cellular uptake of oxidized low density lipoprotein. Oxidized low density lipoprotein may be an important factor involved in the regulation of Fas-induced apoptosis via Ox-LDL/LOX-1 interaction in vascular endothelial cells. The results may provide insights into the pathogenesis of accelerated atherosclerosis in patients with hyperlipidemia.] Question: Based on the provided context, do the terms [FLICE protein] and [Fas protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not indicate a direct interaction between the FLICE protein and the Fas protein. While the context discusses the role of oxidized low density lipoprotein in potentiating Fas-induced apoptosis and mentions various death mediators, including FLICE, it does not describe any direct interaction between FLICE and Fas. Instead, it focuses on the effects of oxidized low density lipoprotein on the sensitization of Fas-mediated apoptosis through the LOX-1 receptor. Therefore, based on the given information, there is no evidence of a direct interaction between FLICE and Fas.</s>
672235 2A2723964 2A2860488	pigment epithelium-derived factor	HSP47	[INST]Context: [PMID: 22706122 [Mutations of noncollagen genes in osteogenesis imperfecta--implications of the gene products in collagen biosynthesis and pathogenesis of disease]. Recent investigations revealed that the 'brittle bone' phenotype in osteogenesis imperfecta is caused not only by dominant mutations in collagen type I genes, but also by recessively inherited mutations in genes responsible for the post-translational processing of type I procollagen as well as for bone formation. The phenotype of patients with mutations in noncollagen genes overlaps with very severe type III and lethal type II osteogenesis imperfecta caused by mutations in collagen genes. Mutations in genes that encode proteins involved in collagen prolyl 3-hydroxylation eliminated Pro986 hydroxylation and caused an increase in modification of collagen helix by prolyl 4-hydroxylase and lysyl hydroxylase. Loss of complex proteins' function as collagen chaperones may dominate the disease mechanism. The latest findings added to the spectrum of OI-causing and collagen-influencing factors other chaperones (HSP47 and FKBP65) and protein BMP-1, which emphasizes the complexity of collagen folding and secretion as well as their importance in bone formation. Furthermore, mutations in genes encoding transcription factor SP7/Osterix and pigment epithelium-derived factor constitute a novel mechanism for osteogenesis imperfecta, which is independent of changes in biosynthesis and processing of collagen.] Question: Based on the provided context, do the terms [pigment epithelium-derived factor protein] and [HSP47 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the roles of various proteins in collagen biosynthesis and the pathogenesis of osteogenesis imperfecta. It mentions pigment epithelium-derived factor (PEDF) and HSP47 as separate entities involved in the disease mechanism. However, there is no direct interaction mentioned between PEDF and HSP47. Instead, they are presented as separate factors that influence collagen processing and bone formation independently. Therefore, based on the given information, there is no evidence to suggest that PEDF and HSP47 interact with each other.</s>
267313 2A2507305 2A2925389	DNAJA1	UGDH	[INST]Context: [PMID: 35363364 Identification of epilepsy concomitant candidate genes recognized in Saudi epileptic patients. The program goals are to recognize and reduce the incidence of genetic diseases in the Kingdom of Saudi Arabia . Epilepsy has a high prevalence in kingdom of saudi arabia reaching around 6.54 of 1000 individuals with a subsequent massive financial burden. One of the main risk factors for this high prevalence and associated with increased risk of epilepsy development is consanguinity marriage, which is traditional in kingdom of saudi arabia. In this review, we executed a comprehensive state-of-art literature review regarding epilepsy genetics to offer a perception into the genes associated with epilepsy recognized in Saudi epileptic patients. Several genes' mutations were incorporated in this review including AFG3L2, ASPM, ATN1, ATP1A2, BMP5, CCDC88A, C12orf57, DNAJA1, EML1, ERLIN2, FRRS1L, GABRG3, NRXN3, MDH1, KCNJ10, KCNMA1, KCNT1, KIAA0226, OPHN1, PCCA, PCCB, PEX, PGAP2, PI4K2A, PODXL, PRICKLE1, PNKP, RELN, SCN2A, SCN1B, SLC2A1, SLC19A3, SLC25, SIAH1, SYNJ1, SZT2, TBCK, TMX2, TSC1, TSC2, TSEN, WDR45B, WWOX, UBR, UGDH, and YIF1B. For each of these genes, we tried to explain a little about the gene associated proteins and their roles in epilepsy development.] Question: Based on the provided context, do the terms [DNAJA1 protein] and [UGDH protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context lists several genes associated with epilepsy, including DNAJA1 and UGDH, but it does not mention any direct interaction between the DNAJA1 protein and the UGDH protein. The context focuses on the roles of these genes in epilepsy development rather than describing any specific interactions between their protein products. Therefore, based on the given information, there is no evidence to suggest that DNAJA1 and UGDH proteins interact with each other.</s>
225403 2A2577828 2A2439390	Huntingtin	ataxin 2	[INST]Context: [PMID: 30707359 Evoprotein-protein interaction 1.0: a Web Platform for Within- and Between-Species Multiple Interactome Comparisons and Application to Nine PolyQ Proteins Determining Neurodegenerative Diseases. We show its usefulness by performing a comparative study of the interactome of the nine polyglutamine disease proteins, namely androgen receptor, atrophin-1, ataxin 1, ataxin 2, ataxin 3, ataxin 7, calcium voltage-gated channel subunit alpha1 A (CACNA1A), Huntingtin, and TATA-binding protein . Here we show that none of the human interactors of these proteins is common to all nine interactomes. Only 15 proteins are common to at least 4 of these polyglutamine disease proteins, and 40% of these are involved in ubiquitin protein ligase-binding function. Comparisons with Mus musculus PPIs are also made for androgen receptor and tata-binding protein, using Evoprotein-protein interaction BLAST search approach (a unique feature of EvoPPI), with the goal of understanding why there is a significant excess of common interactors for these proteins in humans.] Question: Based on the provided context, do the terms [Huntingtin protein] and [ataxin 2 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the interactomes of nine polyglutamine disease proteins, including Huntingtin and ataxin 2, but it does not mention a direct interaction between Huntingtin protein and ataxin 2 protein. Instead, it focuses on the common interactors among these proteins and their roles in ubiquitin protein ligase-binding function. Therefore, based on the given information, there is no evidence to suggest that Huntingtin protein and ataxin 2 protein interact with each other.</s>
43567 2A2918856 2A2520685	CTs	epidermal growth factor receptor	[INST]Context: [PMID: 26686532 Sequential endocrine therapy is recommended for postmenopausal women with hormone receptor-positive /human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer and without visceral symptoms. Treatment preferences were collected by treatment class of ET-based regimens versus chemotherapy and by agent for postmenopausal HR+/HER2- metastatic breast cancer patients after prior nonsteroidal aromatase inhibitor use in the adjuvant or metastatic breast cancer setting. Among first-line ETs, anastrozole was the most frequently used treatment (35%), followed by everolimus-based (EVE, 34%) and fulvestrant-based (FUL, 15%) therapy. Comparing EVE versus FUL, physicians preferred EVE in all lines but first line. CTs were used in early lines for patients with visceral symptoms.] Question: Based on the provided context, do the terms [CTs protein] and [epidermal growth factor receptor protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the use of different endocrine therapies (ETs) and chemotherapy (CTs) in the treatment of postmenopausal hormone receptor-positive/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. While it mentions the use of CTs and the epidermal growth factor receptor (EGFR), there is no direct interaction mentioned between CTs protein and epidermal growth factor receptor protein. Instead, they are presented as separate agents used in different treatment settings.</s>
423643 2A2652854 2A2652867	LC3	LC3B	[INST]Context: [PMID: 25955014 Divergent roles of BECN1 in LC3 lipidation and autophagosomal function. BECN1/Beclin 1 is regarded as a critical component in the class III phosphatidylinositol 3-kinase complex to trigger autophagy in mammalian cells. Despite its significant role in a number of cellular and physiological processes, the exact function of BECN1 in autophagy remains controversial. Here we created a BECN1 knockout human cell line using the TALEN technique. Surprisingly, the complete loss of BECN1 had little effect on LC3 (MAP1LC3B/LC3B) lipidation, and LC3B puncta resembling autophagosomes by fluorescence microscopy were still evident albeit significantly smaller than those in the wild-type cells. Electron microscopy analysis revealed that BECN1 deficiency led to malformed autophagosome-like structures containing multiple layers of membranes under amino acid starvation. We further confirmed that the phosphatidylinositol 3-kinase complex activity and autophagy flux were disrupted in BECN1(-/-) cells. Our results demonstrate the essential role of BECN1 in the functional formation of autophagosomes, but not in LC3B lipidation.] Question: Based on the provided context, do the terms [LC3 protein] and [LC3B protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The terms LC3 protein" and "LC3B protein" refer to the same entity, MAP1LC3B/LC3B. Therefore, they do not interact with each other as they are not distinct entities. The context discusses the role of BECN1 in LC3B lipidation and autophagosomal function, but it does not mention any interaction between LC3 protein and LC3B protein.</s>"
169785 2A2764298 2A2922527	KRAS	UBA3	[INST]Context: [PMID: 21482774 Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen. Therapies that target estrogen signaling have made a very considerable contribution to reducing mortality from breast cancer. However, resistance to tamoxifen remains a major clinical problem. Here we have used a genome-wide functional profiling approach to identify multiple genes that confer resistance or sensitivity to tamoxifen. Combining whole-genome shRNA screening with massively parallel sequencing, we have profiled the impact of more than 56,670 RNA interference reagents targeting 16,487 genes on the cellular response to tamoxifen. This screen, along with subsequent validation experiments, identifies a compendium of genes whose silencing causes tamoxifen resistance (including BAP1, CLPP, GPRC5D, NAE1, NF1, NIPBL, NSD1, RAD21, RARG, SMC3, and UBA3) and also a set of genes whose silencing causes sensitivity to this endocrine agent (C10orf72, C15orf55/NUT, EDF1, ING5, KRAS, NOC3L, PPP1R15B, RRAS2, TMPRSS2, and TPM4). Multiple individual genes, including NF1, a regulator of RAS signaling, also correlate with clinical outcome after tamoxifen treatment.] Question: Based on the provided context, do the terms [KRAS protein] and [UBA3 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the KRAS protein and the UBA3 protein. Instead, it lists these proteins as part of a compendium of genes whose silencing causes sensitivity or resistance to tamoxifen. There is no indication that KRAS and UBA3 interact with each other in the context of tamoxifen sensitivity or resistance.</s>
365759 2A2592211 2A2592321	hsc70	hsp27	[INST]Context: [PMID: 21276479 Ultraviolet B retards growth, induces oxidative stress, and modulates DNA repair-related gene and heat shock protein gene expression in the monogonont rotifer, Brachionus sp. Ultraviolet B radiation causes direct cellular damage by breakage of DNA strands and oxidative stress induction in aquatic organisms. To understand the effect of ultraviolet b radiation on the rotifer, Brachionus sp., several parameters including 24-h survival rate, population growth rate, and reactive oxygen species level were measured after exposure to a wide range of ultraviolet b doses. To check the expression of other important inducible genes such as replication protein A, DNA-dependent protein kinase, Ku70, Ku80, and heat shock proteins after ultraviolet b radiation, we observed dose- and time-dependency at 2kJ/m(2). Results showed that ultraviolet b remarkably inhibited the population growth of Brachionus sp. The level of intracellular reactive oxygen species was high at 2kJ/m(2), suggesting that 2kJ/m(2) would already be toxic. This result was supported by other enzymatic activities, such as GSH levels, glutathione peroxidase, glutathione S-transferase, and glutathione reductase. For dose dependency, low doses of ultraviolet b radiation (2, 4, and 6kJ/m(2)) significantly up-regulated the examined genes (e.g. replication protein a, dna-dependent protein kinase, Ku70, and Ku80). For the time course study, replication protein a genes showed immediate up-regulation but returned to basal or lower expression levels compared to the control 3h after ultraviolet b exposure. At the basal level, the hsp90alpha1 gene showed the highest expression, and followed by hsp10, hsp30, hsp60, and hsc70, and hsp90beta in adults (w/o egg). In eggs, the hsp10 gene was expressed the highest, and followed by hsp30, hsp27, hsp90alpha1, and hsp60 genes. In real-time RT-PCR array on rotifer hsp genes, low doses of ultraviolet b radiation (2 and 4kJ/m(2)) showed up-regulation of several hsp genes but most of the hsp genes showed down-regulation at 8kJ/m(2) and higher, indicating that significant Hsp-mediated cellular damage already occurred at low doses. For the time course study of four hsp genes (hsp20, hsp27, hsp70, hsp90alpha1), they showed a significant correlation for ultraviolet b radiation (2kJ/m(2)). In this paper, we demonstrated that ultraviolet b radiation would affect growth retardation with up- or down-regulation of some important genes in DNA replication, repair process, and chaperoning.] Question: Based on the provided context, do the terms [hsc70 protein] and [hsp27 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the expression of various heat shock proteins (HSPs) in response to ultraviolet B radiation in the rotifer Brachionus sp. It mentions the expression levels of hsc70 and hsp27 proteins but does not indicate any direct interaction between these two proteins. Instead, it focuses on their individual expression patterns and roles in the cellular response to ultraviolet B radiation. Therefore, there is no evidence of a direct interaction between hsc70 and hsp27 proteins in the given context.</s>
698798 2A2869526 2A2601220	PGN	IL6	[INST]Context: [PMID: 25361854 High and interrelated rates of PD-L1+CD14+ antigen-presenting cells and regulatory T cells mark the microenvironment of metastatic lymph nodes from patients with cervical cancer. A better understanding of the microenvironment in relation to lymph node metastasis is essential for the development of effective immunotherapeutic strategies against cervical cancer. In the present study, we investigated the microenvironment of tumor-draining lymph nodes of patients with cervical cancer by comprehensive flow cytometry-based phenotyping and enumeration of immune-cell subsets in tumor-negative (LN(-), n = 20) versus tumor-positive lymph nodes (LN(+), n = 8), and by the study of cytokine release profiles (n = 4 for both LN(-) and LN(+)). We found significantly lower CD4(+) and higher CD8(+) T-cell frequencies in LN(+) samples, accompanied by increased surface levels of activation markers (HLA-DR; ICOS; PD-1; CTLA-4) and the memory marker CD45RO. The LN(+) antigen-presenting cell subset correlated with significantly elevated frequencies of FoxP3(+) regulatory T cells (Treg). After in vitro stimulation with different Toll-like receptor ligands (PGN; Poly-IC; R848), we observed higher production levels of IL6, IL10, and TNFalpha but lower levels of IFNgamma in LN(+) samples. We conclude that, despite increased T-cell differentiation and activation, a switch to a profound immune-suppressive microenvironment in LN(+) of patients with cervical cancer will enable immune escape. Our data indicate that the CD14(+)PD-L1(+) APC/Treg axis is a particularly attractive and relevant therapeutic target to specifically tackle microenvironmental immune suppression and thus enhances the efficacy of immunotherapy in patients with metastasized cervical cancer.] Question: Based on the provided context, do the terms [PGN protein] and [IL6 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not indicate a direct interaction between PGN protein and IL6 protein. Instead, it describes the production levels of various cytokines, including IL6, in response to stimulation with different Toll-like receptor ligands, such as PGN. The context mentions that there are higher production levels of IL6 after stimulation with PGN, but it does not suggest a direct interaction between PGN protein and IL6 protein. Instead, it describes the effects of PGN on cytokine production, which includes IL6.</s>
102328 2A2704682 2A2454115	cellular tumor antigen p53	caspase-8	[INST]Context: [PMID: 29434892 Effects of harmaline on cell growth of human liver cancer through the p53/p21 and Fas/fas ligand signaling pathways. The effects of harmaline on the viability and apoptosis of human liver carcinoma were investigated in vitro. HepG2 cells were treated with harmaline (0-10 _M), and the proliferation and apoptosis of HepG2 cells were investigated using an MTT assay and flow cytometry, respectively. The protein expression of cellular tumor antigen p53 (p53), cyclin-dependent kinase inhibitor 1 (p21), tumor necrosis factor receptor superfamily member 6 (Fas), Fas ligand and caspase-8 was subsequently measured using western blotting. Harmaline significantly increased p53, p21, Fas and fas ligand protein expression in HepG2 cells. Additionally, treatment with harmaline significantly increased the expression of caspase-8 and caspase-8/3 activity. The results from the present study suggest that harmaline suppresses the viability, but induces the apoptosis, of human liver carcinoma cells through upregulation of the p53/p21 and Fas/fas ligand signaling pathways.] Question: Based on the provided context, do the terms [cellular tumor antigen p53 protein] and [caspase-8 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context describes the effects of harmaline on the expression of various proteins involved in the p53/p21 and Fas/fas ligand signaling pathways in HepG2 cells. While it mentions that harmaline increases the expression of cellular tumor antigen p53 (p53) and caspase-8, it does not indicate a direct interaction between the p53 protein and the caspase-8 protein. Instead, it describes the upregulation of these proteins as part of the broader signaling pathways affected by harmaline. Therefore, there is no direct interaction mentioned between p53 and caspase-8 in the context provided.</s>
43261 2A2918856 2A2909421	prealbumin	transferrin	[INST]Context: [PMID: 26866011 Evaluation of Protein-Energy Wasting and Inflammation on Patients Undergoing Continuous Ambulatory Peritoneal Dialysis and its Correlations. BACKGROUND: Protein-energy wasting and heightened inflammation are prevalent in patients undergoing continuous ambulatory peritoneal dialysis and is a strong risk factor for morbidity and mortality in these patients. Evaluation of protein-energy wasting, prevalence of inflammation as well as interrelationship between various nutritional indices and inflammation has not been studied in much detail in patients undergoing continuous ambulatory peritoneal dialysis. OBJECTIVES: This study was conducted to evaluate the interrelationship between protein-energy wasting and inflammation in patients undergoing continuous ambulatory peritoneal dialysis. PATIENTS AND METHODS: Sixty-three patients undergoing continuous ambulatory peritoneal dialysis (M = 28, F = 35) were assessed with regard to their nutritional status and inflammation after a minimum of 3 months continuous ambulatory peritoneal dialysis initiation. In addition, their serum albumin, prealbumin, transferrin, and cholesterol level were measured. Also, inflammation in these patients was assessed by High-Sensitivity C-Reactive Protein (hs-CRP > 3 mg/L) and Interleukin-6 (IL-6 > 2 _g/mL). Later on, diagnosis of malnutrition was made based on different methods. Correlation between inflammation and various nutritional assessment indices were analyzed statistically. RESULTS: Mean (SD) age of the patients was 57.6 (11.6) years. The mean values of serum protein, albumin, prealbumin, transferrin, cholesterol, triglyceride, hs-CRP, and IL-6 were 5.9 g/dL, 3.0 g/dL, 21.11 mg/dL, 130.6 mg/dL, 155.9 mg/dL, 136.1 mg/dL, 8.8 +- 7.6 mg/L, and 8.4 +- 12.2 _g/dL, respectively. 11.63 (17.4%), 34.63 (54%), and 18.65 (28.6%) patients undergoing continuous ambulatory peritoneal dialysis had normal, moderate, and severe malnutrition status, respectively. According to serum albumin level; 13.63 (21%), 39.63 (62%), and 11.63 (17%) patients undergoing continuous ambulatory peritoneal dialysis had normal, moderate, and severe malnutrition status, respectively. 33.63 (52%), 23.63 (37%), and 7.63 (11%) patients undergoing continuous ambulatory peritoneal dialysis had normal, moderate, and severe malnutrition status, respectively. About 76.1% and 9.5% of patients undergoing continuous ambulatory peritoneal dialysis were malnourished based on lean tissue index and fat tissue index, respectively. Based on hs-CRP and IL-6 findings, 70% (44/63) and 71.8% (45/63) of patients undergoing continuous ambulatory peritoneal dialysis had high inflammation, respectively. High sensitive C-reactive protein correlated negatively (significantly) with serum albumin, prealbumin, and transferrin. Interleukin -6 correlated negatively (significantly) with mid-arm circumference; Serum albumin, cholesterol, and transferrin. There was significant positive correlation between hs-CRP and IL-6. There is statistically significant difference in total protein intake (g/d), protein intake (g/kg/d), serum protein (g/dL), albumin (g/dL), transferrin (mg/dL), and cholesterol (mg/dL) between patients with and without inflammation. CONCLUSIONS: Protein-energy wasting (80% - 85%) by various methods and inflammation (70%) was very prevalent among patients undergoing continuous ambulatory peritoneal dialysis. Inflammatory markers are suggested to be included in the regular assessment of patients undergoing continuous ambulatory peritoneal dialysis, for the better management of protein-energy wasting.] Question: Based on the provided context, do the terms [prealbumin protein] and [transferrin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the levels and correlations of various nutritional indices and inflammatory markers in patients undergoing continuous ambulatory peritoneal dialysis. While it mentions that high-sensitive C-reactive protein (hs-CRP) and interleukin-6 (IL-6) correlate negatively with serum albumin, prealbumin, and transferrin, it does not indicate a direct interaction between prealbumin and transferrin proteins. Instead, it describes their individual correlations with inflammation markers, suggesting that they are affected by inflammation but not interacting with each other.</s>
659562 2A2548752 2A2587344	Gadd45	HMGB1	[INST]Context: [PMID: 26669670 The HLA-B*35 allele modulates ER stress, inflammation and proliferation in PBMCs from Limited Cutaneous Systemic Sclerosis patients. INTRODUCTION: HLA-B*35 is associated with increased risk of developing pulmonary hypertension in SSc patients. We previously reported that HLA-B*35 induces endothelial cell dysfunction via activation of ER stress/UPR and upregulation of the inflammatory response. Because PBMCs from lcSSc-PAH patients are also characterized by activation of ER stress/UPR and inflammation, the goal of this study was to assess whether the presence of HLA-B*35 contributes to those characteristics. METHODS: PBMCs were purified from healthy controls (n___=___49 HC) and lcSSc patients, (n___=___44 with PAH, n___=___53 without PAH). RESULTS: ER stress markers, in particular the chaperones BiP and DNAJB1 were significantly elevated in PBMC samples carrying the HLA-B*35 allele. IL-6 expression was also significantly increased in HLA-B*35 lcSSc PBMCs and positively correlated with ER stress markers. Likewise, HMGB1 was increased in HLA-B*35-positive lcSSc PBMCs. Among genes downregulated by HLA-B*35 lentivirus were genes related to complement (C1QB, C1QC), cell cycle and apoptosis (Bax, Gadd45). Interestingly, complement genes (C1QC and C1QB) showed elevated expression in lcSSc without PAH, but were expressed at the low levels in lcSSc-PAH. Furthermore, HLA-B*35 correlated with decreased expression of cyclin inhibitors (p21, p57) and pro-apoptotic genes (Bax, Gadd45) in lcSSc B35 subjects. FYN, a tyrosine kinase involved in proliferation of immune cells, was among the genes that were positively regulated by HLA-B*35. CONCLUSIONS: Our study demonstrates that HLA-B*35 contributes to the dysregulated expression of selected ER stress, inflammation and proliferation related genes in lcSSc patient PBMCs, as well as healthy individuals, thus supporting a pathogenic role of HLA-B*35 in the development of PAH in SSc patients.] Question: Based on the provided context, do the terms [Gadd45 protein] and [HMGB1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not indicate a direct interaction between Gadd45 protein and HMGB1 protein. While both proteins are mentioned in the context of their expression levels in PBMCs from lcSSc patients, there is no specific information or evidence suggesting that they interact with each other. Instead, they are discussed as separate entities that are affected by the presence of the HLA-B*35 allele.</s>
102624 2A2704682 2A2884721	Tumor protein p53	KARS	[INST]Context: [PMID: 34277785 Integration of clinicopathological and mutational data offers insight into lung cancer with tumor spread through air spaces. Background: Tumor spread through air spaces was defined as a unique tumor invasion pattern in adenocarcinoma by The World Health Organization Classification of Lung Tumors in 2015. Our objectives were to comprehensively demonstrate the clinicopathological and genetic signatures in STAS-positive lung cancer patients. Methods: The clinicopathological and gene alteration characteristics of 878 STAS-positive lung cancer patients were presented. Results: spread through air spaces was identified in 391 female and 481 male patients, of which adenocarcinoma accounted for the majority of cases (92.6%). The concomitant solid or micropapillary subtype was observed in 92.12% patients with adenocarcinoma. Furthermore, in the subgroup of nodules within 3 cm, the distribution of the solid and micropapillary subtypes were significantly frequent in lymph node-positive patients (P<0.001). Tumor protein p53 alterations were more frequent in smoking patients (27.6%, P=0.007), human epidermal growth factor receptor 2 (HER2) alterations were more common in female (10.8%, P=0.025), while Kirsten rat sarcoma viral oncogene (KRAS) (20.3%, P=0.024) and tumor protein p53 (45.9%, P=0.003) were more prevalent in males. Epidermal growth factor receptor, tumor protein p53, KARS, anaplastic lymphoma kinase, and ROS proto-oncogene 1 (ROS1) were the five most frequent alterations in STAS-positive adenocarcinoma.] Question: Based on the provided context, do the terms [Tumor protein p53 protein] and [KARS protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the Tumor protein p53 protein and the KARS protein. Instead, it discusses the frequency of alterations in these proteins in STAS-positive lung cancer patients, highlighting their prevalence in different subgroups based on factors such as smoking status and gender. There is no indication that these proteins interact with each other in the context of the study.</s>
39782 2A2603855 2A2443554	INSM1	BHLHE40	[INST]Context: [PMID: 29751772 Expression profiling of cell-intrinsic regulators in the process of differentiation of human iPSCs into retinal lineages. BACKGROUND: Differentiation of human induced pluripotent stem cells into retinal lineages offers great potential for medical application. METHODS: In this study, we used microarrays to analyze transcriptomes of terminally differentiated retinal ganglion cell and retinal pigment epithelium lineages, as well as intermediate retinal progenitor cells of optic vesicles derived from human induced pluripotent stem cells. In our analysis, we specifically focused on the classes of transcripts that encode intrinsic regulators of gene expression: the transcription factors and epigenetic chromatin state regulators. RESULTS: We found that among the most highly overexpressed TF-encoding genes in the OV/retinal ganglion cell lineage were three members of the Collier/Olfactory-1/Early B-cell family: EBF1, EBF2 and EBF3. Knockdown of EBF1 led to significant impairment of differentiation of human induced pluripotent stem cells into RGCs. EBF1 was shown to act upstream of ISL1 and BRN3A, the well-characterized regulators of retinal ganglion cell lineage specification. TF-encoding genes DLX1, DLX2 and INSM1 were the most highly overexpressed genes in the optic vesicles, indicating their important role in the early stages of retinal differentiation. Along with MITF, the two paralogs, BHLHE41 and BHLHE40, were the most robust TF markers of retinal pigment epithelium cells. The markedly contrasted expression of ACTL6B, encoding the component of chromatin remodeling complex SWI/SNF, discriminated hiPSC-derived OV/retinal ganglion cell and retinal pigment epithelium lineages. CONCLUSIONS: We identified novel, potentially important intrinsic regulators of retinal ganglion cell and retinal pigment epithelium cell lineage specification in the process of differentiation from human induced pluripotent stem cells. We demonstrated the crucial role played by EBF1 in differentiation of RGCs. We identified intrinsic regulator biomarker signatures of these two retinal cell types that can be applied with high confidence to confirm the cell lineage identities.] Question: Based on the provided context, do the terms [INSM1 protein] and [BHLHE40 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the INSM1 protein and the BHLHE40 protein. Instead, it discusses their roles as TF markers for different retinal cell types (INSM1 for optic vesicles and BHLHE40 for retinal pigment epithelium cells) without indicating any interaction between them. Therefore, based on the given information, there is no evidence to suggest that INSM1 and BHLHE40 proteins interact with each other.</s>
399993 2A2863073 2A2924442	SIRT3	USP22	[INST]Context: [PMID: 32763411 High glucose-induced peroxiredoxin-3 acetylation contributes to glucotoxicity in pancreatic beta-cells: Prevention by Teneligliptin. Chronic hyperglycemia has deleterious effects on pancreatic beta-cell function and survival in type 2 diabetes due to the low expression level of endogenous antioxidants in the beta-cells. Peroxiredoxin-3 is a mitochondria specific H202 scavenger and protects the cell from mitochondrial damage. However, nothing is known about how glucotoxicity influences peroxiredoxin-3 function in the pancreatic beta cells. Exposure of rat insulinoma INS-1__^cells and human beta cells (1.1B4) to high glucose conditions (30mM) stimulated acetylation of peroxiredoxin-3 which facilitates its hyper-oxidation causing mitochondrial dysfunction by SIRT1 degradation. SIRT1 deficiency induces beta cell apoptosis via NOX-JNK-p66Shc signalosome activation. Herein we investigated the direct effect of Teneligliptin, a newer DPP-4 inhibitor on beta-cell function and survival in response to high glucose conditions. Teneligliptin treatment enhances SIRT1 protein levels and activity by USP22, an ubiquitin specific peptidase. Activated SIRT1 prevents high glucose-induced peroxiredoxin-3 acetylation by SIRT3 resulted in inhibition of peroxiredoxin-3 hyper-oxidation thereby strengthening the mitochondrial antioxidant defense. Notably, we identify peroxiredoxin-3 as a novel SIRT3 target and show their physical interaction. Intriguingly, inhibition of SIRT1 activity by EX-527 or SIRT1 siRNA knockdown exacerbated the SIRT3 mediated peroxiredoxin-3 deacetylation which leads to peroxiredoxin-3 hyper-oxidation and beta-cell apoptosis by the activation of NOX-JNK-p66Shc signalosome. Collectively, our results unveil a novel and first direct effect of high glucose on peroxiredoxin-3 acetylation on beta-cell dysfunction by impaired antioxidant defense and SIRT1 mediated SIRT3-peroxiredoxin-3 activation by Teneligliptin suppresses high glucose-mediated mitochondrial dysfunction.] Question: Based on the provided context, do the terms [SIRT3 protein] and [USP22 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between SIRT3 protein and USP22 protein. Instead, it describes how Teneligliptin enhances SIRT1 protein levels and activity by USP22, which in turn prevents high glucose-induced peroxiredoxin-3 acetylation by SIRT3. There is no indication that SIRT3 and USP22 interact directly with each other.</s>
219565 2A2629724 2A2771261	lipoprotein lipase	renin	[INST]Context: [PMID: 18325076 Genetic profile of ischemic cerebrovascular disease and carotid stenosis. OBJECTIVES: Carotid artery stenosis (CS) is a major risk factor for ischemic cerebrovascular disease and is therefore of interest in genetic investigating. MATERIALS AND METHODS: Previously published markers in suspected susceptibility genes were genotyped in ischemic cerebrovascular disease patients and controls (928/602). Ischemic cerebrovascular disease cases were subtyped according to Trial of Org 10172 in Acute Stroke Treatment (TOAST) or subdivided into CS and non-CS patients by ultrasonography in a separate analysis. RESULTS: Three polymorphisms located in the lipoprotein lipase, angiotensinogen and guanine nucleotide-binding protein beta-3 genes were significantly associated with ischemic cerebrovascular disease after correction for age and gender. The strongest association was found for the protective lipoprotein lipase Ser447Term polymorphism. Factor VII, apolipoprotein E and two renin polymorphisms were differentially frequent in patients with evidence of CS compared with non-CS patients. CONCLUSIONS: We have found that some previously described susceptibility polymorphisms are weakly associated with ischemic cerebrovascular disease and that subdivision of patients into CS and non-CS groups may help to identify new candidate polymorphisms.] Question: Based on the provided context, do the terms [lipoprotein lipase protein] and [renin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the association of various genetic polymorphisms with ischemic cerebrovascular disease and carotid stenosis. While it mentions lipoprotein lipase and renin polymorphisms, it does not indicate any direct interaction between the lipoprotein lipase protein and the renin protein. Instead, it focuses on the differential frequencies of these polymorphisms in patients with and without carotid stenosis. Therefore, there is no evidence of a direct interaction between the lipoprotein lipase protein and the renin protein based on the given information.</s>
64817 2A2547785 2A2590057	glyceraldehyde-3-phosphate dehydrogenase	Hsp90	[INST]Context: [PMID: 25399588 The recent re-evaluation of the number of protein-coding genes in the human genome (approximately 19000) is one reason for believing that protein moonlighting may be a more general phenomenon than the current number of moonlighting proteins would suggest, and preliminary studies of the proportion of proteins that moonlight would concur with this hypothesis. Protein moonlighting could be one way of explaining the seemingly small number of proteins that are encoded in the human genome. It is emerging that moonlighting proteins can exhibit novel biological functions, thus extending the range of the human functional proteome. For example, glyceraldehyde-3-phosphate dehydrogenase, heat-shock protein 60 and tRNA synthetases play a wide range of biological roles in eukaryotic cells, and a growing number of eukaryotic moonlighting proteins are recognized to play important roles in physiological processes such as sperm capacitation, implantation, immune regulation in pregnancy, blood coagulation, vascular regeneration and control of inflammation. The dark side of protein moonlighting finds a range of moonlighting proteins playing roles in various human diseases including cancer, cardiovascular disease, HIV and cystic fibrosis. However, some moonlighting proteins are being tested for their therapeutic potential, including immunoglobulin heavy-chain-binding protein, for rheumatoid arthritis, and Hsp90 for wound healing. In addition, it has emerged over the last 20 years that a large number of bacterial moonlighting proteins play important roles in bacteria-host interactions as virulence factors and are therefore potential therapeutic targets in bacterial infections.] Question: Based on the provided context, do the terms [glyceraldehyde-3-phosphate dehydrogenase protein] and [Hsp90 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the roles of glyceraldehyde-3-phosphate dehydrogenase and Hsp90 as moonlighting proteins in various biological processes and diseases. However, there is no mention of a direct interaction between glyceraldehyde-3-phosphate dehydrogenase and Hsp90. Instead, they are presented as separate entities with distinct functions and roles in different contexts. Therefore, based on the given information, there is no evidence to suggest that these two proteins interact with each other.</s>
47821 2A2417667 2A2629724	apolipoprotein A-I	lipoprotein lipase	[INST]Context: [PMID: 12519412 Tibolone lowers high density lipoprotein cholesterol by increasing hepatic lipase activity but does not impair cholesterol efflux. OBJECTIVE: Androgens and other drugs that reduce plasma concentrations of high density lipoprotein cholesterol are often considered to be pro-atherogenic. Tibolone lowers HDL-cholesterol by 20% but the clinical significance of this effect is unknown. METHODS: In a randomized, double-blind study, 34 women received 2.5 mg tibolone daily and 34 women received placebo. Serum concentrations of lipids, lipoprotein subclasses and apolipoproteins, together with plasma activities of lipid transfer proteins and lipolytic enzymes and the capacity of plasma to induce cholesterol efflux from cultured cells, were measured. RESULTS: Compared to placebo, tibolone reduced serum concentrations of HDL-cholesterol (-14%), high density lipoprotein phosphatidylcholine (-14%), apolipoprotein A-I (-12%), high density lipoprotein subclasses lipoprotein A-I (-20%), HDL-apoE (-16%), pre beta-LpA-I (-10%) and alpha-LpA-I (-12%) and increased hepatic lipase activity (+25%) and high density lipoprotein sphingomyelin : phosphatidylcholine ratio (10.5%), but did not alter serum concentrations of high density lipoprotein sphingomyelin, apoA-IV and LpA-I/A-II, lipoprotein lipase, the plasma activities of lecithin : cholesterol acyl transferase, cholesteryl ester transfer protein, phospholipid transfer protein or the plasma capacity to release cholesterol from cultured fibroblasts or Fu5AH hepatocytes. CONCLUSIONS: Tibolone lowers HDL-cholesterol in part by increasing hepatic lipase activity. Conservation of sphingomyelin and apoA-II in high density lipoprotein, as well as cholesteryl ester transfer protein activity, preserves the capacity of plasma to release cholesterol, despite the lower concentrations of HDL-cholesterol. This may have important implications for the use of steroid effects on high density lipoprotein concentrations as surrogates for atherosclerosis.] Question: Based on the provided context, do the terms [apolipoprotein A-I protein] and [lipoprotein lipase protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not indicate any direct interaction between apolipoprotein A-I protein and lipoprotein lipase protein. While both proteins are mentioned in the context of their roles in lipid metabolism and HDL-cholesterol levels, there is no evidence or description of a direct interaction between them. Instead, they are discussed as separate entities with distinct functions and effects on lipid profiles.</s>
361588 2A2454391 2A2924815	cathepsin B	ubiquitin carboxyl-terminal hydrolase isozyme L1	[INST]Context: [PMID: 12833515 Proteome analysis of dermal fibroblasts cultured in vitro from human healthy subjects of different ages. Aging is a complex multifactorial process still far from being completely understood. On the other hand, we observed 38 proteins exhibiting more than three-fold reproducible variations with aging, some (45%) being reduced such as F-actin capping protein alpha1, proteasome subunit alpha type 3, heat shock protein 27, ubiquitin carboxyl-terminal hydrolase isozyme L1, mitochondrial thioredoxin-dependent peroxide reductase, cathepsin B, glutathione S-transferase P, cyclophilin A and calgizzarin. In contrast, T-complex protein 1, probable protein disulfide isomerase ER60, phosphoglycerate kinase 1, Ran-specific GTPase-activating protein, proteasome subunit alpha type 5, triosephosphate isomerase and superoxide dismutase (Mn) increased with age. Furthermore, annexin 1, elongation factor 1beta, proteasome activator complex subunit 1, phosphoglycerate mutase, superoxide dismutase (Cu-Zn) and cofilin, exhibited the highest levels in adult cells; Whereas, septin 2 homolog, RNA-binding protein regulatory subunit and ATP synthase D chain revealed the lowest values in adults. The present investigation, underlining the complexity of the aging process, highlights the role of synthetic and degradative pathways in modulating the whole cell machinery and emphasizes that metabolic impairment with age could depend partly on different expression of a number of genes and leading to an imbalance among functional proteins.] Question: Based on the provided context, do the terms [cathepsin B protein] and [ubiquitin carboxyl-terminal hydrolase isozyme L1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between cathepsin B protein and ubiquitin carboxyl-terminal hydrolase isozyme L1 protein. Instead, it lists these proteins as part of a group of proteins that are reduced with aging. There is no indication that these two proteins interact with each other in the context of the aging process or any other biological process.</s>
217776 2A2454115 2A2587344	caspase-8	high-mobility group box 1	[INST]Context: [PMID: 34733114 Increased Death of Peripheral Blood Mononuclear Cells after TLR4 Inhibition in Sepsis Is Not via TNF/TNF Receptor-Mediated Apoptotic Pathway. Background: Apoptosis is one of the causes of immune depression in sepsis. Pyroptosis also occurs in sepsis. The toll-like receptor 4 and receptor for advanced glycation end products (RAGE) have been shown to play important roles in apoptosis and pyroptosis. However, it is still unknown whether TLR4 inhibition decreases apoptosis in sepsis. Methods: Stimulated peripheral blood mononuclear cells with or without lipopolysaccharides and high-mobility group box 1 were cultured with or without TLR4 inhibition using monoclonal antibodies from 20 patients with sepsis. Caspase-3, caspase-8, and caspase-9 activities were measured. The cell death of peripheral blood mononuclear cells was detected using a flow cytofluorimeter. Results: After TLR4 inhibition, b cell lymphoma 2 to bcl2-associated x ratio elevated both in lipopolysaccharides and HMGB1-stimulated peripheral blood mononuclear cells. The activities of caspase-3, caspase-8, and caspase-9 did not change in lipopolysaccharides or HMGB1-stimulated peripheral blood mononuclear cells. The cell death of lipopolysaccharides and HMGB1-stimulated CD8 lymphocytes and monocytes increased after TLR4 inhibition. The cell death of CD4 lymphocytes was unchanged. Conclusion: The apoptosis did not decrease, while TLR4 was inhibited. After TLR4 inhibition, there was an unknown mechanism to keep cell death in stimulated peripheral blood mononuclear cells in patients with sepsis.] Question: Based on the provided context, do the terms [caspase-8 protein] and [high-mobility group box 1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not indicate a direct interaction between caspase-8 protein and high-mobility group box 1 (HMGB1) protein. The study focuses on the effects of TLR4 inhibition on apoptosis and cell death in peripheral blood mononuclear cells from patients with sepsis. While it mentions the involvement of caspase-8 in the apoptotic pathway and the stimulation of cells with HMGB1, there is no specific evidence or description of a direct interaction between caspase-8 and HMGB1. Instead, they are presented as separate factors influencing the cellular processes in the context of sepsis.</s>
143211 2A2535594 2A2685847	FBXW7	NOTCH1	[INST]Context: [PMID: 32164600 Genetic mutational analysis of pediatric acute lymphoblastic leukemia from a single center in China using exon sequencing. BACKGROUND: Acute lymphoblastic leukemia, the most common childhood malignancy, is characterized by recurring structural chromosomal alterations and genetic alterations, whose detection is critical in diagnosis, risk stratification and prognostication. However, the genetic mechanisms that give rise to acute lymphoblastic leukemia remain poorly understood. METHODS: Using next-generation sequencing in matched germline and tumor samples from 140 pediatric Chinese patients with acute lymphoblastic leukemia, we landscaped the gene mutations and estimated the mutation frequencies in this disease. RESULTS: Our results showed that the top driver oncogenes having a mutation prevalence over 5% in childhood acute lymphoblastic leukemia included KRAS (8.76%), NRAS (6.4%), FLT3 (5.7%) and KMT2D (5.0%). While the most frequently mutated genes were KRAS, NRAS and FLT3 in B cell acute lymphoblastic leukemia, the most common mutations were enriched in NOTCH1 (23.1%), FBXW7 (23.1%) and PHF6 (11.5%) in T cell acute lymphoblastic leukemia . These mutant genes are involved in key molecular processes, including the Ras pathway, the Notch pathway, epigenetic modification, and cell-cycle regulation. Strikingly, more than 50% of mutations occurred in the high-hyperdiploid acute lymphoblastic leukemia existed in Ras pathway, especially FLT3 (20%). We also found that the epigenetic regulator gene KMT2D, which is frequently mutated in acute lymphoblastic leukemia, may be involved in driving leukemia transformation, as evidenced by an in vitro functional assay. CONCLUSION: Overall, this study provides further insights into the genetic basis of acute lymphoblastic leukemia and shows that Ras mutations are predominant in childhood acute lymphoblastic leukemia, especially in the high-hyperdiploid subtype in our research.] Question: Based on the provided context, do the terms [FBXW7 protein] and [NOTCH1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the FBXW7 protein and the NOTCH1 protein. While both proteins are involved in key molecular processes in T cell acute lymphoblastic leukemia, there is no specific evidence or description of an interaction between them. The context focuses on the mutation frequencies and roles of these proteins in the disease but does not indicate a direct interaction between FBXW7 and NOTCH1.</s>
169654 2A2764298 2A2596622	N-RAS	IDH1	[INST]Context: [PMID: 26285909 Mutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic Trioxide. BACKGROUND: Acute promyelocytic leukemia is a model for synergistic target cancer therapy using all-trans retinoic acid and arsenic trioxide, which yields a very high 5-year overall survival rate of 85 to 90%. Nevertheless, about 15% of acute promyelocytic leukemia patients still get early death or relapse. We performed this study to address the possible impact of additional gene mutations on the outcome of acute promyelocytic leukemia. METHODS: We included a consecutive series of 266 cases as training group, and then validated the results in a testing group of 269 patients to investigate the potential prognostic gene mutations, including FLT3-ITD or -TKD, N-RAS, C-KIT, NPM1, CEPBA, WT1, ASXL1, DNMT3A, MLL (fusions and PTD), IDH1, IDH2 and TET2. RESULTS: More high-risk patients (50.4%) carried additional mutations, as compared with intermediate- and low-risk ones. CONCLUSION: In an era of ATRA/arsenic trioxide treatment, both molecular markers and clinical parameter based stratification systems should be used as prognostic factors for acute promyelocytic leukemia.] Question: Based on the provided context, do the terms [N-RAS protein] and [IDH1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the N-RAS protein and the IDH1 protein. It lists various gene mutations, including those related to N-RAS and IDH1, as potential prognostic factors in acute promyelocytic leukemia. However, there is no indication that these two proteins interact with each other in the context of the study. Instead, they are presented as separate entities that may influence the outcome of the disease.</s>
635163 2A2590068 2A2592309	HSP 90	HSP 27	[INST]Context: [PMID: 16825994 Expression and prognostic examination of heat shock proteins (HSP 27, HSP 70, and HSP 90) in medulloblastoma. HSP expression levels were determined in medulloblastomas and tested whether heat shock proteins expression was associated with prognostic parameters. Expression of antiapoptotic HSP 27, HSP 70, and HSP 90 was investigated by immunohistochemistry, on paraffin-embedded sections from 65 patients. Sample evaluation was based on the estimated percentage of HSP positive tumor cells. On the basis of the average expression rate of heat shock proteins, at HSP 27 and HSP 90 with a 10% cut off, and at HSP 70 with a 70% cut off 2 groups were created. The amount of expression of any of the HSP types was not significantly associated with known prognostic factors (age of patient, extent of resection, presence of metastasis) and histologic subtype. After an average follow-up period of 4.30 years, no significant difference was observed in survival depending on the expression of HSP 27 or HSP 70 or HSP 90.] Question: Based on the provided context, do the terms [HSP 90 protein] and [HSP 27 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the expression levels of HSP 27, HSP 70, and HSP 90 in medulloblastomas and their association with prognostic parameters. However, it does not mention any direct interaction between HSP 90 protein and HSP 27 protein. Instead, it focuses on the individual expression levels of each heat shock protein and their potential association with survival outcomes. Therefore, there is no evidence of an interaction between HSP 90 protein and HSP 27 protein in the given context.</s>
687148 2A2894359 2A2905345	Tax1BP1	TNFSF10	[INST]Context: [PMID: 16876223 Hepatitis C virus core protein induces expression of genes regulating immune evasion and anti-apoptosis in hepatocytes. Hepatitis C virus Core protein is implicated in the development of hepatocellular carcinoma . We utilized a HepG2 human hepatocyte cell line with inducible expression of hepatitis c virus Core protein to investigate the early effects of Core protein on hepatocyte gene expression and to identify molecular processes modulated by the Core protein. A significant change was observed in the expression of 407 genes, which included genes regulating apoptosis, immune response, and cell cycle. The decreased expression of chemo-attractants such as TNFSF10, CCL20, and osteopontin was observed, which suggested that hepatitis c virus Core expression could lead to suppression of inflammatory response as well as trafficking of macrophages and neutrophils to the site of hepatitis c virus infection. An increased expression of anti-apoptosis factors including PAK2, API5, BH1, Tax1BP1, DAXX, and TNFAIP3/A20 was observed. Some of these genes were also linked to the regulation of NFKB activation and that the alteration of their expression levels, by hepatitis c virus Core, might lead to the suppression NFKB activation of inflammatory responses. Our data suggested that Core expression may contribute to the viral persistence by protecting infected hepatocytes from cell death by the suppressing apoptosis and inflammatory reaction to hepatitis c virus viral infection.] Question: Based on the provided context, do the terms [Tax1BP1 protein] and [TNFSF10 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between Tax1BP1 protein and TNFSF10 protein. Instead, it discusses the effects of hepatitis C virus Core protein on the expression of various genes, including Tax1BP1 and TNFSF10. The context indicates that the expression of TNFSF10 is decreased, which suggests a suppression of inflammatory response, while Tax1BP1 expression is increased, which is linked to anti-apoptosis factors. However, there is no direct interaction mentioned between these two proteins.</s>
671026 2A2936598 2A2624476	vinculin	leptin receptor	[INST]Context: [PMID: 22773832 Induction of specific microRNAs inhibits cutaneous wound healing. Chronic nonhealing wounds, such as venous ulcers, are a widespread and serious medical problem with high morbidity and mortality. Among these candidates, miR-16, -20a, -21, -106a -130a, and -203 were confirmed to be aberrantly overexpressed in a cohort study of 10 VU patients by quantitative PCR and in situ hybridizations. These microRNAs were predicted to target multiple genes important for wound healing, including early growth response factor 3, vinculin, and leptin receptor . Overexpression of the top up-regulated miRNAs, miR-21 and miR-130a, in primary human keratinocytes down-regulated expression of the endogenous leptin receptor and early growth response factor 3. The luciferase reporter assay verified leptin receptor as a direct target for miR-21 and miR-130a. Both miR-21 and miR-130a delayed epithelialization in an acute human skin wound model. Furthermore, in vivo overexpression of miR-21 inhibited epithelialization and granulation tissue formation in a rat wound model. Our results identify a novel mechanism in which overexpression of specific set of microRNAs inhibits wound healing, resulting in new potential molecular markers and targets for therapeutic intervention. From MeSH: Chickens. Dogs. Mice. Rats.] Question: Based on the provided context, do the terms [vinculin protein] and [leptin receptor protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not indicate a direct interaction between the vinculin protein and the leptin receptor protein. While both proteins are mentioned as potential targets of specific microRNAs, there is no evidence or description of a direct interaction between them. Instead, the context focuses on the role of microRNAs in regulating the expression of these proteins and their impact on wound healing.</s>
184044 2A2572260 2A2572245	GLUT3	GLUT1	[INST]Context: [PMID: 27825869 Transendothelial glucose transport is not restricted by extracellular hyperglycaemia. Endothelial cells are routinely exposed to elevated glucose concentrations post-prandially in healthy individuals and permanently in patients with metabolic syndrome and diabetes, and so we assessed their sugar transport capabilities in response to high glucose. In human umbilical vein, saphenous vein, microdermal vessels and aorta, GLUT1 (SLC2A1), GLUT3 (SLC2A3), GLUT6 (SLC2A6), and in microdermal vessels also GLUT12 (SLC2A12), were the main glucose transporters as assessed by mRNA, with no fructose transporters nor SGLT1 . GLUT1 and GLUT3 proteins were detected in all cell types and were responsible for ~60% glucose uptake in human umbilical vein, where both GLUT1 and GLUT3, but not GLUT6 siRNA knock-down, reduced the transport. Under shear conditions, GLUT1 protein decreased, GLUT3 increased, and 14C-deoxy-glucose uptake was attenuated. In high glucose, lipid storage was increased, cell numbers were lower, 14C-deoxy-glucose uptake decreased owing to attenuated GLUT3 protein and less surface GLUT1, and trans-endothelial transport of glucose increased due to cell layer permeability changes. We conclude that glucose transport by endothelial cells is relatively resistant to effects of elevated glucose. Cells would continue to supply it to the underlying tissues at a rate proportional to the blood glucose concentration, independent of insulin or fructose.] Question: Based on the provided context, do the terms [GLUT3 protein] and [GLUT1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the roles of GLUT1 and GLUT3 proteins in glucose transport by endothelial cells but does not indicate any direct interaction between the two proteins. Instead, it describes their individual contributions to glucose uptake and how their expression levels change under different conditions. GLUT1 and GLUT3 are mentioned as separate entities responsible for different aspects of glucose transport, but there is no evidence of a direct interaction between them.</s>
65189 2A2547785 2A2401969	GAPDH	ACACA	[INST]Context: [PMID: 31920968 Quantitative Analysis of Proteome in Non-functional Pituitary Adenomas: Clinical Relevance and Potential Benefits for the Patients. Background: Non-functional pituitary adenoma is a common tumor that occurs in the pituitary gland, and generally without any symptoms at its early stage and without clinical elevation of hormones, which is commonly diagnosed when it grows up to compress its surrounding tissues and organs. Currently, the pathogenesis of non-functional pituitary adenoma has not been clarified yet. It is necessary to investigate molecular alterations in non-functional pituitary adenoma, and identify reliable biomarkers and drug therapeutic targets for effective treatments. Differentially expressed genes between non-functional pituitary adenoma and control tissues were obtained from GEO datasets. Two hub molecules (SRC and AKT1) were verified with Western blotting. Results: Totally 6076 proteins in non-functional pituitary adenoma tissues were identified, and 3598 differentially expressed genes between non-functional pituitary adenoma and control tissues were identified from GEO database. KEGG pathway analysis of 6076 proteins obtained 114 statistically significant pathways, including endocytosis, and spliceosome signaling pathways. KEGG pathway analysis of 1088 overlapped molecules obtained 52 statistically significant pathways, including focal adhesion, cGMP-PKG pathway, and platelet activation signaling pathways. According to the association degree in Cytoscape, ten hub molecules (DEGs; proteins) were identified, including GAPDH, ALB, ACACA, SRC, ENO2, CALM1, POTEE, HSPA8, DECR1, and AKT1. Western-blotting analysis confirmed the upregulated expressions of SRC and PTMScan experiment confirmed the increased levels of pAKT1, in NFPAs compared to controls. Conclusions: This study established the large-scale quantitative protein profiling of non-functional pituitary adenoma tissue proteome. It also provided the basic data to discover reliable biomarkers and therapeutic targets for non-functional pituitary adenoma patients.] Question: Based on the provided context, do the terms [GAPDH protein] and [ACACA protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between GAPDH protein and ACACA protein. While both proteins are identified as hub molecules in the study, there is no specific information or evidence provided that indicates they interact with each other. The context focuses on their roles as part of a larger set of differentially expressed genes and proteins in non-functional pituitary adenoma, but it does not detail any direct interaction between GAPDH and ACACA.</s>
618606 2A2613339 2A2571820	ERG	GSTP1	[INST]Context: [PMID: 34191807 GSTP1 positive prostatic adenocarcinomas are more common in Black than White men in the United States. GSTP1 is a member of the Glutathione-S-transferase family silenced by CpG island DNA hypermethylation in 90-95% of prostate cancers. However, prostate cancers expressing GSTP1 have not been well characterized. We used immunohistochemistry against GSTP1 to examine 1673 primary prostatic adenocarcinomas on tissue microarrays with redundant sampling from the index tumor from prostatectomies. GSTP1 protein was positive in at least one TMA core in 7.7% of cases and in all TMA cores in 4.4% of cases. The percentage of adenocarcinomas from Black patients who had any GSTP1 positive TMA cores was 14.9%, which was 2.5 times higher than the percentage from White patients (5.9%; P < 0.001). Further, the percentages of tumors from Black patients who had all TMA spots positive for GSTP1 (9.5%) was 3-fold higher than the percentage from White patients (3.2%; P<0.001). In terms of association with other molecular alterations, GSTP1 positivity was enriched in ERG positive cancers among Black men. By in situ hybridization, GSTP1 mRNA expression was concordant with protein staining, supporting the lack of silencing of at least some GSTP1 alleles in GSTP1-positive tumor cells. This observation should prompt additional studies to determine whether GSTP1 positive cases represent a distinct molecular subtype of prostate cancer and whether GSTP1 expression could provide a biological underpinning for the observed disparate outcomes for Black men.] Question: Based on the provided context, do the terms [ERG protein] and [GSTP1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the association of GSTP1 protein positivity with ERG protein positivity in prostate cancers among Black men. However, it does not indicate a direct interaction between the ERG protein and the GSTP1 protein. Instead, it describes an enrichment of GSTP1 positivity in ERG-positive cancers, suggesting a correlation rather than a direct interaction. Therefore, based on the given information, there is no evidence of a direct interaction between the ERG protein and the GSTP1 protein.</s>
576506 2A2416086 2A2903080	annexin V	Epo	[INST]Context: [PMID: 16574939 Erythropoiesis abnormalities contribute to early-onset anemia in patients with septic shock. RATIONALE: The intimate mechanisms of early onset anemia observed in critically ill patients with septic shock remain unclear. OBJECTIVES: We investigated erythropoiesis abnormalities in this setting by studying morphologic, functional, and biochemical patterns of erythroid lineage. METHODS: Erythroid lineage in the bone marrow from patients with septic shock who developed early-onset anemia was compared with that of healthy control subjects. Biochemical and flow cytometry patterns of apoptosis were dissected by exploring antiapoptotic (erythropoietin [Epo] receptor-dependent) and proapoptotic (death receptor-dependent) pathways. Apoptosis of glycophorin-A-positive erythroid precursors was increased in patients versus control subjects as assessed by labeling with annexin V (26.1 +/- 8.8 vs. 3.1 +/- 2.9%, p < 0.05) or 3-3'-dihexyloxacarbocyanine iodide (55.9 +/- 10.5 vs. 19.1 +/- 5.4%, p < 0.05), respectively. This was associated with significant overexpression of Fas on erythroid precursors and higher tumor necrosis factor-alpha plasma levels in patients with septic shock vs. control subjects. Moreover, growth capacities of late erythroid progenitors of burst-forming unit erythroids at Day 10 were impaired in the presence of serum from patients with septic shock as compared with the effect of serum from control subjects (27 +/- 12 vs. 109 +/- 27 per 10(5) seeded cells, respectively; Saturating concentrations of recombinant human Epo restored growth capacity of patients' burst-forming unit erythroids (72 +/- 14 per 10(5) seeded cells) in autologous conditions of serum. CONCLUSIONS: Early-onset anemia that may be observed in patients with septic shock is associated with defective erythropoiesis related to an excess of apoptosis that can be counterbalanced in vitro by recombinant human epo.] Question: Based on the provided context, do the terms [annexin V protein] and [Epo protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the role of annexin V and erythropoietin (Epo) in the context of erythropoiesis abnormalities in patients with septic shock. Annexin V is used as a marker to assess apoptosis in erythroid precursors, while erythropoietin (Epo) is mentioned in relation to its receptor-dependent antiapoptotic effects and its ability to restore growth capacity of erythroid progenitors. However, there is no direct interaction mentioned between annexin V protein and Epo protein. Instead, they are presented as separate entities involved in different aspects of the erythropoiesis process.</s>
522263 2A2771261 2A2558984	renin	HCG	[INST]Context: [PMID: 11679499 The role of enalapril in the prevention of ovarian hyperstimulation syndrome: a rabbit model. BACKGROUND: The purpose of our study was to investigate the role of enalapril in the prevention of ovarian hyperstimulation syndrome. METHODS: Twenty New Zealand female rabbits were included in the study. A total of 75 IU FSH + 75 IU LH was given daily by i.m. route for the first 7 days and additionally 2500 IU HCG was given on the last day of ovarian stimulation. Between days 0 and 9, oral enalapril tablets (2 mg/kg) were given twice daily to 10 rabbits (group 1). The remaining 10 rabbits did not receive enalapril (group 2). Laparatomy was performed on all rabbits at day 9. Serum renin, interleukin-6, oestradiol, progesterone, prolactin and aldosterone concentrations were assayed at day 0 and again at day 9 for all rabbits. RESULTS: Serum renin and interleukin-6 concentrations at day 9 increased significantly compared with basal values in both groups (P < 0.05). Renin was correlated with interleukin-6 at day 9 in both groups (P < 0.05). Administration of enalapril did not prevent the formation of ascites in group 1 despite the low serum aldosterone concentrations. CONCLUSIONS: Renin-angiotensin system and interleukin-6 may play a role in the aetiopathogenesis of ovarian hyperstimulation syndrome. Administration of enalapril did not seem to have any beneficial effect in reducing the severity of ovarian hyperstimulation syndrome. From MeSH: Rabbits.] Question: Based on the provided context, do the terms [renin protein] and [HCG protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between renin protein and HCG protein. The study focuses on the role of enalapril in the prevention of ovarian hyperstimulation syndrome and discusses the levels of various hormones and proteins, including renin and HCG, but does not indicate any direct interaction between renin and HCG. Instead, it describes the effects of enalapril on renin and interleukin-6 levels, as well as the role of the renin-angiotensin system and interleukin-6 in the aetiopathogenesis of ovarian hyperstimulation syndrome.</s>
91699 2A2722226 2A2514431	PIN1	PIN	[INST]Context: [PMID: 19309458 Functional expression and characterization of Arabidopsis ABCB, AUX 1 and PIN auxin transporters in Schizosaccharomyces pombe. Heterologous expression systems based on tobacco BY-2 cells, Arabidopsis cell cultures, Xenopus oocytes, Saccharomyces cerevisiae, and human HeLa cells have been used to express and characterize PIN, ABCB (PGP), and AUX/LAX auxin transporters from Arabidopsis. We have developed an accessible Schizosaccharomyces pombe system for comparative studies of plant transport proteins. The system includes knockout mutants in all ABC and putative auxin transport genes and Gateway((R))-compatible expression vectors for functional analysis and subcellular localization of recombinant proteins. We expressed Arabidopsis ABCB1 and ABCB19 in mam1pdr1 host lines under the inducible nmt41 promoter. ABCB19 showed a higher (3)H-IAA export activity than ABCB1. Arabidopsis PIN proteins were expressed in a mutant lacking the auxin effluxer like 1 gene. PIN1 showed higher activity than PIN2 with similar protein expression levels. Expression of AUX1 in a permease-deficient vat3 mutant resulted in increased net auxin uptake activity. Finally, ABCB4 expressed in mam1pdr1 displayed a concentration-dependent reversal of (3)H-IAA transport that is consistent with its observed activity in planta. Structural modelling suggests that ABCB4 has three substrate interaction sites rather than the two found in ABCB19, thus providing a rationale for the observed substrate activation.] Question: Based on the provided context, do the terms [PIN1 protein] and [PIN protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the expression and characterization of various auxin transporters, including PIN1 and PIN proteins, in the Schizosaccharomyces pombe system. However, there is no mention of a direct interaction between PIN1 protein and PIN protein. Instead, the context describes the individual activities and properties of these proteins in the context of auxin transport. Therefore, based on the given information, there is no evidence to suggest that PIN1 protein and PIN protein interact with each other.</s>
295912 2A2503928 2A2403354	DKC1	ACD	[INST]Context: [PMID: 26668621 Downregulation of telomerase maintenance-related ACD expression in patients undergoing immunosuppresive therapy following kidney transplantation. Chronic administration of immunosuppressants has been associated with long-term consequences, including a higher risk of neoplasm development. The processes regulating telomere function exert a major influence on human cancer biology. The present study aimed to assess the effect of immunosuppressive therapy on the expression of genes associated with telomere maintenance and protection in patients following renal transplantation. A total of 51 patients that had undergone kidney transplantation and 54 healthy controls were enrolled in the study. The 51 transplant patients received a three-drug immunosuppressive regimen consisting of cyclosporine A, prednisone and mycophenolate mofetil. In stage 1 of the study, the expression profiles of 123 transcripts, which represented 70 genes, were assessed in peripheral mononuclear blood cells using an oligonucleotide microarray technique in 8 transplant recipients and 4 healthy control subjects. However, only the ACD (adrenocortical dysplasia homolog) gene, encoding the telomere-binding protein POT1-interacting protein 1, was sufficiently specific for telomere homeostasis. The expression of ACD was downregulated in transplant recipients (fold change, 2.11; P=0.006). In stage 2 of the study, reverse transcription-quantitative polymerase chain reaction analysis of ACD, DKC1 and hTERT mRNA was conducted for all transplant patients and control subjects. The results confirmed the downregulation of the ACD gene in patients that had received immunosuppressive therapy (P=0.002). The results of the present study indicate that the downregulation of ACD gene transcription, and thus telomere-binding protein pot1-interacting protein 1 protein expression, may enhance the capacity for cell immortalization, despite normal levels of other key telomere maintenance factors, in patients undergoing immunosuppressive therapy. Furthermore, the results indicate that telomere-binding protein pot1-interacting protein 1 has potential for use as an early clinical marker and/or therapeutic target for cancer in patients following organ transplantation.] Question: Based on the provided context, do the terms [DKC1 protein] and [ACD protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between DKC1 protein and ACD protein. The study focuses on the downregulation of ACD gene expression in patients undergoing immunosuppressive therapy and its potential implications for telomere maintenance and cancer risk. While DKC1 is mentioned in the study, there is no indication that it interacts with ACD protein. Instead, the study primarily discusses the role of ACD in telomere homeostasis and its downregulation in transplant recipients.</s>
216701 2A2454115 2A2577828	Caspase 8	Huntingtin	[INST]Context: [PMID: 21724973 Whole-genome gene expression modifications associated with nitrosamine exposure and micronucleus frequency in human blood cells. N-nitroso compounds are suspected human carcinogens and relevant in human exposure. Since lymphocytic micronuclei represent a validated biomarker of human cancer risk, establishing a link between NOC exposure and micronuclei frequency in humans and concurrently investigating associated transcriptomic responses may provide crucial information on underlying molecular mechanisms that predispose to carcinogenicity. We used lymphocytes, from adult females participating in the pan-European biomarker research project NewGeneris, as a surrogate tissue for analysing such potentially carcinogenic gene expression and micronuclei formation events in target organs. To assess NOC exposure, urine samples were analysed for marker nitrosamines. We demonstrated a significant association between micronuclei frequency and urinary n-nitroso compounds (r = 0.41, P = 0.025) and identified modifications in among others cytoskeleton remodeling, cell cycle, apoptosis and survival, signal transduction, immune response, G-protein signaling and development pathways, which indicate a response to NOC-induced genotoxicity. Moreover, we established a network of genes, the most important ones of which include FBXW7, BUB3, Caspase 2, Caspase 8, SMAD3, Huntingtin and MGMT, which are involved in processes relevant in carcinogenesis.] Question: Based on the provided context, do the terms [Caspase 8 protein] and [Huntingtin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the association between micronuclei frequency and urinary nitrosamines, as well as gene expression modifications associated with nitrosamine exposure. It mentions several genes and proteins involved in various pathways, including Caspase 8 and Huntingtin. However, there is no direct interaction mentioned between Caspase 8 protein and Huntingtin protein. Instead, they are presented as separate entities involved in different processes relevant to carcinogenesis. Therefore, based on the given information, there is no evidence to suggest that Caspase 8 protein and Huntingtin protein interact with each other.</s>
67392 2A2516824 2A2516744	EF-1delta	elongation factor 1beta	[INST]Context: [PMID: 10409717 Mutations in elongation factor 1beta, a guanine nucleotide exchange factor, enhance translational fidelity. Translation elongation factor 1beta is a member of the family of guanine nucleotide exchange factors, proteins whose activities are important for the regulation of G proteins critical to many cellular processes. Elongation factor 1beta is a highly conserved protein that catalyzes the exchange of bound GDP for GTP on EF-1alpha, a required step to ensure continued protein synthesis. In this work, we demonstrate that the highly conserved C-terminal region of Saccharomyces cerevisiae elongation factor 1beta is sufficient for normal cell growth. This region of yeast and metazoan elongation factor 1beta and the metazoan EF-1beta-like protein EF-1delta is highly conserved. Human elongation factor 1beta, but not human EF-1delta, is functional in place of yeast elongation factor 1beta, even though both elongation factor 1beta and EF-1delta have previously been shown to have guanine nucleotide exchange activity in vitro. Based on the sequence and functional homology, mutagenesis of two C-terminal residues identical in all elongation factor 1beta protein sequences was performed, resulting in mutants with growth defects and sensitivity to translation inhibitors. These mutants also enhance translational fidelity at nonsense codons, which correlates with a reduction in total protein synthesis. These results indicate the critical function of elongation factor 1beta in regulating EF-1alpha activity, cell growth, translation rates, and translational fidelity. Saccharomyces cerevisiae.] Question: Based on the provided context, do the terms [EF-1delta protein] and [elongation factor 1beta protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the roles and functions of elongation factor 1beta and EF-1delta proteins, but it does not mention any direct interaction between these two proteins. Instead, it describes their individual roles in protein synthesis, translational fidelity, and cell growth. The context highlights the functional homology and sequence conservation between elongation factor 1beta and EF-1delta, but it does not indicate that they interact with each other.</s>
216853 2A2454115 2A2520685	CASP8	EGFR	[INST]Context: [PMID: 33452985 Features of the Copy Number Variation of Certain Genes in Tumor Cells in Patients with Serous Ovarian Adenocarcinoma. We analyzed the peculiarities of the copy number variation of genes that regulate apoptosis, DNA repair, cell proliferation, metabolism, and estrogen reception in tumor and normal cells of high-grade and low-grade serous adenocarcinoma of the ovaries. Using real-time qPCR method, the relative copy number of 34 genes (BAX, BCL2, TP53, MDM2, CASP9, CASP3, CASP7, CASP8, PRKCI, SOX2, OCT4, PIK3, PTEN, C-MYC, SOX18, AKT1, NOTCH1, BRCA1, BRCA2, EXO1, SCNN1A, KRAS, EGFR, BRAF, CYP1A1, CYP1A2, CYP1B1, CYP19A, ESR1, ESR2, GPER, STS, SULT1A, and SULT1E1) was determined in normal and tumor cells of the ovaries extracted by contactless capture laser microsection from FFPE-blocks of 200 patients. The most typical molecular markers of ovarian serous adenocarcinoma cells were identified: copy number of PIK3CA, BCL2, BAX, CASP3, and CASP8 genes. Based on the differences in the gene copy number variation, two molecular subtypes of serous adenocarcinoma were identified, corresponding to two histological subtypes: high-grade (MDM2, SOX2, ESR1, CYP1B1, SULT1E1, TP53, BRCA2) and low-grade (PIK3CA, PTEN, BCL2, BAX, and CASP3). Each of these subtypes was also characterized by molecular heterogeneity and can be subdivided into several subgroups: 3 subgroups for high-grade and 4 subgroups for low-grade serous adenocarcinoma. These findings extend our understanding of the molecular mechanisms of carcinogenesis in the ovarian tissue, confirm molecular difference between the two histological subtypes of serous adenocarcinoma probably underlying their different clinical course.] Question: Based on the provided context, do the terms [CASP8 protein] and [EGFR protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the CASP8 protein and the EGFR protein. The context discusses the copy number variation of various genes in tumor cells of ovarian serous adenocarcinoma, but it does not describe any specific interaction between CASP8 and EGFR. Instead, it focuses on the roles of these genes in regulating apoptosis, DNA repair, cell proliferation, metabolism, and estrogen reception. Therefore, based on the given information, there is no evidence to suggest that CASP8 and EGFR interact with each other.</s>
349033 2A2617955 2A2856131	ST12	ST1	[INST]Context: [PMID: 33660483 [Progress of researches on Blastocystis infections in humans and animals in China]. Blastocystis infections have been detected in healthy populations, children, students, outpatients and inpatients, as well as diarrhea patients in China. High prevalence of Blastocystis infections has been reported in immunocompromised patients, and relatively high prevalence was seen in individuals living in Guangxi and Yunnan regions. Based on the small subunit ribosomal RNA (SSU rRNA) gene sequence, a total of 17 ST1 to ST17 of Blastocystis have been characterized until now, among which ST1 to ST9 and ST12 infect humans and animals, and ST10 to ST17 only infect animals. In China, ST1 to ST3 are predominant human Blastocystis ST1 to ST17, and ST1/ST3, ST1/ST2 and ST2/ST3 mixed infections have been also identified.] Question: Based on the provided context, do the terms [ST12 protein] and [ST1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the different subtypes (ST1 to ST17) of Blastocystis and their prevalence in humans and animals. It mentions that ST1 to ST9 and ST12 infect humans and animals, while ST10 to ST17 only infect animals. However, there is no mention of any direct interaction between ST12 protein and ST1 protein. The context focuses on the prevalence and distribution of different subtypes rather than their interactions.</s>
390088 2A2532268 2A2601220	heart-type fatty acid binding protein	interleukin-6	[INST]Context: [PMID: 24046510 Biomarkers in acute cardiac care are gaining increasing interest given their clinical benefits. These include ST2 and chromogranin A in acute dyspnea and acute heart failure, matrix metalloproteinase in acute chest pain, heart-type fatty acid binding protein in acute coronary syndrome, CD40 ligand and interleukin-6 in acute myocardial infarction, blood ammonia and lactate in cardiac arrest, as well as tumor necrosis factor-alpha in atrial fibrillation. Endothelial dysfunction, oxidative stress and inflammation are involved in the physiopathology of most cardiac diseases, whether acute or chronic.] Question: Based on the provided context, do the terms [heart-type fatty acid binding protein protein] and [interleukin-6 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context lists various biomarkers and their roles in different cardiac conditions, including heart-type fatty acid binding protein in acute coronary syndrome and interleukin-6 in acute myocardial infarction. However, there is no mention of a direct interaction between heart-type fatty acid binding protein and interleukin-6. Instead, they are presented as separate biomarkers associated with different cardiac conditions. Therefore, based on the given information, there is no evidence to suggest that these two proteins interact with each other.</s>
104131 2A2576391 2A2855015	beta globin	HbA	[INST]Context: [PMID: 9521753 Preparation and kinetic characterization of a series of betaW37 variants of human hemoglobin A: evidence for high-affinity T quaternary structures. Four variants of human beta globin in which the Trp at position 37 has been replaced with a Tyr, Ala, Gly, or Glu have been expressed in Escherichia coli. These globins have been combined with normal human alpha chains and heme to form tetrameric hemoglobin molecules. The kinetics of CO binding to the deoxygenated derivatives following rapid mixing and of CO rebinding following flash photolysis have been examined as functions of pH in the presence and absence of the organic phosphate inositol hexaphosphate, IHP. The kinetic measurements indicate that replacement of the tryptophan with other residues destabilizes the hemoglobin tetramer, resulting in considerable dissociation of even the deoxygenated hemoglobins into alphabeta dimers at micromolar protein concentrations. Substitutions at beta37 also alter the properties of the deoxygenated hemoglobin tetramer. The alteration of the functional properties of the T states of these variants as well as the tendency of the deoxygenated derivatives to dissociate into alphabeta dimers increases in the order HbA < betaW37Y < betaW37A < betaW37G < betaW37E. Measurements of the geminate rebinding of CO establish a kinetic difference between the normal R state tetramer and the alphabeta dimer consistent with quaternary enhancement, the greater affinity of oxygen for the R state tetramer than for the alphabeta dimer. Kinetics of geminate rebinding also suggest that quaternary enhancement may be altered by substitutions at the beta37 position. From MeSH: Escherichia coli.] Question: Based on the provided context, do the terms [beta globin protein] and [HbA protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The context provided discusses the preparation and kinetic characterization of various beta globin variants and their interactions with alpha chains to form hemoglobin molecules. While it mentions the interaction between beta globin and alpha chains to form hemoglobin, it does not indicate any direct interaction between beta globin protein and HbA protein. Instead, HbA is used as a reference point to compare the properties of the variants. Therefore, there is no direct interaction mentioned between beta globin protein and HbA protein.</s>
423695 2A2652854 2A2892349	microtubule-associated protein 1 light chain 3 alpha	TDP-43	[INST]Context: [PMID: 29790198 The role of lysosomes and autophagosomes in frontotemporal lobar degeneration. INTRODUCTION: Cell biological and genetic evidence implicate failures in degrading aggregating proteins, such as tau and TDP-43, through the autophagy or lysosomal pathways in the pathogenesis of frontotemporal lobar degeneration . METHODS: We investigated changes in the degradative pathways in 60 patients with different pathological or genetic forms of frontotemporal lobar degeneration employing immunohistochemistry for marker proteins such as lysosomal-associated membrane proteins 1 and 2 (LAMP-2), cathepsin D and microtubule-associated protein 1 light chain 3 alpha . RESULTS: Lower levels of neuronal lysosomal-associated membrane proteins 1 immunostaining were present in the dentate gyrus and temporal cortex in FTLD-tau compared to FTLD-TDP. There was less lysosomal-associated membrane proteins 1 immunostaining in FTLD-tau with MAPT mutations, and FTLD-tau with Pick bodies, compared to FTLD-TDP types A and B, and less lysosomal-associated membrane proteins 1 immunostaining in FTLD-TDP type C than in FTLD-TDP types A and B. There were no differences in neuronal LAMP-2, cathepsin d, EEA-1 or light chain 3 alpha immunostaining between any of the five frontotemporal lobar degeneration histological or four genetic groups, nor between FTLD-TDP and FTLD-tau. CONCLUSIONS: The underlying pathological mechanism in FTLD-tau may lie with a relative deficiency of lysosomes, or defective vesicular transport, whereas the failure to clear TDP-43 aggregates may lie with lysosomal dysfunction rather than a lack of available lysosomes or degradative enzymes.] Question: Based on the provided context, do the terms [microtubule-associated protein 1 light chain 3 alpha protein] and [TDP-43 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the roles of lysosomes and autophagosomes in frontotemporal lobar degeneration and mentions various proteins involved in these pathways, including microtubule-associated protein 1 light chain 3 alpha (LC3) and TDP-43. However, there is no direct interaction mentioned between microtubule-associated protein 1 light chain 3 alpha protein and TDP-43 protein. Instead, the context focuses on the roles of these proteins in different pathological mechanisms related to frontotemporal lobar degeneration.</s>
330103 2A2679759 2A2571820	Ndrg1	Gstp1	[INST]Context: [PMID: 22114700 Proteomic signatures of human oral epithelial cells in HIV-infected subjects. HIV infected subjects on highly active antiretroviral therapy are susceptible to comorbid viral, bacterial and fungal infections in the oral cavity. In a discovery phase two Dimensional Difference Gel Electrophoresis (2-D DIGE) analyses of human oral gingival epithelial cell (HOEC) lysates were carried out; Down regulated proteins in HIV-infected subjects include proteins associated with maintenance of protein folding and pro- and anti-inflammatory responses (e.g., heat-shock proteins, Cryab, Calr, IL-1RA, and Galectin-3-binding protein) as well as proteins involved in redox homeostasis and detoxification (e.g., Gstp1, Prdx1, and Ero1). Up regulated proteins include: protein disulfide isomerases, proteins whose expression is negatively regulated by Hsp90 (e.g., Ndrg1), and proteins that maintain cellular integrity (e.g., Vimentin). Additionally in HIV-infected patient samples Heat Shock Factor 1 is down regulated, which explains the reduced heat shock responses, while activation of the MAPK signal transduction cascade is observed. Overall, highly active antiretroviral therapy provides an incomplete immune recovery of the oral epithelial cells of the oral cavity for HIV-infected subjects, and the toxic side effects of highly active antiretroviral therapy and/or HIV chronicity silence expression of multiple proteins that in healthy subjects function to provide robust innate immune responses and combat cellular stress. From MeSH: HIV-1.] Question: Based on the provided context, do the terms [Ndrg1 protein] and [Gstp1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between Ndrg1 protein and Gstp1 protein. Instead, it describes the upregulation of Ndrg1 and the downregulation of Gstp1 in HIV-infected subjects. The context focuses on the changes in protein expression levels in response to HIV infection and highly active antiretroviral therapy, but it does not indicate any direct interaction between Ndrg1 and Gstp1.</s>
325325 2A2568164 2A2482891	gps 2	gps 1	[INST]Context: [PMID: 25216413 Glasgow Prognostic Score can be a useful indicator to determine prognosis of patients with colorectal carcinoma. The aim of the current study was to elucidate a further significance of glasgow prognostic score in colorectal carcinoma. Correlation of glasgow prognostic score and modified glasgow prognostic score, which are composed of combined score provided for serum elevation of C-reactive protein and hypoalbuminemia examined before surgical treatment, with clinicopathologic features was investigated in 272 patients with colorectal carcinoma. Survival of glasgow prognostic score 1 patients was significantly worse than that of glasgow prognostic score 0 patients (P= 0.009), and survival of glasgow prognostic score 2 patients was significantly worse than that of glasgow prognostic score 1 patients (P < 0.0001). Similarly, survival of mglasgow prognostic score 1 patients was significantly worse than that of mglasgow prognostic score 0 patients (P = 0.009), and survival of modified gps 2 patients was significantly worse than that of modified gps 1 patients (P = 0.0006). Both glasgow prognostic score and mglasgow prognostic score could classify outcome of patients with a clear stratification, and could be applied as prognostic indicators in colorectal carcinoma.] Question: Based on the provided context, do the terms [gps 2 protein] and [gps 1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The terms gps 2 protein" and "gps 1 protein" do not interact with each other in the provided context. The context discusses the Glasgow Prognostic Score (GPS) and Modified Glasgow Prognostic Score (MGPS), which are used to assess the prognosis of patients with colorectal carcinoma. The terms "gps 2 protein" and "gps 1 protein" are not mentioned as interacting entities; instead, they are used to describe different categories or levels within the prognostic scores. The focus is on the prognostic significance of these scores rather than any direct interaction between proteins.</s>"
36187 2A2936581 2A2704682	Vimentin	p53	[INST]Context: [PMID: 28779345 N-terminal truncations of human bHLH transcription factor Twist1 leads to the formation of aggresomes. Dysregulation of these mechanisms facilitates the aggregation of misfolded proteins and forms aggresomes in the juxta nuclear position of the cell which are removed by lysosome-mediated autophagy pathway in the subsequent cell division. Accumulation of misfolded proteins in the cell is hallmark of several neurological disorders and other diseases including cancer. However, the exact mechanism of aggresome formation and clearance is not thoroughly understood. Reports have shown that several proteins including p300, p53, TAU, alpha-synuclein, SOD, etc. contain intrinsically disordered region which has the tendency to form aggresome. To study the nature of aggresome formation and stability of the aggresome, we have chosen Twist1 as a model protein since it has intrinsically disordered region s. Twist1 is a bHLH transcription factor which plays a major role in epithelial mesenchymal transition and shown to interact with HAT domain of p300 and p53. In the present study, we generated several deletion mutants of human Twist1 with different fluorescent tags and delineated the regions responsible for aggresome formation. The Twist1 protein contains two NLS motifs at the N-terminal region. We showed that the deletions of regions spanning the amino acids 30-46 (Twist1delta30-46) which lacks the first NLS motif form larger and intense aggregates while the deletion of residues from 47 to 100 (Twist1delta47-100) which lacks the second NLS motif generates smaller and less intense aggregates in the juxta nuclear position. This suggests that both the NLS motifs are needed for the proper nuclear localization of Twist1. The aggresome formation of the Twist1 deletion mutants was confirmed by counterstaining with known aggresome markers: Vimentin, HDAC6, and gamma tubulin and further validated by MG-132 treatment. In addition, it was found that the aggresomes generated by the Twist1delta30-46 construct are more stable than the aggresome produced by the Twist1delta47-100 construct as well as the wild-type Twist1 protein.] Question: Based on the provided context, do the terms [Vimentin protein] and [p53 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between Vimentin protein and p53 protein. The context discusses the role of Twist1 in aggresome formation and its interaction with the HAT domain of p300 and p53. However, it does not indicate any direct interaction between Vimentin and p53. Instead, it focuses on the role of Twist1 and its deletion mutants in aggresome formation and stability.</s>
7712 2A2860621 2A2901699	SETDB1	TRIM28	[INST]Context: [PMID: 31856708 DUF3669, a 'domain of unknown function' within ZNF746 and ZNF777, oligomerizes and contributes to transcriptional repression. BACKGROUND: ZNF746 and ZNF777 belong to a subset of the large Kruppel-associated box zinc finger transcription factor family. They contain, like four other members in human, an additional conserved domain, the 'domain of unknown function 3669' (DUF3669). Previous work on members of this subfamily suggested involvement in transcriptional regulation and aberrant ZNF746 overexpression leads to neuronal cell death in Parkinson's disease. RESULTS: Here we demonstrate that N-terminal protein segments of the ZNF746a major isoform and ZNF777 act in concert to exert moderate transcriptional repression activities. Importantly, DUF3669 provides a novel protein-protein interaction interface and mediates direct physical interaction between the members of the subfamily in oligomers. The ZNF746 protein segment encoded by exons 5 and 6 boosted repressor potency, potentially due to the presence of an acceptor lysine for sumoylation at K189. Neither ZNF746a nor ZNF777 protein segments stably associated with TRIM28 within cells. This increase is due to canonical mechanisms known for kruppel-associated box domains since it did not take place in HAP1 knockout models of TRIM28 and SETDB1. A glycine to glutamic acid replacement that complies with a bona fide conserved 'MLE' sequence within KRAB-A led to a further strong gain in repressor potency to levels comparable to those of the canonical ZNF10 kruppel-associated box domain. Each gain of repressive activity was accompanied by an enhanced interaction with TRIM28 protein. CONCLUSION: DUF3669 adds a protein-protein interaction surface to a subgroup of KRAB-zinc finger proteins within an N-terminal configuration with variant kruppel-associated box and adjacent sequences likely regulated by sumoylation.] Question: Based on the provided context, do the terms [SETDB1 protein] and [TRIM28 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between SETDB1 protein and TRIM28 protein. Instead, it discusses the interaction of ZNF746 and ZNF777 with TRIM28 and the role of sumoylation in transcriptional regulation. There is no indication that SETDB1 protein interacts with TRIM28 protein in the given context.</s>
183155 2A2854814 2A2558984	CGB	CGA	[INST]Context: [PMID: 21832169 Expression and production of human chorionic gonadotropin in the normal secretory endometrium: evidence of CGB7 and/or CGB6 beta human chorionic gonadotropin subunit gene expression. We have previously confirmed glandular cell CGB and CGA subunit mRNA gene expression as well as the expression of their dimeric and single-subunit human chorionic gonadotropin proteins in normal secretory transformed endometrium. The objective of this study was to investigate the endometrial epithelial gene locus of the human hCG/LH gene cluster from CGB genes responsible for gene expression. For this study, endometrial specimens were selected from women characterized using our endometrium score and human chorionic gonadotropin staining index that had normal secretory transformed endometrium and optimal human chorionic gonadotropin staining. Using full-length CGB mRNA sequence analysis, we found that epithelial CGB is (co)expressed as the product of gene locus CGB7 and CGB6 (48%), as single CGB7 (42%), or to a lower percentage as single CGB6 (10%). In addition to known differences between these genes and CGB5, the nucleotide sequence of the mRNA differs between CGB7 and CGB6 in the untranslated promoter region and in translated exon 2. Immunohistochemical results show that endometrial joint CGB7 and CGB6, single CGB7, and single CGB6 mRNA expression lead to the release of endometrial human chorionic gonadotropin. Gene-specific antibodies for CGB7 reveal secretory endometrial human chorionic gonadotropin production, which is not observed for gene-specific CGB5 antibodies, whereas the placenta is positive for CGB5 and negative for CGB7 antibody as revealed by immunohistochemistry and Western blot human chorionic gonadotropin isoform analysis. Only endometrial CGB7 expression seems to be supported specifically by secretory endometrial transcription factors. In conclusion, epithelial human chorionic gonadotropin is expressed and produced as CGB7 and/or CGB6 but not CGB5, and it is produced together with CGA as a secretory transformation marker in the normal secretory phase endometrium.] Question: Based on the provided context, do the terms [CGB protein] and [CGA protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that the expression of CGB and CGA subunits leads to the production of human chorionic gonadotropin (hCG). Specifically, it mentions that epithelial human chorionic gonadotropin is expressed and produced as CGB7 and/or CGB6 but not CGB5, and it is produced together with CGA as a secretory transformation marker in the normal secretory phase endometrium." This suggests that the CGB protein and CGA protein interact to form the hCG molecule, indicating an interaction between the two proteins.</s>"
11440 2A2651311 2A2516455	mitofilin	endothelin-1	[INST]Context: [PMID: 29619900 The role of mitofilin in left ventricular hypertrophy in hemodialysis patients. Left ventricular hypertrophy is a common abnormality in hemodialysis patients. Mitochondrial dysfunction contributes to the progression of left ventricular hypertrophy. As an inner mitochondrial membrane structural protein, mitofilin plays a key role in maintaining mitochondrial structure and function. The aim of this study was to investigate the relationship between mitofilin and left ventricular hypertrophy in hemodialysis patients. A total of 98___hemodialysis patients and 32 healthy controls were included in the study. Serum N-terminal proBNP, endothelin-1, and atrial natriuretic peptide were examined. The protein level of mitofilin and the mitochondrial DNA copy number were estimated in peripheral blood mononuclear cells . The left ventricle mass index was positively correlated with the n-terminal probnp, endothelin-1, and atrial natriuretic peptide levels, and it was negatively correlated with mitochondrial dna copy number and mitofilin levels. Multiple regression analysis showed that the n-terminal probnp, endothelin-1, and atrial natriuretic peptide levels as well as mitofilin levels and mitochondrial dna copy number were associated with the left ventricle mass index. Although further research of these associations is needed, this result suggests that left ventricular hypertrophy may affect the levels of mitofilin in hemodialysis patients.] Question: Based on the provided context, do the terms [mitofilin protein] and [endothelin-1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not indicate a direct interaction between mitofilin protein and endothelin-1 protein. Instead, it describes the correlation between various biomarkers and left ventricular hypertrophy in hemodialysis patients. While both mitofilin and endothelin-1 are mentioned in the context of left ventricular hypertrophy, there is no direct interaction described between the two proteins. The context focuses on their individual roles and correlations with left ventricular hypertrophy rather than any interaction between them.</s>
663100 2A2457399 2A2457284	monocyte chemotactic protein-3	eotaxin	[INST]Context: [PMID: 10359886 Effect of AA-2414, a thromboxane A2 receptor antagonist, on airway inflammation in subjects with asthma. BACKGROUND: Asthma is a chronic inflammatory disease of the airways. The chemokines are potent chemoattractants for eosinophils and other types of cells associated with allergic inflammation. AA-2414, a new thromboxane A2 receptor antagonist, reduces bronchial hyperresponsiveness in asthmatic subjects, but its mechanism of action is unclear. OBJECTIVE: We tested the hypothesis that the beneficial effects of AA-2414 in asthma result from reduction in the number of inflammatory cells infiltrating the airway associated with inhibition of chemokine release. Lung function and bronchial responsiveness to methacholine were measured before and after treatment. RESULTS: After treatment, significant improvements in symptom score (P <.05), peak expiratory flow (P <.01), diurnal variation of peak expiratory flow (P <.01), and bronchial responsiveness (P <.01) were observed in the AA-2414 group compared with the placebo group. These improvements were accompanied by a significant decrease in the number of submucosal EG2(+) eosinophils (P <.05). There was also a reduction in the number of cells expressing RANTES (P <.05) and macrophage inflammatory protein -1alpha (P <.05) in the epithelium and of cells expressing monocyte chemotactic protein-3 (P <.01), RANTES (P <.05), MIP-1alpha (P <.01), and eotaxin (P <.01) in the submucosa in the AA-2414 treatment group. A significant correlation was found between the number of EG2(+) eosinophils and numbers of monocyte chemotactic protein-3(+) (rs = 0.52, P <.005), MIP-1alpha+ (rs = 0.34, P <.05), and eotaxin+ cells (r s = 0.47, P <.01) in the submucosa. There was a significant negative correlation between the increase in bronchial responsiveness and the change in number of submucosal EG2(+) cells (rs = -0.65, P <.001). CONCLUSIONS: These findings suggest that AA-2414 treatment of patients with asthma may inhibit activated eosinophil infiltration in part by modulating the expression of chemokines in bronchial tissues.] Question: Based on the provided context, do the terms [monocyte chemotactic protein-3 protein] and [eotaxin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the effects of AA-2414 on chemokine expression in bronchial tissues of asthmatic subjects. While it mentions the reduction in the number of cells expressing monocyte chemotactic protein-3 (MCP-3) and eotaxin, it does not indicate a direct interaction between these two proteins. Instead, it describes their individual roles in the inflammatory process and their modulation by AA-2414 treatment. Therefore, there is no evidence of a direct interaction between monocyte chemotactic protein-3 and eotaxin in the context provided.</s>
5808 2A2516570 2A2590068	EF1A1	HSP90B	[INST]Context: [PMID: 33053689 Sequenced Combinations of Cisplatin and Selected Phytochemicals towards Overcoming Drug Resistance in Ovarian Tumour Models. In the present study, cisplatin, artemisinin, and oleanolic acid were evaluated alone, and in combination, on human ovarian A2780, A2780ZD0473R, and A2780cisR cancer cell lines, with the aim of overcoming cisplatin resistance and side effects. Cytotoxicity was assessed by MTT reduction assay. MALDI TOF/TOF MS/MS and 2-DE gel electrophoresis were used to identify protein biomarkers in ovarian cancer and to evaluate combination effects. Moreover, 49 proteins differently expressed by 2 ___ fold were: CYPA, EIF5A1, Op18, p18, LDHB, P4HB, HSP7C, GRP94, ERp57, mortalin, IMMT, CLIC1, NM23, PSA3,1433Z, and HSP90B were down-regulated, whereas hnRNPA1, hnRNPA2/B1, EF2, GOT1, EF1A1, VIME, BIP, ATP5H, APG2, VINC, KPYM, RAN, PSA7, TPI, PGK1, ACTG and VDAC1 were up-regulated, while TCPA, TCPH, TCPB, PRDX6, EF1G, ATPA, ENOA, PRDX1, MCM7, GBLP, PSAT, Hop, EFTU, PGAM1, SERA and CAH2 were not-expressed in A2780cisR cells. The proteins were found to play critical roles in cell cycle regulation, metabolism, and biosynthetic processes and drug resistance and detoxification. Results indicate that appropriately sequenced combinations of cisplatin with artemisinin and oleanolic acid may provide a means to reduce side effects and circumvent platinum resistance.] Question: Based on the provided context, do the terms [EF1A1 protein] and [HSP90B protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between EF1A1 protein and HSP90B protein. The context lists various proteins that are differentially expressed in ovarian cancer cells and their roles in cell cycle regulation, metabolism, and drug resistance. However, it does not indicate any specific interaction between EF1A1 and HSP90B proteins. Therefore, based on the given information, there is no evidence to suggest that these two proteins interact with each other.</s>
242409 2A2580790 2A2700093	Hex A	beta-N-acetylhexosaminidase	[INST]Context: [PMID: 10481922 Thermodynamic characterisation of the mutated isoenzyme A of beta-N-acetylhexosaminidase in GM2-gangliosidosis B1 variant. Here we report the determination of the activation energies of the plasma isoenzymes of beta-N-acetylhexosaminidase (Hex, EC 3.2.1.52), isolated by chromatography in DEAE-cellulose, using the neutral chromogenic substrate 3,3'dichlorophenylsulfonphthaleinyl-N-acetyl-beta-D-glucosaminide. The activation energy of mutated Hex A isoenzyme (Ea approximately 71.5 kJ/mol) from a patient with GM2-gangliosidosis B1 variant, homozygote for the G533-->A (Arg178His) mutation, was significantly higher than that of normal Hex A (Ea approximately 41.8 kJ/mol) and analogous to that of Hex B isoenzyme (Ea approximately 75.1 kJ/mol). The determination of this thermodynamic variable of Hex in different biological specimens could allow for a straightforward biochemical characterisation of the GM2-gangliosidosis B1 variant.] Question: Based on the provided context, do the terms [Hex A protein] and [beta-N-acetylhexosaminidase protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The terms [Hex A protein] and [beta-N-acetylhexosaminidase protein] refer to the same enzyme, beta-N-acetylhexosaminidase, with Hex A being a specific isoenzyme of this enzyme. Therefore, they are not separate entities that interact with each other. Instead, they are different forms of the same protein.</s>
635053 2A2590068 2A2722266	HSP84	SDK3	[INST]Context: [PMID: 10079081 Endogenous substrates of sphingosine-dependent kinases are chaperone proteins: heat shock proteins, glucose-regulated proteins, protein disulfide isomerase, and calreticulin. Protein kinases whose activity is detectable only in the presence of sphingosine or N,N'-dimethyl-Sph, but not in the presence of 15 other sphingolipids, phospholipids, and glycerolipids tested (Megidish, T., et al. (1995) Biochem. We showed previously that a purified SDK (termed 'SDK1') phosphorylates a specific Ser position of adapter/chaperone protein 14-3-3 isoforms beta, eta, and zeta but not tau or sigma (Megidish, T., et al. (1998) J. In this study we found the following: (i) other sphingosine-dependent kinases with different substrate specificities are present in cytosolic and membrane extracts of mouse Balb/c 3T3 (A31) fibroblasts. (ii) The activation of these sphingosine-dependent kinases is specific to D-erythro-sphingosine and its N-methyl derivatives, the effect of L-threo-Sph or its N-methyl derivatives is minimal, and nonspecific cationic amphiphiles have no effect at all. An SDK separated as fractions 'TN31-33' phosphorylated a 50 kDa substrate which was identified as calreticulin, as well as two endogenous substrates with molecular mass 58 and 55 kDa, both identified as protein disulfide isomerase . This SDK, which specifically phosphorylates calreticulin and protein disulfide isomerase, both molecular chaperones found at high levels in endoplasmic reticulum, is tentatively termed 'SDK2'. One glucose-regulated protein substrate had the same amino acid sequence as GRP94 (synonym: endoplasmin); Another heat shock proteins substrate had the same amino acid sequence as mouse HSP86 or HSP84, the analogues of human HSP90. An SDK activity separated and present in 'fraction 42' from Q-Sepharose chromatography specifically phosphorylated GRP105 (or GRP94) and HSP68 but did not phosphorylate protein disulfide isomerase or 14-3-3. This SDK is clearly different from other sphingosine-dependent kinases in its substrate specificity and is tentatively termed 'SDK3'. Interestingly, substrates of all these sphingosine-dependent kinases so far identified are molecular chaperones or adapters capable of binding to enzymes and key molecules involved in signal transduction, maintaining tertiary structure of bioactive molecules, or maintaining cellular homeostasis in response to environmental stress. Thus, the essential role of sphingosine and dimethyl-sph is to activate molecular chaperones, thereby providing a link to the mechanism by which SDK activity regulates cellular homeostasis and signal transduction. From MeSH: Mice.] Question: Based on the provided context, do the terms [HSP84 protein] and [SDK3 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context describes the activities of different sphingosine-dependent kinases (SDKs) and their specific substrates. While it mentions that SDK3 phosphorylates HSP84 (or HSP86), it does not indicate a direct interaction between HSP84 protein and SDK3 protein. Instead, it describes the phosphorylation of HSP84 by SDK3 as part of the kinase's substrate specificity. Therefore, there is no direct interaction mentioned between the two proteins.</s>
513487 2A2909968 2A2714801	Trim27	Cbfb	[INST]Context: [PMID: 29897614 Trim27 confers myeloid hematopoiesis competitiveness by up-regulating myeloid master genes. Trim27 (Zinc finger protein RFP) is a potential regulator of hematopoietic stem cells, yet its role in hematopoiesis remains elusive. Here, we investigated the roles of Trim27 in hematopoiesis by enforcing its expression in mouse and human hematopoietic stem and progenitor cells . Ectopic expression of Trim27 in mouse fetal liver hematopoietic stem and progenitor cells confers repopulating advantage with myeloid dominance. However, the number of hematopoietic stem cells from Trim27 group was comparable with empty vector control group, indicating that overexpression of Trim27 unlikely expanded hematopoietic stem cells. Transcriptome analysis of Trim27-overexpressing myeloid progenitor cells (MP) indicated that Trim27 up-regulated essential regulators of myelopoiesis, including Spi1 and Cebpg, up-regulated myeloid proliferation-related signaling genes Nras, Runx1, and Cbfb, up-regulated JAK/STAT signaling inhibitors Socs2, Socs3, and Cish, and up-regulated myeloid maturation-related genes Adam8 and Dek. Moreover, the myeloproliferative advantage caused by overexpressing Trim27/TRIM27 is conserved between mouse and human hematopoiesis. To our knowledge, this is the first study showing that Trim27 confers competitive hematopoiesis by promoting myeloid bias differentiation of hematopoietic stem and progenitor cells, but not by expanding hematopoietic stem cells. Mice.] Question: Based on the provided context, do the terms [Trim27 protein] and [Cbfb protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not indicate a direct interaction between the Trim27 protein and the Cbfb protein. Instead, it mentions that Trim27 up-regulates Cbfb as part of its role in promoting myeloid bias differentiation of hematopoietic stem and progenitor cells. This suggests that Trim27 influences the expression of Cbfb but does not imply a direct interaction between the two proteins.</s>
443441 2A2908767 2A2905345	DcR1	TRAIL	[INST]Context: [PMID: 21156789 Ursolic acid, a pentacyclin triterpene, potentiates TRAIL-induced apoptosis through p53-independent up-regulation of death receptors: evidence for the role of reactive oxygen species and JNK. In the present report, we investigated the effect of ursolic acid, a pentacyclic triterpenoid found in rosemary and holy basil, on apoptosis induced by TRAIL. We found that ursolic acid potentiated TRAIL-induced apoptosis in cancer cells. In addition, ursolic acid also sensitized TRAIL-resistant cancer cells to the cytokine. When we investigated the mechanism, we found that ursolic acid down-regulated cell survival proteins and induced the cell surface expression of both TRAIL receptors, death receptors 4 and 5 (DR4 and -5). Induction of receptors by ursolic acid occurred independently of cell type. Gene silencing of either receptor by small interfering RNA reduced the apoptosis induced by ursolic acid and the effect of TRAIL. In addition, ursolic acid also decreased the expression of decoy receptor 2 but not DcR1. Induction of DRs was independent of p53 because ursolic acid induced DR4 and DR5 in HCT116 p53(-/-) cells. Induction of DRs, however, was dependent on JNK because ursolic acid induced JNK, and its pharmacologic inhibition abolished the induction of the receptors. The down-regulation of survival proteins and up-regulation of the DRs required reactive oxygen species because ursolic acid induced reactive oxygen species, and its quenching abolished the effect of the terpene. Also, potentiation of TRAIL-induced apoptosis by ursolic acid was significantly reduced by both reactive oxygen species quenchers and JNK inhibitor. In addition, ursolic acid was also found to induce the expression of DRs, down-regulate cell survival proteins, and activate JNK in orthotopically implanted human colorectal cancer in a nude mouse model. Overall, our results showed that ursolic acid potentiates TRAIL-induced apoptosis through activation of reactive oxygen species and JNK-mediated up-regulation of DRs and down-regulation of decoy receptor 2 and cell survival proteins. Mice.] Question: Based on the provided context, do the terms [DcR1 protein] and [TRAIL protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the DcR1 protein and the TRAIL protein. Instead, it discusses the effects of ursolic acid on the expression of various proteins, including DcR1 and TRAIL receptors (DR4 and DR5), and their roles in apoptosis. The context focuses on the up-regulation of death receptors and down-regulation of decoy receptor 2, as well as the activation of JNK and reactive oxygen species, but it does not describe any direct interaction between DcR1 and TRAIL.</s>
43832 2A2918856 2A2734750	TTR	PPARA	[INST]Context: [PMID: 34126818 Proteomics based drug repositioning applied to improve in vitro fertilization implantation: an artificial intelligence model. Embryo implantation is one of the most inefficient steps in assisted reproduction, so the identifying drugs with a potential clinical application to improve it has a strong interest. This work applies artificial intelligence and systems biology-based mathematical modeling strategies to unveil potential treatments by computationally analyzing and integrating available molecular and clinical data from patients. The mathematical models of embryo implantation computationally generated here simulate the molecular networks underneath this biological process. Once generated, these models were analyzed in order to identify potential repositioned drugs (drugs already used for other indications) able to improve embryo implantation by modulating the molecular pathways involved. Interestingly, the repositioning analysis has identified drugs considering two endpoints: (1) drugs able to modulate the activity of proteins whose role in embryo implantation is already bibliographically acknowledged, and (2) drugs that modulate key proteins in embryo implantation previously predicted through a mechanistic analysis of the mathematical models. As a result, a list of 23 drug candidates to improve embryo implantation after IVF was identified by the mathematical models. This list includes many of the compounds already tested for this purpose, which reinforces the predictive capacity of our approach, together with novel repositioned candidates (e.g., Infliximab, Polaprezinc, and Amrinone). In conclusion, the present study exploits existing molecular and clinical information to offer new hypotheses regarding molecular mechanisms in embryo implantation and therapeutic candidates to improve it. This information will be very useful to guide future research.Abbreviations: IVF: in vitro fertilization; EI: Embryo implantation; VEGF: vascular endothelial growth factor; PPARA: peroxisome proliferator activated receptor-alpha PXR: pregnane X receptor; TTR: transthyretin;] Question: Based on the provided context, do the terms [TTR protein] and [PPARA protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the TTR protein and the PPARA protein. While both proteins are mentioned in the context of embryo implantation and the potential repositioning of drugs to improve it, there is no specific information or evidence provided that indicates a direct interaction between TTR and PPARA. The context focuses on the broader molecular pathways and mechanisms involved in embryo implantation rather than specific protein-protein interactions.</s>
659510 2A2548752 2A2630432	GADD45A	Lamin A/C	[INST]Context: [PMID: 19082486 Grade-dependent effects on cell cycle progression and apoptosis in response to doxorubicin in human bladder cancer cell lines. Doxorubicin is an important component of combination therapy for muscle-invasive urinary bladder cancer. Treatment with this topoisomerase II poison is able to interfere with cell cycle progression and lead to cancer cell death. Using FACS analysis, Western immunoblotting and semi-quantitative RT-PCR, we studied the effects of doxorubicin on cell cycle progression and apoptosis, and also explored the possibility of using groups of genes as biomarkers of prognosis and/or response to doxorubicin treatment in human urinary bladder cancer cells. Doxorubicin induced dose-dependent G2/M and/or G1/S cell cycle arrest, followed by grade- and dose-dependent reduction in the amount of the cytosolic trimeric form of FasL, activation of Caspase-8, Caspase-9, Caspase-3, cleavage of PARP, Lamin A/C, Bcl-XL/S and interestingly Hsp90, and finally cell death. Data presented here also suggest the use of the expression patterns of Cyclin-E2, Cyclin-F, p63, p73, FasL, TRAIL, Tweak, Tweak-R, XAF-1, OPG and Bok genes for identification of the differentiation grade, and Cyclin-B2, GADD45A, p73, FasL, Bik, Bim, TRAIL, Fas, Tweak-R, XAF-1, Bcl-2, Survivin, OPG, DcR2 and Bcl-XL genes for the detection of response to doxorubicin in human bladder cancer cells.] Question: Based on the provided context, do the terms [GADD45A protein] and [Lamin A/C protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the effects of doxorubicin on cell cycle progression and apoptosis in human bladder cancer cells, including the activation of various proteins such as Caspase-8, Caspase-9, Caspase-3, and the cleavage of PARP, Lamin A/C, and Bcl-XL/S. However, there is no direct mention or evidence of an interaction between GADD45A protein and Lamin A/C protein. The context describes the effects of doxorubicin on these proteins separately, without indicating any direct interaction between them.</s>
412090 2A2481140 2A2514491	CREB1	DNM2	[INST]Context: [PMID: 32041280 A Network-Based Bioinformatics Approach to Identify Molecular Biomarkers for Type 2 Diabetes that Are Linked to the Progression of Neurological Diseases. Clinical studies, including epidemiological and neuropathological analyses, indicate that patients with type 2 diabetes have worse progression of neurological diseases, suggesting pathogenic links between neurological diseases and type 2 diabetes. To address these problems, we developed a high-throughput network-based quantitative pipeline using agnostic approaches to identify genes expressed abnormally in both type 2 diabetes and neurological diseases, to identify some of the shared molecular pathways that may underpin type 2 diabetes and ND interaction. We employed gene expression transcriptomic datasets from control and disease-affected individuals and identified differentially expressed genes in tissues of patients with type 2 diabetes and ND when compared to unaffected control individuals. One hundred and ninety seven differentially expressed genes (99 up-regulated and 98 down-regulated in affected individuals) that were common to both the type 2 diabetes and the ND datasets were identified. The overlapping differentially expressed genes (i.e., seen in both type 2 diabetes and ND datasets) were then used to extract the most significant GO terms. We performed validation of these results with gold benchmark databases and literature searching, which identified which genes and pathways had been previously linked to neurological diseases or type 2 diabetes and which are novel. Hub proteins in the pathways were identified (including DNM2, DNM1, MYH14, PACSIN2, TFRC, PDE4D, ENTPD1, PLK4, CDC20B, and CDC14A) using protein-protein interaction analysis which have not previously been described as playing a role in these diseases. We thus identified the following TFs as important in driving expression of our T2D/ND common genes: FOXC1, GATA2, FOXL1, YY1, E2F1, NFIC, NFYA, USF2, HINFP, MEF2A, SRF, NFKB1, USF2, HINFP, MEF2A, SRF, NFKB1, PDE4D, CREB1, SP1, HOXA5, SREBF1, TFAP2A, STAT3, POU2F2, TP53, PPARG, and JUN. MicroRNAs that affect expression of these genes include mir-335-5p, mir-16-5p, mir-93-5p, mir-17-5p, mir-124-3p. Thus, our transcriptomic data analysis identifies novel potential links between neurological diseases and type 2 diabetes pathologies that may underlie comorbidity interactions, links that may include potential targets for therapeutic intervention. In sum, our neighborhood-based benchmarking and multilayer network topology methods identified novel putative biomarkers that indicate how type 2 diabetes and these neurological diseases interact and pathways that, in the future, may be targeted for treatment.] Question: Based on the provided context, do the terms [CREB1 protein] and [DNM2 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention a direct interaction between the CREB1 protein and the DNM2 protein. While both proteins are identified as part of the pathways and networks involved in type 2 diabetes and neurological diseases, there is no specific evidence or description indicating that they interact with each other. The context focuses on the broader pathways and molecular mechanisms rather than specific protein-protein interactions.</s>
401783 2A2763616 2A2525541	mRNA export factor RAE1	p300	[INST]Context: [PMID: 21467841 RNA export factor RAE1 contributes to NUP98-HOXA9-mediated leukemogenesis. Chromosomal translocations involving chimeric fusions of the nucleoporin NUP98 protein have often been described in acute myelogenous leukemia . All the fusion proteins have an identical NUP98 N terminus, which contains the GLEBS motif for interaction with the mRNA export factor RAE1 and FG repeats that associate with the transcription factors HDAC1 and p300. We previously showed that RAE1 depletion caused aneuploidy, which enhanced tumorigenesis. We speculated that RAE1 may also be directly involved in NUP98 fusion-mediated leukemogenesis. We show here that RNA interference -mediated knockdown of NUP98 caused severe chromosome segregation defects and disrupted RAE1 but not HDAC1 expression and localization. Next, we performed rescue experiments to confirm that the RAE1-NUP98 complex orchestrates proper chromosome segregation. Interestingly, we found diverse behaviors of NUP98 and the leukemogenic fusion protein NUP98-HOXA9 throughout the cell cycle. Strikingly, in NUP98-HOXA9-transfected cells, RAE1 protein were reduced and mis-localized. Our cellular interpretations were further confirmed by NUP98-HOXA9 transgenic mice and the NUP98-HOXA9 acute myelogenous leukemia patient. These data suggest that RAE1 orchestrates NUP98-mediated leukemogenesis and raise the possibility that targeting this negative feedback loop may provide a new strategy for the therapy of aggressive leukemias. Mice.] Question: Based on the provided context, do the terms [mRNA export factor RAE1 protein] and [p300 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the mRNA export factor RAE1 protein and the p300 protein. Instead, it describes the interaction of NUP98 with RAE1 and HDAC1, but not with p300. Therefore, based on the given information, there is no evidence to suggest that RAE1 and p300 interact with each other.</s>
462628 2A2415436 2A2685847	PRMT5	Notch1	[INST]Context: [PMID: 34659878 Systemic therapies for salivary gland adenoid cystic carcinoma. Adenoid cystic carcinoma is a slow growing, but relentless cancer. Due to its rarity and lack of understanding of its molecular etiology, no standard chemotherapy for adenoid cystic carcinoma currently exists and many patients suffer from recurrent and/or metastatic disease. To describe and summarize existing clinical trial studies and preclinical discoveries, we surveyed the PubMed on developmental therapeutics for adenoid cystic carcinoma. Objective response rates to monotherapy with cytotoxic agents were approximately 10% with cisplatin, 5-FU, gemcitabine, mitoxantrone, epirubicin, vinorelbine and paclitaxel. Among molecularly targeted drugs, the most studied drugs are inhibitors targeting the vascular endothelial growth factor receptor to inhibit tumor angiogenesis. Among those, lenvatinib and axitinib showed a relatively high objective response rate of 11-16% and 9-17%, respectively. Given high recurrence rates and chemoresistance of adenoid cystic carcinoma, treatments targeting cancer stem cells, which function as tumor-initiating cells and drive chemoresistance, may be particularly valuable. Cancer stem cells have been shown to be targetable via MYB, Notch1, p53 and epigenetic mechanisms. Myb overexpression is characteristic in adenoid cystic carcinoma but was previously thought to present a difficult target due to its nature as a transcription factor. However, due to the development Myb-targeted inhibitors and an ongoing clinical trial of MYB-targeted cancer vaccine therapy, MYB is becoming an increasingly attractive therapeutic target. Within the field of epigenetics, treatment with PRMT5 inhibitors has shown 21% partial response rate in phase I clinical trial. Immunotherapies, such as PD-1 inhibitors, are also associated with cancer stem cells, but have not been effective against adenoid cystic carcinoma. However, clinical trials of cancer vaccine therapies are actively being conducted. In addition to conventional chemotherapies and inhibitors of angiogenesis, the emergence of new therapies such as immunotherapy and those targeting cancer stemness is expected to bring clinical benefits to patients in the future.] Question: Based on the provided context, do the terms [PRMT5 protein] and [Notch1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses various molecularly targeted drugs and therapies for adenoid cystic carcinoma, including PRMT5 inhibitors and Notch1 inhibitors. However, there is no direct mention or evidence of an interaction between the PRMT5 protein and the Notch1 protein. The context describes these proteins as separate targets for cancer stem cell therapy and immunotherapy, respectively, but does not indicate any interaction between them.</s>
73322 2A2526426 2A2859998	ErbB3	CDCrel-1	[INST]Context: [PMID: 15632191 RING finger ubiquitin-protein isopeptide ligase Nrdp1/FLRF regulates parkin stability and activity. Parkin is a ubiquitin-protein isopeptide ligase. It has been suggested that loss of function in parkin causes accumulation and aggregation of its substrates, leading to death of dopaminergic neurons in Parkinson disease. Using the yeast two-hybrid screen, we isolated a RING finger protein that interacted with the N terminus of parkin in a Drosophila cDNA library. Interaction between human parkin and the mammalian RING finger protein homologue Nrdp1/FLRF, a ubiquitin-protein isopeptide ligase that ubiquitinates ErbB3 and ErbB4, was validated by in vitro binding assay, co-immunoprecipitation, and immunofluorescence co-localization. Significantly, pulse-chase experiments showed that cotransfection of Nrdp1 and parkin reduced the half-life of parkin from 5 to 2.5 h. Consistent with these findings, we further observed that degradation of CDCrel-1, a parkin substrate, was facilitated by overexpression of parkin protein. However, co-transfection of Nrdp1 with parkin reversed the effects of parkin on CDCrel-1 degradation. We conclude that Nrdp1 is a parkin modifier that accelerates degradation of parkin, resulting in a reduction of parkin activity.] Question: Based on the provided context, do the terms [ErbB3 protein] and [CDCrel-1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between ErbB3 protein and CDCrel-1 protein. Instead, it describes the interaction of Nrdp1/FLRF with parkin and its effects on the degradation of parkin and CDCrel-1. ErbB3 is mentioned as a substrate of Nrdp1, while CDCrel-1 is a substrate of parkin. There is no indication that ErbB3 and CDCrel-1 interact with each other directly.</s>
565010 2A2672324 2A2903080	MYO10	TIMP1	[INST]Context: [PMID: 35391790 Identification of Novel Biomarkers With Diagnostic Value and Immune Infiltration in Burn Injury. Burn injury is an intractable problem in the field of surgery where screening relevant target genes and exploring pathological mechanisms through bioinformatic methods has become a necessity. Herein, we integrated three burn injury mRNA microarray datasets from the Gene Expression Omnibus database to analyze the hub differentially expressed genes between burn injury patient samples and healthy human samples; Finally, we evaluated the immune infiltration in the burn injury microenvironment. A total of 84 intersection differentially expressed genes (32 upregulated and 52 downregulated) were screened in burn injury patients via integrated analyses. Upregulated genes were primarily enriched in regulation of T cell activation, regulation of response to DNA damage stimulus, positive regulation of innate immune response, positive regulation of defense response. We also identified 10 hub genes from the protein-protein interaction network (CCNB2, MYO10, TTK, POLQ, VASP, TIMP1, CDK16, MMP1, ZYX, and PKMYT1). Next, we found that 22 immune cells were substantially changed during the burn injury by CIBERSORT. In addition, we verified that VASP and POLQ are two novel diagnostic markers in burn processes with high diagnostic efficacy via immunohistochemistry. In summary, we identified several key genes involved in burn injury and provided a favorable basis for elucidating the molecular mechanisms of burn injury through comprehensive bioinformatic analysis.] Question: Based on the provided context, do the terms [MYO10 protein] and [TIMP1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between MYO10 protein and TIMP1 protein. While both proteins are identified as hub genes involved in burn injury, there is no specific information or evidence indicating that they interact with each other. The context focuses on their individual roles and enrichment in specific pathways rather than any direct interaction between the two proteins.</s>
403219 2A2592161 2A2764502	HSPA4	RBBP4	[INST]Context: [PMID: 29100048 Novel candidate genes of the PARK7 interactome as mediators of apoptosis and acetylation in multiple sclerosis: An in silico analysis. BACKGROUND: currently only 4 studies have explored the potential role of PARK7's dysregulation in MS pathophysiology Currently, no study has evaluated the potential role of the PARK7 interactome in MS. OBJECTIVE: The aim of our study was to assess the differential expression of PARK7 mRNA in peripheral blood mononuclears donated from MS versus healthy patients using data mining techniques. METHODS: The PARK7 interactome data from the GDS3920 profile were scrutinized for differentially expressed genes ; 12 of these (NDUFA4, UBA2, TDP2, NPM1, NDUFS3, SUMO1, PIAS2, KIAA0101, RBBP4, NONO, RBBP7 AND HSPA4) are reported for the first time in MS. Stepwise Linear Discriminant Function Analysis constructed a predictive model (Wilk's lambda = 0.176, chi2 = 45.204, p = 1.5275e-10) with 2 variables (TIDP2, RBBP4) that achieved 96.6% accuracy when discriminating between patients and controls. Gene Enrichment Analysis revealed that induction and regulation of programmed / intrinsic cell death represented the most salient Gene Ontology annotations. Cross-validation on systemic lupus erythematosus and ischemic stroke datasets revealed that these functions are unique to the MS dataset.] Question: Based on the provided context, do the terms [HSPA4 protein] and [RBBP4 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the HSPA4 protein and the RBBP4 protein. While both proteins are part of the PARK7 interactome and are differentially expressed in MS, there is no specific information indicating that they interact with each other. The context focuses on the differential expression of these proteins and their roles in apoptosis and acetylation in MS, but it does not describe any direct interaction between HSPA4 and RBBP4.</s>
644158 2A2886324 2A2922513	SYN1	UBE1	[INST]Context: [PMID: 8088799 Physical mapping in a yeast artificial chromosome contig of 11 markers on the human X chromosome in Xp11.23. By using yeast artificial chromosome clones, we have generated a physical map of the short arm of the human X chromosome at Xp11.23. The region analyzed spans the distal marker UBE1 and the ARAF1/TIMP/SYN1/PFC gene cluster and further extends proximally to include ELK1, ZNF21, ZNF81, and OATL1 in a single contig. We have uniquely placed UBE1 and the SYN1 gene cluster in a 330-kb yeast artificial chromosome within the contig. In addition, the genes SYP and TFE3 are physically linked in a yeast artificial chromosome of 400 kb from the more centromeric portion of Xp11.23. These derivatives show that ZNF81 and ZNF21 lie within an approximately 130-kb segment and that SYN1.2 and ELK1 are less than 50 kb apart.] Question: Based on the provided context, do the terms [SYN1 protein] and [UBE1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context describes the physical mapping of markers on the human X chromosome and does not mention any direct interaction between the SYN1 protein and the UBE1 protein. The context focuses on the relative positions of these genes within the chromosome and does not provide any information about their functional or protein-level interactions. Therefore, based on the given information, there is no evidence to suggest that the SYN1 protein and the UBE1 protein interact with each other.</s>
198287 2A2430988 2A2596509	ATF3	ID2	[INST]Context: [PMID: 15897246 Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients. Ecteinascidin 743 (ET-743; Yondelis, Trabectedin) is a marine anticancer agent that induces long-lasting objective remissions and tumor control in a subset of patients with pretreated/resistant soft-tissue sarcoma. Drug-induced tumor control is achievable in 22% of such patients, but there is no clear indication of the molecular features correlated with clinical sensitivity/resistance to ET-743. Nine low-passage, soft-tissue sarcoma cell lines, explanted from chemo-naive patients with different patterns of sensitivity, have been profiled with a cDNA microarray containing 6,700 cancer-related genes. The molecular signature of these cell lines was analyzed at baseline and at four different times after ET-743 exposure. The association of levels of TP53 mutation and TP73 expression with ET-743 sensitivity and cell cycle kinetics after treatment was also analyzed. Gene expression profile analysis revealed up-regulation of 86 genes and down-regulation of 244 genes in response to ET-743. The ET-743 gene expression signature identified a group of genes related with cell cycle control, stress, and DNA-damage response (JUNB, ATF3, CS-1, SAT, GADD45B, and ID2) that were up-regulated in all the cell lines studied. The transcriptional signature 72 hours after ET-743 administration, associated with ET-743 sensitivity, showed a more efficient induction of genes involved in DNA-damage response and apoptosis, such as RAD17, BRCA1, PAR4, CDKN1A, and P53DINP1, in the sensitive cell line group. The transcriptional signature described here may lead to the identification of ET-743 downstream mediators and transcription regulators and the proposal of strategies by which ET-743-sensitive tumors may be identified.] Question: Based on the provided context, do the terms [ATF3 protein] and [ID2 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the up-regulation of various genes, including ATF3 and ID2, in response to Ecteinascidin 743 (ET-743) treatment. However, there is no direct mention of an interaction between the ATF3 protein and the ID2 protein. The context describes their roles in the transcriptional signature and cell cycle control but does not indicate any specific interaction between these two proteins.</s>
384142 2A2705948 2A2418080	glycodelin	ApoD	[INST]Context: [PMID: 12021176 Global gene profiling in human endometrium during the window of implantation. Herein, we have investigated global gene expression during the window of implantation (peak E2 and progesterone levels) in well characterized human endometrial biopsies timed to the LH surge, compared with the late proliferative phase (peak E2 level) of the menstrual cycle. Up-regulated genes included those for cholesterol trafficking and transport [apolipoprotein (Apo)E being the most induced gene, 100-fold], prostaglandin biosynthesis (PLA2) and action (PGE2 receptor), proteoglycan synthesis (glucuronyltransferase), secretory proteins [glycodelin, mammaglobin, Dickkopf-1 (Dkk-1, a Wnt inhibitor)], IGF binding protein, and TGF-beta superfamilies, signal transduction, extracellular matrix components (osteopontin, laminin), neurotransmitter synthesis (monoamine oxidase) and receptors (gamma aminobutyric acid A receptor pi subunit), numerous immune modulators, detoxification genes (metallothioneins), and genes involved in water and ion transport [e.g. Down-regulated genes included intestinal trefoil factor [the most repressed gene (50-fold)], matrilysin, members of the G protein-coupled receptor signaling pathway, frizzled-related protein (FrpHE, a Wnt antagonist), transcription factors, TGF-beta signaling pathway members, immune modulators (major histocompatibility complex class II subunits), and other cellular functions. Validation of select genes was conducted by Northern analysis and RT-PCR using RNA from endometrial biopsies obtained in the proliferative phase and the implantation window and by RT-PCR using RNA from cultured endometrial epithelial and stromal cells. These approaches confirmed up-regulation of genes corresponding to IGFBP-1, glycodelin, CPE1-R, Dkk-1, mammaglobin, and ApoD and down-regulation for PR membrane component 1, FrpHE, matrilysin, and intestinal trefoil factor, as with the microarray data. Cultured endometrial epithelial cells were found to express mRNAs for glycodelin, CPE-1R, Dkk-1, the gamma aminobutyric acid A receptor pi subunit, mammaglobin, matrilysin, intestinal trefoil factor and PR membrane component 1. The expression of IGFBP-1, CPE1-R, Dkk-1, and ApoD mRNAs increased upon decidualization of stromal cells in vitro with progesterone after E2 priming, whereas FrpHE decreased, consistent with the microarray results. Overall, the data demonstrate numerous genes and gene families not heretofore recognized in human endometrium or associated with the implantation process. Reassuringly, several gene products, known to be differentially expressed in the implantation window or in secretory endometrium, were verified, and the striking regulation of select secretory proteins, water and ion channels, signaling molecules, and immune modulators underscores the important roles of these systems in endometrial development and endometrial-embryonic interactions. In addition, the current study validates using high density oligonucleotide microarray technology to investigate global changes in gene expression in human endometrium.] Question: Based on the provided context, do the terms [glycodelin protein] and [ApoD protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the up-regulation of several genes, including glycodelin and ApoD, during the window of implantation in human endometrium. However, there is no direct mention of an interaction between glycodelin protein and ApoD protein. The context focuses on the differential expression of these proteins and other related genes but does not indicate any specific interaction between glycodelin and ApoD. Therefore, based on the given information, it can be concluded that glycodelin protein and ApoD protein do not interact with each other.</s>
441497 2A2703005 2A2457320	osteopontin	CCL18	[INST]Context: [PMID: 32895164 [Clinical value of biomarkers in diagnosis and treatment of idiopathic pulmonary fibrosis]. Idiopathic pulmonary fibrosis is a chronic interstitial pneumonia characterized by progressive accumulation of fibroblastic foci and destruction of the alveolar structure. Due to an incomplete understanding of the mechanism of the occurrence and progression of idiopathic pulmonary fibrosis, currently no effective means have been available for its early screening or treatment. With a poor overall prognosis, the patients with idiopathic pulmonary fibrosis have a median survival of only 2-4 years. In recent years, several studies have confirmed that dozens of molecules are involved in the development of idiopathic pulmonary fibrosis and can be used as potential biomarkers. These biomarkers play important roles in early diagnosis (such as SP-D, MMP-7, and osteopontin), prognostic evaluation (such as telomerase length, KL-6, mtDNA, HSP-70, LOXL2, CXCL13, miRNA, ICAM-1, and CCL18), and guiding treatment of idiopathic pulmonary fibrosis (such as TOLLIP rs3750920 genotype, SAMS score, and SP-D), and also provide potential therapeutic targets (such as TERT, TERR, RTEC, and PARN).] Question: Based on the provided context, do the terms [osteopontin protein] and [CCL18 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context mentions osteopontin and CCL18 as potential biomarkers involved in the diagnosis and treatment of idiopathic pulmonary fibrosis. However, there is no direct interaction mentioned between osteopontin protein and CCL18 protein. Instead, they are presented as separate entities with distinct roles in the disease process. Therefore, based on the given information, there is no evidence to suggest that osteopontin protein and CCL18 protein interact with each other.</s>
126405 2A2590057 2A2895182	HSP90A	TATA-box binding protein	[INST]Context: [PMID: 34460062 Genomic organization and hypoxia inducible factor responsive regulation of teleost hsp90beta gene during hypoxia stress. BACKGROUND: The physiological significance of a large family of heat-shock proteins, comprised of the cytosolic HSP90A and the endoplasmic reticulum component of HSPB, is evident in prokaryotes and eukaryotes. The HSP90A is believed to play critical roles in diverse physiological functions of cell viability and chromosomal stability including stress management. Heightened abundance of hsp90beta transcript was documented in Channa striatus, a freshwater fish, which is capable of surviving within an extremely hypoxic environment. METHODS AND RESULTS: To better understand the mechanism of hsp90beta gene expression, we investigated its genomic organization. Eleven exons were identified, including a long upstream intron with a remarkable similarity with human, but not with chicken counterpart. The driving capability of this minimal promoter was further validated by its binding ability with TATA-box binding protein and the generation of GFP expressing transgenic zebrafish (F2). Further, deletion of an inverted hypoxia inducible factor motif RCGTG (upstream of the TATA-box) dramatically reduced luciferase expression in a hypoxic environment (CoCl2 treated cultivable cells) and was identified as a cis-acting hypoxia inducible factor responsive element, necessary for the hypoxia-induced expression. CONCLUSIONS: The results obtained herein provide an insight regarding how hsp90beta gene expression is controlled by hypoxia inducible factor responsive element in teleost both during hypoxia stress management and normal physiological functions, and suggested that the hsp90beta gene promoter could be used as a potential candidate for generating ornamental and food-fish transgenics. Zebrafish.] Question: Based on the provided context, do the terms [HSP90A protein] and [TATA-box binding protein protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the genomic organization and hypoxia inducible factor responsive regulation of the hsp90beta gene in teleost fish. It mentions the binding ability of the minimal promoter with the TATA-box binding protein and the generation of GFP expressing transgenic zebrafish. However, there is no direct interaction mentioned between the HSP90A protein and the TATA-box binding protein. Instead, the context focuses on the regulatory mechanisms of the hsp90beta gene and its promoter, not on the interaction between specific proteins.</s>
458135 2A2876688 2A2876709	SUMO-1	SUMO-3	[INST]Context: [PMID: 28545138 SUMO-4: A novel functional candidate in the human placental protein SUMOylation machinery. Functional SUMO family members identified in the human placenta include SUMO-1 to SUMO-3, which are elevated in pre-eclampsia. Whether the fourth isoform, SUMO-4, plays a role in placental development and function remains unknown. OBJECTIVES: We tested the hypothesis that SUMO-4 is expressed in the human placenta and demonstrates altered SUMOylation in pre-eclamptic pregnancies. METHODS: SUMO-4 mRNA (qRT-PCR) and protein (Western blot and immunohistochemistry) were measured in Jar cells, BeWo cells, first trimester placental villous explants and placental tissues across normal gestation and in pre-eclampsia. SUMO-4 expression in response to oxidative stress (H2O2: 0, 0.1, 1 and 5mM), as well as, hypoxia-reperfusion (O2: 1%, 8% and 20%) was measured. Lastly, SUMO-4 binding (covalently vs. non-covalently) to target proteins was investigated. RESULTS: SUMO-4 mRNA and protein were unchanged across gestation. SUMO-4 was present in the villous trophoblast layer throughout gestation. SUMO-4 mRNA expression and protein levels were increased ~2.2-fold and ~1.8-fold in pre-eclamptic placentas compared to age-matched controls, respectively (p<0.01). SUMO-4 mRNA and protein expression increased in Jars, BeWos and first trimester placental explants with 5mM H2O2 treatment, as well as with exposure to hypoxia-reperfusion. SUMO-1 to SUMO-3 did not show consistent trends across models. SUMO-4 hyper-SUMOylation was predominantly covalent in nature. CONCLUSIONS: SUMO-4 is expressed in normal placental development. SUMO-4 expression was increased in pre-eclamptic placentas and in models of oxidative stress and hypoxic injury. These data suggests that SUMO-4 hyper-SUMOylation may be a potential post-translational mechanism in the stressed pre-eclamptic placenta.] Question: Based on the provided context, do the terms [SUMO-1 protein] and [SUMO-3 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between SUMO-1 protein and SUMO-3 protein. It discusses the expression and roles of SUMO-1 to SUMO-3 in the human placenta, particularly in pre-eclampsia and under oxidative stress and hypoxic conditions. However, there is no specific information indicating that SUMO-1 and SUMO-3 interact with each other. Instead, the context focuses on the individual roles and expression patterns of these SUMO isoforms.</s>
339220 2A2794120 2A2781253	L26	L10	[INST]Context: [PMID: 1174537 Characterization of N-ethylmaleimide-reactive proteins from human tonsillar ribosomes by two-dimensional polyacrylamide gel electrophoresis. Human tonsillar 80-S ribosomes were 17% and 43% inactivated by 1 mM N-ethylmaleimide after 12 min at 30 or 37 degrees C, respectively. The ribosomes were unaffected by the reagent during the same period of time at 0 or 20 degrees C. 4, 12, 27 and 59 sulfhydryl groups per 80-S ribosomes were found labeled by 1 mM N-ethyl[14C] maleimide after 12 min at 0, 20, 30 or 37 degrees C, respectively. After 12 min at 37 degrees C, there was a several-fold increase in the extent of radioactivity found in each of these proteins and, additionally, S1, S2, S4, S5, S15, S22 and S31 were also found among labeled 40-S proteins. After 3 min at 37 degrees C, L10, L17, L20 (and/or S20), L26, L32 and L33, and after 12 min at 37 degrees C, additionally L1, L2, L7, L9, L11, L15, L16, L18, and L25 were labeled among 60-S proteins. l17 and 32 were the most N-ethylmaleimide-reactive proteins under these conditions. 26% and 39% of the radioactivity incorporated into the 80 S or 60 S ribosomal protein, respectively, was found in these two proteins. After 12 min at 0 degrees C, S3, L17, L32 and L33 were the only labeled proteins.] Question: Based on the provided context, do the terms [L26 protein] and [L10 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context describes the labeling of various ribosomal proteins by N-ethylmaleimide under different temperature conditions. While it mentions that L26 and L10 are labeled among the 60-S ribosomal proteins after 3 and 12 minutes at 37 degrees C, respectively, there is no indication of a direct interaction between L26 and L10 proteins. The context focuses on the reactivity of these proteins with N-ethylmaleimide rather than any interaction between them.</s>
708986 2A2871057 2A2571813	AGT	GSTO1	[INST]Context: [PMID: 31924810 Genetic Variants Associated with Chronic Kidney Disease in a Spanish Population. Chronic kidney disease patients have many affected physiological pathways. A total of 722 Spanish adults, including 548 patients and 174 controls, were genotyped to better understand the effects of genetic risk loci on the susceptibility to chronic kidney disease. We analyzed 38 single nucleotide polymorphisms in candidate genes associated with the inflammatory response (interleukins IL-1A, IL-4, IL-6, IL-10, TNF-alpha, ICAM-1), fibrogenesis (TGFB1), homocysteine synthesis (MTHFR), DNA repair (OGG1, MUTYH, XRCC1, ERCC2, ERCC4), renin-angiotensin-aldosterone system (CYP11B2, AGT), phase-II metabolism (GSTP1, GSTO1, GSTO2), antioxidant capacity (SOD1, SOD2, CAT, GPX1, GPX3, GPX4), and some other genes previously reported to be associated with chronic kidney disease (GLO1, SLC7A9, SHROOM3, UMOD, VEGFA, MGP, KL). The results showed associations of GPX1, GSTO1, GSTO2, UMOD, and MGP with chronic kidney disease. Additionally, associations with chronic kidney disease related pathologies, such as hypertension (GPX4, CYP11B2, ERCC4), cardiovascular disease, diabetes and cancer predisposition (ERCC2) were also observed. Different genes showed association with biochemical parameters characteristic for chronic kidney disease, such as creatinine (GPX1, GSTO1, GSTO2, KL, MGP), glomerular filtration rate (GPX1, GSTO1, KL, ICAM-1, MGP), hemoglobin (ERCC2, SHROOM3), resistance index erythropoietin (SOD2, VEGFA, MTHFR, KL), albumin (SOD1, GSTO2, ERCC2, SOD2), phosphorus (IL-4, ERCC4 SOD1, GPX4, GPX1), parathyroid hormone (IL-1A, IL-6, SHROOM3, UMOD, ICAM-1), C-reactive protein (SOD2, TGFB1,GSTP1, XRCC1), and ferritin (SOD2, GSTP1, SLC7A9, GPX4). To our knowledge, this is the second comprehensive study carried out in Spanish patients linking genetic polymorphisms and chronic kidney disease.] Question: Based on the provided context, do the terms [AGT protein] and [GSTO1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the AGT protein and the GSTO1 protein. Instead, it lists associations of these proteins with chronic kidney disease and related pathologies separately. There is no indication that these proteins interact with each other to produce a combined effect on chronic kidney disease or any other related condition.</s>
126601 2A2590057 2A2590068	hsp90	hsp90 beta	[INST]Context: [PMID: 8523429 Differential cytoprotection against heat stress or hypoxia following expression of specific stress protein genes in myogenic cells. Cells respond to sub-lethal hear stress by preferential synthesis and accumulation of several members of functionally and compartmentally distinct families of heat shock (or stress) proteins (such as hsp70, hsp90, hsp60 and hsp27). Some of these have been implicated in the development of thermotolerance and resistance to other environmental stresses. The aim of this investigation was to determine the ability of hsp70, hsp90 or hsp60 to individually protect embryonal rat heart-derived H9c2 myocytes against both (i) heat stress and (ii) substrate-free hypoxia. When H9c2 cells were subjected to a sub-lethal stress (43 degrees C for 30 min) they were shown to have elevated levels of hsp70, hsp90 and hsp60 which was maximal between 14-24 h and was associated with increased survival at 24 h against a subsequent lethal heat stress (47 degrees C for 2 h) (20.4 +/- 2.6% v 7.3 +/- 1.8%; P < 0.002). H9c2 myocytes were transfected with a plasmid containing human hsp70i, hsp90 beta or hsp60 expressed under the control of the constitutively active human beta-actin promoter or with control vector alone (containing no hsp gene). Stable colonies of primary transfectants selected for neomycin resistance showed different degrees of over-expression of hsp70i, hsp90 beta or hsp60 expression as determined by Western blotting using specific monoclonal antisera. Cells constitutively expressing high levels of hsp70i showed significantly higher survival against lethal heat stress compared to cells transfected with vector alone (39.2 +/- 6.5% v 4.5 +/- 1.0%; P < 0.0001) and also against 20 h of substrate-free hypoxia (86.4 +/- 3.0% v 3.5 +/- 0.7%; P < 0.0001). Cells constitutively expressing high levels of hsp90 beta also showed significantly higher survival against heat stress (21.5 +/- 3.0% v 9.8 +/- 3.7%; P < 0.05) but were not resistant to 20 hours of substrate-free hypoxia (0.5 +/- 1.0% v 2.0 +/- 1.7%). Cells transfected with the hsp60 plasmid showed no increased survival against either heat stress or substrate-free hypoxia. These results demonstrate that transfection of H9c2 cells with either hsp70i, hsp90 beta or hsp60 genes confers different patterns of protection against heat stress and substrate-free hypoxia, indicating functional differences between stress proteins in their ability to protect against divergent stresses. Rats.] Question: Based on the provided context, do the terms [hsp90 protein] and [hsp90 beta protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The terms hsp90 protein" and "hsp90 beta protein" do not interact with each other in the provided context. The context discusses the expression of different stress proteins, including hsp90 beta, and their effects on cell survival under heat stress and hypoxia. However, there is no mention of a direct interaction between the general "hsp90 protein" and the specific "hsp90 beta protein." Instead, they are presented as separate entities with different roles in cellular protection.</s>"
65527 2A2547785 2A2516455	glyceraldehyde 3-phosphate dehydrogenase	endothelin 1	[INST]Context: [PMID: 33838689 Effect of Shuangdan Mingmu capsule, a Chinese herbal formula, on oxidative stress-induced apoptosis of pericytes through PARP/GAPDH pathway. BACKGROUND: Diabetic retinopathy has become a worldwide concern because of the rising prevalence rate of diabetes mellitus . Despite much energy has been committed to diabetic retinopathy research, it remains a difficulty for diabetic patients all over the world. Since apoptosis of retinal microvascular pericytes is the early characteristic of diabetic retinopathy, this study aimed to reveal the mechanism of Shuangdan Mingmu capsule, a Chinese patent medicine, on oxidative stress-induced apoptosis of pericytes implicated with poly (ADP-ribose) polymerase (PARP) / glyceraldehyde 3-phosphate dehydrogenase (GAPDH) pathway. METHODS: Network pharmacology approach was performed to predict biofunction of components of shuangdan mingmu capsule dissolved in plasma on diabetic retinopathy. Both PARP1 and GAPDH were found involved in the hub network of protein-protein interaction of potential targets and were found to take part in many bioprocesses, including responding to the regulation of reactive oxygen species metabolic process, apoptotic signaling pathway, and response to oxygen levels through enrichment analysis. Human retinal microvascular pericytes cultured with media containing 0.5___mM hydrogen oxide for 4___h was performed as an oxidative-damage model. Different concentrations of shuangdan mingmu capsule, PARP1 inhibitor, PARP1 activation, and GAPDH inhibitor were used to intervene the oxidative-damage model with N-Acetyl-L-cysteine as a contrast. Flow cytometry was performed to determine the apoptosis rate of cells and the expression of reactive oxygen species. Cell counting kit 8 was used to determine the activity of pericytes. Moreover, nitric oxide concentration of cells supernatant and expression of endothelial nitric oxide synthase, superoxide dismutase, B cell lymphoma 2, vascular endothelial growth factor, endothelin 1, PARP1, and GAPDH were tested through RT-qPCR, western blot, or immunocytochemistry . RESULTS: Overproduction of reactive oxygen species, high apoptotic rate, and attenuated activity of pericytes were observed after cells were incubated with media containing 0.5___mM hydrogen oxide. Moreover, downregulation of superoxide dismutase, nitric oxide, b cell lymphoma 2, and GAPDH, and upregulation of VEGFA, endothelin 1, and PARP1 were discovered after cells were exposed to 0.5___mM hydrogen oxide in this study, which could be improved by PARP1 inhibitor and shuangdan mingmu capsule in a dose-dependent way, whereas worsened by PARP1 activation and GAPDH inhibitor. CONCLUSIONS: shuangdan mingmu capsule may attenuate oxidative stress-induced apoptosis of pericytes through downregulating PARP expression and upregulating GAPDH expression.] Question: Based on the provided context, do the terms [glyceraldehyde 3-phosphate dehydrogenase protein] and [endothelin 1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not indicate a direct interaction between glyceraldehyde 3-phosphate dehydrogenase (GAPDH) protein and endothelin 1 protein. Instead, it describes the effects of various interventions (such as PARP1 inhibitor, PARP1 activation, and GAPDH inhibitor) on the expression of these proteins and other related molecules in the context of oxidative stress-induced apoptosis of pericytes. While both proteins are mentioned in the study, there is no direct interaction between them described in the context.</s>
551719 2A2610838 2A2854079	cytokeratin 8	selenium binding protein 1	[INST]Context: [PMID: 15378696 Gastric adenocarcinoma is one of the most common cancers in Asian countries including China. Although its incidence rates in the West are lower than that in Asia, gastric cancer is still a major health problem worldwide, being second only to lung cancers in the number of deaths it causes. Helicobacter pylori infection has been identified as the major pathogen, but the detailed pathogenesis of gastric carcinoma remains elusive. In this study, we used a proteomic approach to globally analyze the protein profiles of paired surgical specimens of primary gastric adenocarcinoma and nontumor mucosa aiming at identifying specific disease-associated proteins as potential clinical biomarkers and for carcinogenetic study. Some of these alterations involve variations in the expression of cytoskeleton proteins, including an increase in cytokeratin 8 and tropomyosin isoform and a decrease in cytokeratin 20. Diverse regulations also occurred with proteins involved in cell proliferation and differentiation, such as GMP reductase 2 and creatine kinase B, and proteins bearing potential tumor suppressor activities, including prohibitin and selenium binding protein 1. More interestingly, a human stomach-specific protein, 18 kDa antrum mucosa protein, was found to be dramatically under-expressed in cancer tissues, implicating a possible special pathological role for this protein in gastric carcinogenesis. Further comprehensive evaluation by globally considering the altered factors may result in the discovery of a biomarker index for effective assessment of the disease and may provide in-depth information for better understanding the pathogenesis of gastric cancer.] Question: Based on the provided context, do the terms [cytokeratin 8 protein] and [selenium binding protein 1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the altered expression of various proteins in gastric adenocarcinoma, including cytokeratin 8 and selenium binding protein 1. However, there is no mention of a direct interaction between cytokeratin 8 protein and selenium binding protein 1 protein. The context describes their individual roles and changes in expression levels but does not indicate any interaction between these two proteins.</s>
545933 2A2640021 2A2736925	MAP4	PRDX6	[INST]Context: [PMID: 28222113 Differentially expressed proteins underlying childhood cortical dysplasia with epilepsy identified by iTRAQ proteomic profiling. Cortical dysplasia accounts for at least 14% of epilepsy cases, and is mostly seen in children. However, the understanding of molecular mechanisms and pathogenesis underlying cortical dysplasia is limited. The aim of this cross-sectional study is to identify potential key molecules in the mechanisms of cortical dysplasia by screening the proteins expressed in brain tissues of childhood cortical dysplasia patients with epilepsy using isobaric tags for relative and absolute quantitation-based tandem mass spectrometry compared to controls, and several differentially expressed proteins that are not reported to be associated with cortical dysplasia previously were selected for validation using real-time polymerase chain reaction, immunoblotting and immunohistochemistry. 153 out of 3340 proteins were identified differentially expressed between childhood cortical dysplasia patients and controls. And FSCN1, CRMP1, NDRG1, DPYSL5, MAP4, and FABP3 were selected for validation and identified to be increased in childhood cortical dysplasia patients, while PRDX6 and PSAP were identified decreased. We identified differential expression of FSCN1, CRMP1, NDRG1, DPYSL5, MAP4, FABP3, PRDX6 and PSAP in childhood cortical dysplasia patients, these proteins are involved in various processes and have various function.] Question: Based on the provided context, do the terms [MAP4 protein] and [PRDX6 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between MAP4 protein and PRDX6 protein. It only lists these proteins as differentially expressed in childhood cortical dysplasia patients compared to controls. There is no indication that these proteins interact with each other or have a combined effect on the condition. Instead, they are presented as separate entities with different expression levels.</s>
174310 2A2735098 2A2652473	PPIA	MAPK9	[INST]Context: [PMID: 32364075 Diabetes-specific Modulation of Peripheral Blood Gene Expression Signatures in Colorectal Cancer. BACKGROUND: Type 2 diabetes and colorectal cancer are both known to modulate gene expression patterns in peripheral blood leukocytes . OBJECTIVE: As type 2 diabetes has been shown to increase the incidence of colorectal cancer, we were prompted to check whether diabetes affects mRNA signatures in peripheral blood leukocytes isolated from colorectal cancer patients. METHODS: Twenty-two patients were recruited to the study and classified into four cohorts (healthy controls; type 2 diabetes; colorectal cancer; colorectal cancer and T2DM). RESULTS: 49 genes were found to be significantly up- or downregulated in tumorous diabetic individuals as compared to tumor-free diabetic controls, while 11 transcripts were differentially regulated in patients with colorectal cancer versus healthy, tumor-free and nondiabetic controls. Importantly, these gene sets were completely distinct, implying that diabetes exerts a profound influence on the transcription of signaling genes in colorectal cancer. The top 5 genes showing the most significant expression differences in both contexts were PCK2, MAPK9, CCND1, HMBS, TLR3 (p___0.0040) and CREBBP, PPIA, NFKBIL1, MDM2 and SELPLG (p___0.0121), respectively. CONCLUSION: We propose that differentially expressed genes listed above might be potential biomarkers of colorectal cancer and should be studied further on larger patient groups. Diabetes might promote colorectal carcinogenesis by impairing signaling pathways in peripheral blood leukocytes.] Question: Based on the provided context, do the terms [PPIA protein] and [MAPK9 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between PPIA protein and MAPK9 protein. While both proteins are listed among the top differentially expressed genes in the study, there is no indication that they interact with each other. The context focuses on the overall gene expression patterns in peripheral blood leukocytes from colorectal cancer patients with and without diabetes, but it does not provide specific details about interactions between individual proteins.</s>
666254 2A2476268 2A2735967	COMT	DARPP32	[INST]Context: [PMID: 21563886 Dopamine and the management of attentional resources: genetic markers of striatal D2 dopamine predict individual differences in the attentional blink. Given that dopamine plays a crucial role working memory, the present study tested whether individual differences in the size of the attentional blink can be predicted by differences in genetic predisposition related to the efficiency of dopaminergic pathways. Polymorphisms related to mesocortical and nigrostriatal dopaminergic pathways were considered, as well as polymorphisms related to norepinephrine, a transmitter system that has also been suspected to play a role in the attentional blink. In a sample of 157 healthy adults, we studied the dependency of the individual magnitude of the attentional blink and the C957T polymorphism at the DRD2 gene (associated with striatal DA/D2 receptors), the DARPP32 polymorphism (associated with striatal DA/D1), the COMT Val(158)Met polymorphism (associated with frontal DA), DBH444 g/a and DBH5'-ins/del polymorphisms (polymorphisms strongly correlated with dopamine beta hydroxylase, the enzyme catalyzing the DA-norepinephrine conversion) and NET T-182C (a polymorphism related to the norepinephrine transporter). DRD2 C957T T/T homozygotes showed a significantly smaller attentional blink, whereas polymorphisms associated with frontal dopamine and norepinephrine were unrelated to performance. This outcome pattern suggests a crucial role of the nigrostriatal dopaminergic pathway and of nigrostriatal D2 receptors, in particular, in the management of attentional resources.] Question: Based on the provided context, do the terms [COMT protein] and [DARPP32 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the roles of various genetic polymorphisms related to dopamine and norepinephrine in the attentional blink, specifically mentioning the COMT Val(158)Met polymorphism and the DARPP32 polymorphism. However, there is no direct interaction mentioned between the COMT protein and the DARPP32 protein. Instead, they are presented as separate entities associated with different dopaminergic pathways and their effects on attentional resources. Therefore, based on the given information, there is no evidence to suggest that the COMT protein and the DARPP32 protein interact with each other.</s>
690581 2A2621019 2A2735967	DLG4	PPP1R1B	[INST]Context: [PMID: 35142030 Neurodegeneration and astrogliosis in the entorhinal cortex in Alzheimer's disease: Stereological layer-specific assessment and proteomic analysis. INTRODUCTION: The entorhinal cortex is among the earliest areas involved in Alzheimer's disease. Human entorhinal cortex atrophy is, in part, due to neural loss, but microglial and/or astroglial involvement in the different layers remains unclear. Additionally, -omic approaches in the human entorhinal cortex are scarce. METHODS: Herein, stereological layer-specific and proteomic analyses were carried out in the human brain. RESULTS: Neurodegeneration, microglial reduction, and astrogliosis have been demonstrated, and proteomic data have revealed relationships with up- (S100A6, PPP1R1B, BAG3, and PRDX6) and downregulated (GSK3B, SYN1, DLG4, and RAB3A) proteins. Namely, clusters of these proteins were related to synaptic, neuroinflammatory, and oxidative stress processes. DISCUSSION: Differential layer involvement among neural and glial populations determined by proteinopathies and identified proteins related to neurodegeneration and astrogliosis could explain how the cortical circuitry facilitates pathological spreading within the medial temporal lobe.] Question: Based on the provided context, do the terms [DLG4 protein] and [PPP1R1B protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between DLG4 protein and PPP1R1B protein. Instead, it lists these proteins as part of a proteomic analysis that reveals relationships with up- and downregulated proteins in the human entorhinal cortex. The context discusses the roles of these proteins in synaptic, neuroinflammatory, and oxidative stress processes but does not indicate any specific interaction between DLG4 and PPP1R1B.</s>
576712 2A2416086 2A2905922	Annexin V	TNFRSF6	[INST]Context: [PMID: 11096418 Regulation of TNFRSF6 (Fas) expression in ataxia telangiectasia cells by ionizing radiation. Several studies have shown that ionizing radiation induces transcription of the TNFRSF6 (Fas) gene, leading to augmented TNFRSF6 protein levels at the surface of irradiated cells. We have examined TNFRSF6 expression in an apparently normal lymphocyte line and in a lymphocyte cell line derived from a patient with ataxia telangiectasia before and after exposure to radiation (0-10 Gy). Plasma membranes were isolated from normal lymphocytes and ataxia telangiectasia cells and subjected to Western blot analysis, using a TNFRSF6-specific monoclonal antibody to probe resolved proteins transferred onto nitrocellulose membranes. In both cell types, the presence of a 48-kDa band corresponding to the molecular mass of TNFRSF6 was revealed. Analysis of FITC-conjugated anti-TNFRSF6 antibody-stained normal lymphocytes and ataxia telangiectasia cells confirmed TNFRSF6 expression in both cell types. In MTT assays, ataxia telangiectasia cells treated with agonistic anti-TNFRSF6 Ab (CH.11) displayed a 25.9% decrease in cell viability, relative to cells treated with isotype-matched IgM Ab, suggesting the presence of a biologically active TNFRSF6 receptor at the ataxia telangiectasia cell surface. Exposure to cycloheximide (0-5 microg/ml), a metabolic inhibitor, enhanced sensitivity of ataxia telangiectasia cells to CH.11. Normal lymphocytes exhibited increased levels of apoptosis (approximately 34% cell death relative to cells treated with isotype-matched IgM Ab) when exposed to CH.11; However, the degree of cell death was not altered significantly with increasing concentrations of cycloheximide. When ataxia telangiectasia cells were exposed to 0.1, 0.5, 2 and 10 Gy, the activities of caspases 3 and 8 increased in a dose-dependent manner at 24 h postirradiation and reached a plateau by 72 h. A similar trend for activation of caspase 3 and 8 was observed in normal lymphocytes after irradiation. To assess the roles of TNFRSF6 and/or caspase 8 in radiation-induced cell death of ataxia telangiectasia and normal lymphocytes, and to determine whether hyper-radiosensitivity in ataxia telangiectasia cells is correlated with increased activity of these two components of the TNFRSF6 pathway, ataxia telangiectasia and normal lymphocytes were irradiated in the presence of ZB4, an anti-TNFRSF6 blocking antibody, and a caspase 8 inhibitor (Z-IETD-FMK). Apoptosis was determined by Annexin V staining using flow cytometry. Incubation with ZB4 anti-TNFRSF6 antibody did not alter the fraction of apoptotic cells in either ataxia telangiectasia cells or normal lymphocytes treated with doses of radiation ranging from 0-10 Gy. In contrast, apoptosis was significantly reduced in both cell lines in the presence of Z-IETD-FMK when samples were exposed to low-dose (< or = 2 Gy) radiation. Relative to control samples (those not incubated with Z-IETD-FMK), no difference in the level of apoptosis was observed in ataxia telangiectasia or normal lymphocytes treated with 10 Gy. These data indicate that: (a) despite radiation-induced up-regulation of TNFRSF6 at the cell surface, the death-promoting receptor does not play a role in radiation-mediated cytotoxicity; (b) apoptosis in lymphocytes irradiated with low (< or = 2 Gy) but not high doses (>2 Gy) proceeds at least in part through activation of caspase 8; And (3) since blocking anti-TNFRSF6 antibody (ZB4) did not reduce levels of apoptosis in irradiated ataxia telangiectasia cells to those of normal lymphocytes, TNFRSF6 is unlikely to play a significant role in the hyper-radiosensitivity exhibited by cells having the ataxia telangiectasia phenotype.] Question: Based on the provided context, do the terms [Annexin V protein] and [TNFRSF6 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the roles of TNFRSF6 (Fas) and caspase 8 in radiation-induced cell death in ataxia telangiectasia and normal lymphocytes. It mentions the use of Annexin V staining to determine apoptosis levels but does not indicate a direct interaction between Annexin V protein and TNFRSF6 protein. Instead, Annexin V is used as a marker to assess apoptosis, which is influenced by the activity of TNFRSF6 and caspase 8, but not as a direct interaction between the two proteins.</s>
102728 2A2704682 2A2748379	tumor protein p53	phosphatase and tensin homolog	[INST]Context: [PMID: 29302581 Novel Genetic Associations Between Lung Cancer and Indoor Radon Exposure. Background: Lung cancer is the leading cause of cancer-related death worldwide, for which smoking is considered as the primary risk factor. The present study was conducted to determine whether genetic alterations induced by radon exposure are associated with the susceptible risk of lung cancer in never smokers. Methods: To accurately identify mutations within individual tumors, next generation sequencing was conduct for 19 pairs of lung cancer tissue. Results: Alterations in several genes were implicated in lung cancer resulting from exposure to radon indoors, namely those in epidermal growth factor receptor, tumor protein p53, NK2 homeobox 1 (NKX2.1), phosphatase and tensin homolog (PTEN), chromodomain helicase DNA binding protein 7 (CHD7), discoidin domain receptor tyrosine kinase 2 (DDR2), lysine methyltransferase 2C (MLL3), chromodomain helicase DNA binding protein 5 (CHD5), FAT atypical cadherin 1 (FAT1), and dual specificity phosphatase 27 (putative) (DUSP27). Conclusions: While these genes might regulate the carcinogenic pathways of radioactivity, further analysis is needed to determine whether the genes are indeed completely responsible for causing lung cancer in never smokers exposed to residential radon.] Question: Based on the provided context, do the terms [tumor protein p53 protein] and [phosphatase and tensin homolog protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context lists several genes implicated in lung cancer resulting from exposure to radon indoors, including tumor protein p53 (TP53) and phosphatase and tensin homolog (PTEN). However, it does not mention any direct interaction between the tumor protein p53 protein and the phosphatase and tensin homolog protein. The context focuses on the role of these genes in the carcinogenic pathways but does not describe any specific interaction between the proteins encoded by these genes.</s>
682563 2A2457284 2A2680606	eotaxin	TH1	[INST]Context: [PMID: 31655881 The time course of nasal cytokine secretion in patients with aspirin-exacerbated respiratory disease undergoing aspirin desensitization: preliminary data. PURPOSE: Aspirin-exacerbated respiratory disease is a severe form of chronic rhinosinusitis with nasal polyps accompanied by asthma and an aspirin intolerance. The underlying pathomechanism of aspirin-exacerbated respiratory disease still remains unclear, recent data suggest a complex inflammatory imbalance. In the present study, we investigated the cytokine patterns in aspirin-exacerbated respiratory disease, chronic rhinosinusitis with nasal polyps and healthy control patients. Furthermore, we describe the change in cytokine level in the course of aspirin desensitization with continuous intake of aspirin. METHODS: The study included a total of 104 participants, 48 healthy controls, 45 patients with nasal polyps and 11 patients with aspirin-exacerbated respiratory disease undergoing aspirin desensitization. Nasal secretions were analyzed for IL-1beta, IL-4, IL-5, IL-10, IL-12, IL-13, IL-17, THF-alpha, IFN-gamma, eotaxin and ECP using Bio-Plex Human Cytokine Assay and Uni-CAP FEIA. Baseline measurements of cytokine levels were performed in all 104 patients; In patients with aspirin-exacerbated respiratory disease, follow-up was performed 1-6 and 6-24 months after the initiation of aspirin desensitization. RESULTS: Our preliminary results show a TH2 dominated, eosinophilic milieu in aspirin-exacerbated respiratory disease patients, which decreased in the first weeks of aspirin desensitization. However, after 6 months of aspirin desensitization, proinflammatory cytokines show a tendency to increase again. Also, TH1 as well as Treg associated cytokine seem to increase over time. CONCLUSIONS: For the first time, the present work shows the cytokine pattern in nasal secretions of aspirin-exacerbated respiratory disease patients before and during aspirin desensitization. Further investigation of the complex interaction of inflammatory cytokines during aspirin desensitization might reveal important insights into the disease entity of aspirin-exacerbated respiratory disease and open up new horizons for a targeted therapy.] Question: Based on the provided context, do the terms [eotaxin protein] and [TH1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between eotaxin protein and TH1 protein. While both are part of the inflammatory cytokine milieu in aspirin-exacerbated respiratory disease, the text describes their levels and trends separately without indicating any direct interaction between them. The focus is on the overall cytokine patterns and their changes during aspirin desensitization rather than specific interactions between individual cytokines.</s>
477883 2A2457295 2A2457399	MCP-4	MCP-3	[INST]Context: [PMID: 10516663 Characterization of chemokine CCR3 agonist-mediated eosinophil recruitment in the Brown-Norway rat. The ability of various C-C chemokines to elicit tissue eosinophil infiltration following intradermal injection or peripheral blood eosinophilia following intravenous injection were compared in the Brown-Norway rat. Eotaxin (0.1 - 3 microg site-1) of human and murine origin produced equivalent, dose-dependent increases in eosinophil peroxidase activity in rat dermis 4 h post-injection. Human eotaxin-2 was equipotent with human eotaxin in terms of dermal eosinophil recruitment. Other human CCR3 agonists, such as MCP-3, RANTES and MCP-4 failed to increase dermal eosinophil peroxidase activity at doses up to 1 microg site-1 whereas the latter did produce a small effect at 3 microg site-1. Consistent with observations in vivo, human eotaxin displaced [125I]-eotaxin from rat spleen membranes more potently (IC50=2 nM) than did MCP-4 (IC50=500 nM). RANTES did not compete with the radiolabelled chemokine at concentrations up to 1 microM. Human eotaxin (5 microg) administered intravenously increased circulating eosinophils approximately 3 fold whereas MCP-4 (5 microg i.v.) increased circulating monocytes approximately 3 fold without affecting eosinophil numbers. Dexamethasone pretreatment inhibited eotaxin-induced dermal eosinophil influx only at a steroid dose (0.1 mg kg-1, s.c.) which significantly reduced circulating eosinophil numbers. The steroid also reduced eosinophilia in peripheral blood resulting from systemic eotaxin administration (5 microg, i.v.). These data suggest differences in rat CCR3 relative to other species as surmised from a distinctive rank order of chemokine potency. In addition to its chemotactic effects eotaxin, but not MCP-4, promotes eosinophil recruitment into the circulation. One of the mechanisms by which glucocorticoids, such as dexamethasone, acutely inhibits eotaxin-induced dermal eosinophil influx is to diminish the circulating numbers of these cells available for tissue recruitment. From MeSH: Rats.] Question: Based on the provided context, do the terms [MCP-4 protein] and [MCP-3 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between MCP-4 protein and MCP-3 protein. Instead, it discusses the effects of various chemokines, including MCP-3 and MCP-4, on eosinophil recruitment and peripheral blood eosinophilia in Brown-Norway rats. The context describes the potency and effects of each chemokine separately, without indicating any interaction between MCP-4 and MCP-3.</s>
403778 2A2592161 2A2601113	Hsp70	IL-33	[INST]Context: [PMID: 20731692 Standardized tape stripping prior to patch testing induces upregulation of Hsp90, Hsp70, IL-33, TNF-alpha and IL-8/CXCL8 mRNA: new insights into the involvement of 'alarmins'. It is under discussion whether the cutaneous inflammation induced by tape stripping is a pivotal element in enhancing the allergic contact dermatitis response. OBJECTIVES: To investigate epidermal mRNA expression of mediators implicated in the regulation of inflammation induced by tape stripping according to our standardized protocol in human skin. We measured epidermal mRNAs coding for cytokines [tumour necrosis factor-alpha (TNF-alpha), interferon-gamma, interleukin -1alpha, IL-1beta, IL-33, IL-10, IL-8/CXCL8, chemokine (C-C motif) ligand 2 (CCL2)/MCP-1 (monocyte chemotactic protein-1), chemokine (C-C motif) ligand 5 (CCL5)/RANTES (regulated upon activation normal T-cell expressed, and presumably secreted), IL-6, granulocyte-macrophage colony-stimulating factor ], an adhesion molecule [intercellular adhesion molecule type 1 (ICAM-1)], heat shock proteins (Hsp27, Hsp70 and Hsp90), and the inflammasome complex [NACHT-LRR-PYD-containing protein-3 (NALP3), apoptosis-associated speck-like protein containing a CARD /CARD5 (caspase recruitment domain-containing protein-5) and caspase-1] in tape-stripped skin of the upper back relative to untreated skin of the upper back, using quantitative real-time reverse transcription polymerase chain reaction technology. RESULTS: Epidermal mRNA expression levels of TNF-alpha, Hsp90, Hsp70, IL-33, and IL-8/CXCL8 were significantly upregulated, whereas CCL5/RANTES expression was significantly downregulated 6 hr after standardized tape stripping. CONCLUSIONS: Tape stripping the skin according to our standardized protocol shows immunostimulatory effects, with induction of keratinocyte-derived 'alarmins' and cytokines mounting an immune response, which may contribute to the increased sensitivity of the strip patch test versus the patch test.] Question: Based on the provided context, do the terms [Hsp70 protein] and [IL-33 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the upregulation of various epidermal mRNAs, including Hsp70 and IL-33, following tape stripping. However, it does not mention any direct interaction between the Hsp70 protein and the IL-33 protein. Instead, it describes their individual upregulation as part of the immune response induced by tape stripping. Therefore, there is no evidence of a direct interaction between Hsp70 and IL-33 in the given context.</s>
221462 2A2556000 2A2875098	Gemin7	Unrip	[INST]Context: [PMID: 20515655 Analysis of SMN-neurite granules: Core Cajal body components are absent from SMN-cytoplasmic complexes. Childhood spinal muscular atrophy is caused by a reduction in survival motor neuron protein. Survival motor neuron is a ubiquitously expressed house keeping protein that is involved in RNA production and processing. However, although survival motor neuron is expressed in every cell type, only the lower motor neurons of the spinal cord are degraded in spinal muscular atrophy. Recently, survival motor neuron has been linked to the axonal transport of beta-actin mRNA from the cell body down to the growth cones. Beta-Actin is transported actively in neurite granules . To address this we have analysed SMN-neurite granules in a human neuronal cell line, SH-SY5Y, using antibodies against the majority of reported SMN-binding partners, including: Gemin2, Gemin3, Gemin4, Gemin5, Gemin6, Gemin7, Sm core proteins, fibrillarin, EWS, PFNII, Unrip and ZPR1. The obtained results highlight the metamorphic nature of the survival motor neuron complex, suggesting that not all the 'core' SMN-binding proteins are transported in SMN-NGs.] Question: Based on the provided context, do the terms [Gemin7 protein] and [Unrip protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the analysis of SMN-neurite granules and the presence of various SMN-binding proteins, including Gemin7 and Unrip. However, it does not mention any direct interaction between Gemin7 protein and Unrip protein. Instead, it lists them as separate components that are part of the SMN complex but does not indicate any specific interaction between them.</s>
66999 2A2944014 2A2763386	Ku70	Rad51	[INST]Context: [PMID: 25216575 Human papillomavirus type 16 E7 oncoprotein causes a delay in repair of DNA damage. BACKGROUND AND PURPOSE: Patients with human papillomavirus related (HPV+) head and neck cancers demonstrate improved clinical outcomes compared to traditional HPV negative (HPV-) HNC patients. We have recently shown that HPV+ HNC cells are more sensitive to radiation than HPV- HNC cells. However, roles of HPV oncogenes in regulating the response of DNA damage repair remain unknown. MATERIAL AND METHODS: Using immortalized normal oral epithelial cell lines, HPV+ HNC derived cell lines, and HPV16 E7-transgenic mice we assessed the repair of DNA damage using gamma-H2AX foci, single and split dose clonogenic survival assays, and immunoblot. The ability of E7 to modulate expression of proteins associated with DNA repair pathways was assessed by immunoblot. RESULTS: HPV16 E7 increased retention of gamma-H2AX nuclear foci and significantly decreased sublethal DNA damage repair. While phospho-ATM, phospho-ATR, Ku70, and Ku80 expressions were not altered by E7, Rad51 was induced by E7. Correspondingly, HPV+ HNC cell lines showed retention of Rad51 after gamma-radiation. CONCLUSIONS: Our findings provide further understanding as to how HPV16 E7 manipulates cellular DNA damage responses that may underlie its oncogenic potential and influence the altered sensitivity to radiation seen in HPV+ HNC as compared to HPV- HNC. Mice.] Question: Based on the provided context, do the terms [Ku70 protein] and [Rad51 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not indicate a direct interaction between the Ku70 protein and the Rad51 protein. While both proteins are involved in DNA repair pathways, the context mentions that the expression of Ku70 and Ku80 was not altered by E7, whereas Rad51 was induced by E7. This suggests that E7 influences the expression of these proteins independently rather than through a direct interaction between Ku70 and Rad51.</s>
574623 2A2734750 2A2587344	peroxisome proliferator-activated receptor-alpha	High mobility group box-1	[INST]Context: [PMID: 24928512 High mobility group box-1 participates in the pathogenesis of alcoholic liver disease . Growing clinical and experimental evidence suggests that sterile inflammation contributes to alcoholic liver disease . High mobility group box-1 is highly induced during liver injury; Thus, the aim of this work was to determine whether high mobility group box-1 contributes to the pathogenesis of alcoholic liver disease. Liver biopsies from patients with alcoholic liver disease showed a robust increase in high mobility group box-1 expression and translocation, which correlated with disease stage, compared with healthy explants. Similar findings were observed in chronic ethanol-fed wild-type mice. Using primary cell culture, we validated the ability of hepatocytes from ethanol-fed mice to secrete a large amount of high mobility group box-1. Selective ablation of Hmgb1 in hepatocytes protected mice from alcohol-induced liver injury due to increased carnitine palmitoyltransferase-1, phosphorylated 5'AMP-activated protein kinase-alpha, and phosphorylated peroxisome proliferator-activated receptor-alpha expression along with elevated LDL plus VLDL export. Native and post-translationally modified high mobility group box-1 were detected in humans and mice with alcoholic liver disease. In liver and serum from control mice and in serum from healthy volunteers, the lysine residues within the peptides containing nuclear localization signals 1 and 2 were non-acetylated, and all cysteine residues were reduced. However, in livers from ethanol-fed mice, in addition to all thiol/non-acetylated isoforms of high mobility group box-1, we observed acetylated NLS1 and NLS2, a unique phosphorylation site in serine 35, and an increase in oxidation of high mobility group box-1 to the disulfide isoform. In serum from ethanol-fed mice and from patients with alcoholic liver disease, there was disulfide-bonded hyperacetylated high mobility group box-1, disulfide-bonded non-acetylated high mobility group box-1, and high mobility group box-1 phosphorylated in serine 35. Hepatocytes appeared to be a major source of these high mobility group box-1 isoforms. Thus, hepatocyte high mobility group box-1 participates in the pathogenesis of alcoholic liver disease and undergoes post-translational modifications that could condition its toxic effects. Mice.] Question: Based on the provided context, do the terms [peroxisome proliferator-activated receptor-alpha protein] and [High mobility group box-1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not indicate a direct interaction between the peroxisome proliferator-activated receptor-alpha protein and the high mobility group box-1 protein. Instead, it describes the effects of high mobility group box-1 on the expression of peroxisome proliferator-activated receptor-alpha and its downstream targets, such as carnitine palmitoyltransferase-1 and phosphorylated 5'AMP-activated protein kinase-alpha. The context suggests that high mobility group box-1 influences the activity of peroxisome proliferator-activated receptor-alpha indirectly, rather than through a direct interaction.</s>
169632 2A2764298 2A2439242	NRAS	ATRX	[INST]Context: [PMID: 30028779 Female genitourinary tract melanoma: mutation analysis with clinicopathologic correlation: a single-institution experience. Female genitourinary tract melanoma is a rare and often-fatal form of mucosal melanoma. We describe our institutional experience with 55 cases of female genitourinary tract melanoma, 16 of which were evaluated with next-generation sequencing targeting 151 cancer-associated genes. Tumors tended to be thicker than conventional melanoma at presentation (median: 3.2___mm), were frequently ulcerated (50%), and characterized by incomplete initial resections. Genomic analysis revealed mutually exclusive mutations in TP53 and KIT in 25%, while 19% of cases showed BRAF mutation. NRAS mutation was found in 13% of cases. Mutation in ATRX, previously undescribed in mucosal melanoma, was seen in three (10%) of 16 patients. Only invasive melanoma cases were included in statistical analyses. Patients with three or more mutations had marginally worse overall survival rates than those with two or less (P=0.07). Further studies are required for potential adjuvant treatment modalities to improve survival outcomes of female genitourinary tract melanoma.] Question: Based on the provided context, do the terms [NRAS protein] and [ATRX protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the NRAS protein and the ATRX protein. It describes the occurrence of mutations in these genes in female genitourinary tract melanoma but does not indicate any interaction between the proteins encoded by these genes. Instead, it focuses on the individual roles of these mutations in the context of melanoma.</s>
25923 2A2749708 2A2610558	PTN	APACHE	[INST]Context: [PMID: 34608231 Longitudinal urinary biomarkers of immunological activation in covid-19 patients without clinically apparent kidney disease versus acute and chronic failure. Kidney function is affected in COVID-19, while kidney itself modulates the immune response. Here, hypothesize if COVID-19 urine biomarkers level can assess immune activation vs. clinical trajectory. Considering the kidney's critical role in modulating the immune response, we sought to analyze activation markers in patients with pre-existing dysfunction. This was a cross-sectional study of 68 patients. Serum level ferritin, procalcitonin, IL-6 assessed immune activation overall, while the response to viral burden was gauged with serum level of spike protein and alphaspike IgM and IgG. The burden of pre-existing conditions correlated with urine DCN, CAIX and PTN, but inversely with IL-5 or MCP-4. Higher urinary IL-12 and lower CAIX, CCL23, IL-15, IL-18, MCP-1, MCP-3, MUC-16, PD-L1, TNFRS12A, and TNFRS21 signified non-survivors. APACHE correlated with urine TNFRS12, PGF, CAIX, DCN, CXCL6, and EGF. Admission urine LAG-3 and IL-2 predicted death. Acute kidney injury was associated, and to a certain degree, predicted by IFNg, TWEAK, MMP7, and MUC-16. Remdesavir had a more profound effect on the urine biomarkers than steroids. Urinary biomarkers correlated with clinical status, kidney function, markers of the immune system activation, and probability of demise in COVID-19. From MeSH: COVID-19. SARS-CoV-2.] Question: Based on the provided context, do the terms [PTN protein] and [APACHE protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between PTN protein and APACHE protein. PTN protein (pleiotrophin) is mentioned in relation to its correlation with pre-existing conditions and its association with urine biomarkers, while APACHE (Acute Physiology and Chronic Health Evaluation) is mentioned in relation to its correlation with urine biomarkers and clinical status. There is no indication that these two proteins interact with each other directly. Instead, they are presented as separate entities with their own associations and correlations within the context of COVID-19 and its effects on the immune system and kidney function.</s>
244188 2A2671257 2A2763386	MUTYH	RAD51	[INST]Context: [PMID: 29854292 Breast cancer arising in very young patients may be biologically distinct; We characterized a group of very young patients (___ 35 years) for BRCA germline mutation and for somatic mutations in luminal (HER2 negative) breast cancer. Thirteen of 79 unselected very young patients were BRCA1/2 germline mutation carriers. Of the non-BRCA tumors, eight with luminal subtype (HER2 negative) were submitted for whole exome sequencing and integrated with 29 luminal samples from the COSMIC database or previous literature for analysis. A median of six candidate driver genes was mutated by single nucleotide variants in each sample and the most frequently mutated genes were PIK3CA, GATA3, TP53 and MAP2K4. Potential cancer drivers affected in the present non-BRCA tumors include GRHL2, PIK3AP1, CACNA1E, SEMA6D, SMURF2, RSBN1 and MTHFD2. Sixteen out of 37 luminal tumors (43%) harbored single nucleotide variants in DNA repair genes, such as ATR, BAP1, ERCC6, FANCD2, FANCL, MLH1, MUTYH, PALB2, POLD1, POLE, RAD9A, RAD51 and TP53, and 54% presented pathogenic mutations (frameshift or nonsense) in at least one gene involved in gene transcription. The differential biology of luminal early-age onset breast cancer needs a deeper genomic investigation.] Question: Based on the provided context, do the terms [MUTYH protein] and [RAD51 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the MUTYH protein and the RAD51 protein. It lists these proteins as part of a group of DNA repair genes that are mutated in luminal tumors, but it does not describe any specific interaction between MUTYH and RAD51. Therefore, based on the given information, there is no evidence to suggest that these two proteins interact with each other.</s>
390164 2A2532268 2A2905922	FABP3	FAs	[INST]Context: [PMID: 30790507 Linoleic Acid Increases Prostaglandin E2 Release and Reduces Mitochondrial Respiration and Cell Viability in Human Trophoblast-Like Cells. However, omega 6 FAs can alter cellular metabolism via inflammation or modulation of mitochondrial function. Fetal linoleic acid is obtained from the maternal diet, and FAs are transported to the fetus via placental fatty acid transporters and binding proteins (FABPs), but specific proteins responsible for linoleic acid transport in placental trophoblasts are unknown. Dietary linoleic acid consumption is increasing, but the effect of elevated linoleic acid on trophoblast function is not clear. METHODS: Swan71 trophoblasts were exposed to physiological and supraphysiological concentrations of linoleic acid for 24 hours. Cell viability, citrate synthase activity and mitochondrial respiration were determined. RESULTS: Exposure to 300 and 500 muM linoleic acid increased FATP1 and FATP4 mRNA expression. 500 muM linoleic acid increased FATP1 and FATP4 protein expression. Exposure to 500 muM increased FABP5 mRNA expression, while exposure to 100 to 500 muM linoleic acid decreased FABP3 mRNA expression. 300 and 500 muM linoleic acid decreased FABP3 protein expression. Cell viability was decreased by exposure to linoleic acid (100 to 1000 muM). Citrate synthase activity and routine mitochondrial respiration were significantly decreased by exposure to 300 and 500 muM linoleic acid, and maximal respiration and spare respiratory capacity were decreased by exposure to 100 to 500 muM linoleic acid. 300 and 500 muM linoleic acid increased reactive oxygen species generation in human trophoblasts. Moreover, exposure to 300 and 500 muM linoleic acid decreased IL-6 secretion. Exposure to 500 muM linoleic acid increased IL-8, NF-kappaB and PPAR-gamma mRNA expression, but decreased NF-kappaB protein expression. 300 muM linoleic acid decreased IL-8 protein expression. Further, exposure to 100 to 500 muM linoleic acid increased prostaglandin E2 and leukotriene B___ release. CONCLUSION: Exposure to linoleic acid decreases cell viability, alters mRNA expression of fatty acid transport related proteins, mitochondrial respiration and function, and inflammatory responses in trophoblasts. These findings may have implications on placental function when women consume high levels of linoleic acid.] Question: Based on the provided context, do the terms [FABP3 protein] and [FAs protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the effects of linoleic acid on various proteins and cellular processes in human trophoblasts. While it mentions changes in the expression of FABP3 protein and FAs (fatty acids), there is no direct interaction described between FABP3 protein and FAs protein. Instead, the context focuses on the effects of linoleic acid on the expression and function of these proteins separately. Therefore, based on the given information, there is no evidence of a direct interaction between FABP3 protein and FAs protein.</s>
592631 2A2916787 2A2596018	TXNRD1	IGFBP3	[INST]Context: [PMID: 34996932 A novel 14-gene signature for overall survival in lung adenocarcinoma based on the Bayesian hierarchical Cox proportional hazards model. There have been few investigations of cancer prognosis models based on Bayesian hierarchical models. In this study, we used a novel Bayesian method to screen mRNAs and estimate the effects of mRNAs on the prognosis of patients with lung adenocarcinoma. Based on the identified mRNAs, we can build a prognostic model combining mRNAs and clinical features, allowing us to explore new molecules with the potential to predict the prognosis of lung adenocarcinoma. The mRNA data (n___=___594) and clinical data (n___=___470) for lung adenocarcinoma were obtained from the TCGA database. Gene set enrichment analysis, univariate Cox proportional hazards regression, and the Bayesian hierarchical Cox proportional hazards model were used to explore the mRNAs related to the prognosis of lung adenocarcinoma. With the Bayesian hierarchical Cox proportional hazards model, a 14-gene signature that included CPS1, CTPS2, DARS2, IGFBP3, MCM5, MCM7, NME4, NT5E, PLK1, POLR3G, PTTG1, SERPINB5, TXNRD1, and TYMS was established to predict overall survival in lung adenocarcinoma. The C-index of the model was 0.733 and 0.735, respectively, after performing cross-validation and external validation, a nomogram was provided for better prediction in clinical application. Bayesian hierarchical Cox proportional hazards models can be used to integrate high-dimensional omics information into a prediction model for lung adenocarcinoma to improve the prognostic prediction and discover potential targets. This approach may be a powerful predictive tool for clinicians treating malignant tumours.] Question: Based on the provided context, do the terms [TXNRD1 protein] and [IGFBP3 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the TXNRD1 protein and the IGFBP3 protein. The context focuses on the identification of a 14-gene signature for overall survival in lung adenocarcinoma using a Bayesian hierarchical Cox proportional hazards model. While both TXNRD1 and IGFBP3 are included in the 14-gene signature, there is no specific information or evidence provided that suggests a direct interaction between these two proteins.</s>
650504 2A2418080 2A2903080	apolipoprotein D	TIMP-1	[INST]Context: [PMID: 16186358 PURPOSE: To identify and characterize genes differentially expressed in anterior segment tissues of eyes with pseudoexfoliation syndrome and glaucoma. METHODS: Anterior segment tissues (iris, ciliary processes, lens epithelium) were obtained from eight surgically enucleated eyes with PEX-associated open-angle or closed-angle glaucomas and eight age-matched glaucomatous control eyes without pseudoexfoliation. CDNA libraries were generated from three pseudoexfoliation and three control specimens, and their gene expression patterns were compared by means of cDNA subtraction. RESULTS: Subtraction of cDNA libraries identified 27 candidate genes for differential expression in pseudoexfoliation tissues, of which 23 genes were confirmed by virtual Northern blot, RT-PCR, and in situ hybridization. One set of genes consistently upregulated in anterior segment tissues from different patients with pseudoexfoliation comprised latent transforming growth factor binding proteins (LTBP-1 and -2), which are structural components of elastic microfibrils, the cross-linking enzyme transglutaminase-2, tissue inhibitor of matrix metalloproteinase-2 (TIMP-2), A-kinase anchor protein-2, apolipoprotein D, and the adenosine receptor-A3 . Genes reproducibly downregulated in pseudoexfoliation tissues included TIMP-1, clusterin, microsomal glutathione-S-transferase-1, and serum amyloid A1. Further transcripts, such as elastase, GST-T1, integrin beta4, and dehydrocholesterol reductase, did not show a consistent differential expression pattern in tissues obtained from different patients. Although fibrillin-1 was not isolated from subtracted cDNA libraries, upregulated expression of this elastic microfibrillar component was also demonstrated by RT-PCR and in situ hybridization. CONCLUSIONS: Differentially expressed genes with a high level of reproducibility in different tissues and different patients with pseudoexfoliation syndrome are mainly related to extracellular matrix metabolism and cellular stress. The underlying pathophysiology of pseudoexfoliation syndrome appears to be associated with an excessive production of elastic microfibril components, enzymatic cross-linking processes, a proteolytic imbalance between matrix metalloproteinases and their inhibitors, and increased cellular and oxidative stress supporting the notion of pseudoexfoliation syndrome as a stress-induced elastic microfibrillopathy.] Question: Based on the provided context, do the terms [apolipoprotein D protein] and [TIMP-1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between apolipoprotein D protein and TIMP-1 protein. Instead, it lists them as part of a set of genes that are differentially expressed in pseudoexfoliation tissues. Apolipoprotein D is mentioned as being upregulated, while TIMP-1 is downregulated. There is no indication that these two proteins interact with each other in the context of pseudoexfoliation syndrome.</s>
99744 2A2415145 2A2439390	ANG	ATXN2	[INST]Context: [PMID: 31432357 Identification and characterization of novel and rare susceptible variants in Indian amyotrophic lateral sclerosis patients. Rare missense variants play a crucial role in amyotrophic lateral sclerosis pathophysiology. We report rare/novel missense variants from 154 Indian amyotrophic lateral sclerosis patients, identified through targeted sequencing of 25 ALS-associated genes. As pathogenic variants could explain only a small percentage of amyotrophic lateral sclerosis pathophysiology in our cohort, we investigated the frequency of tolerated and benign novel/rare variants, which could be potentially amyotrophic lateral sclerosis susceptible. With one novel variant each in ERBB4, SETX, DCTN1, and MATR3; Four rare variants, one each in PON2 and ANG and two different rare variants in SETX. Furthermore, an oligogenic basis of amyotrophic lateral sclerosis was observed in three sporadic als, with co-occurrence of intermediate-length repeat expansions in ATXN2 and a rare/novel variant in DCTN1 and SETX genes. Additionally, molecular dynamics and biochemical functional analysis of an angiogenin variant (R21G) identified from our cohort demonstrated loss of ribonucleolytic and nuclear translocation activities.] Question: Based on the provided context, do the terms [ANG protein] and [ATXN2 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the ANG protein and the ATXN2 protein. While it discusses the co-occurrence of intermediate-length repeat expansions in ATXN2 and a rare/novel variant in SETX genes in three sporadic ALS cases, it does not indicate any interaction between ANG and ATXN2 proteins. The context focuses on the identification and characterization of rare/novel variants in ALS patients and does not provide evidence of a direct interaction between ANG and ATXN2 proteins.</s>
67778 2A2516824 2A2544793	elongation factor 1-delta	fascin	[INST]Context: [PMID: 21737628 Proteomic differential display analysis for TS-1-resistant and -sensitive pancreatic cancer cells using two-dimensional gel electrophoresis and mass spectrometry. TS-1 is an oral anticancer agent containing two biochemical modulators for 5-fluorouracil and tegafur (FT), a metabolically activated prodrug of 5-fluorouracil. TS-1 has been recognized as an effective anticancer drug using standard therapies for patients with advanced pancreatic cancer along with gemcitabine. To identify proteins linked to the TS-1-resistance of pancreatic cancer, we profiled protein expression levels in samples of TS-1-resistant and -sensitive pancreatic cancer cell lines by using two-dimensional gel electrophoresis (2-DE) and liquid chromatography-tandem mass spectrometry . The cytotoxicity of a 5-FU/5-chloro-2,4-dihydroxypyridine (CDHP) combination towards pancreatic cancer cell lines was evaluated by MTS assay. Proteomic analysis showed that eleven spots, including T-complex protein 1 subunit beta, ribonuclease inhibitor, elongation factor 1-delta, peroxiredoxin-2 and superoxide dismutase (Cu-Zn), appeared to be down-regulated, and 29 spots, including hypoxia up-regulated protein 1, lamin-A/C, endoplasmin, fascin and annexin A1, appeared to be up-regulated in TS-1-resistant cells compared with -sensitive cells. These results suggest that the identified proteins showing different expression between TS-1-sensitive and -resistant pancreatic cancer cells possibly relate to TS-1-sensitivity. These findings could be useful to overcome the TS-1-resistance of pancreatic cancer cells.] Question: Based on the provided context, do the terms [elongation factor 1-delta protein] and [fascin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between elongation factor 1-delta protein and fascin protein. Instead, it lists these proteins as part of a proteomic analysis comparing TS-1-resistant and -sensitive pancreatic cancer cells. The context focuses on the differential expression levels of various proteins, including elongation factor 1-delta and fascin, but does not indicate any direct interaction between these two specific proteins.</s>
376400 2A2454552 2A2871385	cathepsin K	c-Src	[INST]Context: [PMID: 18282368 The introduction of bisphosphonates represents an important advance in the care of patients with metastatic bone disease. This review will discuss several novel therapies, including inhibitors of receptor activator of nuclear factor-kappabeta, c-Src, mammalian target of rapamycin, cathepsin K, and alpha(5)beta(3) integrins, which could improve our control over this devastating complication.] Question: Based on the provided context, do the terms [cathepsin K protein] and [c-Src protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses several novel therapies, including inhibitors of receptor activator of nuclear factor-kappabeta, c-Src, mammalian target of rapamycin, cathepsin K, and alpha(5)beta(3) integrins, which could improve our control over metastatic bone disease. However, there is no mention of a direct interaction between cathepsin K protein and c-Src protein. Instead, they are presented as separate entities that are being investigated as potential therapeutic targets.</s>
618071 2A2613339 2A2855033	KCNH2	LQT3	[INST]Context: [PMID: 20659946 A history of stressful life events, prolonged mental stress and arrhythmic events in inherited long QT syndrome. OBJECTIVE: To examine whether a history of stressful life events and prolonged mental stress are associated with arrhythmic events in inherited long QT syndrome . METHODS: Participants who had a molecularly established mutation of KCNQ1, KCNH2 or SCN5A channel and were thus diagnosed as patients with LQT1, LQT2 and LQT3 (n=566), accordingly. Prolonged mental stress was indexed by vital exhaustion, which was measured with the Maastricht Questionnaire. RESULTS: Multinomial logistic regression analysis including patients with long qt syndrome with and without arrhythmic events and the control subjects showed an age- and sex-adjusted association of stressful life events OR=1.15 (95% CI 1.08 to 1.22) and vital exhaustion (OR=3.33 (95% CI 1.63 to 6.78)) with symptomatic status of long qt syndrome. Symptomatic patients with long qt syndrome had experienced more stressful life events (OR=1.16 (95% CI 1.08 to 1.24)) and the level of vital exhaustion (OR=3.40 (95% CI 1.44 to 8.03)) was more than three times higher among patients with long qt syndrome with arrhythmic events than in asymptomatic long qt syndrome mutation carriers. The association between stressful life events and arrhythmic events was independent of age, sex, specifically focused medication and long qt syndrome subtype. CONCLUSIONS: A history of stressful life events and prolonged mental stress are associated with arrhythmic events in long qt syndrome in this large sample of molecularly defined patients with long qt syndrome. It is important for future studies to assess how strong these predisposing factors are for arrhythmic events in long qt syndrome.] Question: Based on the provided context, do the terms [KCNH2 protein] and [LQT3 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the association between stressful life events, prolonged mental stress, and arrhythmic events in patients with inherited long QT syndrome (LQTS). It mentions specific genes and subtypes of LQTS, such as KCNQ1, KCNH2, and SCN5A, but does not describe any direct interaction between the KCNH2 protein and LQT3 protein. Instead, it focuses on the broader clinical and psychological factors that may influence arrhythmic events in LQTS patients. Therefore, there is no evidence of a direct interaction between the KCNH2 protein and LQT3 protein based on the given context.</s>
260846 2A2609186 2A2509801	CD103	cDC2	[INST]Context: [PMID: 30972079 HIV-Exposed Uninfected Infants Have Increased Regulatory T Cells That Correlate With Decreased T Cell Function. Background: HIV-exposed uninfected infants (HEU) are at higher risk of severe infections, hospitalizations and death compared with HIV-unexposed uninfected infants (HUU), but the immune deficit underlying it is not known. To address this gap, we investigated T cell functionality and its relationship to phenotypic profiles of T cells and antigen presenting cells in HEU and HUU. Methods: Blood mononuclear cells from 55 HEU and 16 HUU were stimulated with Staphylococcal Enterotoxin B or mock for 72 h, and tested by flow cytometry for proliferation and expression of Th1, Th2, and regulatory (Treg) markers. In parallel, cells were phenotypically assessed for differentiation profiles of Treg, conventional T cell and antigen presenting cells in unstimulated cells. Results: HEU had lower CD4+ functional responses to SEB/mock and similar CD8+ responses compared with HUU. In the phenotypic T cell panel, HEU showed higher proportions of CD4+ and CD8+ Treg expressing IL10, FOXP3, and CD25; And lower na_^ve and CD4+TGFbeta+ Treg compared with HUU. In the phenotypic antigen presenting cells panel, HEU showed higher proportions of CD1c+ cDC2, CD123+ pDC, CD16+ inflammatory monocytes and cDC and higher expression of CD103 on CD1c-CD123-CD16-cDC1 compared with HUU. Regression analyses adjusted for HIV exposure and multiple comparisons showed that higher CD8+IL10+ and CD8+FOXP3+ Treg in unstimulated cells were associated with lower CD8+ T cell functional responses to SEB/mock. Functionality was not affected by t cell differentiation, but higher antigen presenting cells activation in aggregate was associated with higher CD8+IL10+ Treg responses to staphylococcal enterotoxin b. Conclusions: T cell functionality was decreased in HEU compared with HUU. High CD8+ Treg proportions were the most important predictors of decreased T cell functionality in HEU and HUU.] Question: Based on the provided context, do the terms [CD103 protein] and [cDC2 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not indicate a direct interaction between the CD103 protein and the cDC2 protein. Instead, it describes the phenotypic profiles of antigen presenting cells in HEU and HUU, including the expression of CD103 on CD1c-CD123-CD16-cDC1 and the proportions of CD1c+ cDC2. These are separate observations and do not suggest a direct interaction between CD103 and cDC2.</s>
688773 2A2867468 2A2540291	SP110	FLI1	[INST]Context: [PMID: 34242709 Transcriptome-wide analysis reveals core sets of transcriptional regulators of sensome and inflammation genes in retinal microglia. BACKGROUND: Retinal microglial cells play crucial roles in maintaining normal visual functions in a healthy eye. However, the underlying mechanisms of retinal microglial cells over-activation manifesting the alterations of sensome profile and inflammation state, which contribute to various retinal neurodegenerative diseases, remain elusive. Here, we aimed to identify the core set of sensome and pro-inflammatory genes and their regulators using transcriptome and data mining approaches. METHODS: We performed paired-end RNA-sequencing in primary microglial cell cultures treated with TNFalpha/IFN__ (10 ng/ml for 12 h) and PBS as a control. We examined overlaps of the mouse microglial gene expression profiles with the data-mined human sensome and pro-inflammatory marker genes. The core sets of sensome and pro-inflammatory genes were selected and predicted for transcription factors . RESULTS: TNFalpha/IFN__ induced 668 differentially expressed transcripts in retinal microglial cells relative to the control. The overlapping analysis of the TNFalpha/IFN__-activated microglia genes and the data-mined human gene sets revealed 22 sensome and 61 pro-inflammatory genes. Based on network analysis, we determined 10 genes as the core sets of sensome and pro-inflammatory genes and predicted the top ten transcription factors that regulate them. The SP110, IRF1, FLI1, SP140 (sensome) and RELB, BATF2, NFKB2, TRAFD1, SP100, NFKB1 (inflammation) are differentially expressed between the TNFalpha/IFN__ activated and the non-activated microglia which were validated by quantitative PCR. The outcomes indicate that these transcriptional regulators are highly expressed and may regulate the sensome and inflammatory genes of retinal microglial cells and switch them to over-activation. CONCLUSION: Our results comprise a powerful, cross-species functional genomics resource for sensome and inflammation of retinal microglial cells, which may provide novel therapeutic approaches to prevent retinal neurodegenerative diseases.] Question: Based on the provided context, do the terms [SP110 protein] and [FLI1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the SP110 protein and the FLI1 protein. Instead, it lists them as part of the core sets of sensome genes and predicts them as transcription factors that regulate these genes. There is no indication that these two proteins interact with each other directly.</s>
642573 2A2601142 2A2905922	CD124	CD95	[INST]Context: [PMID: 9890661 Expression of cytokine receptors on different myeloid leukemic cells. We have studied the expression of cytokine receptors CD25 (IL-2Ra,55kD), CD116 (hGM-CSRF,145kD), CD117 (CSFR,145kD), CD120a (TNFR,55kD), CD120b (TNFR,75kD), CD121a (IL-1R, type I, 80kD), CD123 (IL-3R), CD124 (IL-4R, 140kD), CD126 (IL-6R, 80kD), CDw127 (IL-7R, 75kD), CDw128 (IL-8R), CD130 (gp130 subunit), common beta, CD134 (OX40) and also CD95 (Fas antigen) on the myeloid leukemic cells. Cells from peripheral blood or bone marrow of 30 patients with disorders in myeloid lineage included mostly acute myeloid leukemias (with high leukocyte count and percentage of blasts) were analyzed for the expression of surface membrane molecules by indirect immunofluorescence method evaluated by flow cytometry. The leukemic cells demonstrate unique cytokine receptor profiles, which reveal the great diversity of immunophenotypes within the main functional characterization of blood malignancies. The immunophenotype heterogeneity of leukemic cells has proved to be much greater than to match with existing classification criteria. On the other hand, detection of cytokine receptors on the leukemia cells is important for cytokine therapy.] Question: Based on the provided context, do the terms [CD124 protein] and [CD95 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the expression of various cytokine receptors on myeloid leukemic cells, including CD124 (IL-4R) and CD95 (Fas antigen). However, there is no mention of a direct interaction between CD124 protein and CD95 protein. The context focuses on the expression profiles of these receptors on leukemic cells rather than any interaction between them. Therefore, based on the given information, CD124 and CD95 proteins do not interact with each other.</s>
599415 2A2577477 2A2592321	HDAC1	HSP27	[INST]Context: [PMID: 23269627 Combination of AT-101/cisplatin overcomes chemoresistance by inducing apoptosis and modulating epigenetics in human ovarian cancer cells. We investigated the effects of AT-101/cisplatin combination treatment on the expression levels of apoptotic proteins and epigenetic events such as DNA methyltransferase and histone deacetylase enzyme activities in OVCAR-3 and MDAH-2774 ovarian cancer cells. For showing apoptosis, both DNA Fragmentation and caspase 3/7 activity measurements were performed. The expression levels of apoptotic proteins were assessed by human apoptosis antibody array. Dna methyltransferase and histone deacetylase activities were evaluated by ELISA assay and mRNA levels of DNMT1 and HDAC1 genes were quantified by qRT-PCR. Combination of AT-101/cisplatin resulted in strong synergistic cytotoxicity and apoptosis in human ovarian cancer cells. Combination treatment reduced some pivotal anti-apoptotic proteins such as Bcl-2, HIF-1A, cIAP-1, XIAP in OVCAR-3 cells, whereas p21, Bcl-2, cIAP-1, HSP27, Clusterin and XIAP in MDAH-2774 cells. Among the pro-apoptotic proteins, Bad, Bax, Fas, phospho-p53 (S46), Cleaved caspase-3, SMAC/Diablo, TNFR1 and Cytochrome c were induced in OVCAR-3 cells, whereas, Bax, TRAILR2, FADD, p27, phospho-p53 (S46), Cleaved caspase-3, Cytochrome c, SMAC/Diablo and TNFR1 were induced in MDAH-2774 cells. Combination treatment also inhibited both dna methyltransferase and histone deacetylase activities and also mRNA levels in both ovarian cancer cells. AT-101 exhibits great potential in sensitization of human ovarian cancer cells to cisplatin treatment in vitro, suggesting that the combination of AT-101 with cisplatin may hold great promise for development as a novel chemotherapeutic approach to overcome platinum-resistance in human ovarian cancer.] Question: Based on the provided context, do the terms [HDAC1 protein] and [HSP27 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between HDAC1 protein and HSP27 protein. While both proteins are discussed in the context of the effects of AT-101/cisplatin combination treatment on ovarian cancer cells, there is no specific interaction described between HDAC1 and HSP27. Instead, the context focuses on the individual roles of these proteins in the apoptotic and epigenetic pathways affected by the treatment.</s>
425659 2A2459794 2A2600684	cyclin-dependent kinase 4	IkappaB-alpha	[INST]Context: [PMID: 15494532 Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis. Recent studies in multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis, point to the fact that even in the early phase of inflammation, neuronal pathology plays a pivotal role in the sustained disability of affected individuals. We show that the major green tea constituent, (-)-epigallocatechin-3-gallate (EGCG), dramatically suppresses experimental autoimmune encephalomyelitis induced by proteolipid protein 139-151. EGCG reduced clinical severity when given at initiation or after the onset of experimental autoimmune encephalomyelitis by both limiting brain inflammation and reducing neuronal damage. In orally treated mice, we found abrogated proliferation and TNF-alpha production of encephalitogenic T cells. In human myelin-specific CD4+ T cells, cell cycle arrest was induced, down-regulating the cyclin-dependent kinase 4. Interference with both T cell growth and effector function was mediated by blockade of the catalytic activities of the 20S/26S proteasome complex, resulting in intracellular accumulation of IkappaB-alpha and subsequent inhibition of NF-kappaB activation. Because its structure implicates additional antioxidative properties, EGCG was capable of protecting against neuronal injury in living brain tissue induced by N-methyl-D-aspartate or TRAIL and of directly blocking the formation of neurotoxic reactive oxygen species in neurons. Thus, a natural green tea constituent may open up a new therapeutic avenue for young disabled adults with inflammatory brain disease by combining, on one hand, anti-inflammatory and, on the other hand, neuroprotective capacities. Mice.] Question: Based on the provided context, do the terms [cyclin-dependent kinase 4 protein] and [IkappaB-alpha protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not indicate a direct interaction between cyclin-dependent kinase 4 protein and IkappaB-alpha protein. Instead, it describes how EGCG affects T cell proliferation and effector function by blocking the catalytic activities of the 20S/26S proteasome complex, which leads to intracellular accumulation of IkappaB-alpha and subsequent inhibition of NF-kappaB activation. The context mentions cyclin-dependent kinase 4 in relation to cell cycle arrest but does not link it to IkappaB-alpha or suggest a direct interaction between these two proteins.</s>
80729 2A2429565 2A2459929	ASS1	CDKN1A	[INST]Context: [PMID: 31692912 Investigating Novel Genes Potentially Involved in Endometrial Adenocarcinoma using Next-Generation Sequencing and Bioinformatic Approaches. Endometrial cancer is one of the most common cancers in women worldwide, affecting more than 300,000 women annually. Dysregulated gene expression, especially those mediated by microRNAs, play important role in the development and progression of cancer. This study aimed to investigate differentially expressed genes in endometrial adenocarcinoma using next generation sequencing and bioinformatics. The gene expression profiles and microRNA profiles of endometrial adenocarcinoma (cancer part) and normal endometrial tissue (non-cancer part) were assessed with next generation sequencing. We identified 56 significantly dysregulated genes, including 47 upregulated and 9 downregulated genes, in endometrial adenocarcinoma. Most of these genes were associated with defense response, response to stimulus, and immune system process, and further pathway analysis showed that human papillomavirus infection was the most significant pathway in endometrial adenocarcinoma. In addition, these genes were also associated with decreased cell death and survival as well as increased cellular movement. The analyses using Human Protein Atlas, identified 6 genes (PEG10, CLDN1, ASS1, WNT7A, GLDC, and RSAD2) significantly associated with poorer prognosis and 3 genes (SFN, PIGR, and CDKN1A) significantly associated with better prognosis. Combining with the data of microRNA profiles using microRNA target predicting tools, two significantly dysregulated microRNA-mediated gene expression changes in endometrial adenocarcinoma were identified: downregulated hsa-miR-127-5p with upregulated CSTB and upregulated hsa-miR-218-5p with downregulated HPGD. These findings may contribute important new insights into possible novel diagnostic or therapeutic strategies for endometrial adenocarcinoma.] Question: Based on the provided context, do the terms [ASS1 protein] and [CDKN1A protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between ASS1 protein and CDKN1A protein. It only states that ASS1 is associated with poorer prognosis and CDKN1A is associated with better prognosis in endometrial adenocarcinoma. There is no indication that these two proteins interact with each other in the context of endometrial adenocarcinoma.</s>
483969 2A2681555 2A2672591	NEFL	MPZ	[INST]Context: [PMID: 20627571 Clinical characterization and genetic analysis of a possible novel type of dominant Charcot-Marie-Tooth disease. A family of dominant Charcot-Marie-Tooth disease with eleven members, six of them symptomatic, was characterized clinically and genetically. The ages at onset ranged from 10 to 45 years, and the clinical severity varied from no symptom to being wheelchair-bound. The sural nerve biopsies in two patients featured demyelinating changes. No mutation in PMP22, MPZ, GJB1, NEFL, LITAF, EGR2, MFN2, HSP27, HSP22, GADP1, YARS, and DNM2 genes was found in the proband. Haplotype analyzes excluded linkage to the previously reported dominant CMT loci. A genomewide screen with 400 microsatellite markers and multipoint linkage analyzes revealed that the highest LOD score was around 1.6 on chromosome 3q28-q29, suggestive of a weak but possible linkage at this locus.] Question: Based on the provided context, do the terms [NEFL protein] and [MPZ protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the NEFL protein and the MPZ protein. It discusses the clinical and genetic characterization of a family with dominant Charcot-Marie-Tooth disease and the absence of mutations in various genes, including NEFL and MPZ. There is no indication that these two proteins interact with each other in the context of this study.</s>
126601 2A2590057 2A2590068	HSP90AA1	HSP90AB1	[INST]Context: [PMID: 35371008 Global Proteomic Analyses Reveals Abnormal Immune Regulation in Patients With New Onset Ankylosing Spondylitis. Background: Ankylosing spondylitis is a chronic inflammatory disease with serious consequences and a high rate of morbidity and mortality, In our previous work, we reveal the key features of proteins in new-onset ankylosing spondylitis patients. Material and Methods: Ankylosing spondylitis is a chronic inflammatory condition that affects the spine, and inflammation plays an essential role in ankylosing spondylitis pathogenesis. The inflammatory process in ankylosing spondylitis, however, is still poorly understood due to its intricacy. Systematic proteomic and phosphorylation analyses of peripheral blood mononuclear cells were used to investigate potential pathways involved in ankylosing spondylitis pathogenesis. Results: Liquid chromatography-tandem mass spectrometry analysis was performed and discovered 782 differentially expressed proteins and 122 differentially phosphorylated proteins between 9 new-onset ankylosing spondylitis patients and 9 healthy controls. Parallel reaction monitoring analysis verified that 3 proteins (HSP90AB1, HSP90AA1 and HSPA8) in the antigen processing and presentation pathway, 6 proteins (including ITPR1, MYLK and STIM1) in the platelet activation pathway and 10 proteins (including MYL12A, MYL9 and ROCK2) in the leukocyte transendothelial migration pathway were highly expressed in the peripheral blood mononuclear cells of ankylosing spondylitis patients. Conclusion: The key proteins involved in antigen processing and presentation, platelet activation and leukocyte transendothelial migration revealed abnormal immune regulation in patients with new-onset ankylosing spondylitis. These proteins might be used as candidate markers for ankylosing spondylitis diagnosis and new therapeutic targets, as well as elucidating the pathophysiology of ankylosing spondylitis.] Question: Based on the provided context, do the terms [HSP90AA1 protein] and [HSP90AB1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context mentions that HSP90AB1 and HSP90AA1 are among the proteins highly expressed in the peripheral blood mononuclear cells of ankylosing spondylitis patients. However, it does not indicate any direct interaction between these two proteins. Instead, it lists them as part of the antigen processing and presentation pathway, suggesting they are involved in the same pathway but not necessarily interacting with each other.</s>
455204 2A2733890 2A2884721	p85	syk	[INST]Context: [PMID: 10979966 Phosphatidylinositol-3 kinase regulates p21ras activation during IgE-mediated stimulation of human basophils. Cross-linking of IgE or a bacterial product (f-Met-Leu-Phe; FMLP) induces the release of leukotriene C4 and histamine in human basophils. However, the signaling mechanisms in human basophils are only partially understood. It has been demonstrated that extracellular signal-regulated kinases (ERK1/2) specifically regulate the pathway for leukotriene c4 generation, but not for histamine release and interleukin-4 production. More recent studies have suggested that tyrosine kinase (syk)-mediated phosphorylation of shc is responsible for the ras-ERK cascade via the formation of shc-Grb2-Sos2 following stimulation with anti-IgE antibody, but not FMLP, in human basophils. However, while characterizing the role of phosphatidylinositol -3 kinase in signaling pathways leading to basophil mediator release, it was noted that this pathway might also regulate p21ras activation. Anti-IgE antibody, but not FMLP, resulted in phosphorylation of p85 (regulatory subunit of PI3 kinase), suggesting activation of PI3 kinase. Inhibition of PI3 kinase by selective inhibitor (LY294002) abolished anti-IgE antibody- but not FMLP-induced phosphorylation of MEK1 (MAPK kinase/ERK kinase) and ERKs while inhibiting leukotriene c4 generation as well as histamine release. But, further upstream, phosphorylation of syk and of shc and inducible association between shc and Grb2 were not affected. These results suggest that functional responses may be dependent on the activity of PI3 kinase, which regulates at least 2 important signaling pathways: by regulating activation of ras for the MEK-ERK pathway and the increase in [Ca(++)](i).] Question: Based on the provided context, do the terms [p85 protein] and [syk protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not indicate a direct interaction between the p85 protein and the syk protein. While both proteins are involved in the signaling pathways leading to mediator release in human basophils, they are described as part of different pathways. The context mentions that phosphorylation of p85 (regulatory subunit of PI3 kinase) suggests activation of PI3 kinase, which regulates the MEK-ERK pathway. However, it also states that phosphorylation of syk and shc, as well as the inducible association between shc and Grb2, are not affected by PI3 kinase inhibition. This suggests that the p85 protein and the syk protein are part of separate signaling pathways and do not directly interact with each other.</s>
159718 2A2623617 2A2528133	LGALS4	ETHE1	[INST]Context: [PMID: 34249670 Colorectal cancer is one of the major causes of cancer deaths across the world. Patients' survival at time of diagnosis depends mainly on stage of the tumor. Therefore, understanding the molecular mechanisms from low-grade to high-grade stages of cancer that lead to cellular migration from one tissue/organ to another tissue/organ is essential for implementing therapeutic approaches. We suggested for the first time that downregulation of mitochondrial genes, including ETHE1, SQOR, TST, and GPX3, would help colorectal cancer cells to produce more energy under hypoxic conditions through mechanisms that are different from 'Warburg Effect'. Augmentation of given antioxidants and repression of P4HA1 and COL1A2 genes could be a choice of colorectal cancer treatment. Moreover, promoting active GSK-3beta together with expression control of EIF2B would prevent EMT. We also proposed that OAS1 expression enhancement can induce the anti-cancer effects of interferon-gamma, while suppression of CTSH hinders formation of focal adhesions. ATF5 expression suppression sensitizes cancer cells to anchorage-dependent death signals, while LGALS4 induction recovers cell-cell junctions. These inhibitions and inductions would be another combinatory mechanism that inhibits EMT and cell migration. Furthermore, expression inhibition of TMPO, TOP2A, RFC3, GINS1, and CKS2 genes could prevent tumor growth. Besides, TRIB3 suppression would be a promising target for anti-angiogenic therapy. SORD is a poorly studied enzyme in cancer, found to be upregulated in colorectal cancer. Finally, TMEM131 and DARS genes were identified in this study whose roles have never been interrogated in any kind of cancer, neither as a biomarker nor curative target.] Question: Based on the provided context, do the terms [LGALS4 protein] and [ETHE1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the roles of various genes and proteins in colorectal cancer, including LGALS4 and ETHE1. However, there is no direct interaction mentioned between LGALS4 protein and ETHE1 protein. Instead, the context describes their individual roles in the cancer process, such as LGALS4's role in recovering cell-cell junctions and ETHE1's role in energy production under hypoxic conditions. Therefore, based on the given information, there is no evidence of a direct interaction between LGALS4 protein and ETHE1 protein.</s>
668703 2A2652496 2A2884721	P38alpha	Syk	[INST]Context: [PMID: 27104822 Effect of Narrow Spectrum Versus Selective Kinase Inhibitors on the Intestinal Proinflammatory Immune Response in Ulcerative Colitis. BACKGROUND: Kinases are key mediators of inflammation, highlighting the potential of kinase inhibitors as treatments for inflammatory disorders. Selective kinase inhibitors, however, have proved disappointing, particularly in the treatment of rheumatoid arthritis and inflammatory bowel disease. METHODS: The activity of a narrow spectrum kinase inhibitor, TOP1210, has been compared with selective kinase inhibitors (BIRB-796, dasatinib and BAY-61-3606) in a range of kinase assays, inflammatory cell assays, and in inflamed biopsies from patients with ulcerative colitis . Effects on recombinant P38alpha, Src, and Syk kinase activities were assessed using Z-lyte assays (Invitrogen, Paisley, United Kingdom). Anti-inflammatory effects were assessed by measurement of proinflammatory cytokine release from peripheral blood mononuclear cells, primary macrophages, HT29 cells, inflamed colonic ulcerative colitis biopsies, and myofibroblasts isolated from inflamed colonic ulcerative colitis mucosa. RESULTS: TOP1210 potently inhibits P38alpha, Src, and Syk kinase activities. Similarly, TOP1210 demonstrates potent inhibitory activity against proinflammatory cytokine release in each of the cellular assays and the inflamed colonic ulcerative colitis biopsies and myofibroblasts isolated from inflamed colonic ulcerative colitis mucosa. However, combination of the selective inhibitors led to improved efficacy and potency in both cellular and ulcerative colitis biopsy assays. CONCLUSIONS: Targeted, multikinase inhibition with TOP1210 leads to a broad efficacy profile in both the innate and adaptive immune responses, with significant advantages over existing selective kinase approaches, and potentially offers a much improved therapeutic benefit in inflammatory bowel disease.] Question: Based on the provided context, do the terms [P38alpha protein] and [Syk protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the activities of various kinase inhibitors, including TOP1210, and their effects on different kinases such as P38alpha and Syk. However, there is no direct mention of an interaction between the P38alpha protein and the Syk protein. Instead, the context describes the inhibitory effects of TOP1210 on these kinases separately and their broader effects on inflammatory responses. Therefore, based on the given information, there is no evidence to suggest that P38alpha and Syk proteins interact with each other.</s>
691616 2A2638899 2A2401969	Maf1	acetyl-CoA carboxylase 1	[INST]Context: [PMID: 29843042 Taxifolin binds with liver-x-receptor (alpha & beta) to attenuate DMBA-induced mammary carcinogenesis through mTOR/Maf-1/PTEN pathway. AIM: 7,12-dimethylbenz(a)anthracene, a PAH derivative initializes cascades of signaling events that alters a variety of enzymes responsible for lipid and glucose homeostasis resulting in enhanced availability and consumption of energy producing molecules for the development of carcinogenesis. 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoAR) is a key enzyme regulating the pathway of synthesis of cholesterol whereas liver-X-receptor regulates lipid, carbohydrate metabolism in various malignancies including mammary carcinogenesis . In this study Taxifolin, a potential flavanoid has been subjected to evaluate its anti-cancer potential on . METHODS: We designed to screen the molecular docking analysis of taxifolin on LXRalpha, LXRbeta, HMG-CoAR, mTOR and PTEN using MAESTRO tool comparing with their reference ligands. Mammary carcinogenesis was developed by the administration of dimethylbenz(a)anthracene in the air pouch (under the mammary fat pad) of the female Sprague-Dawley rats (55 days old). After 90 days of cancer induction, the chemotherapeutic potential of taxifolin was evaluated by administering taxifolin at different doses (10, 20 and 40__^mg/kg b.w./day). RESULTS: The docking analysis revealed significant interaction with liver-x-receptor (alpha&beta), HMG-CoAR, mTOR and PTEN. The docking results were validated with the enzyme inhibition assay using HMG-CoAR (EC 1.1.1.34). Taxifolin inhibited the HMG-CoAR activity with an IC50 value of 97.54__^_+-__^2.5__^nM whereas the reference molecule pavastatin revealed an IC50 value of 84.35__^_+-__^1.2__^nM. Moreover, taxifolin modulated the energy regulation on DMBA-induced mammary carcinogenesis in SD-rats by significantly restoring the cancer-induced alterations in body weight, tumor growth and lipid, lipoproteins, lipid metabolizing enzymes and glycolytic enzymes. Taxifolin interacted with LXRs, HMG-CoAR, metabolic enzymes and restored the altered metabolism that accelerates uncontrolled cell proliferation in mammary carcinogenesis. Moreover, taxifolin also altered the mRNA and protein expressions of HMG-CoAR, liver-x-receptor (alpha,beta), Maf1, PTEN, phosphoinositide 3-kinase, Akt, mTOR, fatty acid synthase and acetyl-CoA carboxylase 1 in a dose dependent manner. CONCLUSION: These results validate the anti-cancer potential of taxifolin in DMBA-induced mammary carcinogenesis through LXR-mTOR/Maf1/PTEN axis.] Question: Based on the provided context, do the terms [Maf1 protein] and [acetyl-CoA carboxylase 1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the Maf1 protein and the acetyl-CoA carboxylase 1 protein. While both proteins are involved in metabolic pathways and are modulated by taxifolin in the study, there is no specific interaction described between them. Instead, they are presented as separate entities affected by the treatment.</s>
311827 2A2626897 2A2459092	CD58	CD81	[INST]Context: [PMID: 19644865 Changes in surface markers of human mesenchymal stem cells during the chondrogenic differentiation and dedifferentiation processes in vitro. OBJECTIVE: To investigate surface markers showing specific changes during the chondrogenic differentiation and dedifferentiation of human mesenchymal stem cells . METHODS: Human mesenchymal stem cells from adult bone marrow were subjected to chondrogenic differentiation in 3-dimensional alginate culture with or without transforming growth factor beta3 for 2 weeks, followed by dedifferentiation in monolayer for 1 week. Surface antigens were selected from those previously reported to show changes in expression during dedifferentiation of human articular chondrocytes . RESULTS: Flow cytometry was used to identify 3 groups of surface antigens with differential expression patterns that were quite different from those previously reported on human articular chondrocytes. Two groups of antigens were expressed at high levels on human mesenchymal stem cells. The expression of the first group of antigens (CD44, CD58, CD81, CD90, CD105, and CD166) was decreased reversibly by the 3-dimensional alginate culture and irreversibly in the presence of transforming growth factor beta3, except for CD81, which showed reversible changes regardless of transforming growth factor beta3. The expression of the second group of antigens (CD49c, CD49e, and CD151) was decreased during chondrogenic differentiation only in the presence of transforming growth factor beta3. During all experimental stages, the expression of the third group of antigens (CD14, CD26, CD49f, CD54, CD106, CD119, and CD140a) was maintained at low levels (expressed on <30% of cells), although with some fluctuations. CONCLUSION: We speculate that the second group of surface antigens could be negative markers for chondrogenic differentiation of human mesenchymal stem cells.] Question: Based on the provided context, do the terms [CD58 protein] and [CD81 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the expression patterns of various surface antigens, including CD58 and CD81, during the chondrogenic differentiation and dedifferentiation processes of human mesenchymal stem cells. However, there is no mention of a direct interaction between CD58 protein and CD81 protein. Instead, the context describes how the expression levels of these proteins change under different experimental conditions, but it does not indicate any direct interaction between them.</s>
33125 2A2769796 2A2769798	RECQL4	RECQL5	[INST]Context: [PMID: 32523948 RECQL5 at the Intersection of Replication and Transcription. Maintenance of genome stability is essential to prevent the accumulation of DNA mutations that can initiate oncogenesis and facilitate tumor progression. Studies of DNA repair genes have revealed a highly dynamic and redundant network of genes and proteins responsible for maintaining genome stability. Cancer cells are often deficient in DNA repair, and the resulting genome instability decreases their fitness but also allows for more rapid evolution under selective pressure. Of particular interest for genome stability are the RecQ class of helicases. Five genes in this class, RECQL1, BLM, WRN, RECQL4, and RECQL5, are unique to mammals, as simpler eukaryotes and bacteria appear to have only one homolog, RecQ. Whereas loss of function mutations of BLM, WRN, and RECQL4 in humans are associated with specific diseases, RECQL1 and RECQL5 have not yet been associated with specific disorders. Mice deficient in Recql5 are more likely to develop cancer, and human cells deficient in RECQL5 display chromosomal instability and elevated sister chromatid exchange events, similar to cells deficient in any of the other RecQ helicases. Recent studies support the hypothesis that RECQL5 can resolve intermediate DNA repair structures resulting from the collision of DNA transcription and replication machinery. In this review, we aim to summarize current knowledge regarding RECQL5 in the context of DNA repair, replication, and transcription to help uncover the role of RECQL5 in the maintenance of genome stability.] Question: Based on the provided context, do the terms [RECQL4 protein] and [RECQL5 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the roles of RECQL4 and RECQL5 proteins in DNA repair, replication, and transcription, but it does not mention any direct interaction between the two proteins. Instead, it describes their individual functions and the consequences of their deficiencies in maintaining genome stability. Therefore, based on the given information, there is no evidence to suggest that RECQL4 and RECQL5 proteins interact with each other.</s>
31296 2A2464191 2A2459937	CHD3	CDKN1B	[INST]Context: [PMID: 26551667 The mutational landscape of cutaneous T cell lymphoma and S__zary syndrome. S__zary syndrome is a leukemic and aggressive form of cutaneous T cell lymphoma resulting from the malignant transformation of skin-homing central memory CD4(+) T cells. Here we performed whole-exome sequencing of tumor-normal sample pairs from 25 patients with S__zary syndrome and 17 patients with other CTCLs. These analyses identified a distinctive pattern of somatic copy number alterations in S__zary syndrome, including highly prevalent chromosomal deletions involving the TP53, RB1, PTEN, DNMT3A and CDKN1B tumor suppressors. Mutation analysis identified a broad spectrum of somatic mutations in key genes involved in epigenetic regulation (TET2, CREBBP, KMT2D (MLL2), KMT2C (MLL3), BRD9, SMARCA4 and CHD3) and signaling, including MAPK1, BRAF, CARD11 and PRKG1 mutations driving increased MAPK, NF-kappaB and NFAT activity upon T cell receptor stimulation. Collectively, our findings provide new insights into the genetics of S__zary syndrome and cutaneous t cell lymphoma and support the development of personalized therapies targeting key oncogenically activated signaling pathways for the treatment of these diseases.] Question: Based on the provided context, do the terms [CHD3 protein] and [CDKN1B protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the CHD3 protein and the CDKN1B protein. Instead, it discusses the roles of these proteins in the context of somatic mutations and their involvement in epigenetic regulation and signaling pathways in S__zary syndrome and cutaneous T cell lymphoma. There is no indication that CHD3 and CDKN1B interact with each other directly.</s>
31955 2A2464191 2A2897977	ZFH	TGIF	[INST]Context: [PMID: 12736825 A genomewide survey of developmentally relevant genes in Ciona intestinalis. Genes for homeobox transcription factors. Homeobox-containing genes play crucial roles in various developmental processes, including body-plan specification, pattern formation and cell-type specification. The present study searched the draft genome sequence and cDNA/EST database of the basal chordate Ciona intestinalis to identify 83 homeobox-containing genes in this animal. This number of homeobox genes in the Ciona genome is smaller than that in the Caenorhabditis elegans, Drosophila melanogaster, human and mouse genomes. Of the 83 genes, 76 have possible human orthologues and 7 may be unique to Ciona. The ascidian homeobox genes were classified into 11 classes, including Hox class, NK class, Paired class, POU class, LIM class, TALE class, SIX class, Prox class, Cut class, ZFH class and HNF1 class, according to the classification scheme devised for known homeobox genes. As to the Hox cluster, the Ciona genome contains single copies of each of the paralogous groups, suggesting that there is a single Hox cluster, if any, but genes orthologous to Hox7, 8, 9 and 11 were not found in the genome. In addition, loss of genes had occurred independently in the Ciona lineage and was noticed in Gbx of the EHGbox subclass, Sax, NK3, Vax and vent of the NK class, Cart, Og9, Anf and Mix of the Paired class, POU-I, III, V and VI of the POU class, Lhx6/7 of the LIM class, TGIF of the TALE class, Cux and SATB of the Cut class, and ZFH1 of the ZFH class, which might have reduced the number of Ciona homeobox genes. Interestingly, one of the newly identified Ciona intestinalis genes and its vertebrate counterparts constitute a novel subclass of HNF1 class homeobox genes. From MeSH: Ciona intestinalis.] Question: Based on the provided context, do the terms [ZFH protein] and [TGIF protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the classification of homeobox-containing genes in Ciona intestinalis and mentions the loss of certain genes, including TGIF and ZFH1, in the Ciona lineage. However, there is no mention of a direct interaction between ZFH protein and TGIF protein. The context focuses on the presence or absence of these genes and their subclasses rather than any specific interaction between the proteins they encode.</s>
281733 2A2496572 2A2401213	deoxycytidine kinase	deoxycytidine deaminase	[INST]Context: [PMID: 7085768 Pyrimidine excretion by macrophages was studied in order to identify the potential immunoregulatory effector molecules. Deoxycytidine was found in the culture medium of thioglycollate-elicited mouse peritoneal macrophages, along with thymidine, which was shown by others to be a possible immunoregulatory substance. The identification of deoxycytidine was based on: (1) cochromatography with the authentic compound in four different solvents, (2) UV absorption spectral analysis, and (3) the enzymatic peak shift method. Phagocytosis of nucleated chicken erythrocytes, but not enucleated sheep erythrocytes, increased deoxycytidine excretion. The macrophages lacked both deoxycytidine kinase and deoxycytidine deaminase, which is consistent with their excretory pattern. Since it has been known that deoxycytidine can protect cells against cytotoxic effects of thymidine, we propose that deoxycytidine has a role in preventing immunosuppression by thimidine. In patients with adenosine deaminase deficiency, however, immunosuppression caused by combined toxicity of thymidine and deoxyadenosine may not be adequately prevented by deoxycytidine. From MeSH: Mice.] Question: Based on the provided context, do the terms [deoxycytidine kinase protein] and [deoxycytidine deaminase protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The context provided does not indicate any direct interaction between deoxycytidine kinase protein and deoxycytidine deaminase protein. Instead, it mentions that macrophages lack both enzymes, which is consistent with their excretory pattern of deoxycytidine. There is no information suggesting that these two proteins interact with each other or have a combined effect on the excretion of deoxycytidine.</s>
492005 2A2889302 2A2514487	synaptotagmin I	dynamin I	[INST]Context: [PMID: 15781228 Preserved synaptic vesicle recycling in hippocampal neurons in a mouse Alzheimer's disease model. A recently described triple-transgenic mouse model (3xTg, PS1(M146V), APP(Swe), and tau(P301L)) develops a neuropathology similar to the brains of Alzheimer's disease patients including progressive deposits of plaques and tangles [Neuron 39 (2003) 409]. These mice also show age-related deficits in hippocampal synaptic plasticity that occurs before the development of plaques and tangles. Here we report unchanged synaptic vesicle recycling, as measured by FM1-43 release, in the hippocampal neurons of the 3xTg mice. Expression levels of presynaptic protein synaptophysin and of proteins involved in synaptic vesicle recycling including AP180, dynamin I, and synaptotagmin I also remain unaffected. These data suggest that the synaptic deficits observed in the 3xTg neurons may not arise from the preserved synaptic vesicle recycling. From MeSH: Mice.] Question: Based on the provided context, do the terms [synaptotagmin I protein] and [dynamin I protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the expression levels of various proteins involved in synaptic vesicle recycling, including synaptotagmin I and dynamin I, in hippocampal neurons of 3xTg mice. However, it does not mention any direct interaction between synaptotagmin I and dynamin I. Instead, it lists them as separate proteins whose expression levels remain unaffected in the 3xTg mice. Therefore, based on the given information, there is no evidence to suggest that synaptotagmin I and dynamin I interact with each other.</s>
153087 2A2521345 2A2481140	eukaryotic translation initiation factor 3 subunit E	cAMP responsive element binding protein 1	[INST]Context: [PMID: 30854058 Identification of B-cell translocation gene 1-controlled gene networks in diffuse large B-cell lymphoma: A study based on bioinformatics analysis. The present study evaluated the impact of b-cell translocation gene 1 gene expression on the clinical outcome of diffuse large B-cell lymphoma and investigated potential mechanisms using the Gene Expression Omnibus database. In 498 cases, the expression of b-cell translocation gene 1 in diffuse large b-cell lymphoma was associated with treatment response (chi2=19.020; P<0.001) and International Prognostic Index score (chi2=5.320; P=0.025). From the overlapping analysis of 407 BTG1-associated genes and 22,187 DLBCL-associated genes, 401 genes were identified as BTG1-associated diffuse large b-cell lymphoma genes. Pathway analysis revealed that BTG1-associated diffuse large b-cell lymphoma genes were associated with cancer progression and diffuse large b-cell lymphoma signaling pathways. Additionally, 24 genes with high degrees in the network were identified as hub genes, which included genes associated with 'ribosome' [ribosomal protein (RP) L11, RPL3, RPS29, RPL19, RPL15 and RPL12], 'cell cycle' (ubiquitin carboxyl extension protein 52, ATM and Ras homolog family member H), 'mitogen-activated protein kinase pathway' (mitogen-activated protein kinase 1), 'histone modification' (ASH1-like protein) and 'transcription/translation' (eukaryotic translation initiation factor 3 subunit E, eukaryotic translation elongation factor 1 delta, transcription termination factor 1, cAMP responsive element binding protein 1 and RNA polymerase II subunit F). In conclusion, b-cell translocation gene 1 may serve as a predictive biomarker for diffuse large b-cell lymphoma prognosis. Additionally, bioinformatics analysis indicated that b-cell translocation gene 1 may exhibit key functions in the progression and development of diffuse large b-cell lymphoma.] Question: Based on the provided context, do the terms [eukaryotic translation initiation factor 3 subunit E protein] and [cAMP responsive element binding protein 1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not indicate a direct interaction between the eukaryotic translation initiation factor 3 subunit E protein and the cAMP responsive element binding protein 1 protein. Instead, it lists these proteins as part of a broader set of hub genes associated with various cellular processes, such as ribosome, cell cycle, mitogen-activated protein kinase pathway, histone modification, and transcription/translation. There is no specific mention of an interaction between these two proteins in the context of diffuse large B-cell lymphoma.</s>
102652 2A2704682 2A2529968	Trp53	Ezh2	[INST]Context: [PMID: 27135738 An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation. B cell lymphoma and melanoma harbor recurrent mutations in the gene encoding the EZH2 histone methyltransferase (EZH2), but the carcinogenic role of these mutations is unclear. Here we describe a mouse model in which the most common somatic Ezh2 gain-of-function mutation (EZH2(Y646F) in human; Ezh2(Y641F) in mouse) is conditionally expressed. Expression of Ezh2(Y641F) in mouse B cells or melanocytes caused high-penetrance lymphoma or melanoma, respectively. Overexpression of the anti-apoptotic protein Bcl2, but not the oncoprotein Myc, or loss of the tumor suppressor protein p53 (encoded by Trp53 in mice) further accelerated lymphoma progression. Expression of the mutant Braf but not the mutant Nras oncoprotein further accelerated melanoma progression. These results suggest that Ezh2(Y641F) induces lymphoma and melanoma through a vast reorganization of chromatin structure, inducing both repression and activation of polycomb-regulated loci. Mice.] Question: Based on the provided context, do the terms [Trp53 protein] and [Ezh2 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not indicate a direct interaction between the Trp53 protein and the Ezh2 protein. Instead, it describes the effects of the Ezh2(Y641F) mutation on lymphoma and melanoma progression in the presence or absence of other factors, such as Bcl2, Myc, and p53. The context mentions that loss of the tumor suppressor protein p53 (encoded by Trp53) further accelerated lymphoma progression, but it does not suggest a direct interaction between the Trp53 protein and the Ezh2 protein.</s>
102594 2A2704682 2A2537764	TP53	FGFR-3	[INST]Context: [PMID: 33418206 Bioinformatics analysis of candidate genes involved in ethanol-induced microtia pathogenesis based on a human genome database: GeneCards. OBJECTIVE: Ethanol used by women during pregnancy increases the risk for microtia in the foetus. Traditionally, laboratory experiments and Mouse Genome Informatics have been used to explore microtia pathogenesis. The aim of this study was to screen and verify hub genes involved in ethanol-induced microtia and to explore the potential molecular mechanisms. METHODS: Overlapping genes related to ethanol and microtia were acquired from the GeneCards database and filtered by confidence score. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis results were visualized with the clusterProfiler R package. RESULTS: Overall, 41 genes related to both ethanol and microtia were identified. The genes most relevant to ethanol-induced microtia pathogenesis included FGFR-2, FGFR-3, FGF-8, TP53, IGF1, SHH, CTNNB1, and PAX6, among others. Most genes were strongly enriched for tissue and organ development in gene ontology analysis. Additionally, many genes were enriched in the Ras, FoxO, MAPK, and PI3K-Akt signalling pathways in kyoto encyclopedia of genes and genomes analysis. CONCLUSIONS: Bioinformatics analysis was conducted on genes currently known to be related to ethanol-induced microtia pathogenesis. We propose that mechanisms involving FGF-family genes, TP53, IGF1 and SHH contribute significantly to ethanol-induced microtia and the accompanying malformation of other structures.] Question: Based on the provided context, do the terms [TP53 protein] and [FGFR-3 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the TP53 protein and the FGFR-3 protein. While both proteins are identified as relevant to ethanol-induced microtia pathogenesis, the text does not describe any specific interaction between them. Instead, it lists them as part of a broader set of genes involved in the process, without specifying any direct molecular interaction between TP53 and FGFR-3.</s>
97061 2A2565064 2A2558984	G alpha o	hCG	[INST]Context: [PMID: 9061052 Expression of G proteins in human placentas from pregnancies complicated by gestational hypertension. Preeclampsia (gestational hypertension) is accompanied by decreased hPL and increased hCG levels in maternal serum. The expression of these peptides as well as the endocrine mechanisms responsible for their regulation in preeclampsia are unknown. We have demonstrated that regulatory GTP-binding proteins (G proteins) are implicated in the modulation of hPL production by placentas from normal pregnancies. In order to extend our knowledge on placental endocrinology, we analyzed in this study the expression of hPL and beta-hCG mRNAs as well as placental G protein alpha-subunits in pregnancies complicated by gestational hypertension. Western and Northern blot analyses were respectively performed on membrane protein and total mRNA preparations from human placentas of preeclamptic (n = 7) and normal pregnancies (n = 4). The levels of hPL and beta-hCG mRNAs were respectively 108% and 105% of those from normal placentas, suggesting that the altered circulating levels of hPL and beta-hCG are not related to dysfunctional mRNA expression of these peptides. Specifically, G alpha i2, G alpha i3, G alpha o, G alpha s, and G alpha q/11 levels reached 87%, 81%, 91%, 99%, and 103% respectively of those from normal placentas. In parallel with the protein levels, their mRNAs expression were respectively 93%, 89%, 113%, 104%, and 94% of normal values for G alpha i2, G alpha i3, G alpha o, G alpha s, and G alpha q/11. These results suggest that neither a change in hPL and beta-hCG expression nor a change in signal transduction machinery is implicated in the altered circulating levels of hPL and beta-hCG in preeclampsia.] Question: Based on the provided context, do the terms [G alpha o protein] and [hCG protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the expression of various G proteins and hCG in placentas from pregnancies complicated by gestational hypertension. While it mentions the levels of G alpha o protein and hCG protein, it does not indicate any direct interaction between these two proteins. Instead, it focuses on the expression levels of these proteins and their mRNAs in the context of preeclampsia. Therefore, there is no evidence of a direct interaction between G alpha o protein and hCG protein based on the given information.</s>
73615 2A2526426 2A2509801	HER3	Cdc2	[INST]Context: [PMID: 24909175 A novel function of HER2/Neu in the activation of G2/M checkpoint in response to gamma-irradiation. In response to gamma-irradiation -induced DNA damage, activation of cell cycle checkpoints results in cell cycle arrest, allowing time for DNA repair before cell cycle re-entry. Human cells contain G1 and G2 cell cycle checkpoints. While G1 checkpoint is defective in most cancer cells, commonly due to mutations and/or alterations in the key regulators of G1 checkpoint (for example, p53, cyclin D), G2 checkpoint is rarely impaired in cancer cells, which is important for cancer cell survival. G2 checkpoint activation involves activation of ataxia telangiectasia-mutated /ATM- and rad3-related signalings, which leads to the inhibition of Cdc2 kinase and subsequent G2/M cell cycle arrest. Previous studies from our laboratory show that G2 checkpoint activation following irradiation exposure of MCF-7 breast cancer cells is dependent on the activation of extracellular signal-regulated protein kinase 1 and 2 (ERK1/2) signaling. As HER receptor tyrosine kinases, which have important roles in cell proliferation and survival, have been shown to activate ERK1/2 signaling in response to various stimuli, we investigated the role of HER receptor tyrosine kinases in IR-induced G2/M checkpoint response in breast cancer cells. Results of the present studies indicate that irradiation exposure resulted in a striking increase in the phosphorylation of HER1, HER2, HER3 and HER4 in MCF-7 cells, indicative of activation of these proteins. Furthermore, specific inhibition of HER2 using an inhibitor, short hairpin RNA and dominant-negative mutant HER2 abolished IR-induced activation of ATM/and rad3-related signaling, phosphorylation of Cdc2-Y15 and subsequent induction of G2/M arrest. Moreover, the inhibition of HER2 also abrogated IR-induced ERK1/2 phosphorylation. In contrast, inhibition of HER1 using specific inhibitors or decreasing expression of HER3 or HER4 using short hairpin RNAs did not block the induction of G2/M arrest following irradiation. These results suggest an important role of HER2 in the activation of G2/M checkpoint response following irradiation.] Question: Based on the provided context, do the terms [HER3 protein] and [Cdc2 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not indicate a direct interaction between HER3 protein and Cdc2 protein. While the context discusses the role of HER2 in the activation of G2/M checkpoint response following irradiation, it does not mention any direct interaction between HER3 and Cdc2. Instead, it focuses on the role of HER2 in activating ATM/and rad3-related signaling, which leads to the phosphorylation of Cdc2-Y15 and subsequent G2/M arrest. Therefore, based on the given information, there is no evidence of a direct interaction between HER3 protein and Cdc2 protein.</s>
23571 2A2516848 2A2544472	EEF1G	FTL	[INST]Context: [PMID: 16820872 Gene expression profiling of human HBV- and/or HCV-associated hepatocellular carcinoma cells using expressed sequence tags. Liver cancer is one of the leading causes of cancer death worldwide. To identify novel target genes that are related to liver carcinogenesis, we examined new genes that are differentially expressed in human hepatocellular carcinoma cell lines and tissues based on the expressed sequence tag frequency. Eleven libraries were constructed from seven hepatocellular carcinoma cell lines and three normal liver tissue samples obtained from Korean patients. An analysis of gene expression profiles for hepatocellular carcinoma was performed using the frequency of ESTs obtained from these cDNA libraries. Genes were identified (n=120) as being either up- or down-regulated in human liver cancer cells. Among these, 14 genes (FTL, K-ALPHA1, LDHA, RPL4, ENO1, ANXA2, RPL9, RPL10, RPL13A, GNB2L1, AMBP, GC, A1BG, and SERPINC1), in addition to previously well-known liver cancer related genes, were confirmed to be differentially expressed in seven liver cancer cell lines and 17 hepatocellular carcinoma tissues by semi-quantitative RT-PCR. In addition, 73 genes, in which there was a significant difference (P>0.99) between HBV- and HCV-associated hepatocellular carcinoma cells, were selected. Of these, expression patterns of 14 (RPLP0, AKR1C, KRT8, GPX4, RPS15, ID1, RPS21, VIM, EEF1G, EIF4A1, HLA-C, FN1, CD44, and RPS10) were confirmed by semi-quantitative RT-PCR in four of HBV- and three of HCV-associated hepatocellular carcinoma cell lines. Among those genes, an immunohistochemical analysis for ANXA2 showed that it is expressed at high levels in hepatocellular carcinoma. Using an analysis of expressed sequence tag frequency, the newly identified genes, especially ANXA2, represent potential biomarkers for hepatocellular carcinoma and useful targets for elucidating the molecular mechanisms associated with hepatocellular carcinoma involving virological etiology. From MeSH: Hepatitis B virus.] Question: Based on the provided context, do the terms [EEF1G protein] and [FTL protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the EEF1G protein and the FTL protein. The context discusses the differential expression of various genes in hepatocellular carcinoma cells and tissues, including EEF1G and FTL, but it does not provide any information about a direct interaction between these two proteins. Therefore, based on the given information, there is no evidence to suggest that EEF1G and FTL interact with each other.</s>
245787 2A2499839 2A2509909	protein DRP1	DNA polymerase beta	[INST]Context: [PMID: 32131898 Hippocampal tau oligomerization early in tau pathology coincides with a transient alteration of mitochondrial homeostasis and DNA repair in a mouse model of tauopathy. Insoluble intracellular aggregation of tau proteins into filaments and neurodegeneration are histopathological hallmarks of Alzheimer disease and other tauopathies. Recently, prefibrillar, soluble, oligomeric tau intermediates have emerged as relevant pathological tau species; Here, we show that hippocampal neurons in six-month-old transgenic mouse model of tauopathy, THY-Tau22, are enriched with oligomeric tau, contain elongated mitochondria, and display cellular stress, but no overt cytotoxicity compared to the control mice. The levels of several key mitochondrial proteins were markedly different between the THY-Tau22 and control mice hippocampi including the mitochondrial SIRT3, PINK1, ANT1 and the fission protein DRP1. DNA base excision repair is the primary defense system against oxidative DNA damage and it was elevated in six-month-old transgenic mice. DNA polymerase beta, the key base excision repair DNA polymerase, was enriched in the cytoplasm of hippocampal neurons in six-month-old transgenic mice and localized with and within mitochondria. Polbeta also co-localized with mitochondria in human alzheimer disease brains in neurons containing oligomeric tau. Most of these altered mitochondrial and DNA repair events were specific to the transgenic mice at 6___months of age and were not different from control mice at 12___months of age when tau pathology reaches its maximum and oligomeric forms of tau are no longer detectable. To our knowledge, this work provides the first description of multiple stress responses involving mitochondrial homeostasis and base excision repair early during the progression of tau pathology, and represents an important advance in the etiopathogenesis of tauopathies.] Question: Based on the provided context, do the terms [protein DRP1 protein] and [DNA polymerase beta protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not indicate a direct interaction between the DRP1 protein and DNA polymerase beta protein. While both proteins are mentioned in the context of mitochondrial homeostasis and DNA repair, respectively, there is no specific evidence or description of a direct interaction between them. Instead, they are discussed as part of separate pathways or processes involved in the cellular stress response in the transgenic mice.</s>
521324 2A2399815 2A2601220	alpha-2-macroglobulin	Interleukin-6	[INST]Context: [PMID: 12528325 Enteral application of an immunoglobulin-enriched colostrum milk preparation for reducing endotoxin translocation and acute phase response in patients undergoing coronary bypass surgery--a randomized placebo-controlled pilot trial. OBJECTIVE: To evaluate the influence of enteral application of an immunoglobulin enriched bovine milk preparation on endotoxin plasma levels, endotoxin neutralizing capacity of plasma (ENC) and the acute phase response (IL-6, CRP) during and after cardiac surgery, in a pilot study. DESIGN, PATIENTS AND METHODS: 60 patients who underwent coronary bypass operations, were evenly enrolled in a placebo-controlled randomized study. The patients were treated by enteral application of either 42 g of a bovine colostrum milk preparation per day or placebo, for 2 days preoperatively. Interleukin-6, CRP, transferrin, alpha-2-macroglobulin, albumin, apo-A, apo-B, IgG, IgA, IgM were determined by ELISA and nephelometrically. The clinical course was followed up by daily evaluation of the Apache-II-score. Endotoxin and ENC levels were elevated at the end of the operation and seemed to have a trigger function for the acute phase response. However, there was no reduction (calculated as the area under the curve) in patients receiving the colostrum milk preparation throughout the observation period. Plasma levels of endotoxin binding proteins did not differ. In the colostrum group, there was a tendency to reduced IL-6 levels throughout the observation period. CRP-levels of all patients peaked 48 h after the operation but were lower (p = 0.034) in the verum group. CONCLUSION: This study revealed that endotoxemia occurs early in an elective non-intestinal surgical intervention, and is followed by a subsequent increase in mediators of the acute phase reaction. The prophylactic enteral application of a bovine milk preparation for two days in cardiac patients did reduce postoperative CRP-plasma levels but, contrary to a former double-blind study in abdominal surgery, failed to curtail perioperative endotoxemia. From MeSH: Cattle.] Question: Based on the provided context, do the terms [alpha-2-macroglobulin protein] and [Interleukin-6 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not indicate a direct interaction between alpha-2-macroglobulin protein and Interleukin-6 protein. While both proteins are mentioned in the context of the study, there is no specific evidence or description that suggests they interact with each other. Instead, they are presented as separate entities measured in the study to evaluate the effects of the colostrum milk preparation on various parameters related to endotoxemia and the acute phase response.</s>
648554 2A2600684 2A2905345	IkappaBalpha	TNF-related apoptosis-inducing ligand	[INST]Context: [PMID: 12526088 Triptolide sensitizes lung cancer cells to TNF-related apoptosis-inducing ligand -induced apoptosis by inhibition of NF-kappaB activation. TNF-related apoptosis-inducing ligand (TRAIL/Apo- 2L), a newly identified member of the TNF family promotes apoptosis by binding to the transmembrane receptors (TRAIL-R1/DR4 and TRAIL-R2/DR5). Tnf-related apoptosis-inducing ligand known to activate NF-kappaB in number of tumor cells including A549 (wt p53) and NCI-H1299 (null p53) lung cancer cells exerts relatively selective cytotoxic affects to the human tumor cell lines without much effect on the normal cells. We set out to identify an agent that would sensitize lung cancer cells to TRAIL-induced apoptosis through inhibition of NF-kappaB activation. We found that triptolide, an oxygenated diterpene extracted and purified from the Chinese herb Tripterygium wilfordii sensitized A549 and NCI-H1299 cells to TRAIL-induced apoptosis through inhibition of NF-kappaB activation. Pretreatment with MG132 which is a well-known NF-kappaB inhibitor by blocking degradation of IkappaBalpha also greatly sensitized lung cancer cells to TRAIL-induced apoptosis. Triptolide did not block DNA binding of NF-kappaB activated by tnf-related apoptosis-inducing ligand as in the case of TNF-alpha. It has been already proven that triptolide blocks transactivation of p65 which plays a key role in NF-kappaB activation. These observations suggest that triptolide may be a potentially useful drug to enhance TRAIL-induced tumor killing in lung cancer.] Question: Based on the provided context, do the terms [IkappaBalpha protein] and [TNF-related apoptosis-inducing ligand protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not indicate a direct interaction between IkappaBalpha protein and TNF-related apoptosis-inducing ligand protein. Instead, it describes how triptolide inhibits NF-kappaB activation, which involves the degradation of IkappaBalpha, and how this inhibition sensitizes lung cancer cells to TRAIL-induced apoptosis. The context does not suggest that TNF-related apoptosis-inducing ligand directly interacts with IkappaBalpha.</s>
300528 2A2852768 2A2508374	UBA2	dynamin-related protein 1	[INST]Context: [PMID: 33110216 Inhibition of dynamin-related protein 1 small ubiquitin-like modification by augmenter of liver regeneration protects the liver from ischemia-reperfusion injury. Although an imbalance between mitochondrial fission and fusion has been identified as the cause of ischemic reperfusion injury, the detailed mechanism remains unclear. Augmenter of liver regeneration was reported to prevent mitochondrial fission by inhibiting dynamin-related protein 1 phosphorylation, contributing partially to its liver protection. Apart from phosphorylation, dynamin-related protein 1 activity is also regulated by small ubiquitin-like modification, which accelerates mitochondrial fission. This study aimed to investigate whether ALR-mediated protection from hepatic ischemic reperfusion injury might be associated with an effect on dynamin-related protein 1 small ubiquitin-like modification. Liver tissues were harvested from both humans and from heterozygous augmenter of liver regeneration knockout mice, which underwent ischemic reperfusion injury. The small ubiquitin-like modification and phosphorylation of dynamin-related protein 1 and their modulation by augmenter of liver regeneration were investigated. Hepatic dynamin-related protein 1 small ubiquitin-like modification was significantly increased in human transplanted livers and IRI-livers of mice. ALR-transfection significantly decreased dynamin-related protein 1 small ubiquitin-like modification, attenuated the IRI-induced mitochondrial fission and preserved mitochondrial stability and function. This study showed that the binding of transcription factor Yin Yang-1 to its downstream target gene UBA2, a subunit of SUMO-E1 enzyme heterodimer, was critical to control dynamin-related protein 1 small ubiquitin-like modification. By interacting with yin yang-1, augmenter of liver regeneration inhibits its nuclear import and dramatically decreases the transcriptional level of UBA2. Consequently, mitochondrial fission was significantly reduced, and mitochondrial function was maintained. This study showed that the regulation of dynamin-related protein 1 small ubiquitin-like modification by augmenter of liver regeneration protects mitochondria from fission, rescuing hepatocytes from IRI-induced apoptosis. These new findings provide a potential target for clinical intervention to reduce the effects of ischemic reperfusion injury during hepatic surgery.] Question: Based on the provided context, do the terms [UBA2 protein] and [dynamin-related protein 1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that UBA2 protein, a subunit of the SUMO-E1 enzyme heterodimer, is involved in the regulation of dynamin-related protein 1 (Drp1) small ubiquitin-like modification (SUMOylation). Specifically, the study shows that the binding of transcription factor Yin Yang-1 to UBA2 is critical to control Drp1 SUMOylation. By interacting with Yin Yang-1, augmenter of liver regeneration inhibits its nuclear import and decreases the transcriptional level of UBA2, which in turn reduces Drp1 SUMOylation and mitochondrial fission. This indicates a direct interaction between UBA2 protein and Drp1 protein in the context of SUMOylation and mitochondrial fission.</s>
571445 2A2922851 2A2617612	UBE2C	TK1	[INST]Context: [PMID: 34297801 Single-Cell Transcriptomics Identifies a Unique Entity and Signature Markers of Transit-Amplifying Cells in Human Corneal Limbus. Purpose: Differentiated from adult stem cells, transit-amplifying cells play an important role in tissue homeostasis, development, and regeneration. This study aimed to characterize the gene expression profile of a candidate TAC population in limbal basal epithelial cells using single-cell RNA sequencing . Methods: Single cells isolated from the basal corneal limbus were subjected to single-cell rna sequencing using the 10x Genomics platform. Results: Single-cell transcriptomics of 16,360 limbal basal cells revealed 12 cell clusters. The specific expression patterns of RRM2, TK1, CENPF, NUSAP1, UBE2C, and CDC20 were well correlated in a time- and cycle-dependent manner with proliferation stages in the cell growth and regeneration models. The findings provide insight into adult stem cells and transit-amplifying cells and lay the foundation for understanding corneal homeostasis and diseases.] Question: Based on the provided context, do the terms [UBE2C protein] and [TK1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the UBE2C protein and the TK1 protein. Instead, it describes the expression patterns of various genes, including UBE2C and TK1, in relation to proliferation stages in corneal limbal cells. The context focuses on the correlation of gene expression with proliferation stages rather than any direct interaction between the proteins themselves.</s>
469816 2A2684835 2A2508404	NOC4L	DNA methyltransferase 1	[INST]Context: [PMID: 33194643 Differentially Methylated Regions in Desmoid-Type Fibromatosis: A Comparison Between CTNNB1 S45F and T41A Tumors. Introduction: The majority of desmoid-type fibromatosis tumors harbor a beta-catenin mutation, affecting specific codons in CTNNB1 exon 3. The aim of this pilot study was to examine the genome-wide DNA methylation profiles of S45F and T41A mutated desmoid-type fibromatosis, to explain the observed differences in clinical behavior between these desmoid-type fibromatosis subtypes. Material and Methods: Genome-wide analysis of DNA methylation was performed using MeD-seq on formalin-fixed, paraffin-embedded primary desmoid-type fibromatosis samples harboring a S45F (n = 14) or a T41A (n = 15) mutation. Protein-protein interactions between wild-type beta-catenin and mutant variants and DNA methyltransferase 1 were examined by immunoprecipitation experiments. Only ten differentially methylated regions displayed a fold change of ___1.5 and six of them were found associated with the following genes: NLRP4, FOXK2, PERM1, CCDC6, NOC4L, and DUX4L6. The effects of differentially methylated regions on gene expression yielded a significant difference (p < 0.05) in the expression between S45F and T41A for CCDC6 and FOXK2 but not for all Affymetrix probe-sets used to detect these genes. Immunoprecipitations did not reveal an association of wild-type beta-catenin or mutant variants with dna methyltransferase 1. Conclusion: This study demonstrated that S45F and T41A desmoid-type fibromatosis tumors did not exhibit gross differences in DNA methylation patterns. This implies that distinct DNA methylation profiles are not the sole determinant for the divergent clinical behavior of these different desmoid-type fibromatosis mutant subtypes.] Question: Based on the provided context, do the terms [NOC4L protein] and [DNA methyltransferase 1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the NOC4L protein and DNA methyltransferase 1 protein. The study focuses on the genome-wide DNA methylation profiles of desmoid-type fibromatosis tumors and does not provide evidence of a direct interaction between these two proteins. Instead, it discusses the differential methylation of certain genes and the lack of association between wild-type beta-catenin or mutant variants with DNA methyltransferase 1.</s>
215607 2A2851467 2A2649179	RXRalpha	MGLL	[INST]Context: [PMID: 24262292 Effect of pre-existing maternal obesity, gestational diabetes and adipokines on the expression of genes involved in lipid metabolism in adipose tissue. OBJECTIVE: To determine the effect of maternal obesity, gestational diabetes mellitus and adipokines on the expression of genes involved in fatty acid uptake, transport, synthesis and metabolism. MATERIALS/METHODS: Human subcutaneous and omental adipose tissues were obtained from lean, overweight and obese normal glucose tolerant women and women with gestational diabetes mellitus. Adipose tissue explants were performed to determine the effect of the adipokines TNFalpha, IL-1beta and leptin on adipose tissue gene expression. RESULTS: Pre-existing maternal obesity and gestational diabetes mellitus are associated with decreased expression in genes involved in fatty acid uptake and intracellular transport (LPL, FATP2, FATP6, FABPpm and ASCL1), triacylglyceride biosynthesis (MGAT1,7 MGAT2 and DGAT1), lipogenesis (FASN) and lipolysis (PNPLA2, HSL and MGLL). Decreased gene expression was also observed for the transcription factors involved in lipid metabolism (LXRalpha, PPARalpha, PPARdelta, PPARgamma, RXRalpha and SREBP1c). On the other hand, the gene expression of the adipokines TNFalpha, IL-1beta and or leptin was increased in adipose tissue from obese and gestational diabetes mellitus women. Functional in vitro studies revealed that these adipokines decreased the gene expression of LPL, FATP2, FATP6, ASCL1, PNPLA2, PPARdelta, PPARgamma and RXRalpha. CONCLUSIONS: Pregnancies complicated by pre-existing maternal obesity and gestational diabetes mellitus are associated with abnormal adipose tissue lipid metabolism, which may play a role in the pathogenesis of these diseases. Mothers.] Question: Based on the provided context, do the terms [RXRalpha protein] and [MGLL protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not indicate a direct interaction between the RXRalpha protein and the MGLL protein. The context discusses the effects of pre-existing maternal obesity, gestational diabetes mellitus, and adipokines on the expression of genes involved in lipid metabolism, including RXRalpha and MGLL. However, it does not mention any direct interaction between these two proteins. Instead, it describes their individual roles in the metabolic pathways and how their gene expression is affected by the conditions mentioned.</s>
197585 2A2430988 2A2652867	activating transcription factor 3	microtubule-associated protein 1 light chain 3B	[INST]Context: [PMID: 26432159 Roles of oxidative stress and the ERK1/2, PTEN and p70S6K signaling pathways in arsenite-induced autophagy. Studies show that arsenite induces oxidative stress and modifies cellular function via phosphorylation of proteins and inhibition of DNA repair enzymes. Autophagy, which has multiple physiological and pathological roles in cellular function, is initiated by oxidative stress and is regulated by the signaling pathways of phosphatidylinositol 3-phosphate kinase /mammalian target of rapamycin (mTOR)/p70S6 kinase (p70S6K) and extracellular signaling-regulated protein kinase 1/2 (ERK1/2) that play important roles in oncogenesis. However, the effects of arsenite-induced oxidative stress on autophagy and on expression of related proteins are not fully understood. This study found that cells treated with sodium arsenite had reduced 8-oxoguanine DNA glycosylase 1 (OGG1) and increased 8-hydroxy-2'-deoxyguanosine and activating transcription factor 3 in SV-40 immortalized human uroepithelial (SV-HUC-1) cells. Arsenite also increased the number of autophagosomes and increased levels of the autophagy markers Beclin-1 and microtubule-associated protein 1 light chain 3B. Reactive oxygen species scavenger decreased arsenite-induced autophagy in SV-HUC-1 cells. Our previous work showed that arsenite induced phosphorylation of the ERK1/2 signaling pathway. The current study further showed that arsenite decreased phosphatase and tensin homologue (PTEN) levels and increased phospho-p70S6 kinase in SV-HUC-1 cells. However, both kinase inhibitor U0126 and the DNA (cytosine-5-)-methyltransferase 1 (DNMT1) inhibitor 5-aza-deoxycytidine abolished the effect of arsenite on expressions of PTEN and phospho-p70s6 kinase. These results show that autophagy induced by arsenite exposure is mediated by oxidative stress, which regulates activation of the PTEN, p70S6K and ERK1/2 signaling pathways. Thus, this study clarifies the role of autophagy in arsenite-induced urothelial carcinogenesis. Rats.] Question: Based on the provided context, do the terms [activating transcription factor 3 protein] and [microtubule-associated protein 1 light chain 3B protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not indicate a direct interaction between activating transcription factor 3 (ATF3) protein and microtubule-associated protein 1 light chain 3B (LC3B) protein. While both proteins are mentioned in the context of arsenite-induced autophagy and oxidative stress, there is no specific evidence or description of a direct interaction between ATF3 and LC3B. Instead, they are discussed as part of the broader cellular response to arsenite exposure, with ATF3 being involved in oxidative stress and LC3B being a marker of autophagy.</s>
183155 2A2854814 2A2558984	cg beta	cg alpha	[INST]Context: [PMID: 3095105 We devised an in vivo biological assay for ovarian growth inhibiting activity to examine extracts of human pregnancy urine for the presence of ovarian growth inhibiting factor. Diethylstilbestrol capsules were implanted sc in immature hypophysectomized female rats; FSH was injected sc with or without test substance for 5 days. Rats with unstimulated ovaries were implanted with blank capsules and given the vehicle without FSH. The ovarian growth inhibition of the ovarian weight gain achieved in rats treated with diethylstilbestrol and FSH. Crude commercial human CG preparations, extracted from pregnancy urine, were chromatographed on Sephadex G-100, and the fractions were tested for ovarian growth inhibiting activity. Ovarian growth inhibiting activity was heat sensitive, not extracted by ether, and precipitated by acetone. Ovarian growth inhibiting activity was stable in acid at pH 2, but was inactivated by digestion with trypsin. The active material contained human cg alpha, human cg beta, and beta-carboxyterminal peptide-immunoreactivity and its inhibiting activity could be removed from solution by immunoadsorption with antisera specific for human cg beta. The activity was eluted from the affinity column at low pH, and eluted material contained all of the immunodeterminants of human cg. Virtually identical dose-response curves of ovarian inhibition were obtained using equivalent doses of beta-carboxyterminal peptide immunoreactivity of purified inhibitor and purified human cg (CR123). The inhibiting activity reached plateau of 80-90% at doses of 50-100 ng hCG/rat. Upon rechromatography on Sephadex G-100, the ovarian growth activity that was pooled from fractions corresponding to the 12,000-20,000 mol wt range was recovered in fractions corresponding to the elution position of human cg. We conclude that the low mol wt inhibiting activity observed in the crude pregnancy extracts is due to human cg and that human cg is a very potent inhibitor of FSH/diethylstilbestrol stimulation of ovarian growth. From MeSH: Rats.] Question: Based on the provided context, do the terms [cg beta protein] and [cg alpha protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the properties and characteristics of human chorionic gonadotropin (hCG) and its components, including the alpha and beta subunits. It mentions that the ovarian growth inhibiting activity is associated with hCG and that the activity can be removed by immunoadsorption with antisera specific for human cg beta. However, there is no direct interaction mentioned between the cg alpha protein and cg beta protein. Instead, they are presented as separate components of hCG that contribute to the overall activity.</s>
568714 2A2533374 2A2905345	FADD	tnf-related apoptosis-inducing ligand	[INST]Context: [PMID: 11593384 Analysis of FasL and tnf-related apoptosis-inducing ligand induced apoptosis pathways in glioma cells. FasL and TNF-related apoptosis-inducing ligand belong to a subgroup of the TNF superfamily which induce apoptosis by binding to their death domain containing receptors. In the present study we have utilized a panel of seven cell lines derived from human malignant gliomas to characterize molecular pathways through which FasL and tnf-related apoptosis-inducing ligand induce apoptosis in sensitive glioma cells and the mechanisms of resistance in cell lines which survive the death stimuli. Our findings indicate that FADD and Caspase-8 are essential for FasL and tnf-related apoptosis-inducing ligand mediated apoptosis in glioma cells. One sensitive cell line (D270) can be protected from FasL and tnf-related apoptosis-inducing ligand induced death by anti-apoptotic Bcl-2 family members while another (D645) cannot, implying that these lines may represent glioma examples of type II and type I cells respectively. For the first time we demonstrate resistance to FasL but not to tnf-related apoptosis-inducing ligand within the one glioma cell line. Furthermore, we report distinct mechanisms of resistance within different glioma lines, including downregulation of Caspase-8 in U373MG. Cycloheximide sensitized four of the resistant cell lines suggesting the presence of labile inhibitors. None of the known apoptosis inhibitors examined accounted for the observed resistance, suggesting novel inhibitors may exist in glioma cells.] Question: Based on the provided context, do the terms [FADD protein] and [tnf-related apoptosis-inducing ligand protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the roles of FADD protein and TNF-related apoptosis-inducing ligand (TRAIL) in inducing apoptosis in glioma cells. While it mentions that FADD is essential for TRAIL-mediated apoptosis, it does not indicate a direct interaction between FADD protein and TRAIL protein. Instead, it describes how TRAIL binds to its death domain containing receptors and activates downstream pathways involving FADD and Caspase-8. Therefore, the terms [FADD protein] and [tnf-related apoptosis-inducing ligand protein] are not interacting in the way described in the examples of interacting terms.</s>
502243 2A2847424 2A2680606	p40	Th1	[INST]Context: [PMID: 27780253 BACKGROUND: Interleukin -12 and IL-23 are heterodimers that share the p40 subunit, and both cytokines are critical in the differentiation of T helper 1 and Th17 cells, respectively. Th1 and Th17 effector cells have been implicated in the pathogenesis of experimental autoimmune encephalitis, an animal model of the human central nervous system autoimmune demyelinating disorder multiple sclerosis . However, ustekinumab, a monoclonal antibody against p40 failed to show efficacy over placebo in a phase II clinical trial in patients with multiple sclerosis. The role of p40 in initial T cell priming and maintenance in secondary lymphoid tissues is not yet well understood. METHODS: Active experimental autoimmune encephalitis was induced in the B6.129-IL12b strain of p40eYFP reporter mice (yet40 mice), and Th1 and Th17 polarized cells were adoptively transferred into p40-deficient mice. Cellular subsets were phenotyped by multi-parameter flow cytometry, and p40 tissue expression was identified by confocal microscopy. RESULTS: We show that yet40 mice are susceptible to experimental autoimmune encephalitis, and that p40 is highly expressed in secondary lymphoid organs and the central nervous system during all stages of the disease. Interestingly, p40 expression in the recipient is not required for experimental autoimmune encephalitis induction after adoptive transfer of activated and differentiated encephalitogenic Th1 and Th17 cells into p40-deficient mice. Peripheral antagonism of T helper cell trophic factors critical for the differentiation and maintenance of Th1 and Th17 cells ameliorates experimental autoimmune encephalitis, indicating that p40 may play a critical role in the induction of central nervous system autoimmunity but not in its perpetuation. CONCLUSION: Our data may explain why ustekinumab did not ameliorate paraclinical and clinical disease in patients with multiple sclerosis. In patients with already established disease, activated antigen-specific encephalitogenic CD4+ T cells are likely already differentiated, and are not dependent on p40 for maintenance. A clinical trial of longer duration with anti-p40 mAbs or other forms of pharmacological p40 antagonism, or sequential anti-p40 therapy following T cell depletion may show a benefit by affecting de novo generation of autoimmune T cells. From MeSH: Mice.] Question: Based on the provided context, do the terms [p40 protein] and [Th1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The context provided discusses the roles of p40 protein and Th1 cells in the pathogenesis of experimental autoimmune encephalitis and multiple sclerosis. While it mentions that p40 is a subunit of IL-12 and IL-23, which are critical for the differentiation of Th1 and Th17 cells, respectively, it does not indicate a direct interaction between the p40 protein and Th1 protein. Instead, it describes how p40 is involved in the differentiation and maintenance of these cells, but not in a direct interaction with Th1 cells.</s>
648589 2A2600684 2A2601220	IkappaB alpha	interleukin -6	[INST]Context: [PMID: 20181940 Elevated CO2 selectively inhibits interleukin-6 and tumor necrosis factor expression and decreases phagocytosis in the macrophage. Elevated blood and tissue CO(2), or hypercapnia, is common in severe lung disease. Patients with hypercapnia often develop lung infections and have an increased risk of death following pneumonia. To explore whether hypercapnia interferes with host defense, we studied the effects of elevated P(CO2) on macrophage innate immune responses. In differentiated human THP-1 macrophages and human and mouse alveolar macrophages stimulated with lipopolysaccharide and other Toll-like receptor ligands, hypercapnia inhibited expression of tumor necrosis factor and interleukin -6, nuclear factor -kappaB-dependent cytokines critical for antimicrobial host defense. Inhibition of IL-6 expression by hypercapnia was concentration dependent, rapid, reversible, and independent of extracellular and intracellular acidosis. In contrast, hypercapnia did not down-regulate IL-10 or interferon-beta, which do not require NF-kappaB. Notably, hypercapnia did not affect LPS-induced degradation of IkappaB alpha, nuclear translocation of RelA/p65, or activation of mitogen-activated protein kinases, but it did block IL-6 promoter-driven luciferase activity in mouse RAW 264.7 macrophages. Elevated P(CO2) also decreased phagocytosis of opsonized polystyrene beads and heat-killed bacteria in THP-1 and human alveolar macrophages. By interfering with essential innate immune functions in the macrophage, hypercapnia may cause a previously unrecognized defect in resistance to pulmonary infection in patients with advanced lung disease. Mice.] Question: Based on the provided context, do the terms [IkappaB alpha protein] and [interleukin -6 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The context provided does not indicate a direct interaction between IkappaB alpha protein and interleukin-6 protein. Instead, it describes how hypercapnia affects the expression of interleukin-6 and other cytokines, including the degradation of IkappaB alpha. The degradation of IkappaB alpha is mentioned as part of the mechanism by which hypercapnia inhibits the expression of interleukin-6, but it does not imply a direct interaction between the two proteins. Therefore, based on the provided context, there is no evidence of a direct interaction between IkappaB alpha protein and interleukin-6 protein.</s>
430188 2A2587825 2A2546801	HNRNPL	FUS	[INST]Context: [PMID: 29458410 Human regulatory proteins associate with non-coding RNAs from the epstein-barr virus IR1 region. OBJECTIVE: The function of Epstein-Barr virus stable intronic sequence RNAs, non-coding RNAs transcribed from a region required for EBV-mediated cellular transformation, remain unknown. To better understand the function of ebv-sisRNA-1 and ebv-sisRNA-2 from the internal repeat 1 region of epstein-barr virus, we used a combination of bioinformatics and biochemistry to identify associated RNA binding proteins. The findings reported here are part of ongoing studies to determine the functions of non-coding RNAs from the IR1 region of epstein-barr virus. RESULTS: Human regulatory proteins heterogeneous nuclear ribonucleoprotein A1, HNRNPC, HNRNPL, HuR (human antigen R), and protein LIN28A (lin-28 homolog A) were predicted to bind ebv-sisRNA-1 and/or ebv-sisRNA-2; FUS (fused in sarcoma) was predicted to associate with ebv-sisRNA-2. Protein interactions were validated using a combination of RNA immunoprecipitation and biotin pulldown assays. Both sisRNAs also precipitated with HNRNPD and NONO (non-POU domain-containing octamer-binding protein). Our findings suggest interesting roles for sisRNAs (through their interactions with regulatory proteins) and provide further evidence for the existence of non-spliced stable non-coding RNAs.] Question: Based on the provided context, do the terms [HNRNPL protein] and [FUS protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between HNRNPL protein and FUS protein. While both proteins are predicted to associate with different non-coding RNAs from the Epstein-Barr virus IR1 region, there is no indication that they interact with each other. The context describes their individual interactions with the RNAs but does not suggest any combined or direct interaction between HNRNPL and FUS.</s>
7357 2A2926071 2A2680398	Nae1	ubiquitin-like modifier nedd8	[INST]Context: [PMID: 28238764 Cullin E3 Ligase Activity Is Required for Myoblast Differentiation. The role of cullin E3-ubiquitin ligases for muscle homeostasis is best known during muscle atrophy, as the cullin-1 substrate adaptor atrogin-1 is among the most well-characterized muscle atrogins. We investigated whether cullin activity was also crucial during terminal myoblast differentiation and aggregation of acetylcholine receptors for the establishment of neuromuscular junctions in vitro. The activity of cullin E3-ligases is modulated through post-translational modification with the small ubiquitin-like modifier nedd8. Using either the Nae1 inhibitor MLN4924 (Pevonedistat) or siRNA against nedd8 in early or late stages of differentiation on C2C12 myoblasts, and primary satellite cells from mouse and human, we show that cullin E3-ligase activity is necessary for each step of the muscle cell differentiation program in vitro. We further investigate known transcriptional repressors for terminal muscle differentiation, namely ZBTB38, Bhlhe41, and Id1. MLN4924 is currently undergoing clinical trials in cancer patients, and our experiments highlight concerns on the homeostasis and regenerative capacity of muscles in these patients who often experience cachexia. Mice.] Question: Based on the provided context, do the terms [Nae1 protein] and [ubiquitin-like modifier nedd8 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that the activity of cullin E3-ligases is modulated through post-translational modification with the small ubiquitin-like modifier nedd8. The Nae1 inhibitor MLN4924 (Pevonedistat) is used to inhibit cullin E3-ligase activity, which suggests that Nae1 and ubiquitin-like modifier nedd8 interact in the process of modulating cullin E3-ligase activity. This interaction is crucial for muscle cell differentiation and aggregation of acetylcholine receptors.</s>
332657 2A2497017 2A2547361	DCTN2	CDH1	[INST]Context: [PMID: 34722557 Construction and Identification of a Novel 5-Gene Signature for Predicting the Prognosis in Breast Cancer. Background: Breast cancer is one of the most common malignancies in women worldwide. The purpose of this study was to identify the hub genes and construct prognostic signature that could predict the survival of patients with breast cancer . Drug-resistance hub genes were identified by weighted gene co-expression network analysis, and a multigene risk model was constructed by univariate and multivariate Cox regression analysis based on the TCGA cohort. Results: A 5-gene signature (GP6, MAK, DCTN2, TMEM156, and FKBP14) was constructed as a prognostic risk model. The nomogram comprising 5-gene signature showed better performance compared with other clinical features, Further, in the high-risk group, high M2 macrophage scores were related with bad prognosis, and the frequency of TP53 mutations was greater in the high-risk group than in the low-risk group. In the low-risk group, high CD8+ T cell scores were associated with a good prognosis, and the frequency of CDH1 mutations was greater in the low-risk group than that in the high-risk group. At the same time, patients in the low risk group have a good response to immunotherapy in terms of immunotherapy. The results of immunohistochemistry showed that MAK, GP6, and TEMEM156 were significantly highly expressed in tumor tissues, and DCTN2 was highly expressed in normal tissues. Conclusions: Our study may find potential new targets against breast cancer, and provide new insight into the underlying mechanisms.] Question: Based on the provided context, do the terms [DCTN2 protein] and [CDH1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between DCTN2 protein and CDH1 protein. Instead, it discusses the frequency of mutations in these genes in relation to the risk groups and their association with prognosis and immunotherapy response in breast cancer. There is no indication that DCTN2 and CDH1 proteins interact with each other.</s>
2525 2A2486374 2A2918856	CTAPIII	transthyretin	[INST]Context: [PMID: 21708402 Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer. OBJECTIVE: The low prevalence of ovarian cancer demands both high sensitivity (>75%) and specificity (99.6%) to achieve a positive predictive value of 10% for successful early detection. We have attempted to improve sensitivity by combining CA125 with proteomic markers. METHODS: Sera from 41 patients with early stage (I/II) and 51 with late stage (III/IV) epithelial ovarian cancer, 40 with benign disease and 99 healthy individuals, were analyzed to measure 7 proteins [Apolipoprotein A1 (Apo-A1), truncated transthyretin, transferrin, hepcidin, _-2-microglobulin, Connective Tissue Activating Protein III, and Inter-alpha-trypsin inhibitor heavy chain 4 ]. RESULTS: In a training set analysis, the 3 most effective biomarkers (Apo-A1, truncated transthyretin and CTAPIII) exhibited 54% sensitivity at 98% specificity, CA125 alone produced 68% sensitivity and the combination increased sensitivity to 88%. In a validation set, the marker panel plus CA125 produced a sensitivity of 84% at 98% specificity (P=0.015, McNemar's test). CONCLUSION: Combining a panel of proteomic markers with CA125 could provide a first step in a sequential two-stage strategy with transvaginal sonography for early detection of ovarian cancer.] Question: Based on the provided context, do the terms [CTAPIII protein] and [transthyretin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the use of various proteins, including CTAPIII and truncated transthyretin, as biomarkers for detecting early-stage epithelial ovarian cancer. It mentions that these proteins, along with CA125, are used to improve the sensitivity of early detection. However, there is no direct interaction mentioned between CTAPIII protein and transthyretin protein. Instead, they are presented as separate biomarkers that contribute to the overall sensitivity of the detection method.</s>
247783 2A2440486 2A2871954	B2M	SFRS4	[INST]Context: [PMID: 21527436 Identification of stable endogenous reference genes for real-time polymerase chain reaction in the human fetal gonad using an external standard technique. For real-time polymerase chain reaction (RT-PCR) this commonly depends upon identification of stable (non-variable) endogenous reference genes, with housekeeping genes the most commonly used. In this report we describe the use of an external mRNA standard to identify stable housekeeping genes in the human fetal gonad. Total RNA was extracted from second trimester human fetal gonads and a standard amount of luciferase mRNA was added at the start of the extraction process. Levels of luciferase were then measured relative to each of seven housekeeping genes (SDHA, TBP, B2M, PMM1, SFRS4, HMBS and UBC) by RT-PCR. Measurement of overall variation in transcript expression showed that PMM1 was the most stable HKG in the ovary while B2M was most stable in the testis. This study describes a method for identification of endogenous, stable reference genes for RT-polymerase chain reaction studies of transcript expression levels which is objective and not dependent on prior assumptions of HKG expression. This technique is likely to be applicable to most tissues and, in this case, identifies suitable housekeeping genes for studies into human gonadal development.] Question: Based on the provided context, do the terms [B2M protein] and [SFRS4 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the identification of stable housekeeping genes (HKGs) for real-time polymerase chain reaction (RT-PCR) studies in the human fetal gonad. It mentions the use of an external mRNA standard and the measurement of transcript expression levels relative to various HKGs, including B2M and SFRS4. However, there is no indication or evidence that B2M protein and SFRS4 protein interact with each other. The context focuses on the stability of these genes as reference points for RT-PCR analysis rather than on any direct interaction between the proteins they encode.</s>
578892 2A2459951 2A2529968	cdkn2b	enhancer of zeste homolog 2	[INST]Context: [PMID: 32850364 Deregulation of Polycomb Repressive Complex-2 in Mantle Cell Lymphoma Confers Growth Advantage by Epigenetic Suppression of cdkn2b. The polycomb repressive complex 2 maintains the transcriptional repression of target genes through its catalytic component enhancer of zeste homolog 2 . Through modulating critical gene expression, enhancer of zeste homolog 2 also plays a role in cancer development and progression by promoting cancer cell survival and invasion. Mutations in enhancer of zeste homolog 2 are prevalent in certain B-cell lymphoma subtypes such as diffuse large cell lymphoma and follicular lymphoma; While no enhancer of zeste homolog 2 mutation has been reported in the mantle cell lymphoma . Here we demonstrate that the polycomb repressive complex 2 components enhancer of zeste homolog 2, EED and SUZ12 are upregulated in the mantle cell lymphoma cells as compared to normal B-cells. Moreover, stably transfected cells with wild-type enhancer of zeste homolog 2 or-EED showed increased cell growth and H3K27-trimehtylation. However, unlike wild-type enhancer of zeste homolog 2, ectopic expression of a deletion construct of enhancer of zeste homolog 2 (EZH2delta550-738 lacking SET domain) had no growth advantage over control cells. Pharmacological inhibition of enhancer of zeste homolog 2 suppressed H3K27me3 and had significant inhibitory effect on cell growth and colony forming capacity (p < 0.05) of mantle cell lymphoma cells, and this effect was more or less comparable to the anti-proliferative effects of enhancer of zeste homolog 2 inhibition in cells harboring EZH2-mutation. Mechanistically, enhancer of zeste homolog 2 appears to downregulate expression of cdkn2b gene via enhanced H3K27me3, a well-known suppressive epigenetic mark, at the cdkn2b promoter region. Overall, these results highlight that deregulation of PRC2/enhancer of zeste homolog 2 is associated with epigenetic suppression of cdkn2b in mantle cell lymphoma, and in part responsible for increased cell growth, thus the enhancer of zeste homolog 2 inhibitors may have therapeutic potential in the patients with mantle cell lymphoma.] Question: Based on the provided context, do the terms [cdkn2b protein] and [enhancer of zeste homolog 2 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that the enhancer of zeste homolog 2 (EZH2) protein epigenetically suppresses the expression of the cdkn2b gene by enhancing H3K27me3 at the cdkn2b promoter region. This suggests a direct interaction between the EZH2 protein and the cdkn2b gene, where EZH2 influences the expression of cdkn2b through epigenetic modifications.</s>
611030 2A2665527 2A2910113	MTSS1	TRIB3	[INST]Context: [PMID: 32415564 Zinc Gluconate Induces Potentially Cancer Chemopreventive Activity in Barrett's Esophagus: A Phase 1 Pilot Study. BACKGROUND: Chemopreventive effects of zinc for esophageal cancer have been well documented in animal models. This prospective study explores if a similar, potentially chemopreventive action can be seen in Barrett's esophagus in humans. AIMS: To determine if molecular evidence can be obtained potentially indicating zinc's chemopreventive action in Barrett's metaplasia. METHODS: Patients with a prior barrett's esophagus diagnosis were placed on oral zinc gluconate (14 days of 26.4 mg zinc BID) or a sodium gluconate placebo, prior to their surveillance endoscopy procedure. These included downregulation of transcripts encoding proinflammatory proteins (IL32, IL1beta, IL15, IL7R, IL2R, IL15R, IL3R), upregulation of anti-inflammatory mediators (IL1RA), downregulation of transcripts mediating epithelial-to-mesenchymal transition (LIF, MYB, LYN, MTA1, SRC, SNAIL1, and TWIST1), and upregulation of transcripts that oppose epithelial-to-mesenchymal transition (BMP7, MTSS1, TRIB3, GRHL1). MiRNA arrays showed significant upregulation of seven miRs with tumor suppressor activity (-125b-5P, -132-3P, -548z, -551a, -504, -518, and -34a-5P). Of proteins analyzed by Western blot, increased expression of the pro-apoptotic protein, BAX, and the tight junctional protein, CLAUDIN-7, along with decreased expression of BCL-2 and VEGF-R2 were noteworthy. CONCLUSIONS: When these mRNA, miRNA, and protein molecular data are considered collectively, a cancer chemopreventive action by zinc in Barrett's metaplasia may be possible for this precancerous esophageal tissue. These results and the extensive prior animal model studies argue for a future prospective clinical trial for this safe, easily-administered, and inexpensive micronutrient, that could determine if a chemopreventive action truly exists.] Question: Based on the provided context, do the terms [MTSS1 protein] and [TRIB3 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the upregulation of transcripts that oppose epithelial-to-mesenchymal transition (EMT), including MTSS1 and TRIB3. However, it does not mention any direct interaction between the MTSS1 protein and the TRIB3 protein. Instead, it lists them as separate entities that contribute to the overall anti-EMT effect. Therefore, based on the given information, there is no evidence of a direct interaction between MTSS1 and TRIB3 proteins.</s>
622801 2A2865793 2A2714841	INI-1	CD31	[INST]Context: [PMID: 30200169 Long period of relative quiescence in distal-type epithelioid sarcoma of the forearm with recurrence after surgery: A case report. BACKGROUND: Epithelioid sarcoma is a rare malignant mesenchymal tumor that only accounts for 0.6% to 1.0% of all cases of sarcomas. Epithelioid sarcoma with a relative quiescent state of more than 10 years is extremely rare.Here, we present a rare case of epithelioid sarcoma in the forearm of a 17-year-old girl. The patient had a congenital mass in her forearm that measured approximately 1cm; The mass was located in the middle and lower part of the left forearm and involved the dorsal muscle group, intermuscular space, and subcutaneous tissues without clear boundaries.The patient underwent surgery, and the tumor recurred twice within 1 year postoperatively. RESULTS: Histopathologically, the tumor comprised large polygonal epithelioid cells with abundant eosinophilic cytoplasm arranged in cell nests. Central necrosis and focal myxoid change could be seen in the tumor tissues. Immunostaining showed that the tumor cells were positive for CD34, CK, EMA, and vimentin but negative for CD31, S-100, and INI-1. CONCLUSION: Based on these findings, the tumor was diagnosed as epithelioid sarcoma of distal form. Distal-type epithelioid sarcoma could have a long period of relative quiescence, after which it could grow rapidly and relapse multiple times over a short duration.] Question: Based on the provided context, do the terms [INI-1 protein] and [CD31 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the INI-1 protein and the CD31 protein. Instead, it describes the immunostaining results for the tumor cells, indicating that the tumor cells were positive for certain proteins (e.g., CD34, CK, EMA, and vimentin) and negative for others (e.g., CD31 and INI-1). The absence of interaction is implied by the fact that the context lists these proteins as separate markers without any indication of their interaction.</s>
316556 2A2565398 2A2509801	GM130	cdc2	[INST]Context: [PMID: 15561761 Monocrotaline pyrrole-induced endothelial cell megalocytosis involves a Golgi blockade mechanism. Pyrrolizidine alkaloids initiate disease in the lung (pulmonary hypertension), liver (veno-occlusive disease and cirrhosis), and kidneys (afferent arteriolar block and mesangiolysis) by inducing a megalocytotic phenotype in target endothelial and parenchymal cells. A 'hit-and-run' type of exposure to the bioactive pyrrolizidine results, within 2-3 days, in enlarged cells with large nuclei and enlarged Golgi and endoplasmic reticulum, while the cells remain in G2/M block. In the present study, we recapitulated monocrotaline pyrrole -induced megalocytosis in cultures of bovine pulmonary arterial endothelial cells, human Hep3B hepatocytes, human type II-like alveolar epithelial cells (A549), and human pulmonary arterial smooth muscle cells and investigated the subcellular mechanism involved. There was an inverse relationship between reduction in caveolin -1 levels and stimulation of promitogenic STAT3 and ERK1/2 cell signaling. In megalocytotic pulmonary arterial endothelial cells, the Golgi scaffolding protein GM130 was shifted from membranes with heavy density to those with a lighter density. This lighter Golgi fraction was enriched for hypo-oligomeric Cav-1, indicating dysfunctional trafficking of cargo. There was an increase in Ser25 phosphorylation of GM130 (typically a prelude to Golgi fragmentation and mitosis) and increased association between pGM130, cdc2 kinase, and Cav-1. Nevertheless, megalocytotic MCTP-treated cells showed reduced entry into mitosis upon stimulation with 2-methoxyestradiol, reduced 2-ME-induced Golgi fragmentation, and a slowing of Golgi reassembly after nocodazole-induced fragmentation. These data suggest that a disruption of the trafficking and mitosis sensor functions of the Golgi may represent the subcellular mechanism leading to MCTP-induced megalocytosis ('the Golgi blockade hypothesis'). Swine.] Question: Based on the provided context, do the terms [GM130 protein] and [cdc2 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that there is an increased association between pGM130 (phosphorylated GM130) and cdc2 kinase in megalocytotic MCTP-treated cells. This suggests that GM130 protein and cdc2 protein interact with each other in the context of the Golgi blockade mechanism. The increased association implies a functional interaction, particularly in the context of mitosis and Golgi fragmentation.</s>
43236 2A2918856 2A2417667	transthyretin	apolipoprotein A-I	[INST]Context: [PMID: 24349355 Serum protein signatures differentiating autoimmune pancreatitis versus pancreatic cancer. Autoimmune pancreatitis is defined by characteristic lymphoplasmacytic infiltrate, ductal strictures and a pancreatic enlargement or mass that can mimic pancreatic cancer . The distinction between this benign disease and pancreatic cancer can be challenging. However, an accurate diagnosis may pre-empt the misdiagnosis of cancer, allowing the appropriate medical treatment of autoimmune pancreatitis and, consequently, decreasing the number of unnecessary pancreatic resections. Mass spectrometry and two-dimensional differential gel electrophoresis (2D-DIGE) have been applied to analyse serum protein alterations associated with autoimmune pancreatitis and pancreatic cancer, and to identify protein signatures indicative of the diseases. Patients' sera were immunodepleted from the 20 most prominent serum proteins prior to further 2D-DIGE and image analysis. Serum profiling data analysis with 2D-DIGE revealed 39 protein peaks able to discriminate between autoimmune pancreatitis and pancreatic cancer. Among them apolipoprotein A-I, apolipoprotein A-II, transthyretin, and tetranectin were identified and found as 3.0-, 3.5-, 2-, and 1.6-fold decreased in pancreatic cancer sera, respectively, whereas haptoglobin and apolipoprotein E were found to be 3.8- and 1.6-fold elevated in pancreatic cancer sera. With the exception of haptoglobin the ELISA results of the identified proteins confirmed the 2D-DIGE image analysis characteristics. Integration of the identified serum proteins as autoimmune pancreatitis markers may have considerable potential to provide additional information for the diagnosis of autoimmune pancreatitis to choose the appropriate treatment. From MeSH: Helicobacter pylori.] Question: Based on the provided context, do the terms [transthyretin protein] and [apolipoprotein A-I protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the identification of serum protein signatures that differentiate autoimmune pancreatitis from pancreatic cancer. It mentions that transthyretin and apolipoprotein A-I are among the proteins found to be decreased in pancreatic cancer sera. However, there is no indication that these two proteins interact with each other. Instead, they are presented as separate entities whose levels are altered in pancreatic cancer. Therefore, based on the given information, there is no evidence of an interaction between transthyretin protein and apolipoprotein A-I protein.</s>
306184 2A2459929 2A2418243	CDKN1A	PMAIP1	[INST]Context: [PMID: 33422507 Synthetic cyclopenta[b]indoles exhibit antineoplastic activity by targeting microtubule dynamics in acute myeloid leukemia cells. Acute promyelocytic leukemia is associated with PML-RARalpha oncogene, which is treated using all-trans retinoic acid -based chemotherapy. However, chemoresistance is observed in 20-30% of treated patients and represents a clinical challenge, raising the importance of the development of new therapeutic options. In the present study, the effects of three synthetic cyclopenta[b]indoles on the leukemia phenotype were investigated using NB4 (ATRA-sensitive) and NB4-R2 (ATRA-resistant) cells. Among the tested synthetic cyclopenta[b]indoles, compound 2, which contains a heterocyclic nucleus, was the most active, presenting time-dependent cytotoxic activity in the muM range in acute promyelocytic leukemia cells, without cytotoxicity for normal leukocytes, and was selected for further characterization. Compound 2 significantly decreased clonogenicity, increased apoptosis, and caused cell cycle arrest at S and G2/M phases in a drug concentration-dependent manner. Morphological analyses indicated aberrant mitosis and diffuse tubulin staining upon compound 2 exposure, which corroborates cell cycle findings. In the molecular scenario, compound 2 reduced STMN1 expression and activity, and induced PARP1 cleavage and H2AX and CHK2 phosphorylation, and modulated CDKN1A, PMAIP1, GADD45A, and XRCC3 expressions, indicating reduction of cell proliferation, apoptosis, and DNA damage. Moreover, in the in vivo tubulin polymerization assay, NB4 and NB4-R2 cells showed a reduction in the levels of polymerized tubulin upon compound 2 exposure, which indicates tubulin as a target of the drug. Taken together, these data indicated that compound 2 exhibits antileukemic effects through disrupting the microtubule dynamics, identifying a possible novel potential antineoplastic agent for the treatment of ATRA-resistant acute promyelocytic leukemia.] Question: Based on the provided context, do the terms [CDKN1A protein] and [PMAIP1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not indicate a direct interaction between CDKN1A protein and PMAIP1 protein. Instead, it mentions that compound 2 modulates the expression of these proteins as part of its effects on cell proliferation, apoptosis, and DNA damage. The modulation of these proteins is presented as part of the broader mechanism of action of compound 2, rather than a direct interaction between CDKN1A and PMAIP1.</s>
268431 2A2855015 2A2576061	HbA	HbA2	[INST]Context: [PMID: 7679879 G gamma A gamma (beta+) hereditary persistence of fetal hemoglobin: the G gamma -158 C-->T mutation in cis to the -175 T-->C mutation of the A gamma-globin gene results in increased G gamma-globin synthesis. Hereditary persistence of fetal hemoglobin can be generally classified into deletional and nondeletional forms. The family described in the present study has characteristics of both types of hereditary persistence of fetal hemoglobin. The proband is a healthy 30-year-old black woman. Analysis of her hemoglobin revealed 40.4% HbS, 40.9% HbF (G gamma/A gamma ratio 0.53), 16.8% HbA, and 1.9% HbA2. All of her hematologic indices were normal, and the distribution of HbF in her red cells was pancellular. Family studies demonstrated that the proband has one chromosome 11 bearing the beta s-globin gene and the other bearing a G gamma A gamma (beta+) hereditary persistence of fetal hemoglobin determinant in cis to the beta A-globin gene. Gene mapping studies of the region between the G gamma- and beta-globin genes were normal. The -158 C-->T mutation has been associated with elevated G gamma levels and high HbF in hemolysis, although its role in causing these effects is unclear. The present study suggests that this mutation can also enhance G gamma-globin expression in cis to the -175 T-->C mutation in the absence of hemolysis. We propose calling these linked mutations the G gamma A gamma(beta+) hereditary persistence of fetal hemoglobin.] Question: Based on the provided context, do the terms [HbA protein] and [HbA2 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the hemoglobin types (HbS, HbF, HbA, and HbA2) and their proportions in the proband's blood. It does not mention any direct interaction between HbA protein and HbA2 protein. Instead, it describes the presence and distribution of these hemoglobin types in the context of hereditary persistence of fetal hemoglobin. Therefore, there is no evidence of interaction between HbA and HbA2 proteins based on the given information.</s>
446192 2A2446146 2A2736893	BBOX1	PRDX1	[INST]Context: [PMID: 15046786 Microarray analysis of the effect of diesel exhaust particles on in vitro cultured macrophages. Diesel exhaust particles have been reported to induce or aggravate pulmonary diseases, including cancer and asthma. Alveolar macrophages are important cellular targets for diesel exhaust particles and have important immunological and inflammatory properties in the response to foreign substances in the lung. In vitro cultures of human THP-1 cells were differentiated to macrophages and were exposed to 1600 ng/ml diesel exhaust particles during 6 and 24 h. Nine genes (CYP1B1, THBD, Il1b, ITGB7, SEC6, TNFRSF1B, LPXN, LOC51093 and BTG2) are upregulated and seven (PRDX1, CD36, PRKACB, BBOX1, CLK1, STMN1, and HMGB2) are downregulated at both time-points.] Question: Based on the provided context, do the terms [BBOX1 protein] and [PRDX1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the BBOX1 protein and the PRDX1 protein. It only lists the genes that are upregulated or downregulated in response to diesel exhaust particles exposure. There is no indication that these proteins interact with each other or that their expression levels are related in a way that suggests an interaction.</s>
466256 2A2544793 2A2613339	FAN1	Erg-1	[INST]Context: [PMID: 32712126 Molecular, physiological and behavioral characterization of the heterozygous Df[h15q13]/+ mouse model associated with the human 15q13.3 microdeletion syndrome. The human 15q13.3 microdeletion syndrome (DS) is caused by a heterozygous microdeletion affecting six genes: FAN1; MTMR10; TRPM1; KLF13; OTUD7A; And CHRNA7. Carriers are at risk for intellectual disability, epilepsy, autism spectrum disorder, and schizophrenia. Here we used the Df[h15q13]/+ mouse model with an orthologous deletion to further characterize molecular, neurophysiological, and behavioral parameters that are relevant to the 15q13.3 DS. First, we verified the expression and distribution of the alpha7 nicotinic acetylcholine receptor, a gene product of the CHRNA7, in cortical and subcortical areas. Results revealed similar mRNA distribution pattern in wildtype and heterozygous mice, with about half the number of alpha7 nicotinic acetylcholine receptor binding sites in mutants. Hippocampal recordings showed similar input/output responses of field excitatory post-synaptic potentials and theta-burst induced long-term potentiation in wildtype and heterozygous mice. Heterozygous males exhibited impaired spatial learning acquisition in the Barnes Maze. Indicative of increased seizure susceptibility, heterozygous mice developed secondary seizures after 6-Hz corneal stimulation, and had significantly increased sensitivity to the chemoconvulsant pentylenetetrazol resulting in increased spiking in hippocampal EEG recordings. Basal mRNA expression of brain derived neurotrophic factor and activity regulated immediate early genes (c-fos, Arc, Erg-1 and Npas4) during adolescence, a critical period of brain maturation, was unaffected by genotype. Thus, the microdeletion did not show gross neuroanatomical, molecular, and neurophysiological abnormalities despite deficits in spatial learning and increased susceptibility to seizures. Altogether, our results verify the phenotypic profile of the heterozygous Df[h15q13]/+ mouse model and underscore its translational relevance for human 15q13.3 DS. Mice.] Question: Based on the provided context, do the terms [FAN1 protein] and [Erg-1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the FAN1 protein and the Erg-1 protein. The context discusses the expression and distribution of the alpha7 nicotinic acetylcholine receptor, neurophysiological parameters, and behavioral characteristics of the Df[h15q13]/+ mouse model. However, it does not provide any information about an interaction between the FAN1 protein and the Erg-1 protein. Therefore, based on the given information, there is no evidence to suggest that these two proteins interact with each other.</s>
706926 2A2475316 2A2592321	Cofilin-1	Hsp27	[INST]Context: [PMID: 21681992 Proteomic changes in articular cartilage of human endemic osteoarthritis in China. Kashin-Beck disease is a chronic endemic osteochondropathy with unclear pathogenesis. It is a degenerative disease similar to osteoarthritis, but with different manifestations of cartilage damage. The aim of this investigation was to show the protein changes in kashin-beck disease cartilage and to identify the candidate proteins in order to understand the pathogenesis of the disease. Proteins were extracted from the media of primary cell cultures of kashin-beck disease and normal chondrocytes, and separated by two-dimensional fluorescence difference gel electrophoresis (2-D DIGE). The proteins identified are mainly involved in cellular redox homeostasis and stress response (MnSOD, Hsp27, Peroxiredoxin-1, and Cofilin-1), glycolysis (PGK-1, PGM-1, alpha-enolase), and cell motility and cytoskeletal organization (Actin, Calponin-2, and Keratin). These KBD-associated proteins indicate that cytoskeletal remodeling, glycometabolism, and oxidative stress are abnormal in kashin-beck disease articular cartilage.] Question: Based on the provided context, do the terms [Cofilin-1 protein] and [Hsp27 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context lists several proteins involved in various cellular processes in kashin-beck disease articular cartilage, including Cofilin-1 and Hsp27. However, there is no direct mention of an interaction between Cofilin-1 and Hsp27. The context describes their roles in cellular redox homeostasis and stress response, glycolysis, and cell motility and cytoskeletal organization, but it does not indicate that these two specific proteins interact with each other.</s>
273817 2A2897602 2A2419185	TFG	ARL6IP1	[INST]Context: [PMID: 30237576 Autozygome, a rich source of homozygous variants, has been successfully utilized for the high throughput identification of novel autosomal recessive disease genes. METHODS: Autozygome and exome analysis of patients with suspected Mendelian phenotypes. RESULTS: We highlight 30 published candidate genes (ACTL6B, ADAM22, AGTPBP1, APC, C12orf4, C3orf17 (NEPRO), CENPF, CNPY3, COL27A1, DMBX1, FUT8, GOLGA2, KIAA0556, LENG8, MCIDAS, MTMR9, MYH11, QRSL1, RUBCN, SLC25A42, SLC9A1, TBXT, TFG, THUMPD1, TRAF3IP2, UFC1, UFM1, WDR81, XRCC2, ZAK) in which we identified homozygous likely deleterious variants in patients with compatible phenotypes. We also identified homozygous likely deleterious variants in 18 published candidate genes (ABCA2, ARL6IP1, ATP8A2, CDK9, CNKSR1, DGAT1, DMXL2, GEMIN4, HCN2, HCRT, MYO9A, PARS2, PLOD3, PREPL, SCLT1, STX3, TXNRD2, WIPI2) although the associated phenotypes are sufficiently different from the original reports that they represent phenotypic expansion or potentially distinct allelic disorders. CONCLUSIONS: Our results should facilitate the timely relabeling of these candidate disease genes in relevant databases to improve the yield of clinical genomic sequencing.] Question: Based on the provided context, do the terms [TFG protein] and [ARL6IP1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the TFG protein and the ARL6IP1 protein. It lists these proteins as part of a set of candidate genes with homozygous likely deleterious variants identified in patients with compatible phenotypes. However, there is no specific information or evidence provided that suggests a direct interaction between TFG and ARL6IP1. Therefore, based on the given context, it can be concluded that these two proteins do not interact with each other.</s>
272348 2A2671284 2A2717079	mevalonate pyrophosphate decarboxylase	PEX5	[INST]Context: [PMID: 14680974 Cholesterol biosynthesis is not defective in peroxisome biogenesis defective fibroblasts. To evaluate the presumed peroxisomal involvement in cholesterol/isoprenoid biosynthesis, we determined the protein levels and activities of five different enzymes of the presqualene segment of the cholesterol/isoprenoid biosynthetic pathway in primary skin fibroblasts of selected patients with a peroxisomal biogenesis disorder . These five enzymes all have been reported to be partly or exclusively peroxisomal and include HMG-CoA reductase, mevalonate kinase, phosphomevalonate kinase, mevalonate pyrophosphate decarboxylase, and isopentenyl pyrophosphate isomerase. To exclude that genetic differences, resulting in different defects in peroxisomal biogenesis, have differential effects on the activity of the cholesterol biosynthetic enzymes and on de novo cholesterol biosynthesis, we chose fibroblasts of patients with defined defects in one of four different PEX genes leading to Zellweger syndrome (PEX1, PEX5, PEX16 or PEX19). We found that all enzymes measured are at least as active in the peroxisome-deficient cells cultured in cholesterol-depleted medium as in identically cultured control cells. This indicates that if these presumed peroxisomal proteins are mislocalized to the cytosol they do not loose their activity, nor get degraded unlike most other authentic peroxisomal proteins. We also measured de novo cholesterol synthesis from radio-labeled acetate in all cell lines and found similar or even elevated rates for the peroxisomal biogenesis disorder cells when compared to controls.] Question: Based on the provided context, do the terms [mevalonate pyrophosphate decarboxylase protein] and [PEX5 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the activities of various enzymes involved in cholesterol biosynthesis in fibroblasts from patients with peroxisomal biogenesis disorders. It mentions mevalonate pyrophosphate decarboxylase and PEX5 protein in the context of their roles in the cholesterol biosynthesis pathway and the effects of peroxisomal defects on these enzymes. However, there is no direct interaction mentioned between mevalonate pyrophosphate decarboxylase protein and PEX5 protein. Instead, they are discussed as separate entities involved in the same pathway but not interacting with each other.</s>
570109 2A2610206 2A2706294	MAPK8IP2	p21-activated kinase 4	[INST]Context: [PMID: 29048629 Inhibition of neuroblastoma proliferation by PF-3758309, a small-molecule inhibitor that targets p21-activated kinase 4. Neuroblastoma is the most common extracranial solid childhood tumor. Despite the availability of advanced multimodal therapy, high-risk patients still have low survival rates. p21-activated kinase 4 has been shown to regulate many cellular processes in cancer cells, including migration, polarization and proliferation. However, the role of p21-activated kinase 4 in neuroblastoma remains unclear. In the present study, we demonstrated that p21-activated kinase 4 was overexpressed in neuroblastoma tissues and was correlated with tumor malignance and prognosis. To investigate the function of p21-activated kinase 4 in neuroblastoma, we used a small-molecule inhibitor that targets p21-activated kinase 4, that is, PF-3758309. Our results showed that PF-3758309 significantly induced cell cycle arrest at the G1 phase and apoptosis in neuroblastoma cell lines. Meanwhile, the inhibition of p21-activated kinase 4 by PF-3758309 increased the expression of CDKN1A, BAD and BAK1 and decreased the expression of Bcl-2 and Bax. In addition, we screened the target genes of p21-activated kinase 4 by PCR array and found that 23 genes were upregulated (including TP53I3, TBX3, EEF1A2, CDKN1A, IFNB1 and MAPK8IP2) and 20 genes were downregulated (including TNFSF8, Bcl2-A1, Bcl2L1, SOCS3, BIRC3 and NFKB1) after p21-activated kinase 4 inhibition by PF-3758309. Moreover, p21-activated kinase 4 was found to regulate the cell cycle and apoptosis via the ERK signaling pathway. In conclusion, the present study demonstrated, for the first time, the expression and function of p21-activated kinase 4 in neuroblastomas and the inhibitory effect of PF-3758309, which deserves further investigation as an alternative strategy for neuroblastoma treatment.] Question: Based on the provided context, do the terms [MAPK8IP2 protein] and [p21-activated kinase 4 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that p21-activated kinase 4 (PAK4) regulates many cellular processes in cancer cells, including migration, polarization, and proliferation. It also mentions that 23 genes were upregulated after p21-activated kinase 4 inhibition by PF-3758309, including MAPK8IP2. This suggests that MAPK8IP2 protein is a target gene of p21-activated kinase 4, implying an interaction between the two proteins.</s>
293720 2A2547188 2A2852768	FXR1	UBA2	[INST]Context: [PMID: 34267779 Expression and Prognosis Analysis of SUMOylation Regulators in Oral Squamous Cell Carcinoma Based on High-Throughput Sequencing. Introduction: Oral squamous cell carcinoma originates from oral mucosal epithelial cells, accounting for more than 90% of oral cancers. The relationship between the expression and prognostic role of SUMOylation regulators in oral squamous cell carcinoma is rarely studied. Materials and methods: The expression and survival data of oral squamous cell carcinoma were derived from TCGA and GEO databases. Wilcoxon test was used to determine the differential expression of the SUMOylation regulators. A prognostic model based on SUMOylation regulator-related genes was constructed by Cox regression. Results: RANBP2 and SENP6 had the highest SNV frequency. Eleven genes including PIAS3, RANBP2, USPL1, SENP6, SENP2, SENP5, SAE1, UBA2, PIAS4, UBE2I, and SENP3 were highly expressed in oral squamous cell carcinoma. The prognostic model based on nine SUMOylation-regulated genes (TRIM37, UFM1, FUBP1, CCNT1, FXR1, HMG20A, RANBP3, SPATA5, and DDX23) had a strong ability to predict the prognosis of oral squamous cell carcinoma. Conclusion: This study might provide targets for prognostic evaluation and targeted therapy of patients with oral squamous cell carcinoma.] Question: Based on the provided context, do the terms [FXR1 protein] and [UBA2 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the FXR1 protein and the UBA2 protein. The context discusses the expression and prognostic role of SUMOylation regulators in oral squamous cell carcinoma, including the identification of genes that are highly expressed in the disease. However, it does not provide any specific information about an interaction between FXR1 and UBA2 proteins. Therefore, based on the given information, there is no evidence to suggest that these two proteins interact with each other.</s>
660663 2A2905810 2A2532229	TNNT3	FABP4	[INST]Context: [PMID: 21722758 7 Mb de novo deletion within 8q21 in a patient with distal arthrogryposis type 2B . We report on a 7 11/12 years old male patient with normal mental development, club feet, ulnar deviation and mild camptodactyly as well as facial dysmorphism including high forehead, small mouth, broad nasal bridge, epicanthus, high palate, brachycephalus, short neck, and dysplastic ears consistent with distal arthrogryposis type 2B . Mutational analysis of the genes MYH3, TNNI2, TNNT3 and TPM2, known to cause distal arthrogryposis type 2b revealed no apparent disease causing mutation. Prioritisation of possible candidate genes using the bioinformatics tool ENDEAVOUR revealed three favoured genes, HEY1, FABP5 and FABP4 as potential causes of the phenotype. We propose that the 8q21 region contains a further locus which contributes to the genetically heterogeneous distal arthrogryposis type 2b.] Question: Based on the provided context, do the terms [TNNT3 protein] and [FABP4 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the TNNT3 protein and the FABP4 protein. The context discusses the genetic analysis of various genes associated with distal arthrogryposis type 2B, including TNNT3 and FABP4, but it does not indicate any interaction between these two proteins. Instead, it focuses on the potential role of these genes as candidates for causing the phenotype.</s>
19013 2A2874398 2A2497838	STC2	DDIT4	[INST]Context: [PMID: 32251684 Indeno[1,2,3-cd]pyrene and picene mediate actions via estrogen receptor alpha signaling pathway in in vitro cell systems, altering gene expression. However, the global impact of microplastic on human health is by and large either unknown or neglected. By looking at the underlying biochemical mechanisms leading to the global health threat microplastic was discovered to carry persistent organic pollutants, such as polycyclic aromatic hydrocarbons, to marine life. The effect of microplastic-ingestion in the human body remains unfortunately somewhat elusive as of yet. For this reason, we screened for compounds binding to the human estrogen receptor alpha and identified the polycyclic aromatic hydrocarbons compounds indeno[1,2,3-cd]pyrene and picene with a high binding affinity. We applied next generation sequencing to analyze the differentially expressed genes in MCF-7 cells after treatment with indeno[1,2,3-cd]pyrene and picene. We found 8 upregulated genes: ABCC5, CCNG2, CYP1A1, DDIT4, IER3, RUNX2, STC2, and SLC7A5 and 14 downregulated genes: ADORA1, CEBPB, CELSR2, CTSD, CXCL12, KRT19, PGR, PKIB, RARA, RET, SEMA3B, SIAH2, TFAP2C, and XBP1 induced by both ligands and associated with ESR1-regulation. The altered gene expression may influence cell proliferation and metastasis, favoring cancer development with a poor response to therapy. In addition, we confirmed the binding of indeno[1,2,3-cd]pyrene and picene to estrogen receptor alpha using molecular docking and microscale thermophoresis. Estrogen receptor alpha activation was measured with ESR1-overexpressing HEK293 cells and confirmed for indeno[1,2,3-cd]pyrene. In conclusion, we showed an ESR1-mediated influence of the polycyclic aromatic hydrocarbons compounds indeno[1,2,3-cd]pyrene and picene on the gene expression pattern of MCF-7 cells, possibly also promoting breast cancer development in patients.] Question: Based on the provided context, do the terms [STC2 protein] and [DDIT4 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the STC2 protein and the DDIT4 protein. The context discusses the differential gene expression in MCF-7 cells after treatment with indeno[1,2,3-cd]pyrene and picene, listing STC2 and DDIT4 among the upregulated genes. However, it does not provide any information about a direct interaction between these two proteins. Instead, it focuses on their individual roles in the altered gene expression pattern.</s>
161299 2A2642360 2A2599276	CCNL1	EIF4G1	[INST]Context: [PMID: 15761962 Copy number changes of target genes in chromosome 3q25.3-qter of esophageal squamous cell carcinoma: TP63 is amplified in early carcinogenesis but down-regulated as disease progressed. AIM: By using comparative genomic hybridization, gain of 3q was found in 45-86% cases of esophageal squamous cell carcinoma . Chromosome 3q25.3-qter is the minimal common region with several oncogenes found within this region. However, amplification patterns of these genes in esophageal squamous cell carcinoma have never been reported. METHODS: Real-time quantitative PCR was performed to analyze the copy number changes of 13 candidate genes within this region in 60 primary tumors of esophageal squamous cell carcinoma, and possible association of copy number changes with pathologic characteristics was analyzed by statistics. Immunohistochemistry study was also performed on another set of 111 primary tumors of esophageal squamous cell carcinoma to verify the association between TP63 expression change and lymph node metastasis status. RESULTS: The average copy numbers (+/-SE) per haploid genome of individual genes in 60 samples were (from centromere to telomere): SSR3: 4.19 (+/-0.69); CCNL1: 5.24 (+/-0.67); SMC4L1: 2.01 (+/-0.16); EVI1: 2.02 (+/-0.12); EIF5A2: 1.95 (+/-0.12); ECT2: 9.18 (+/-1.68); PIK3CA: 8.13 (+/-1.17); EIF4G1: 1.07 (+/-0.05); SST: 3.07 (+/-0.25); TP63: 2.51 (+/-0.22); Four clusters of amplification were found: SSR3 and CCLN1 at 3q25.31; ECT2 and PIK3CA at 3q26.31-q26.32; And SST, TP63 and TFRC at 3q27.3-q29. Patients with lymph node metastasis had significantly lower copy number of TP63 in the primary tumor than those without lymph node metastasis. Immunohistochemistry study on tissue arrays also showed that patients with lymph node metastasis have significantly lower TP63 staining score in the primary tumor than those without lymph node metastasis. CONCLUSION: This study showed that different amplification patterns were seen among different genes within 3q25.3-qter in esophageal squamous cell carcinoma, and several novel candidate oncogenes (SSR3, SMC4L1, ECT2, and SST) were identified. TP63 is amplified in early stage of esophageal squamous cell carcinoma carcinogenesis but down-regulated in advanced stage of disease.] Question: Based on the provided context, do the terms [CCNL1 protein] and [EIF4G1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the copy number changes of various genes in esophageal squamous cell carcinoma and their association with disease progression. While it mentions the copy number changes of CCNL1 and EIF4G1, it does not provide any information about a direct interaction between the CCNL1 protein and the EIF4G1 protein. The context focuses on the amplification patterns of these genes and their association with pathological characteristics, but it does not indicate any direct interaction between the proteins encoded by these genes.</s>
484378 2A2681555 2A2714841	NF68	PECAM-1	[INST]Context: [PMID: 10830620 Differentiation, proliferation and adhesion of human neuroblastoma cells after treatment with retinoic acid. Because of the known property of spontaneous regression in stage IVS of neuroblastoma all attempts are made to elucidate whether differentiation inducers possibly could be applied for neuroblastoma therapy. Here we examined the influence of retinoic acid in vitro on differentiation, proliferation and adhesion of 10 permanent and 4 primary cell lines as well as of several SCID-mouse tumour transplants. In general, after retinoic acid treatment morphologically different cell types which are characteristic for neuroblastoma cells have changed. N (neuronal)-type cells prolonged their neuronal processes, whereas S (epithelial, substrate-adherent, Schwann cell-like)-type cells lost their adherence to substratum and became apoptotic. Additionally, the reactions of all neuroblastoma cell lines with monoclonal antibodies against beta-tubulin (for neuronal cells) and glial fibrillary acidic protein (for epithelial cells) were determined. The anti-proliferative effect of all-trans-retinoic acid as well as 13-cis-RA was more profound in S-type cells (up to 40% in primary cell lines). To elucidate the role of adhesion molecules during neuronal cell differentiation, we have analysed the adhesion of neuroblastoma cells on poly-D-lysin-precoated plates under retinoic acid influence. While N-type cells displayed an increased adhesion, all S-type cell lines as well as all primary cell lines exhibited a reduced adhesion (IMR-5 and IMR-32: p < 0.001; JW, SR and PM: p < 0.05). Retinoic acid treatment increased predominantly the tested antigens (HCAM, ICAM-1, NCAM, PECAM-1, VCAM-1, cadherin, FGF-R, IGF-R, NGF-R, TGF-beta/1, NF200, NF160, NF68, NSE, HLA-ABC) in all cell lines independently of their phenotypes (TGF-beta/1: p < 0.001; NF68: p < 0.01; PECAM-1 and NGF-R: p < 0.05). In recultured SCID-mouse-passaged tumour cells antigens were down-regulated (FGF-R: p < 0.01), but increased again after retinoic acid influence (TGF-beta/1: p < 0.05). In summary, the retinoic acid differentiation model demonstrates the possibility to interfere in cell adhesion and to diminish growth potential both in N-type as well as S-type neuroblastoma cells. Mice.] Question: Based on the provided context, do the terms [NF68 protein] and [PECAM-1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the effects of retinoic acid on various proteins in neuroblastoma cells, including NF68 and PECAM-1. However, there is no direct interaction mentioned between NF68 protein and PECAM-1 protein. Instead, the context describes the changes in the expression levels of these proteins in response to retinoic acid treatment, but it does not indicate any direct interaction between them.</s>
368353 2A2871148 2A2739390	Sequestosome-1	profilin-1	[INST]Context: [PMID: 31824497 Common Neurodegeneration-Associated Proteins Are Physiologically Expressed by Human B Lymphocytes and Are Interconnected via the Inflammation/Autophagy-Related Proteins TNF Receptor Associated Factor 6 and Sequestosome-1. On another hand, several genes involved in familial forms of neurodegenerative diseases exert key innate immune functions. First, we retrieved the expression patterns of common neurodegeneration-associated proteins in two professional antigen-presenting cells, namely B lymphocytes and dendritic cells. Surprisingly, we found that under physiological conditions, numerous neurodegeneration-associated proteins are abundantly expressed by human B lymphocytes. A survey of the human proteome allowed us to map a unique protein-protein interaction network linking common neurodegeneration-associated proteins and their first shell interactors in human B lymphocytes. Interestingly, network connectivity analysis identified two major hubs that both relate with inflammation and autophagy, namely TNF Receptor Associated Factor 6 and Sequestosome-1 . Moreover, the mapped network in B lymphocytes comprised two additional hub proteins involved in both inflammation and autoimmunity: HSPA8 (Heat Shock Protein Family A Member 8 also known as HSC70) and HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1). Based on these results, we then explored the Immune Epitope Database 'IEDB-AR' and actually found that a large share of neurodegeneration-associated proteins were previously reported to provide endogenous MHC class II-binding peptides in human B lymphocytes. Of note, peptides deriving from amyloid beta A4 protein, sequestosome-1 or profilin-1 were reported to bind multiple allele-specific MHC class II molecules. In contrast, peptides deriving from microtubule-associated protein tau, presenilin 2 and serine/threonine-protein kinase TBK1 were exclusively reported to bind MHC molecules encoded by the HLA-DRB1 1501 allele, a recently-identified susceptibility gene for late onset Alzheimer's disease. Finally, we observed that the whole list of proteins reported to provide endogenous MHC class II-binding peptides in human B lymphocytes is specifically enriched in neurodegeneration-associated proteins. Overall, our work indicates that immunization against neurodegeneration-associated proteins might be a physiological process which is shaped, at least in part, by B lymphocytes.] Question: Based on the provided context, do the terms [Sequestosome-1 protein] and [profilin-1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between Sequestosome-1 protein and profilin-1 protein. While both proteins are discussed in the context of neurodegeneration-associated proteins and their roles in the immune system, there is no specific information indicating that they interact with each other. The context focuses on their individual roles and their interactions with other proteins, but not on a direct interaction between Sequestosome-1 and profilin-1.</s>
535163 2A2450692 2A2739390	carbonic anhydrase 2	profilin 1	[INST]Context: [PMID: 27986506 Proteomic assessment of colorectal cancers and respective resection margins from patients of the Amazon state of Brazil. Colorectal cancer is the third most common type of cancer in the world with a low survival rate and therapeutic efficiency. This tissue is referred to as the resection margin. These proteins are mainly involved in energetic metabolism (e.g. S100 calcium binding protein A11), cell migration (e.g. transgelin), formation of the cytoskeleton (e.g. profilin 1) and degradation of extracellular matrix (e.g. carbonic anhydrase 2). A gene ontology enrichment analysis revealed several proteins related to adhesion, invasion, metastasis, death, and recognition cell. Taken together, our results highlight proteins related to invasion, cell proliferation, and linked to the metastasis of colorectal cancer in tumor tissue. BIOLOGICAL SIGNIFICANCE: Colorectal cancer is the third most common type of cancer in the world with a low survival rate and therapeutic efficiency. This tissue is also referred to as the resection margin. While most studies focus on comparing cancer versus control tissue, this study contrasts the proteomic profiles of colorectal cancer biopsies with their corresponding resection margin at 5cm apart. A gene ontology enrichment analysis revealed several proteins related to adhesion, invasion, metastasis, death, and recognition cell.] Question: Based on the provided context, do the terms [carbonic anhydrase 2 protein] and [profilin 1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between carbonic anhydrase 2 protein and profilin 1 protein. Instead, it lists these proteins as part of a broader set of proteins involved in various cellular processes such as energetic metabolism, cell migration, and degradation of the extracellular matrix. The context does not provide any specific evidence or indication that carbonic anhydrase 2 and profilin 1 interact with each other.</s>
502276 2A2847424 2A2851583	LBP	S100A8	[INST]Context: [PMID: 26222498 Cystic endometrial hyperplasia, mucometra, and pyometra are common uterine diseases in intact dogs, with pyometra being a life threatening disease. This study aimed to determine the gene expression profile of these lesions and potential biomarkers for closed-cervix pyometra, the most severe condition. Total RNA was extracted from 69 fresh endometrium samples collected from 21 healthy female dogs during diestrus, 16 cystic endometrial hyperplasia, 15 mucometra and 17 pyometra (eight open and nine closed-cervixes). Unsupervised analysis revealed two clusters, one mainly composed of diestrus and cystic endometrial hyperplasia samples and the other by 12/15 mucometra and all pyometra samples. When comparing pyometra with other groups, 189 differentially expressed genes were detected. SLPI, PTGS2/COX2, MMP1, S100A8, S100A9 and IL8 were among the top up-regulated genes detected in pyometra, further confirmed by external expression data. Notably, a particular molecular profile in pyometra from animals previously treated with exogenous progesterone compounds was observed in comparison with pyometra from untreated dogs as well as with other groups irrespective of exogenous hormone treatment status. In addition to S100A8 and S100A9 genes, overexpression of the inflammatory cytokines IL1B, TNF and IL6 as well as LTF were detected in the pyometra from treated animals. Interestingly, closed pyometra was more frequently detected in treated dogs (64% versus 33%), with IL1B, TNF, LBP and CXCL10 among the most relevant overexpressed genes. This molecular signature associated with potential biomarkers and therapeutic targets, such as CXCL10 and COX2, should guide future clinical studies. Based on the gene expression profile we suggested that pyometra from progesterone treated dogs is a distinct molecular entity. From MeSH: Dogs.] Question: Based on the provided context, do the terms [LBP protein] and [S100A8 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between LBP protein and S100A8 protein. While both proteins are mentioned in the context of pyometra and their overexpression in treated dogs, there is no specific information indicating that they interact with each other. Instead, they are presented as separate entities that are overexpressed in the same condition.</s>
581963 2A2459937 2A2748680	MEN4	parathyroid hormone	[INST]Context: [PMID: 30641515 The 4 parathyroid glands derive from the third and fourth pharyngeal pouches and descend caudally to the anterior neck. Through the secretion of parathyroid hormone, the parathyroid glands are primarily responsible for maintaining extracellular calcium and phosphorus concentrations. Hypercalcemia may be distinguished in parathyroid-hypercalcemia and nonparathyroid hypercalcemia. The most common disorders include primary hyperparathyroidism, malignancy, granulomatous diseases, and medications. Primary hyperparathyroidism is a disease characterized by excessive secretion of parathyroid hormone. Primary hyperparathyroidism is most commonly due to a single benign parathyroid adenoma (80%) and with multiglandular disease seen in approximately 15-20% of patients. Primary hyperparathyroidism is due to multiglandular involvement consisting of either multiple adenomas or hyperplasia of all 4 glands (5-10%), and very rarely parathyroid carcinoma (<1%). In most patients the disease is sporadic, without a personal or family history of primary hyperparathyroidism. The genetic syndromes associated with primary hyperparathyroidism include multiple endocrine neoplasia type 1, MEN2A, and MEN4, hyperparathyroidism-jaw tumor syndrome, familial isolated primary hyperparathyroidism, familial hypocalciuric hypercalcemia, and neonatal severe hyperparathyroidism. The asymptomatic clinical presentation is most common in countries where biochemical screening is routine. Conversely, target organ involvement at presentation dominates the clinical landscape of primary hyperparathyroidism in other countries, such as China and India, where biochemical screening is not routine practice.] Question: Based on the provided context, do the terms [MEN4 protein] and [parathyroid hormone protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the role of parathyroid hormone in maintaining extracellular calcium and phosphorus concentrations and mentions various disorders associated with hypercalcemia, including primary hyperparathyroidism. It also lists genetic syndromes associated with primary hyperparathyroidism, such as MEN4. However, there is no direct interaction mentioned between the MEN4 protein and parathyroid hormone protein. Instead, they are presented as separate entities related to different aspects of primary hyperparathyroidism. Therefore, based on the given context, there is no evidence of a direct interaction between MEN4 protein and parathyroid hormone protein.</s>
7370 2A2926071 2A2508404	HPP1	DNMT	[INST]Context: [PMID: 26439130 Phytochemical Indicaxanthin Inhibits Colon Cancer Cell Growth and Affects the DNA Methylation Status by Influencing Epigenetically Modifying Enzyme Expression and Activity. BACKGROUND: Recently, we have shown anti-proliferative and pro-apoptotic effects of indicaxanthin associated with epigenetic modulation of the onco-suppressor p16INK4a in the human colon cancer cell line CACO2. In the present study, the epigenetic activity of indicaxanthin and the mechanisms involved were further investigated in other colorectal cancer cell lines. METHODS: LOVO1, CACO2, HT29, HCT116, and DLD1 cells were used to evaluate the potential influence of consistent dietary concentrations of indicaxanthin on DNA methylation, and the epigenetic mechanisms involved were researched. RESULTS: Indicaxanthin exhibited anti-proliferative activity in all cell lines but HT29, induced demethylation in the promoters of some methylation-silenced onco-suppressor genes involved in colorectal carcinogenesis (p16INK4a, GATA4, and ESR1), and left unchanged others which were basally hypermethylated (SFRP1 and HPP1). In apparent contrast, cell exposure to indicaxanthin increased DNMT gene expression, although indicaxanthin appeared to be an inhibitor of DNMT activity. Indicaxanthin also increased the expression of genes involved in DNA demethylation. Finally, an in silico molecular modelling approach suggested stable binding of indicaxanthin at the DNMT1 catalytic site. CONCLUSIONS: Our findings contribute to new knowledge in the field of phytochemicals and specifically suggest dietary indicaxanthin as a potential epigenetic agent to protect colon cells against tumoral alterations.] Question: Based on the provided context, do the terms [HPP1 protein] and [DNMT protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between HPP1 protein and DNMT protein. Instead, it discusses the effects of indicaxanthin on the methylation status of various genes, including HPP1 and DNMT genes. While indicaxanthin influences the expression and activity of DNMT proteins, it does not indicate any direct interaction between HPP1 protein and DNMT protein. Therefore, based on the given information, there is no evidence to suggest that HPP1 protein and DNMT protein interact with each other.</s>
403150 2A2592161 2A2600684	HSP70	IkappaBalpha	[INST]Context: [PMID: 18410682 Extracellular heat shock protein 70 inhibits tumour necrosis factor-alpha induced proinflammatory mediator production in fibroblast-like synoviocytes. Although elevated HSP70 levels have been identified in rheumatoid arthritis synovial tissues and rheumatoid arthritis synovial fluid compared with patients with osteoarthritis and healthy individuals, it remains unclear what role extracellular HSP70 plays in the pathogenesis of rheumatoid arthritis. This study was conducted to investigate the effects of extracellular HSP70 on the production of RA-associated cytokines in fibroblast-like synoviocytes from patients with rheumatoid arthritis and to elucidate the mechanisms involved. METHODS: IL-6, IL-8 and monocyte chemoattractant protein -1 levels in culture supernatants were measured using enzyme-linked immunosorbent assays. Activation of mitogen-activated protein kinases, such as extracellular signal-regulated protein kinases (ERKs), c-Jun amino-terminal kinase (JNK) and p38 MAPK, was detected using Western blotting. RESULTS: Human HSP70 downregulated IL-6, IL-8 and MCP-1 production in rheumatoid arthritis fibroblast-like synoviocytes induced by tumour necrosis factor -alpha in a concentration dependent manner. HSP70 inhibited the activation of ERK, JNK and p38 MAPK in fibroblast-like synoviocytes stimulated by TNF-alpha. Furthermore, HSP70 also significantly inhibited nuclear translocation of nuclear factor-kappaB and degradation of IkappaBalpha induced by TNF-alpha. CONCLUSION: Extracellular HSP70 has an anti-inflammatory effect on rheumatoid arthritis by downregulating production of IL-6, IL-8 and MCP-1 in fibroblast-like synoviocytes, which is mediated through inhibited activation of the mitogen-activated protein kinases and nuclear factor-kappab signal pathways.] Question: Based on the provided context, do the terms [HSP70 protein] and [IkappaBalpha protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that extracellular HSP70 inhibits the degradation of IkappaBalpha induced by TNF-alpha. This suggests that HSP70 influences the activity of IkappaBalpha, which is a key regulator of the nuclear factor-kappaB (NF-kappaB) signaling pathway. Therefore, HSP70 and IkappaBalpha interact in the sense that HSP70 modulates the degradation of IkappaBalpha, thereby affecting the NF-kappaB pathway.</s>
126139 2A2590057 2A2711013	heat shock protein 90 alpha family class A member 1	thyroid hormone receptor interactor 13	[INST]Context: [PMID: 32377703 A risk score system based on DNA methylation levels and a nomogram survival model for lung squamous cell carcinoma. Lung squamous cell carcinoma is one of the primary types of non___small cell lung carcinoma, and patients with recurrent lung squamous cell carcinoma usually have a poor prognosis. The present study was conducted to build a risk score system for lung squamous cell carcinoma. Methylation data on lung squamous cell carcinoma (training set) and on head and neck squamous cell carcinoma (validation set 2) were obtained from The Cancer Genome Atlas database, and GSE39279 (validation set 1) was retrieved from the Gene Expression Omnibus database. For the differentially expressed genes between the high___ and low___risk groups, pathway enrichment analysis was performed by Gene Set Enrichment Analysis. Following screening out of the top 10 genes (aldehyde dehydrogenase 7 family member A1, chromosome 8 open reading frame 48, cytokine___like 1, heat shock protein 90 alpha family class A member 1, isovaleryl___CoA dehydrogenase, phosphodiesterase 3A, PNMA family member 2, SAM domain, SH3 domain and nuclear localization signals 1, thyroid hormone receptor interactor 13 and zinc finger protein 878) and 6 top lncRNAs, risk score systems were constructed. According to Kaplan___Meier analysis, the DNA methylation level___based risk score system exhibited the best performance. In combination with independent clinical prognostic factors, a nomogram survival model was built and successfully predicted patient survival. The 10___DMG methylation level___based risk score system and the nomogram survival model may be applied for predicting the outcomes of patients with lung squamous cell carcinoma.] Question: Based on the provided context, do the terms [heat shock protein 90 alpha family class A member 1 protein] and [thyroid hormone receptor interactor 13 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between heat shock protein 90 alpha family class A member 1 protein and thyroid hormone receptor interactor 13 protein. The context lists these proteins as part of a set of genes and lncRNAs used to construct a risk score system for lung squamous cell carcinoma, but it does not describe any specific interaction between these two proteins. Therefore, based on the given information, there is no evidence to suggest that these two proteins interact with each other.</s>
468543 2A2430998 2A2497838	activating transcription factor 4	REDD1	[INST]Context: [PMID: 22904092 Translation termination efficiency modulates activating transcription factor 4 response by regulating activating transcription factor 4 mRNA translation at 5' short ORFs. The activating transcription factor 4 promotes transcriptional upregulation of specific target genes in response to cellular stress. Activating transcription factor 4 expression is regulated at the translational level by two short open reading frames (uORFs) in its 5'-untranslated region . Here, we describe a mechanism regulating activating transcription factor 4 expression in translation termination-deficient human cells. Using microarray analysis of total RNA and polysome-associated mRNAs, we show that depletion of the eucaryotic release factor 3a induces upregulation of activating transcription factor 4 and of activating transcription factor 4 target genes. We show that eucaryotic release factor 3a depletion modifies activating transcription factor 4 translational control at regulatory uORFs increasing activating transcription factor 4 ORF translation. Finally, we show that the increase of REDD1 expression, one of the upregulated targets of activating transcription factor 4, is responsible for the mammalian target of rapamycin pathway inhibition in eRF3a-depleted cells. Our results shed light on the molecular mechanisms connecting eucaryotic release factor 3a depletion to mammalian target of rapamycin pathway inhibition and give an example of activating transcription factor 4 activation that bypasses the signal transduction cascade leading to the phosphorylation of eIF2alpha. We propose that in mammals, in which the 5'-untranslated region regulatory elements of activating transcription factor 4 mRNA are strictly conserved, variations in translation termination efficiency allow the modulation of the activating transcription factor 4 response.] Question: Based on the provided context, do the terms [activating transcription factor 4 protein] and [REDD1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that the depletion of eucaryotic release factor 3a (eRF3a) leads to the upregulation of activating transcription factor 4 (ATF4) and its target genes, including REDD1. This upregulation of REDD1 is responsible for the inhibition of the mammalian target of rapamycin (mTOR) pathway in eRF3a-depleted cells. Therefore, the ATF4 protein and REDD1 protein interact in the sense that ATF4 regulates the expression of REDD1, which in turn affects the mTOR pathway.</s>
27820 2A2440989 2A2905922	BAT3	FAS	[INST]Context: [PMID: 20385987 Interactions among genetic variants in apoptosis pathway genes, reflux symptoms, body mass index, and smoking indicate two distinct etiologic patterns of esophageal adenocarcinoma. PURPOSE: Apoptosis pathway, gastroesophageal reflux symptoms (reflux), higher body mass index, and tobacco smoking have been individually associated with esophageal adenocarcinoma development. PATIENTS AND METHODS: In total, 305 patients with esophageal adenocarcinoma and 339 age- and sex-matched controls were studied. High-order interactions among reflux, body mass index, smoking, and functional polymorphisms in five apoptotic genes (FAS, FASL, IL1B, TP53BP, and BAT3) were investigated by entropy-based multifactor dimensionality reduction, classification and regression tree, and traditional logistic regression models. However, there was a two-way interaction between IL1B + 3954C>T and reflux (P = .008). In individuals with reflux symptoms, classification and regression tree analysis indicated that strongest interaction was among variant genotypes of IL1B + 3954C>T and BAT3S625P, higher body mass index, and smoking (odds ratio [OR], 5.76; 95% CI, 2.48 to 13.38), a finding independently found using multifactor dimensionality reduction analysis. Gene-environment interaction patterns differ between patients with and without reflux symptoms.] Question: Based on the provided context, do the terms [BAT3 protein] and [FAS protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses interactions among genetic variants in apoptosis pathway genes, reflux symptoms, body mass index, and smoking, but it does not mention any direct interaction between the BAT3 protein and the FAS protein. Instead, it focuses on the interactions between specific genetic variants and environmental factors, such as reflux symptoms, body mass index, and smoking, in relation to esophageal adenocarcinoma development. Therefore, there is no evidence in the context to suggest that the BAT3 protein and the FAS protein interact with each other.</s>
169120 2A2764298 2A2481140	kRAS	CREB	[INST]Context: [PMID: 26148557 Reorganization of metastamiRs in the evolution of metastatic aggressive neuroblastoma cells. BACKGROUND: MetastamiRs have momentous clinical relevance and have been correlated with disease progression in many tumors. In this study, we identified neuroblastoma metastamiRs exploiting unique mouse models of favorable and high-risk metastatic human neuroblastoma. Further, we related their deregulation to the modulation of target proteins and established their association with clinical outcomes. Immunoblotting and TMA-IHC analyses revealed alterations in the expression/phosphorylation of metastamiRs' targets, including ADAMTS-1, AKT1/2/3, ASK1, AURKbeta, Birc1, Birc2, Bric5, beta-CATENIN, CASP8, CD54, CDK4, CREB, CTGF, CXCR4, CYCLIN-D1, EGFR, ELK1, ESR1, CFOS, FOSB, FRA, GRB10, GSK3beta, IL1alpha, JUND, kRAS, KRTAP1, MCP1, MEGF10, MMP2, MMP3, MMP9, MMP10, MTA2, MYB, cMYC, NF2, NOS3, P21, pP38, PTPN3, CLEAVED PARP, PKC, SDF-1beta, SEMA3D, SELE, STAT3, TLR3, TNFalpha, TNFR1, and VEGF in aggressive cells ex vivo and in a manifold of metastatic tumors in vivo. MiRNA mimic (hsa-miR-125b, hsa-miR-27b, hsa-miR-93, hsa-miR-20a) and inhibitor (hsa-miR-1224-3p, hsa-miR-1260) approach for select miRNAs revealed the direct influence of the altered metastamiRs in the regulation of identified protein targets. Clinical outcome association analysis with the validated metastamiRs' targets corresponded strongly with poor overall and relapse-free survival. CONCLUSIONS: For the first time, these results identified a comprehensive list of neuroblastoma metastamiRs, related their deregulation to altered expression of protein targets, and established their association with poor clinical outcomes. The identified set of distinctive neuroblastoma metastamiRs could serve as potential candidates for diagnostic markers for the switch from favorable to high-risk metastatic disease. Mice.] Question: Based on the provided context, do the terms [kRAS protein] and [CREB protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the kRAS protein and the CREB protein. While both proteins are listed among the targets whose expression/phosphorylation is altered in aggressive neuroblastoma cells, there is no specific information indicating that kRAS and CREB interact with each other. The context focuses on the deregulation of metastamiRs and their influence on various protein targets, but it does not describe any direct interaction between kRAS and CREB.</s>
502432 2A2847424 2A2445658	LRP	bleomycin hydrolase	[INST]Context: [PMID: 9090498 Role of oncogenes in resistance and killing by cancer therapeutic agents. Chemotherapeutic drug resistance is a major clinical problem and cause for failure in the therapy of human cancer. One of the goals of molecular oncology is to identify the underlying mechanisms, with the hope that more effective therapies can be developed. Several mechanisms have been suggested to contribute to chemoresistance: 1) amplification or overexpression of the P-glycoprotein family of membrane transporters (eg, MDR1, MRP, LRP) which decrease the intracellular accumulation of chemotherapy; 2) changes in cellular proteins involved in detoxification (eg, glutathione S-transferase pi, metallothioneins, human MutT homologue, bleomycin hydrolase, dihydrofolate reductase) or activation of the chemotherapeutic drugs (DT-diaphorase, nicotinamide adenine dinucleotide phosphate:cytochrome P-450 reductase); 3) changes in molecules involved in DNA repair (eg, O6-methylguanine-DNA methyltransferase, DNA topoisomerase II, hMLH1, p21WAF1/CIP1; 4) activation of oncogenes such as Her-2/neu, bcl-2, bcl-XL, c-myc, ras, c-jun, c-fos, MDM2, p210 BCR-abl, or mutant p53.] Question: Based on the provided context, do the terms [LRP protein] and [bleomycin hydrolase protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses various mechanisms of chemotherapeutic drug resistance, including the role of P-glycoprotein family transporters (such as LRP) and detoxification proteins (such as bleomycin hydrolase). However, there is no mention of a direct interaction between the LRP protein and the bleomycin hydrolase protein. Instead, they are presented as separate entities involved in different mechanisms of drug resistance.</s>
574337 2A2734750 2A2401969	peroxisome proliferator activated receptor alpha	acetyl-coenzyme A carboxylase alpha	[INST]Context: [PMID: 33189279 Differential gene expression in dairy cows under negative energy balance and ketosis: A systematic review and meta-analysis. Development of ketosis in high-producing dairy cows contributes to several animal health issues and highlights the need for a better understanding of the genetic basis of metabolic diseases. To evaluate the pattern of differential gene expression in the liver of cows under negative energy balance, and under subclinical and clinical ketosis, a meta-analysis of gene expression and genome-wide association studies results was performed. An initial systematic review identified 118 articles based on the key words 'cow,' 'liver,' 'negative energy balance,' 'ketosis,' 'expression,' 'qPCR,' 'microarray,' 'proteomic,' 'RNA-Seq,' and 'GWAS.' After further screening for only peer-reviewed and pertinent articles for gene expression during negative energy balance and clinical and subclinical ketosis (considering plasma levels of beta-hydroxybutyrate), 20 articles were included in the analysis. From the systematic review, 430 significant SNPs identified by genome-wide association studies were assigned to genes reported in gene expression studies by considering chromosome and base pair positions in the ARS-UCD 1.2 bovine assembly. Three significant metabolic pathways were associated with negative energy balance and subclinical and clinical ketosis. In addition, 2 important genes, peroxisome proliferator activated receptor alpha and acetyl-coenzyme A carboxylase alpha, were identified, which were differentially expressed in the 3 metabolic conditions. The peroxisome proliferator activated receptor alpha gene is involved in the regulation of lipid metabolism and fatty liver disease and the acetyl-coenzyme A carboxylase alpha gene encodes an enzyme that catalyzes the carboxylation of acetyl-coenzyme A to malonyl-coenzyme A, which is a rate-limiting step in fatty acid synthesis. Gene network analysis revealed co-expression interactions among 34 genes associated with functions involving fatty acid transport and fatty acid metabolism. For the annotated QTL, 9 QTL were identified for ketosis. The genes fibronectin 1 and protein tyrosine kinase 2, which are mainly involved in cell adhesion and formation of extracellular matrix constituents, were enriched for QTL previously associated with the trait 'ketosis' on chromosome 2 and for the trait 'milk iron content' on chromosome 14, respectively. This integration of gene expression and genome-wide association studies data provides an additional understanding of the genetic background of negative energy balance and subclinical and clinical ketosis in dairy cattle. Thus, it is a useful approach to identify biological mechanisms underlying these metabolic conditions in dairy cattle. From MeSH: Cattle.] Question: Based on the provided context, do the terms [peroxisome proliferator activated receptor alpha protein] and [acetyl-coenzyme A carboxylase alpha protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the roles of peroxisome proliferator activated receptor alpha (PPAR\) and acetyl-coenzyme A carboxylase alpha (ACC\) in fatty acid metabolism and their differential expression in cows under negative energy balance and ketosis. However, it does not mention any direct interaction between the PPAR\ protein and the ACC\ protein. Instead, it describes their individual roles in lipid metabolism and fatty liver disease. Therefore, based on the given information, there is no evidence to suggest that these two proteins interact with each other.</s>
648505 2A2600684 2A2712749	IkappaB-alpha	D2-40	[INST]Context: [PMID: 27877228 Lymphangiogenesis in Classical Hodgkin Lymphoma - Preliminary Study with Clinicopathological Correlations. A role for lymphangiogenesis in metastatic breast and prostate cancers has been suggested recently. The relevance of lymphangiogenesis in cancer as a rule, and more specifically in classical Hodgkin lymphoma, is poorly understood in comparison with that of angiogenesis. In a preliminary study we have investigated the role of lymphatic vessels growth in 19 cases of classical Hodgkin lymphoma stained with the D2-40 (podoplanin) antibody. We determined the mean perimeter, surface area, major axis length and complexity factor for each hot spot and correlated them with clinical and biological features of classical Hodgkin lymphoma. No correlations were found with clinical features. However, significant inverse correlations were shown with pRb, BAX and IkappaB-alpha expression. Last, we carried out an additional clinicopathological correlation of the expression of pRb, BAX and IkappaB-alpha in a cohort of classical Hodgkin lymphoma patients previously published.] Question: Based on the provided context, do the terms [IkappaB-alpha protein] and [D2-40 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the role of lymphangiogenesis in classical Hodgkin lymphoma and the correlation of various proteins with clinical and biological features. While it mentions the expression of IkappaB-alpha and D2-40 (podoplanin) in relation to classical Hodgkin lymphoma, there is no direct interaction mentioned between IkappaB-alpha protein and D2-40 protein. Instead, they are presented as separate entities with correlations to different clinical and biological features.</s>
409046 2A2411184 2A2411518	PRAS40	Albumin	[INST]Context: [PMID: 26041739 Low Molecular Weight Fraction of Commercial Human Serum Albumin Induces Morphologic and Transcriptional Changes of Bone Marrow-Derived Mesenchymal Stem Cells. Osteoarthritis is the most common chronic disease of the joint; However, the therapeutic options for severe osteoarthritis are limited. The low molecular weight fraction of commercial 5% human serum albumin (LMWF5A) has been shown to have anti-inflammatory properties that are mediated, in part, by a diketopiperazine that is present in the albumin preparation and that was demonstrated to be safe and effective in reducing pain and improving function when administered intra-articularly in a phase III clinical trial. In the present study, bone marrow-derived mesenchymal stem cells exposed to LMWF5A exhibited an elongated phenotype with diffuse intracellular F-actin, pronounced migratory leading edges, and filopodia-like projections. In addition, LMWF5A promoted chondrogenic condensation in 'micromass' culture, concurrent with the upregulation of collagen 2alpha1 mRNA. Several transcription factors involved in stem cell differentiation were also found to bind oligonucleotide response element probes following exposure to LMWF5A. Finally, a rapid increase in PRAS40 phosphorylation was observed following treatment, potentially resulting in the activation mTORC1. Proteomic analysis of synovial fluid taken from a preliminary set of patients indicated that at 12 weeks following administration of LMWF5A, a microenvironment exists in the knee conducive to stem cell infiltration, self-renewal, and differentiation, in addition to indications of remodeling with a reduction in inflammation. Taken together, these findings imply that LMWF5A treatment may prime stem cells for both mobilization and chondrogenic differentiation, potentially explaining some of the beneficial effects achieved in clinical trials.] Question: Based on the provided context, do the terms [PRAS40 protein] and [Albumin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that LMWF5A, which contains a diketopiperazine, induces changes in bone marrow-derived mesenchymal stem cells, including the rapid increase in PRAS40 phosphorylation. This phosphorylation is potentially linked to the activation of mTORC1. Since PRAS40 is a protein involved in mTORC1 signaling, and LMWF5A is a fraction of human serum albumin, it can be inferred that the albumin protein indirectly interacts with PRAS40 protein through the signaling pathways it activates.</s>
367906 2A2871148 2A2652854	sequestosome 1	LC3	[INST]Context: [PMID: 31228582 Antimony, a novel nerve poison, triggers neuronal autophagic death via reactive oxygen species-mediated inhibition of the protein kinase B/mammalian target of rapamycin pathway. Antimony (Sb), a naturally occurring metal present in air and drinking water, has been found in the human brain, and there is evidence of its toxic effects on neurobehavioral perturbations, suggesting that Sb is a potential nerve poison. Here, we provide the first study on the molecular mechanism underlying Sb-associated neurotoxicity. Mice exposed to antimony potassium tartrate hydrate showed significantly increased neuronal apoptosis. In vitro, Sb triggered apoptosis in PC12 cells in a dose-dependent manner. Mechanically, Sb triggered autophagy as indicated by increased expression of microtubule-associated protein 1 light chain 3-II and accumulation of green fluorescent protein-tagged LC3 dots. Moreover, Sb enhanced autophagic flux and sequestosome 1 (p62) degradation. Subsequent analyses showed that Sb treatment decreased phosphorylation of protein kinase B (Akt) as well as the mammalian target of rapamycin, while an Akt activator protected PC12 cells from autophagy. Moreover, the antioxidant N-acetylcysteine attenuated Sb-induced Akt/mammalian target of rapamycin inhibition and decreased autophagy and apoptosis, with autophagy inhibition also playing a cytoprotective role. In vivo, mice treated with Sb showed higher expression of light chain 3-ii and p62 in the brain, consistent with the in vitro results. In summary, Sb induced autophagic cell death through reactive oxygen species-mediated inhibition of the Akt/mammalian target of rapamycin pathway. From MeSH: Mice. Rats.] Question: Based on the provided context, do the terms [sequestosome 1 protein] and [LC3 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that Sb treatment enhanced autophagic flux and sequestosome 1 (p62) degradation. This suggests that sequestosome 1 protein and LC3 protein interact within the autophagic process. Specifically, sequestosome 1 is involved in the formation of autophagosomes, which are structures that contain LC3 protein. Therefore, the interaction between sequestosome 1 and LC3 proteins is part of the autophagic pathway triggered by Sb.</s>
637910 2A2518953 2A2700120	Cas3	Ogg1	[INST]Context: [PMID: 25304545 Embryonic exposure to carbendazim induces the transcription of genes related to apoptosis, immunotoxicity and endocrine disruption in zebrafish (Danio rerio). Carbendazim is one of the most widespread environmental contaminant that can cause major concern to human and animal reproductive system. To date, very few studies have been conducted on the toxic effect of carbendazim in the non-target organism zebrafish (Danio rerio). The study presented here aimed to assess how carbendazim triggers apoptosis, immunotoxicity and endocrine disruption pathways in zebrafish during its embryo development. Our results demonstrated that the expression patterns of many key genes involved in cell apoptosis pathway (e.g. P53, Mdm2, Bbc3 and Cas8) were significantly up-regulated upon the exposure to carbendazim at the concentration of 500 mug/L, while the Bcl2 and Cas3 were down-regulated at the same concentration, interestingly, the expression level of Ogg1 decreased at all the exposure concentrations. It was also observed that the mRNA levels of CXCL-C1C, CCL1, IL-1b and TNFalpha which were closely related to the innate immune system, were affected in newly hatched zebrafish after exposed to different concentrations of carbendazim. Moreover, the expression of genes that are involved in the hypothalamic-pituitary-gonadal/thyroid axis including VTG, ERalpha, ERbeta2, Dio1, Dio2, Thraa and Thrb were all down-regulated significantly after the exposure to carbendazim. The expression levels of two cytochrome P450 aromatases CYP19a and CYP19b were increased significantly after 20 and 100 mug/L carbendazim exposure, respectively. Taken together, our results indicated that carbendazim had the potential to induce cell apoptosis and cause immune toxicity as well as endocrine disruption in zebrafish during the embryo developmental stage. From MeSH: Zebrafish.] Question: Based on the provided context, do the terms [Cas3 protein] and [Ogg1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the effects of carbendazim exposure on the expression of various genes related to apoptosis, immunotoxicity, and endocrine disruption in zebrafish. While it mentions that the expression levels of Cas3 and Ogg1 are affected by carbendazim exposure, there is no direct interaction mentioned between the Cas3 protein and the Ogg1 protein. Instead, they are presented as separate entities whose expression levels are influenced by the exposure to carbendazim. Therefore, based on the given information, there is no evidence to suggest that Cas3 and Ogg1 interact with each other.</s>
672050 2A2723964 2A2532229	adipose triglyceride lipase	fatty acid binding protein-4	[INST]Context: [PMID: 20512427 Obesity and insulin resistance-related changes in the expression of lipogenic and lipolytic genes in morbidly obese subjects. BACKGROUND: The storage capacity of adipose tissue may be an important factor linking obesity, insulin resistance, and associated morbidities. The aim of this study was to analyze the expression of lipogenic and lipolytic genes in adipose tissue and the influence of insulin resistance. METHODS: We studied the mRNA expression of peroxisome proliferator-activated receptor-gamma and lipogenic and lipolytic enzymes in the visceral and subcutaneous adipose tissue from 23 morbidly obese patients (MO; 13 with low insulin resistance and ten with high IR) and from 15 healthy, lean controls. RESULTS: In the visceral and subcutaneous adipose tissue from the MO, we found an increased expression of peroxisome proliferator-activated receptor-gamma (p___=___0.001 and p___=___0.022, respectively), acyl-coenzyme A /cholesterol acyltransferase (p___<___0.001 and p___<___0.001), aquaporin 7 (p___<___0.001 and p___=___0.003), and adipose triglyceride lipase (p___<___0.001 and p___<___0.001) and a reduced expression of acetyl-coenzyme A carboxylase (p___=___0.004 and p___<___0.001), independently of the state of insulin resistance. The expression of phosphoenolpyruvate carboxykinase and acyl-coenzyme a synthetase, however, was significantly lower in the MO with high insulin resistance (p___<___0.05). Glycerol kinase (p___=___0.010), hormone-sensitive lipase (p___<___0.001), and perilipin (p___=___0.006) were only significantly increased in visceral. Acyl-coenzyme a synthetase (p___=___0.012) and fatty acid binding protein-4 (p___=___0.003) were only significantly decreased in subcutaneous adipose tissue. CONCLUSION: Our results show an upregulation of genes facilitating triglyceride/fatty acid cycling and a reduction in the genes involved in de novo synthesis of fatty acids in morbid obesity. The expression of some of the genes studied seems to be related with the state of insulin resistance.] Question: Based on the provided context, do the terms [adipose triglyceride lipase protein] and [fatty acid binding protein-4 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the expression of various lipogenic and lipolytic genes in adipose tissue from morbidly obese patients and healthy controls. While it mentions the expression levels of adipose triglyceride lipase (ATGL) and fatty acid binding protein-4 (FABP4), it does not indicate any direct interaction between these two proteins. Instead, it describes their individual expression changes in relation to obesity and insulin resistance. Therefore, there is no evidence of a direct interaction between ATGL and FABP4 based on the given information.</s>
363362 2A2866725 2A2594884	SOD2	hexokinase	[INST]Context: [PMID: 27253232 Molecular Mechanisms of Toxicity and Cell Damage by Chemicals in a Human Pancreatic Beta Cell Line, 1.1B4. OBJECTIVES: Mechanisms of toxicity and cell damage were investigated in novel clonal human pancreatic beta cell line, 1.1B4, after exposure to streptozotocin, alloxan, ninhydrin, and hydrogen peroxide. METHODS: Viability, DNA damage, insulin secretion/content, [Ca]i, and glucokinase/hexokinase, mRNA expression were measured by MTT assay, comet assay, radioimmunoassay, fluorometric imaging plate reader, enzyme-coupled photometry, and real-time polymerase chain reaction, respectively. Chronic 18-hour exposure decreased cellular insulin, glucokinase, and hexokinase activities. Chemicals decreased transcription of INS, GCK, PCSK1, PCSK2, and GJA1 (involved in secretory function). Insulin release and [Ca]i responses to nutrients and membrane-depolarizing agents were impaired. Streptozotocin and alloxan up-regulated transcription of genes, SOD1 and SOD2 (antioxidant enzymes). Ninhydrin and hydrogen peroxide up-regulated SOD2 transcription, whereas alloxan and hydrogen peroxide increased CAT transcription. Chemicals induced DNA damage, apoptosis, and increased caspase 3/7 activity. Streptozotocin and alloxan decreased transcription of BCL2 while increasing transcription of BAX. Chemicals did not affect transcription of HSPA4 and HSPA5 and nitrite production. CONCLUSIONS: 1.1B4 cells represent a useful model of human beta cells. Chemicals impaired 1.1B4 cell secretory function and activated antioxidant defense and apoptotic pathways without activating endoplasmic reticulum stress response/nitrosative stress.] Question: Based on the provided context, do the terms [SOD2 protein] and [hexokinase protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not indicate any direct interaction between SOD2 protein and hexokinase protein. The context discusses the effects of various chemicals on the transcription and activity of different proteins, including SOD2 and hexokinase, but it does not mention any direct interaction between these two proteins. Instead, it describes their roles in separate pathways, such as antioxidant defense and metabolic processes, respectively.</s>
423043 2A2889324 2A2706294	Syt5	Pak4	[INST]Context: [PMID: 32820007 LCM-seq reveals unique transcriptional adaptation mechanisms of resistant neurons and identifies protective pathways in spinal muscular atrophy. Somatic motor neurons are selectively vulnerable in spinal muscular atrophy, which is caused by a deficiency of the ubiquitously expressed survival of motor neuron protein. However, some motor neuron groups, including oculomotor and trochlear (ocular), which innervate eye muscles, are for unknown reasons spared. To reveal mechanisms of vulnerability and resistance in spinal muscular atrophy, we investigate the transcriptional dynamics in discrete neuronal populations using laser capture microdissection coupled with RNA sequencing (LCM-seq). Using gene correlation network analysis, we reveal a TRP53-mediated stress response that is intrinsic to all somatic motor neurons independent of their vulnerability, but absent in relatively resistant red nucleus and visceral motor neurons. However, the temporal and spatial expression analysis across neuron types shows that the majority of SMA-induced modulations are cell type-specific. Using Gene Ontology and protein network analyses, we show that ocular motor neurons present unique disease-adaptation mechanisms that could explain their resilience. Specifically, ocular motor neurons up-regulate (1) Syt1, Syt5, and Cplx2, which modulate neurotransmitter release; (2) the neuronal survival factors Gdf15, Chl1, and Lif; (3) Aldh4, that protects cells from oxidative stress; And (4) the caspase inhibitor Pak4. Finally, we show that GDF15 can rescue vulnerable human spinal motor neurons from degeneration. This confirms that adaptation mechanisms identified in resilient neurons can be used to reduce susceptibility of vulnerable neurons. In conclusion, this in-depth longitudinal transcriptomics analysis in spinal muscular atrophy reveals novel cell type-specific changes that, alone and combined, present compelling targets, including Gdf15, for future gene therapy studies aimed toward preserving vulnerable motor neurons. From MeSH: Mice.] Question: Based on the provided context, do the terms [Syt5 protein] and [Pak4 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the roles of Syt5 and Pak4 proteins in the context of ocular motor neurons' resistance to spinal muscular atrophy. Syt5 is mentioned as a protein that modulates neurotransmitter release, while Pak4 is described as a caspase inhibitor. There is no direct interaction mentioned between Syt5 and Pak4 proteins. Instead, they are presented as separate entities contributing to the resilience of ocular motor neurons through different mechanisms.</s>
368460 2A2871148 2A2546801	sequestosome1	FUS RNA binding protein	[INST]Context: [PMID: 27632209 Mutation Frequency of the Major Frontotemporal Dementia Genes, MAPT, GRN and C9ORF72 in a Turkish Cohort of Dementia Patients. 'Microtubule-associated protein tau' (MAPT), 'granulin' (GRN) and 'chromosome 9 open reading frame72' (C9ORF72) gene mutations are the major known genetic causes of frontotemporal dementia . Recent studies suggest that mutations in these genes may also be associated with other forms of dementia. Therefore we investigated whether MAPT, GRN and C9ORF72 gene mutations are major contributors to dementia in a random, unselected Turkish cohort of dementia patients. A combination of whole-exome sequencing, Sanger sequencing and fragment analysis/Southern blot was performed in order to identify pathogenic mutations and novel variants in these genes as well as other FTD-related genes such as the 'charged multivesicular body protein 2B' (CHMP2B), the 'FUS RNA binding protein' (FUS), the 'TAR DNA binding protein' (TARDBP), the 'sequestosome1' (SQSTM1), and the 'valosin containing protein' (VCP). Three patients were found to carry the GGGGCC expansions in the non-coding region of the C9ORF72 gene. In summary, a complete screening for mutations in MAPT, GRN and C9ORF72 genes revealed a frequency of 5.4% of pathogenic mutations in a random cohort of 93 Turkish index patients with dementia. Turkey.] Question: Based on the provided context, do the terms [sequestosome1 protein] and [FUS RNA binding protein protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the sequestosome1 protein and the FUS RNA binding protein. The context lists these proteins as part of a broader screening for mutations in various genes related to frontotemporal dementia, but it does not describe any specific interaction between sequestosome1 and FUS RNA binding protein. Therefore, based on the given information, there is no evidence to suggest that these two proteins interact with each other.</s>
663100 2A2457399 2A2457284	CCL7	CCL11	[INST]Context: [PMID: 26441528 Systematic Review of the Neurobiological Relevance of Chemokines to Psychiatric Disorders. Psychiatric disorders are highly prevalent and disabling conditions of increasing public health relevance. Much recent research has focused on the role of cytokines in the pathophysiology of psychiatric disorders; Chemokines were originally identified as having chemotactic function on immune cells; However, recent evidence has begun to elucidate novel, brain-specific functions of these proteins of relevance to the mechanisms of psychiatric disorders. A systematic review of both human and animal literature in the PubMed and Google Scholar databases was undertaken. Some early mechanistic evidence does associate select chemokines with the neurobiological processes, including neurogenesis, modulation of the neuroinflammatory response, regulation of the hypothalamus-pituitary-adrenal axis, and modulation of neurotransmitter systems. Notable exceptions include CCL11 that has recently been shown to impair hippocampal function in aging___-___of distinct relevance to Alzheimer's disease and depression in the elderly, and pre-natal exposure to CXCL8 that may disrupt early neurodevelopmental periods predisposing to schizophrenia. Pro-inflammatory chemokines, such as CCL2, CCL7, CCL8, CCL12, and CCL13, have been shown to drive chemotaxis of pro-inflammatory cells to the inflamed or injured CNS. Likewise, CX3CL has been implicated in promoting glial cells activation, pro-inflammatory cytokines secretion, expression of ICAM-1, and recruitment of CD4+ T-cells into the CNS during neuroinflammatory processes. With further translational research, chemokines may present novel diagnostic and/or therapeutic targets in psychiatric disorders.] Question: Based on the provided context, do the terms [CCL7 protein] and [CCL11 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between CCL7 protein and CCL11 protein. Instead, it discusses the roles of these chemokines in separate neurobiological processes. CCL7 is mentioned in the context of its role in driving chemotaxis of pro-inflammatory cells to the inflamed or injured CNS, while CCL11 is mentioned in relation to its impairment of hippocampal function in aging, which is relevant to Alzheimer's disease and depression in the elderly. There is no indication that these two proteins interact with each other.</s>
313672 2A2863516 2A2779376	SKP1	ROC1	[INST]Context: [PMID: 15118074 SCFhFBH1 can act as helicase and E3 ubiquitin ligase. In our previous study, we found that a human F-box DNA helicase, named hFBH1, interacted with SKP1 to form an SKP1-Cul1-F-box protein complex together with CUL1 and ROC1 in an F-box-dependent manner. The complex immunoprecipitated from crude cell extracts catalyzed polyubiquitin formation in the presence of the ubiquitin-activating and ubiquitin-conjugating enzymes, E1 and E2, respectively. In this report, we characterized the enzymatic properties of the recombinant SCF(hFBH1) complex purified from insect cells expressing hFBH1, SKP1, CUL1 and ROC1. The helicase and ATPase activities residing in the SCF(hFBH1) complex were indistinguishable from those of the hFBH1 protein alone. Moreover, the ubiquitin ligase activity of the SCF(hFBH1) complex was hardly affected by single-stranded or double-stranded DNA. The potential roles of the SCF(hFBH1) complex in DNA metabolism based upon the enzymatic activities associated with this complex are discussed.] Question: Based on the provided context, do the terms [SKP1 protein] and [ROC1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that SKP1 and ROC1 interact with each other as part of the SCF(hFBH1) complex. Specifically, it mentions that the complex immunoprecipitated from crude cell extracts catalyzed polyubiquitin formation in the presence of E1 and E2, and that the complex was formed by SKP1, CUL1, ROC1, and hFBH1. This suggests that SKP1 and ROC1 are part of the same complex and thus interact with each other.</s>
217874 2A2454115 2A2398800	CASP-8	4E-BP1	[INST]Context: [PMID: 32199248 Profiling inflammatory response in lesions of cutaneous leishmaniasis patients using a non-invasive sampling method combined with a high-throughput protein detection assay. BACKGROUND: Cutaneous leishmaniasis is an infection caused by Leishmania (L.) protozoa transmitted through the bite of infected sand fly. Previously, invasive sampling of blood and skin along with low throughput methods were used for determination of inflammatory response in cutaneous leishmaniasis patients. AIMS/METHODOLOGY: We established a novel approach based on a non-invasive adhesive tape-disc sampling combined with a powerful multiplexing technique called proximity extension assay for profiling 92 inflammatory cytokines, chemokines and surface molecules in the lesions of cutaneous leishmaniasis patients infected with L. tropica. Sample collection was done non-invasively by using adhesive tape-discs from lesion and normal skin of 33 L. tropica positive patients. RESULTS: Out of 92 inflammatory proteins, the level of 34 proteins was significantly increased in the lesions of cutaneous leishmaniasis patients compared to their normal skin. This includes the chemokines CCL2, CCL3, CCL4, CXCL1, CXCL5, CXCL9, CXCL10 and CXCL11, together with the interleukins IL-6, IL-8, IL-18, LIF and OSM. The remaining significantly changed inflammatory proteins include 7 surface molecules and receptors: CD5, CD40, CDCP1, 4E-BP1, TNFRSF9, IL-18R1 and OPG as well as 16 other cytokines and proteins: MMP-1, CSF-1, VEGFA, uPA, EN-RAGE, LAP TGF-beta1, HGF, MMP-10, CASP-8, TNFSF14, STAMPB, ADA, TRAIL and ST1A1. Further, 13 proteins showed an increasing trend, albeit not statistically significant, in the cutaneous leishmaniasis lesions, including TGF-alpha, CCL23, MCP-2, IL-12B, CXCL6, IL-24, FGF-19, TNFbeta, CD6, TRANCE, IL10, SIR2 and CCL20. CONCLUSION: We herein report a novel approach based on a non-invasive sampling method combined with the high-throughput protein assay for profiling inflammatory proteins in cutaneous leishmaniasis lesions. Using this approach, we could profile inflammatory proteins in the lesions from cutaneous leishmaniasis patients. This new non-invasive approach may have implications for studying skin inflammatory mediators in cutaneous leishmaniasis and other skin disorders.] Question: Based on the provided context, do the terms [CASP-8 protein] and [4E-BP1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between CASP-8 protein and 4E-BP1 protein. The context lists these proteins as part of the inflammatory proteins that were significantly changed in the lesions of cutaneous leishmaniasis patients, but it does not describe any specific interaction or combined effect between CASP-8 and 4E-BP1. Therefore, based on the given information, there is no evidence to suggest that these two proteins interact with each other.</s>
478440 2A2457295 2A2486507	CCL13	CXCL13	[INST]Context: [PMID: 32509861 Database Mining of Genes of Prognostic Value for the Prostate Adenocarcinoma Microenvironment Using the Cancer Gene Atlas. Background: Prostate adenocarcinoma is a common malignant tumor in elderly men. Our research uses The Cancer Gene Atlas database to find potential related genes for predicting the prognosis of patients with prostate adenocarcinoma. Methods: We downloaded gene expression profiles and clinical sample information from the cancer gene atlas for 490 patients with prostate adenocarcinoma (patient age: 41-78 years). We categorized patients with prostate adenocarcinoma in the cancer gene atlas into high and low score arrays according to their median immune/stromal scores and identified differentially expressed genes that were significantly correlated with the prognosis of prostate adenocarcinoma. Then, Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway analyses were performed. Results: We found that 8 individual differentially expressed genes, C6, S100A12, MLC1, PAX5, C7, FAM162B, CAMK1G, and TCEAL5, were significantly predictive of favorable overall survival and one DEG, EPYC, was associated with poor overall survival. Gene ontology and kyoto encyclopedia of genes and genomes pathway analyses revealed that the differentially expressed genes were associated with immune responses. Moreover, 30 hub genes were obtained using the PPI network of differentially expressed genes: ITGAM, CD4, CD3E, IL-10, LCP2, ITGB2, ZAP-70, C3, CCL19, CXCL13, CXCL9, BTK, CCL21, CD247, CD28, CD3D, FCER1G, PTPRC, TYROBP, CCR5, ITK, CCL13, CCR1, CCR2, CD79B, CYBB, IL2RG, JAK3, PLCG2, and CD19. These prominent nodes had the most associations with other genes, indicating that they might play crucial roles in the prognosis of prostate adenocarcinoma. Conclusions: We extracted a list of genes associated with the prostate adenocarcinoma microenvironment, which might contribute to the prediction and interpretation of prostate adenocarcinoma prognosis.] Question: Based on the provided context, do the terms [CCL13 protein] and [CXCL13 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between CCL13 protein and CXCL13 protein. While both proteins are listed as part of the hub genes associated with the prognosis of prostate adenocarcinoma, there is no specific information indicating that they interact with each other. The context focuses on their roles in immune responses and their association with the prognosis of prostate adenocarcinoma, but it does not describe any direct interaction between CCL13 and CXCL13.</s>
105257 2A2576391 2A2540980	beta-globin	FLT3-ligand	[INST]Context: [PMID: 21364915 Human pluripotent stem cells differentiated in fully defined medium generate hematopoietic CD34- and CD34+ progenitors with distinct characteristics. BACKGROUND: Differentiation of pluripotent stem cells in vitro provides a powerful means to investigate early developmental fates, including hematopoiesis. Our goal was to induce in vitro, the differentiation of human embryonic stem cells and induced pluripotent stem cells into morphologically and phenotypically mature leukocytes and erythrocytes, in the complete absence of serum and feeder cells. METHODOLOGY/PRINCIPAL FINDINGS: embryonic stem cells and induced pluripotent stem cells were sequentially induced in liquid cultures for 4 days with bone morphogenic protein-4, and for 4 days with FLT3-ligand, stem cell factor, thrombopoietin and vascular endothelium growth factor. Cell differentiation status was investigated by both mRNA expression and FACS expression profiles. In liquid cultures, cells progressively down-modulated Oct-4 expression while a sizeable cell fraction expressed CD34 de novo. SCL/Tal1 and Runx1 transcripts were exclusively detected in CD34(+) cells. In clonal assays, both embryonic stem cells and iPSC-derived cells generated colony-forming unit, albeit with a 150-fold lower efficacy than cord blood CD34(+) cells. ESC-derived CD34(+) cells generated myeloid and fully hemoglobinized erythroid cells whereas CD34(-) cells almost exclusively generated small erythroid colonies. Both embryonic stem cells and iPSC-derived erythroid cells expressed embryonic and fetal globins but were unable to synthesize adult beta-globin in contrast with cord blood cells, suggesting that they had differentiated from primitive rather than from definitive hematopoietic progenitors. CONCLUSIONS/SIGNIFICANCE: Short-term, animal protein-free culture conditions are sufficient to sustain the differentiation of human embryonic stem cells and induced pluripotent stem cells into primitive hematopoietic progenitors, which, in turn, produce more mature blood cell types.] Question: Based on the provided context, do the terms [beta-globin protein] and [FLT3-ligand protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not indicate any direct interaction between beta-globin protein and FLT3-ligand protein. Beta-globin is mentioned in the context of erythroid cell differentiation and its expression, while FLT3-ligand is mentioned as one of the factors used in the differentiation process. There is no direct interaction described between these two proteins. Instead, they are presented as separate entities involved in different aspects of the differentiation process.</s>
174054 2A2735098 2A2906436	peptidylprolyl isomerase A	TOMM20	[INST]Context: [PMID: 35220898 Autophagy deficiency abolishes liver mitochondrial DNA segregation. Mutations in the mitochondrial genome (mtDNA) are ubiquitous in humans and can lead to a broad spectrum of disorders. However, due to the presence of multiple mtDNA molecules in the cell, co-existence of mutant and wild-type mtDNAs (termed heteroplasmy) can mask disease phenotype unless a threshold of mutant molecules is reached. Importantly, the mutant mtDNA level can change across lifespan as mtDNA segregates in an allele- and cell-specific fashion, potentially leading to disease. Segregation of mtDNA is mainly evident in hepatic cells, resulting in an age-dependent increase of mtDNA variants, including non-synonymous potentially deleterious mutations. Here we modeled mtDNA segregation using a well-established heteroplasmic mouse line with mtDNA of NZB/BINJ and C57BL/6N origin on a C57BL/6N nuclear background. This mouse line showed a pronounced age-dependent NZB mtDNA accumulation in the liver, thus leading to enhanced respiration capacity per mtDNA molecule. Remarkably, liver-specific atg7 (autophagy related 7) knockout abolished NZB mtDNA accumulat ion, resulting in close-to-neutral mtDNA segregation through development into adulthood. prkn (parkin RBR E3 ubiquitin protein ligase) knockout also partially prevented NZB mtDNA accumulation in the liver, but to a lesser extent. Hence, we propose that age-related liver mtDNA segregation is a consequence of macroautophagic clearance of the less-fit mtDNA. Considering that NZB/BINJ and C57BL/6N mtDNAs have a level of divergence comparable to that between human Eurasian and African mtDNAs, these findings have potential implications for humans, including the safe use of mitochondrial replacement therapy.Abbreviations: Apob: apolipoprotein B; Atg1: autophagy-related 1; Atg7: autophagy related 7; Atp5a1: ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 1; BL6: C57BL/6N mouse strain; BNIP3: BCL2/adenovirus E1B interacting protein 3; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; MAP1LC3A: microtubule-associated protein 1 light chain 3 alpha; MAP1LC3B: microtubule-associated protein 1 light chain 3 beta; Mt-Atp8: mitochondrially encoded ATP synthase 8; MT-CO1: mitochondrially encoded cytochrome c oxidase I; MT-CO2: mitochondrially encoded cytochrome c oxidase II; Mt-Co3: mitochondrially encoded cytochrome c oxidase III; Mt-Cytb: mitochondrially encoded cytochrome b; MtDNA: mitochondrial DNA; MUL1: mitochondrial ubiquitin ligase activator of NFKB 1; Ndufa9: NADH:ubiquinone oxireductase subunit A9; NDUFB8: NADH:ubiquinone oxireductase subunit B8; Nnt: nicotinamide nucleotide transhydrogenase; NZB: NZB/BINJ mouse strain; OXPHOS: oxidative phosphorylation; PINK1: PTEN induced putative kinase 1; Polg2: polymerase (DNA directed), gamma 2, accessory subunit; Ppara: peroxisome proliferator activated receptor alpha; Ppia: peptidylprolyl isomerase A; Prkn: parkin RBR E3 ubiquitin protein ligase; P100: post-natal day 100; Rpl19: ribosomal protein L19; Rps18: ribosomal protein S18; SDHB: succinate dehydrogenase complex, subunit B, iron sulfur (Ip); SQSTM1: sequestosome 1; Ssbp1: single-stranded DNA binding protein 1; TFAM: transcription factor A, mitochondrial; Tfb1m: transcription factor B1, mitochondrial; Tfb2m: transcription factor B2, mitochondrial; TOMM20: translocase of outer mitochondrial membrane 20; UQCRC2: ubiquinol cytochrome c reductase core protein 2;] Question: Based on the provided context, do the terms [peptidylprolyl isomerase A protein] and [TOMM20 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the peptidylprolyl isomerase A protein (Ppia) and the TOMM20 protein. The context discusses various proteins and their roles in mitochondrial processes, but it does not indicate any specific interaction between Ppia and TOMM20. Therefore, based on the given information, there is no evidence to suggest that these two proteins interact with each other.</s>
67055 2A2944014 2A2525541	XRCC6	EP300	[INST]Context: [PMID: 35003222 Polymorphisms Within DNA Double-Strand Breaks Repair-Related Genes Contribute to Structural Chromosome Abnormality in Recurrent Pregnancy Loss. Background: Structural chromosome abnormality is an important cause of human diseases, including recurrent pregnancy loss . DNA double-strand breaks repair-related genes play critical roles in structural chromosome abnormality. The present study aims to investigate the potential contribution of double-strand breaks repair-related gene polymorphisms to structural chromosome abnormality. Methods: Fifty-four affected recurrent pregnancy loss individuals with structural chromosome abnormality, 88 affected recurrent pregnancy loss individuals without structural chromosome abnormality, and 84 controls were analyzed. Targeted whole-exome sequencing was used for screening single nucleotide polymorphisms in six double-strand breaks repair-related genes (EP300, XRCC6, LIG4, XRCC4, PRKDC, and DCLRE1C), and validation was performed by Sanger sequencing. Finally, we detected the frequency of radiation-induced chromosome translocations in no structural chromosome abnormality samples with significant polymorphisms by fluorescence in situ hybridization . Frequencies of EP300 rs20551, XRCC6 rs132788, and LIG4 rs1805388 were significantly different between structural chromosome abnormality recurrent pregnancy loss and no structural chromosome abnormality recurrent pregnancy loss (p = 0.030, 0.031, and 0.040 respectively). Additionally, the frequency of radiation-induced translocation in no structural chromosome abnormality samples with rs20551, rs132788 or rs1805388 was significantly higher compared with the wild type samples (p = 0.015, 0.012, and 0.007 respectively). Conclusion: Our results suggest that rs20551, rs132788, and rs1805388 might be associated with the risk of structural chromosome abnormality.] Question: Based on the provided context, do the terms [XRCC6 protein] and [EP300 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the roles of various double-strand breaks repair-related genes and their polymorphisms in structural chromosome abnormalities associated with recurrent pregnancy loss. While it mentions the involvement of EP300 and XRCC6 proteins in the DNA double-strand breaks repair process, it does not provide any direct evidence or indication that these two proteins interact with each other. The context focuses on the individual contributions of these genes and their polymorphisms to the risk of structural chromosome abnormalities rather than describing any direct interaction between the EP300 and XRCC6 proteins.</s>
700538 2A2465436 2A2762955	CHMP2B	RAB35	[INST]Context: [PMID: 35000752 BAG3 Regulation of RAB35 Mediates the Endosomal Sorting Complexes Required for Transport/Endolysosome Pathway and Tau Clearance. BACKGROUND: Declining proteostasis with aging contributes to increased susceptibility to neurodegenerative diseases, including Alzheimer's disease . Emerging studies implicate impairment of the endosome-lysosome pathway as a significant factor in the pathogenesis of these diseases. Previously, we demonstrated that BAG3 regulates phosphorylated tau clearance. However, we did not fully define how BAG3 regulates endogenous tau proteostasis, especially in the early stages of disease progression. Live-cell imaging was used to study the dynamics of the endosomal pathway. Immunohistochemistry and immunoblotting were performed in human alzheimer's disease brains and in P301S tau transgenic mice with BAG3 overexpressed. RESULTS: The primary group of neuronal BAG3 interactors identified are involved in the endocytic pathway. We demonstrated that a BAG3-HSP70-TBC1D10B complex attenuates the ability of TBC1D10B to inactivate RAB35. Thus, BAG3 interacts with TBC1D10B to support the activation of RAB35 and recruitment of HRS, initiating endosomal sorting complex required for transport-mediated endosomal tau clearance. Furthermore, TBC1D10B shows significantly less colocalization with BAG3 in alzheimer's disease brains than in age-matched controls. Overexpression of BAG3 in P301S tau transgenic mice increased the colocalization of phosphorylated tau with the endosomal sorting complex required for transport III protein CHMP2B and reduced the levels of the mutant human tau. CONCLUSIONS: We identified a novel BAG3-TBC1D10B-RAB35 regulatory axis that modulates endosomal sorting complex required for transport-dependent protein degradation machinery and tau clearance. Dysregulation of BAG3 could contribute to the pathogenesis of alzheimer's disease.] Question: Based on the provided context, do the terms [CHMP2B protein] and [RAB35 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention a direct interaction between CHMP2B protein and RAB35 protein. Instead, it describes a regulatory pathway involving BAG3, TBC1D10B, and RAB35, which ultimately influences the endosomal sorting complex required for transport (ESCRT) pathway and tau clearance. While CHMP2B is part of the ESCRT machinery, there is no direct interaction mentioned between CHMP2B and RAB35 in the context provided.</s>
622707 2A2865793 2A2587767	SMARCB1	HNRNPH1	[INST]Context: [PMID: 32584970 Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes. Mantle cell lymphoma is a mature B-cell neoplasm initially driven by CCND1 rearrangement with 2 molecular subtypes, conventional mantle cell lymphoma and leukemic non-nodal mantle cell lymphoma, that differ in their clinicobiological behavior. To identify the genetic and epigenetic alterations determining this diversity, we used whole-genome (n = 61) and exome (n = 21) sequencing (74% conventional mcl, 26% nnMCL) combined with transcriptome and DNA methylation profiles in the context of 5 mantle cell lymphoma reference epigenomes. We identified that open and active chromatin at the major translocation cluster locus might facilitate the t(11;14)(q13;32), which modifies the 3-dimensional structure of the involved regions. This translocation is mainly acquired in precursor B cells mediated by recombination-activating genes in both mantle cell lymphoma subtypes, whereas in 8% of cases the translocation occurs in mature B cells mediated by activation-induced cytidine deaminase. We identified novel recurrent mantle cell lymphoma drivers, including CDKN1B, SAMHD1, BCOR, SYNE1, HNRNPH1, SMARCB1, and DAZAP1. Complex structural alterations emerge as a relevant early oncogenic mechanism in mantle cell lymphoma, targeting key driver genes. Breakage-fusion-bridge cycles and translocations activated oncogenes (BMI1, MIR17HG, TERT, MYC, and MYCN), generating gene amplifications and remodeling regulatory regions. Cmantle cell lymphoma carried significant higher numbers of structural variants, copy number alterations, and driver changes than non-nodal mcl, with exclusive alterations of ATM in conventional mcl, whereas TP53 and TERT alterations were slightly enriched in non-nodal mcl. Several drivers had prognostic impact, but only TP53 and MYC aberrations added value independently of genomic complexity. An increasing genomic complexity, together with the presence of breakage-fusion-bridge cycles and high DNA methylation changes related to the proliferative cell history, defines patients with different clinical evolution.] Question: Based on the provided context, do the terms [SMARCB1 protein] and [HNRNPH1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the SMARCB1 protein and the HNRNPH1 protein. Instead, it lists them as novel recurrent mantle cell lymphoma drivers, indicating that they are involved in the pathogenesis of the disease but does not suggest any direct interaction between the two proteins.</s>
578852 2A2459951 2A2903080	p15INK4b	EPO	[INST]Context: [PMID: 15367334 Methylation profiles of thirty four promoter-CpG islands and concordant methylation behaviours of sixteen genes that may contribute to carcinogenesis of astrocytoma. BACKGROUND: Astrocytoma is a common aggressive intracranial tumor and presents a formidable challenge in the clinic. Association of altered DNA methylation patterns of the promoter CpG islands with the expression profile of cancer-related genes, has been found in many human tumors. Therefore, DNA methylation status as such may serve as an epigenetic biomarker for both diagnosis and prognosis of human tumors, including astrocytoma. METHODS: We used the methylation specific PCR in conjunction with sequencing verification to establish the methylation profile of the promoter CpG island of thirty four genes in astrocytoma tissues from fifty three patients (The WHO grading: I: 14, II: 15, III: 12 and IV: 12 cases, respectively). In addition, compatible tissues (normal tissues distant from lesion) from three non-astrocytoma patients were included as the control. RESULTS: Seventeen genes (ABL, APC, APAF1, BRCA1, CSPG2, DAPK1, hMLH1, LKB1, PTEN, p14ARF, p15INK4b, p27KIP1, p57KIP2, RASSF1C, RB1, SURVIVIN, and VHL) displayed a uniformly unmethylated pattern in all the astrocytoma and non-astrocytoma tissues examined. However, the MAGEA1 gene that was inactivated and hypermethylated in non-astrocytoma tissues, was partially demethylated in 24.5% of the astrocytoma tissues (co-existence of the hypermethylated and demethylated alleles). Of the astrocytoma associated hypermethylated genes, the methylation pattern of the CDH13, cyclin a1, DBCCR1, EPO, MYOD1, and p16INK4a genes changed in no more than 5.66% (3/53) of astrocytoma tissues compared to non-astrocytoma controls, while the RASSF1A, p73, AR, MGMT, CDH1, OCT6, MT1A, WT1, and IRF7 genes were more frequently hypermethylated in 69.8%, 47.2%, 41.5%, 35.8%, 32%, 30.2%, 30.2%, 30.2% and 26.4% of astrocytoma tissues, respectively. Demethylation mediated inducible expression of the CDH13, MAGEA1, MGMT, p73 and RASSF1A genes was established in an astrocytoma cell line (U251), demonstrating that expression of these genes is likely regulated by DNA methylation. AR gene hypermethylation was found exclusively in female patients (22/27, 81%, 0/26, 0%, P < 0.001), while the IRF7 gene hypermethylation preferentially occurred in the male counterparts (11/26, 42.3% to 3/27, 11%, P < 0.05). Applying the mathematic method 'the Discovery of Association Rules', we have identified groups consisting of up to three genes that more likely display the altered methylation patterns in concert in astrocytoma. CONCLUSIONS: Of the thirty four genes examined, sixteen genes exhibited astrocytoma associated changes in the methylation profile. In addition to the possible pathological significance, the established concordant methylation profiles of the subsets consisting of two to three target genes may provide useful clues to the development of the useful prognostic as well as diagnostic assays for astrocytoma.] Question: Based on the provided context, do the terms [p15INK4b protein] and [EPO protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the methylation profiles of various genes in astrocytoma tissues and does not mention any direct interaction between the p15INK4b protein and the EPO protein. The context focuses on the methylation status of these genes and their potential roles in astrocytoma carcinogenesis, but it does not provide any information about an interaction between the p15INK4b protein and the EPO protein. Therefore, based on the given information, there is no evidence to suggest that these two proteins interact with each other.</s>
379281 2A2685241 2A2778324	NONO	BAP1	[INST]Context: [PMID: 32251007 Report From the International Society of Urological Pathology Consultation Conference on Molecular Pathology of Urogenital Cancers: III: Molecular Pathology of Kidney Cancer. Renal cell carcinoma subtypes are increasingly being discerned via their molecular underpinnings. In clear cell renal cell carcinoma, VHL mutation and 3p loss are well known; However, other genes with emerging important roles include SETD2, BAP1, and PBRM1, among others. Papillary renal cell carcinoma type 2 is now known to include likely several different molecular entities, such as fumarate hydratase deficient renal cell carcinoma. Some TFE3 fusion partners, such as NONO, GRIPAP1, RBMX, and RBM10 may show a deceptive fluorescence in situ hybridization result due to the proximity of the genes on the same chromosome. Fumarate hydratase and succinate dehydrogenase deficient renal cell carcinoma have implications for patient counseling due to heritable syndromes and the aggressiveness of FH-deficient renal cell carcinoma. Emerging tumor types with strong evidence for distinct diagnostic entities include eosinophilic solid and cystic renal cell carcinoma and TFEB/VEGFA/6p21 amplified renal cell carcinoma. Other emerging entities that are less clearly understood include TCEB1 mutated renal cell carcinoma, renal cell carcinoma with ALK rearrangement, renal neoplasms with mutations of TSC2 or MTOR, and renal cell carcinoma with fibromuscular stroma. In metastatic renal cell carcinoma, the role of molecular studies is not entirely defined at present, although there may be an increasing role for genomic analysis related to specific therapy pathways, such as for tyrosine kinase or MTOR inhibitors.] Question: Based on the provided context, do the terms [NONO protein] and [BAP1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the molecular underpinnings of renal cell carcinoma subtypes and mentions various genes and proteins involved, including NONO and BAP1. However, there is no direct interaction mentioned between the NONO protein and the BAP1 protein. The context focuses on the roles of these proteins in different molecular entities and their implications for diagnosis and patient counseling but does not indicate any interaction between them.</s>
184044 2A2572260 2A2572245	GLUT 3	GLUT 1	[INST]Context: [PMID: 22257417 The effect of hyperglycemia and hypoglycemia on glucose transport and expression of glucose transporters in human lymphocytes B and T: an in vitro study. Glucose transport in lymphocytes is regulated by many agents. It is interesting if only changing glucose concentrations in environment involves the impact on glucose uptake. The aims of this study were to investigate the impact of changing glucose concentrations in medium on deoxy-d-glucose uptake and what these conditions impact on the percent of cells with expression of chosen glucose transporters in human lymphocytes B and T. Isolated lymphocytes B and T obtained from healthy subject were cultivated in different concentrations of glucose. The experiments were carried out using tritium labeled deoxy-d-glucose and flow cytometry. In comparison to normoglycemia, hyperglycemia impairs the uptake of deoxy-d-glucose more than hypoglycemia. Lymphocytes B manifest significantly lower uptake of deoxy-d-glucose than lymphocytes T. Lymphocytes incubated in hyperglycemic and hypoglycemic medium show lower percent cells with expression of GLUT 1 and GLUT 3, and higher percent cells with expression of GLUT 4. The incubation of lymphocytes in hyperglycemic and hypoglycemic medium does not stimulate translocation of glucose transporters 3 and 4 to plasma membrane. Study shows that a change in concentration of glucose in incubation environment influence intracellular expression of glucose transporters in a significant part of lymphocytes B and T.] Question: Based on the provided context, do the terms [GLUT 3 protein] and [GLUT 1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the impact of hyperglycemia and hypoglycemia on the expression of glucose transporters (GLUT 1 and GLUT 3) in human lymphocytes B and T. It mentions that lymphocytes incubated in hyperglycemic and hypoglycemic medium show changes in the percent of cells with expression of GLUT 1 and GLUT 3, but it does not indicate any direct interaction between GLUT 1 protein and GLUT 3 protein. Instead, it describes their individual responses to the changing glucose concentrations. Therefore, there is no evidence of direct interaction between GLUT 1 and GLUT 3 proteins based on the given context.</s>
51342 2A2865919 2A2689479	SNAP-25	NSF	[INST]Context: [PMID: 9084425 Occurrence of two types of secretory vesicles in the human neuroblastoma SH-SY5Y. Western blot analysis showed that the human neuroblastoma SH-SY5Y expresses the proteins synaptotagmin l, synaptobrevin, synapsin-l, rab3a, syntaxin, SNAP-25, NSF, alpha-SNAP, and munc-18, which have been implicated in the movement, docking, and fusion of vesicles during exocytosis from other neuroendocrine cells. The subcellular localization of secretogranins I and II, synaptotagmin l, neuropeptide Y, rab3a, synaptobrevin, synaptophysin, and syntaxin was investigated by immunofluorescence microscopy and revealed punctate staining patterns characteristic of secretory vesicles. The comigration of noradrenaline, secretogranin II, and dopamine-beta-hydroxylase on sucrose-D2O gradient fractions indicates the presence of a population of noradrenaline-containing large dense-cored vesicles . In addition, a lighter vesicle population is also present that does not appear to be noradrenergic and contains a 48-kDa synaptophysin antigen absent from the large dense-cored vesicles. Immunocytochemical experiments show that not all of the vesicles that express synaptotagmin l contain secretogranin II. Thus, our studies suggest that two types of vesicle are present in SH-SY5Y cells, one of which, the large dense-cored vesicles, contains noradrenaline. These findings confirm our previous studies suggesting that depolarization-evoked release of noradrenaline from SH-SY5Y occurs by LDCV exocytosis. This enhances the value of SH-SY5Y as a cell line in which to study the mechanism by which noradrenaline release is regulated.] Question: Based on the provided context, do the terms [SNAP-25 protein] and [NSF protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided mentions that the human neuroblastoma SH-SY5Y expresses several proteins, including SNAP-25 and NSF, which have been implicated in the movement, docking, and fusion of vesicles during exocytosis. This suggests that SNAP-25 and NSF are part of the same molecular machinery involved in vesicle trafficking and fusion, indicating an interaction between these two proteins.</s>
13610 2A2776061 2A2596036	RIF1	IGFBP5	[INST]Context: [PMID: 22037779 Breast cancer is the most common malignancy of women in the developed world. To better understand its pathogenesis, knowledge of normal breast development is crucial, as breast cancer is the result of disregulation of physiologic processes. Comparative transcriptomic analyses were carried out using breast tissues from 28 female cynomolgus macaques (Macaca fascicularis) at the following life stages: prepubertal (n = 5), adolescent (n = 4), adult luteal (n = 5), pregnant (n = 6), lactating (n = 3), and postmenopausal (n = 5). Mammary gland RNA was hybridized to Affymetrix GeneChip(_) Rhesus Macaque Genome Arrays. Gene families or pathways that changed across life stages included those related to estrogen and androgen (ESR1, PGR, TFF1, GREB1, AR, 17HSDB2, 17HSDB7, STS, HSD11B1, AKR1C4), prolactin (PRLR, ELF5, STAT5, CSN1S1), insulin-like growth factor signaling (IGF1, IGFBP1, IGFBP5), extracellular matrix (POSTN, TGFB1, COL5A2, COL12A1, FOXC1, LAMC1, PDGFRA, TGFB2), and differentiation (CD24, CD29, CD44, CD61, ALDH1, BRCA1, FOXA1, POSTN, DICER1, LIG4, KLF4, NOTCH2, RIF1, BMPR1A, TGFB2). Pregnancy and lactation displayed distinct patterns of gene expression. ESR1 and IGF1 were significantly higher in the adolescent compared to the adult animals, whereas differentiation pathways were overrepresented in adult animals and pregnancy-associated life stages. Several of the pathways activated during pubertal development have been implicated in cancer development and metastasis, supporting the idea that other developmental markers may have application as biomarkers for breast cancer. From MeSH: Macaca fascicularis.] Question: Based on the provided context, do the terms [RIF1 protein] and [IGFBP5 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses various gene families and pathways related to breast cancer and normal breast development in cynomolgus macaques. While it mentions several proteins, including RIF1 and IGFBP5, it does not indicate any direct interaction between RIF1 protein and IGFBP5 protein. The context focuses on the expression patterns of these proteins across different life stages and their roles in various pathways but does not describe any specific interaction between RIF1 and IGFBP5.</s>
427929 2A2406504 2A2630432	ACTC	LMNA	[INST]Context: [PMID: 22464770 Genetic testing for dilated cardiomyopathy in clinical practice. BACKGROUND: Familial involvement is common in dilated cardiomyopathy and >40 genes have been implicated in causing disease. However, the role of genetic testing in clinical practice is not well defined. We examined the experience of clinical genetic testing in a diverse dilated cardiomyopathy population to characterize the prevalence and predictors of gene mutations. METHODS AND RESULTS: We studied 264 unrelated adult and pediatric dilated cardiomyopathy index patients referred to 1 reference lab for clinical genetic testing. Up to 10 genes were analyzed (MYH7, TNNT2, TNNI3, TPM1, MYBPC3, ACTC, LMNA, PLN, TAZ, and LDB3), and 70% of patients were tested for all genes. The mean age was 26.6 +- 21.3 years, and 52% had a family history of dilated cardiomyopathy. Rigorous criteria were used to classify DNA variants as clinically relevant (mutations), variants of unknown clinical significance (VUS), or presumed benign. Mutations were found in 17.4% of patients, commonly involving MYH7, LMNA, or TNNT2 (78%). An additional 10.6% of patients had VUS. Genetic testing was rarely positive in older patients without a family history of dilated cardiomyopathy. Conversely in pediatric patients, family history did not increase the sensitivity of genetic testing. CONCLUSIONS: Using rigorous criteria for classifying DNA variants, mutations were identified in 17% of a diverse group of dilated cardiomyopathy index patients referred for clinical genetic testing. The low sensitivity of genetic testing in dilated cardiomyopathy reflects limitations in both current methodology and knowledge of DCM-associated genes.] Question: Based on the provided context, do the terms [ACTC protein] and [LMNA protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the ACTC protein and the LMNA protein. It primarily discusses the prevalence and predictors of gene mutations in dilated cardiomyopathy, listing various genes including MYH7, LMNA, and ACTC. However, there is no specific information or evidence provided that suggests a direct interaction between the ACTC protein and the LMNA protein.</s>
680783 2A2416076 2A2856131	annexin III	syntenin 1	[INST]Context: [PMID: 15292099 Dominant prostasome immunogens for sperm-agglutinating autoantibodies of infertile men. The presence of naturally occurring anti-sperm antibodies is a well-known cause of infertility in men and women, but the antigens for these antibodies are poorly characterized. We have previously shown that prostasomes adhere to sperm cells and that prostasomes are major targets for anti-sperm antibodies associated with infertility. By these techniques, we revealed that prolactin-inducible protein and clusterin were dominant prostasome immunogens for sperm-agglutinating autoantibodies of 20 patients with immunological infertility. Prolactin-inducible protein was identified by 19 of 20 (95%) patient sera and clusterin by 17 of 20 (85%). In addition, 10 sporadically occurring prostasomal antigens were identified in this context, viz alcohol dehydrogenase [NADP+], annexin I, annexin III, BRCA1-associated ring domain protein 1, heat shock 27-kd protein, isocitrate dehydrogenase, lactoylglutathione lyase, NG,NG-dimethylarginine dimethylaminohydrolase 1, peroxiredoxin 2, and syntenin 1.] Question: Based on the provided context, do the terms [annexin III protein] and [syntenin 1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context lists annexin III protein and syntenin 1 protein as two of the sporadically occurring prostasomal antigens identified in the study. However, there is no mention of a direct interaction between annexin III protein and syntenin 1 protein. The context focuses on their identification as antigens for sperm-agglutinating autoantibodies but does not describe any interaction between these two proteins.</s>
669527 2A2439551 2A2617254	AURKB	KIF15	[INST]Context: [PMID: 32482029 [Differential analysis of gene expression profiles in hepatocellular carcinoma patients with high and low levels of alpha-fetoprotein]. Objective: To investigate the differential gene expression profiles of alpha-fetoprotein high- and low-expressing hepatocellular carcinoma, and to provide a theoretical basis for the molecular mechanism and prognosis analysis of hepatocellular carcinoma. Methods: The transcriptome data and related clinical information from 368 hepatocellular carcinoma cases were obtained from the Cancer Gene Atlas public database. The samples were divided into alpha-fetoprotein high expression (AFP(high)) group and low expression (AFP(low)) group according to the quartile of alpha-fetoprotein mRNA expression, with 92 cases in each group. The functional and KEGG pathway enrichment analysis of the differential genes was performed using ClusterProfiler package. Results: The clinical analysis showed that high expression of alpha-fetoprotein was significantly associated with poor pathological differentiation and ethnicity (P<0.05 for both). GO enrichment analysis showed that the highly expressed genes were mainly correlated with the processes of appendage development, limb development, and skeletal system development, while lowly expressed genes were related to metabolic-related processes such as xenobiotic metabolism, steroid metabolism, and cellular response to xenobiotic stimuli. KEGG pathway enrichment analysis revealed that highly expressed genes were mainly involved in primary immunodeficiency, neuroactive ligand-receptor interaction, and cytokine-cytokine receptor interaction, while lowly expressed genes were mainly involved in retinol metabolism, chemical carcinogenesis, steroid hormone biosynthesis and other pathways. A prognostic related gene set that was consisted of AURKB, TTK, CENPA, UBE2C, HJURP, and KIF15 was identified. And the high expression of this gene set was related to the shorter recurrence-free survival and overall survival time in hepatocellular carcinoma patients, and its enrichment score was positively correlated with alpha-fetoprotein expression (r=0.475, P<0.001). The validation results of RNAseq data were basically consistent with the the cancer gene atlas data. The real-time quantitative polymerase chain reaction results showed that AURKB, KIF15, and UBE2C were significantly overexpressed in hepatocellular carcinoma tissues with high alpha-fetoprotein expression. Although the expression of AURKB, TTK, KIF15, and UBE2C was not related to recurrence-free survival and overall survival of hepatocellular carcinoma patients, there was a tendency that the patients with high alpha-fetoprotein levels showed relatively shorter recurrence-free survival time and overall survival time. Conclusions: There is a large difference in gene expression profiles between AFP(high) and AFP(low) hepatocellular carcinoma. The prognostic signature may cooperate with alpha-fetoprotein to promote the initiation and development of hepatocellular carcinoma. It also may explain the tumorigenesis in hepatocellular carcinoma with different alpha-fetoprotein levels, and provide new clues for the prognosis of hepatocellular carcinoma.] Question: Based on the provided context, do the terms [AURKB protein] and [KIF15 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between AURKB protein and KIF15 protein. While both proteins are part of a prognostic signature related to hepatocellular carcinoma and alpha-fetoprotein expression, there is no specific evidence or description indicating that they interact with each other. The context focuses on their individual roles in the prognosis and tumorigenesis of hepatocellular carcinoma but does not suggest a direct interaction between AURKB and KIF15 proteins.</s>
171817 2A2854775 2A2892349	SCFD1	TARDBP	[INST]Context: [PMID: 33414559 Genetic analysis of amyotrophic lateral sclerosis cases in the isolated island population of Malta. Here, we investigate the epidemiology and genetic profile of Maltese patients with amyotrophic lateral sclerosis, identified throughout a 2-year window. Disease onset occurred around mid-age (median age: 64 years, men; 59.5 years, female); Interestingly, the Maltese amyotrophic lateral sclerosis patient cohort was found to be negative for deleterious variants in C9orf72, SOD1, TARDBP or FUS genes, which are the most commonly mutated amyotrophic lateral sclerosis genes globally. Nonetheless, ALS-associated repeat expansions were identified in ATXN2 and NIPA1. Variants predicted to be damaging were also detected in ALS2, DAO, DCTN1, ERBB4, SETX, SCFD1 and SPG11. A total of 40% of patients with sporadic amyotrophic lateral sclerosis had a rare and deleterious variant or repeat expansion in an ALS-associated gene, whilst the genetic cause of two thirds of famyotrophic lateral sclerosis cases could not be pinpointed to known amyotrophic lateral sclerosis genes or risk loci. This warrants further studies to elucidate novel genes that cause amyotrophic lateral sclerosis in this unique population isolate.] Question: Based on the provided context, do the terms [SCFD1 protein] and [TARDBP protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the SCFD1 protein and the TARDBP protein. It discusses the genetic analysis of amyotrophic lateral sclerosis cases in Malta, including the identification of variants in various genes, but it does not specify any interaction between SCFD1 and TARDBP proteins. Therefore, based on the given information, there is no evidence to suggest that these two proteins interact with each other.</s>
217953 2A2454115 2A2778586	caspase 8	large subunit of ribonucleotide reductase	[INST]Context: [PMID: 25828583 Manipulation of apoptosis and necroptosis signaling by herpesviruses. Like apoptosis, necroptosis is an innate immune mechanism that eliminates pathogen-infected cells. Receptor-interacting protein kinase (RIP)3 (also called RIPK3) mediates necrotic death by phosphorylating an executioner protein, MLKL, leading to plasma membrane leakage. The pathway is triggered against viruses that block caspase 8. In murine CMV, the viral inhibitor of caspase 8 activation prevents extrinsic apoptosis but also has the potential to unleash necroptosis. This virus encodes the viral inhibitor of RIP activation to prevent RIP homotypic interaction motif -dependent signal transduction and necroptosis. Recent investigations reveal a similar mechanism at play in the human alpha-herpesviruses, herpes simplex virus 1 and HSV2, where rip homotypic interaction motif competitor function and caspase 8 suppression are carried out by the virus-encoded large subunit of ribonucleotide reductase . In human cells, reductase inhibition of caspase 8 prevents TNF-induced apoptosis, but sensitizes to TNF-induced necroptosis. The rip homotypic interaction motif and caspase 8 interaction domains of reductase collaborate to prevent RIP3-dependent steps and enable both herpesviruses to deflect host cell death machinery that would cut short infection. In mouse cells, HSV1 infection by itself triggers necroptosis by driving RIP3 protein kinase activity. HSV1 reductase contributes to the activation of RIP3 adaptor function in mice, a popular host animal for experimental infection. Based on these studies, infection of RIP3-kinase inactive mice should be explored in models of pathogenesis and latency. The necrotic death pathway that is suppressed during infection in the natural host becomes a cross-species barrier to infection in a non-natural host. Mice.] Question: Based on the provided context, do the terms [caspase 8 protein] and [large subunit of ribonucleotide reductase protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that the large subunit of ribonucleotide reductase protein interacts with caspase 8 protein. Specifically, it mentions that the large subunit of ribonucleotide reductase in herpes simplex virus 1 and HSV2 suppresses caspase 8, preventing TNF-induced apoptosis and sensitizing cells to TNF-induced necroptosis. This interaction is crucial for the viruses to deflect host cell death machinery and enable infection.</s>
103587 2A2773734 2A2472485	EF-C	COL7A1	[INST]Context: [PMID: 29441510 Translating the combination of gene therapy and tissue engineering for treating recessive dystrophic epidermolysis bullosa. The combination of gene therapy and tissue engineering is one of the most promising strategies for the treatment of recessive dystrophic epidermolysis bullosa . Recessive dystrophic epidermolysis bullosa is a rare genetic disease characterised by mutations in the COL7A1 gene, encoding type VII collagen, which forms anchoring fibrils at the dermal-epidermal junction of the skin. This disease causes severe blistering and only palliative treatments are offered. In this study, the base of a strategy combining gene therapy and a tissue-engineered skin substitute (TES), which would be suitable for the permanent closure of skin wounds, was set-up. As a high transduction efficiency into fibroblasts and/or keratinocytes seems to be a prerequisite for a robust and sustained correction of recessive dystrophic epidermolysis bullosa, different envelope pseudotyped retroviral vectors and the transduction enhancer EF-C were tested. At least a 3.1-fold and a 1.3-fold increased transduction were obtained in fibroblasts and keratinocytes, respectively, with EF-C as compared with polybrene. A continuous and intense deposit of haemagglutinin -collagen was observed at the dermal-epidermal junction of self-assembled TESs made of cells transduced with a HA-tagged COL7A1 vector. Furthermore, HA-tagged basal epidermal cells expressing keratin 19 were observed in TESs, suggesting stem cell transduction. This approach could be a valuable therapeutic option to further develop, in order to improve the long-term life quality of recessive dystrophic epidermolysis bullosa patients.] Question: Based on the provided context, do the terms [EF-C protein] and [COL7A1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the use of EF-C as a transduction enhancer for retroviral vectors and the expression of COL7A1 protein in the context of gene therapy for recessive dystrophic epidermolysis bullosa. While both EF-C and COL7A1 are involved in the process of gene therapy and tissue engineering, there is no direct interaction mentioned between the EF-C protein and the COL7A1 protein. EF-C is used to enhance the transduction efficiency of retroviral vectors, which then deliver the COL7A1 gene, but the two proteins themselves are not described as interacting.</s>
518181 2A2735164 2A2693246	PPIB	NUCKS1	[INST]Context: [PMID: 29128114 The aim of the present study was to investigate how maternal diet can influence the adipose tissue of goat kids. Omental adipose tissue proteomes of goat-kids from mothers fed with diet enriched with stearic acid (ST-kids), fish oil and standard diets (CTRL) were determined by quantitative iTRAQ 2D-LC-MS/MS analysis. Stearic acid induces changes in a higher number of proteins when compared to fish oil. Eleven proteins, namely AARS, ECl1, PMSC2, CP, HSPA8, GPD1, RPL7, OGDH, RPL24, FGA and RPL5 were decreased in ST-kids only. Four proteins, namely DLST, EEF1G, BCAP31 and RALA were decreased in fish oil only, and one, NUCKS1, was increased. Four proteins, namely PMSC1, PPIB, TUB5*2 and EIF5A1, were be less abundant in both ST- and FO- kids. Most of the protein whose abundance was decreased in ST kids (10 out of 15) are involved in protein metabolism and catabolism pathways. Qualitative gene expression analysis confirmed that all the proteins identified by mass spectrometry, with the exception of FGA, were produced by adipose tissue. Quantitative gene expression analysis demonstrated that two proteins, namely CP, a minor acute phase protein, and ECl1, involved in fatty acid beta oxidation, were downregulated at mRNA level as well. ECl1 gene expression was downregulated in ST-kids AT as compared to Ctrl-kids and CP was downregulated in both ST- and fish oil. From MeSH: Goats.] Question: Based on the provided context, do the terms [PPIB protein] and [NUCKS1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the PPIB protein and the NUCKS1 protein. The context discusses the changes in the abundance of various proteins in the adipose tissue of goat kids under different dietary conditions, but it does not indicate any specific interaction between PPIB and NUCKS1. Instead, it lists the proteins whose abundance was affected by the diets and their roles in various metabolic pathways.</s>
183155 2A2854814 2A2558984	CgB	CgA	[INST]Context: [PMID: 8162254 Analysis of chromogranin/secretogranin messenger RNAs in human pituitary adenomas. An additional five adenomas were also analyzed by Northern hybridization. Immunohistochemical staining for CgA and for SgIV (with monoclonal antibody HISL-19) was also performed. Most prolactin and adrenocorticotropin adenomas did not express CgA messenger rna or protein, whereas growth hormone tumors had low to moderate amounts of CgA messenger rna by Northern and in situ hybridization analyses and were focally positive for CgA protein. CgB, SgII, SgIII, and SgV messenger rna transcripts were present in most adenomas, and SgIV protein was detected in all groups of tumors. A growth hormone and a null cell adenoma cultured for 7 days also expressed CgA/Sg messenger rna transcripts and protein. Paraffin sections of some adenomas that were negative for CgA protein had detectable CgA messenger rna by in situ hybridization analysis. These results indicate that CgA messenger rna and protein are more commonly expressed in glycoprotein hormone-producing tumors compared with other types of pituitary adenomas and that in situ hybridization for CgA may detect the messenger rna transcripts for CgA even when CgA protein is not detected by immunohistochemistry.] Question: Based on the provided context, do the terms [CgB protein] and [CgA protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the expression of various chromogranin/secretogranin messenger RNAs and proteins in human pituitary adenomas. While it mentions the presence of CgB and CgA proteins, it does not indicate any direct interaction between CgB protein and CgA protein. Instead, it describes their individual expression patterns in different types of adenomas. Therefore, there is no evidence of an interaction between CgB protein and CgA protein based on the given information.</s>
233036 2A2812479 2A2544793	TRIAD3	FSCN1	[INST]Context: [PMID: 17258725 Homozygous PMS2 deletion causes a severe colorectal cancer and multiple adenoma phenotype without extraintestinal cancer. BACKGROUND & AIMS: We report a patient of Indian descent with parental consanguinity, who developed 10 carcinomas and 35 adenomatous polyps at age 23 and duodenal adenocarcinoma at age 25. He also had dysmorphic features, mental retardation, and cafe-au-lait spots but no brain tumor. METHODS: Germ-line screening for APC and MYH/MUTYH mutations was normal as was immunohistochemistry for MLH1 and MSH2 proteins. Investigation by array-comparative genomic hybridization revealed deletion of a small region on chromosome 7. Using polymerase chain reaction, this region was refined to a 400-kilobase deletion, which included exons 9-15 of the PMS2 gene, and all coding regions of oncomodulin, TRIAD3, and FSCN1. Immunohistochemistry showed absent PMS2 expression in all tumors and normal tissue. Most tumors showed microsatellite instability, more marked at dinucleotide than mononucleotide repeats. The tumors harbored no somatic mutations in APC, BRAF, AXIN2, or beta-catenin, but KRAS2 and TGFBR2 mutations were found. CONCLUSIONS: Our patient represents a novel phenotype for homozygous PMS2 mutation and perhaps the most severe colorectal cancer phenotype-in terms of numbers of malignancies at an early age-described to date. PMS2 mutations-and perhaps other homozygous mismatch repair mutations-should be considered in any patient presenting with multiple gastrointestinal tumors, since our patient could not be distinguished clinically from cases with attenuated familial adenomatous polyposis or MUTYH-associated polyposis.] Question: Based on the provided context, do the terms [TRIAD3 protein] and [FSCN1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the TRIAD3 protein and the FSCN1 protein. The context describes the deletion of a region on chromosome 7 that includes these genes but does not indicate any specific interaction between the proteins encoded by these genes. Instead, it focuses on the clinical phenotype and genetic findings associated with the deletion.</s>
439286 2A2924815 2A2587482	PGP 9.5	heme oxygenase-2	[INST]Context: [PMID: 11909697 Immunohistochemical localization of the antioxidant enzymes biliverdin reductase and heme oxygenase-2 in human and pig gastric fundus. The intrinsic antioxidant capacities of the bile pigments biliverdin and bilirubin are increasingly recognized since both heme degradation products can exert beneficial cytoprotective effects due to their scavenging of oxygen free radicals and interaction with antioxidant vitamins. Several studies have been published on the localization of the carbon monoxide producing enzyme heme oxygenase-2, which concomitantly generates biliverdin; Histochemical data on the distribution of biliverdin reductase, converting biliverdin to bilirubin, are still very scarce in large mammals including humans. The present study revealed by means of immunohistochemistry the presence of biliverdin reductase and heme oxygenase-2 in mucosal epithelial cells and in the endothelium of intramural vessels of both human and porcine gastric fundus. In addition, co-labeling with the specific neural marker protein-gene product 9.5 (PGP 9.5) demonstrated that both biliverdin reductase and heme oxygenase-2 were present in all intrinsic nerve cell bodies of both submucous and myenteric plexuses, while double labeling with c-Kit antibody confirmed their presence in intramuscular interstitial cells of Cajal . Our results substantiate the hypothesis that biliverdin reductase, through the production of the potent antioxidant bilirubin, might be an essential component of normal physiologic gastrointestinal defense in man and pig. Swine.] Question: Based on the provided context, do the terms [PGP 9.5 protein] and [heme oxygenase-2 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context describes the localization of biliverdin reductase and heme oxygenase-2 in various tissues and cell types, including intrinsic nerve cell bodies and interstitial cells of Cajal. It mentions that both enzymes are present in these cells but does not indicate any direct interaction between the PGP 9.5 protein and heme oxygenase-2 protein. Instead, it focuses on the presence and distribution of these proteins in different cell types. Therefore, there is no evidence of a direct interaction between PGP 9.5 protein and heme oxygenase-2 protein based on the given context.</s>
458135 2A2876688 2A2876709	SUMO1	SUMO3	[INST]Context: [PMID: 24273646 Sumoylation in gene regulation, human disease, and therapeutic action. Similar to ubiquitination, sumoylation covalently attaches a small ubiquitin-like modifier protein (92-97 amino acids) to the epsilon-amino group of a lysine residue. Sumoylation has been well studied at the molecular and cellular levels, focusing mostly on site-specific conjugation of human SUMO1, SUMO2, and SUMO3, as well as their homologues in various species. In this short review, we will discuss some recent examples to highlight (a) emerging trends about the coordinated regulation of sumoylation and other post-translational modifications in modulating the function of some transcription factors and pathway-specific regulators, (b) diverse roles of sumoylation in gene regulation implicated in stem cells and different pathogenic conditions, and (c) potential therapeutic strategies related to some of the diseases stated above.] Question: Based on the provided context, do the terms [SUMO1 protein] and [SUMO3 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the roles of SUMO1 and SUMO3 in gene regulation and human diseases but does not mention any direct interaction between SUMO1 and SUMO3 proteins. Instead, it focuses on their individual roles and the coordinated regulation of sumoylation with other post-translational modifications. Therefore, there is no evidence of a direct interaction between SUMO1 and SUMO3 proteins based on the given information.</s>
364313 2A2594884 2A2605289	hexokinase	inorganic pyrophosphatase	[INST]Context: [PMID: 6146563 A de novo case of trisomy 10p: gene dosage studies of hexokinase, inorganic pyrophosphatase and adenosine kinase. A female infant with multiple congenital anomalies is presented. Cytogenetic study revealed the presence of a de novo, supernumerary, small telocentric chromosome exhibiting the banding pattern of the short arm of chromosome no. Her clinical features were compatible with the 10p trisomy syndrome. Hexokinase activity was elevated in the patient's erythrocytes, which is consistent with an assignment of hexokinase to 10pter---cen10. The absence of a gene dosage effect for inorganic pyrophosphatase (PP) in this study indicates exclusion of PP from 10pter ----cen10, and therefore implies a regional assignment of cen10----10q24 for PP. Adenosine kinase activity was within control limits, which is consistent with exclusion of adenosine kinase from 10pter----cen10.] Question: Based on the provided context, do the terms [hexokinase protein] and [inorganic pyrophosphatase protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the gene dosage studies of hexokinase and inorganic pyrophosphatase in relation to trisomy 10p. It mentions that hexokinase activity was elevated in the patient's erythrocytes, indicating its assignment to 10pter---cen10, while the absence of a gene dosage effect for inorganic pyrophosphatase suggests its exclusion from 10pter----cen10. However, there is no mention of a direct interaction between hexokinase and inorganic pyrophosphatase proteins. Instead, the context focuses on their separate assignments and activities in relation to the chromosomal abnormality.</s>
490837 2A2895182 2A2874128	TFIID	STAF65gamma	[INST]Context: [PMID: 17967894 SPT3-TAF9-GCN5-acetylase recruits Mediator to the MYC oncoprotein to stimulate transcription and cell proliferation. Here we report physical interactions between the human histone acetyltransferase complex SPT3-TAF9-GCN5-acetylase and a 'core' form of the Mediator complex during transcription activation by the MYC oncoprotein. Knockdown of the STAF65gamma component of SPT3-TAF9-GCN5-acetylase in human cells prevents the stable association of TRRAP and GCN5 with the SPT3 and TAF9 subunits; Impairs transcription of MYC-dependent genes, including MYC transactivation of the telomerase reverse transcriptase promoter; And inhibits proliferation of MYC-dependent cells. STAF65gamma is required for SPT3/SPT3-TAF9-GCN5-acetylase interaction with core Mediator and for MYC recruitment of SPT3, TAF9, and core Mediator components to the telomerase reverse transcriptase promoter but is dispensable for MYC recruitment of TRRAP, GCN5, and p300 and for acetylation of nucleosomes and loading of TFIID and RNA polymerase II on the promoter. These results suggest a novel STAF65gamma-dependent function of STAGA-type complexes in cell proliferation and transcription activation by MYC postloading of TFIID and RNA polymerase II that involves direct recruitment of core Mediator.] Question: Based on the provided context, do the terms [TFIID protein] and [STAF65gamma protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention a direct interaction between the TFIID protein and the STAF65gamma protein. Instead, it describes the roles of STAF65gamma in the recruitment of core Mediator and SPT3-TAF9-GCN5-acetylase to the telomerase reverse transcriptase promoter and its importance for MYC-dependent transcription activation. While STAF65gamma is involved in the recruitment of TFIID and RNA polymerase II, there is no direct interaction mentioned between TFIID and STAF65gamma.</s>
15864 2A2575585 2A2623617	HAP1	GAL4	[INST]Context: [PMID: 7830720 The yeast SIN3 gene product negatively regulates the activity of the human progesterone receptor and positively regulates the activities of GAL4 and the HAP1 activator. The activation of gene transcription in eukaryotic organisms is regulated by sequence-specific DNA-binding proteins as well as by non-DNA-binding proteins. In this report we describe the modulatory functions of a non-DNA-binding protein, SIN3 (also known as SDI1, UME4, RPD1, and GAM2) on the transactivation properties of the human progesterone receptor, GAL4, and the HAP1 activator in yeast. SIN3 positively regulates the transcriptional activities of GAL4 and the HAP1 activator. However, it has no effect on the transcriptional activities of the human glucocorticoid receptor and GCN4. Deletion analysis of the SIN3 paired amphipathic helix motifs shows that the PAH3 motif is essential for SIN3-mediated regulation of human progesterone receptor, GAL4, and the HAP1 activator. These data suggest that SIN3 regulates the transactivation functions of human progesterone receptor, GAL4, and the HAP1 activator by an indirect mechanism. Saccharomyces cerevisiae.] Question: Based on the provided context, do the terms [HAP1 protein] and [GAL4 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context describes the modulatory functions of the SIN3 protein on the transcriptional activities of GAL4 and the HAP1 activator in yeast. It mentions that SIN3 positively regulates the transcriptional activities of both GAL4 and HAP1 but does not indicate any direct interaction between the GAL4 protein and the HAP1 protein themselves. Instead, it focuses on how SIN3 influences their activities independently. Therefore, based on the given information, there is no evidence of a direct interaction between the GAL4 protein and the HAP1 protein.</s>
487645 2A2723734 2A2725459	PLK2	PLXNB2	[INST]Context: [PMID: 35328298 MiR-126 Decreases Proliferation and Mammosphere Formation of MCF-7 and Predicts Prognosis of estrogen receptor-positive Breast Cancer. Breast cancer is a major health burden that affects over one million women each year. It is the most prevalent cancer in women and the number one cancer killer of them worldwide. Of all breast cancer subtypes, estrogen receptor-positive breast cancer is the most commonly diagnosed. The objective of this study is to investigate the contribution of miR-126 in the tumorigenesis of estrogen receptor-positive breast cancer. MiR-126 was downregulated in estrogen receptor-positive breast cancer tissues from young breast cancer patients, as shown through miRNA microarray analysis and RT-qPCR. Subsequently, the effect of the modulation of miR-126 levels on the proliferation, cell cycle progression, and spheres formation of the estrogen receptor-positive breast cancer cell line, MCF-7, was assessed by MTT assay, PI analysis, and mammosphere formation assay, respectively. MiR-126 overexpression significantly decreased MCF-7 proliferation and mammosphere-forming ability, but did not affect cell cycle progression. Then, in silico analysis determined SLC7A5, PLXNB2, CRK, PLK2, SPRED1, and IRS1 as potential targets of miR-126. RT-qPCR data showed that miR-126 overexpression significantly downregulated SLC7A5 and PLXNB2 mRNA levels in MCF-7. Finally, in silico survival analysis showed that high expression of miR-126 or low expression of SLC7A5 correlated with better overall survival of estrogen receptor-positive breast cancer patients. Overall, our study suggests that miR-126 might play a tumor suppressor role in estrogen receptor-positive breast cancer. MiR-126 and SLC7A5 might also be considered potential prognostic biomarkers in estrogen receptor-positive breast cancer.] Question: Based on the provided context, do the terms [PLK2 protein] and [PLXNB2 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the PLK2 protein and the PLXNB2 protein. While both proteins are listed as potential targets of miR-126, there is no indication that they interact with each other. The context focuses on the role of miR-126 in regulating the expression of these proteins and its impact on the proliferation and mammosphere formation of MCF-7 cells, but it does not describe any direct interaction between PLK2 and PLXNB2.</s>
216954 2A2454115 2A2747083	Caspase-8	PSME3	[INST]Context: [PMID: 26410814 Spirulina phycocyanin induces differential protein expression and apoptosis in SKOV-3 cells. The present study was designed to determine the effects of phycocyanin on Human ovarian cancer SKOV-3 cells and the underlying molecular mechanisms of action. The inhibitory effects of phycocyanin on the cell proliferation were detected by MTT assay. Phycocyanin induced apoptosis in SKOV-3 cells was observed by electron microscopy and flow cytometry. The apoptosis rate was increased from 1.6% to 19.8% after phycocyanin exposure. The fluorescence intensity of ROS and the activities of Caspase-3, Caspase-8, and Caspase-9 were increased. There were 698_+-73 and 683_+-79 protein spots resolved in untreated and PC-treated cells, respectively. Forty five differential protein spots were analyzed by MALDI-TOF-MS, including mtSSB, PSME3, and nucleolin. The decreased proteins such as HSP60, nucleolin, PPase, peroxiredoxin-4 and the increased protein (mtSSB) were identified in SKOV-3 cells after phycocyanin treatment, indicating that the effects of phycocyanin on tumor cell apoptosis may be relate to multiple target proteins. And the mitochondrial pathway may be the main pathway for PC-induced apoptosis.] Question: Based on the provided context, do the terms [Caspase-8 protein] and [PSME3 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between Caspase-8 protein and PSME3 protein. While both proteins are involved in the apoptotic process induced by phycocyanin in SKOV-3 cells, there is no specific interaction described between them. Instead, the context highlights the roles of these proteins in different pathways and mechanisms related to apoptosis.</s>
47321 2A2557337 2A2459289	GIT1	Cdc42	[INST]Context: [PMID: 26812085 Cdc42 and k-Ras Control Endothelial Tubulogenesis through Apical Membrane and Cytoskeletal Polarization: Novel Stimulatory Roles for GTPase Effectors, the Small GTPases, Rac2 and Rap1b, and Inhibitory Influence of Arhgap31 and Rasa1. A critical and understudied property of endothelial cells is their ability to form lumens and tube networks. Although considerable information has been obtained concerning these issues, including the role of Cdc42 and Rac1 and their effectors such as Pak2, Pak4, Par6b, and co-regulators such as integrins, MT1-MMP and Par3; In this work, we identify new small GTPase regulators of EC tubulogenesis including k-Ras, Rac2 and Rap1b that act in conjunction with Cdc42 as well as the key downstream effectors, IQGAP1, MRCKbeta, beta-Pix, GIT1, and Rasip1 (which can assemble into multiprotein complexes with key regulators including alpha2beta1 integrin and MT1-MMP). In addition, we identify the negative regulators, Arhgap31 (by inactivating Cdc42 and Rac) and Rasa1 (by inactivating k-Ras) and the positive regulator, Arhgap29 (by inactivating RhoA) which play a major functional role during the EC tubulogenic process. Human EC siRNA suppression or mouse knockout of Rasip1 leads to identical phenotypes where ECs form extensive cord networks, but cannot generate lumens or tubes. Essential roles for these molecules during EC tubulogenesis include; I) establishment of asymmetric EC cytoskeletal polarization (subapical distribution of acetylated tubulin and basal membrane distribution of F-actin); And ii) directed membrane trafficking of pinocytic vacuoles or other intracellular vesicles along acetylated tubulin tracks to the developing apical membrane surface. Cdc42 co-localizes subapically with acetylated tubulin, while Rac1 and k-Ras strongly label vacuole/ vesicle membranes which accumulate and fuse together in a polarized, perinuclear manner. We observe polarized apical membrane and subapical accumulation of key GTPases and effectors regulating EC lumen formation including Cdc42, Rac1, Rac2, k-Ras, Rap1b, activated c-Raf and Rasip1 to control EC tube network assembly. Overall, this work defines novel key regulators and their functional roles during human EC tubulogenesis. Mice.] Question: Based on the provided context, do the terms [GIT1 protein] and [Cdc42 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that GIT1 is one of the key downstream effectors of Cdc42 that plays a role in endothelial tubulogenesis. Specifically, it mentions that Cdc42 co-localizes subapically with acetylated tubulin, while Rac1 and k-Ras strongly label vacuole/vesicle membranes which accumulate and fuse together in a polarized, perinuclear manner. This suggests that Cdc42 and GIT1 interact within the same signaling pathway to regulate EC tubulogenesis.</s>
783 2A2597029 2A2836821	alpha-L-iduronidase	MPS I	[INST]Context: [PMID: 32764324 Mucopolysaccharidosis Type I: A Review of the Natural History and Molecular Pathology. Mucopolysaccharidosis type I (MPS I) is a rare autosomal recessive inherited disease, caused by deficiency of the enzyme alpha-L-iduronidase, resulting in accumulation of the glycosaminoglycans dermatan and heparan sulfate in organs and tissues. If untreated, patients with the severe phenotype die within the first decade of life. Early diagnosis is crucial to prevent the development of fatal disease manifestations, prominently cardiac and respiratory disease, as well as cognitive impairment. Similarities and differences in the three animal models for MPS I are highlighted. Earliest symptoms, which present during the first 6 months of life, include hernias, coarse facial features, recurrent rhinitis and/or upper airway obstructions in the absence of infection, and thoracolumbar kyphosis. During the next 6 months, loss of hearing, corneal clouding, and further musculoskeletal dysplasias develop. Finally, late manifestations including lower airway obstructions and cognitive decline emerge. Cardiac symptoms are common in MPS I and can develop in infancy. The underlying pathogenesis is in the intra- and extracellular accumulation of partially degraded glycosaminoglycans and infiltration of cells with enlarged lysosomes causing tissue expansion and bone deformities. These interfere with the proper arrangement of collagen fibrils, disrupt nerve fibers, and cause devastating secondary pathophysiological cascades including inflammation, oxidative stress, and other disruptions to intracellular and extracellular homeostasis. A greater understanding of the natural history of MPS I will allow early diagnosis and timely management of the disease facilitating better treatment outcomes.] Question: Based on the provided context, do the terms [alpha-L-iduronidase protein] and [MPS I protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The terms alpha-L-iduronidase protein" and "MPS I protein" do not interact with each other in the provided context. The context describes mucopolysaccharidosis type I (MPS I) as a disease caused by the deficiency of the enzyme alpha-L-iduronidase, which leads to the accumulation of glycosaminoglycans. There is no mention of an "MPS I protein" interacting with alpha-L-iduronidase. Instead, the context focuses on the role of the enzyme deficiency in the disease's pathology.</s>"
184044 2A2572260 2A2572245	GLUT-3	GLUT-1	[INST]Context: [PMID: 8736874 Glucose-mediated regulation of GLUT-1 and GLUT-3 mRNA in human retinal endothelial cells.] Question: Based on the provided context, do the terms [GLUT-3 protein] and [GLUT-1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the regulation of GLUT-1 and GLUT-3 mRNA in human retinal endothelial cells in response to glucose. It does not mention any direct interaction between the GLUT-1 protein and the GLUT-3 protein. Instead, it focuses on the regulation of their mRNA levels, which are separate entities from the proteins themselves. Therefore, based on the given information, there is no evidence of an interaction between the GLUT-1 protein and the GLUT-3 protein.</s>
364149 2A2594884 2A2907654	Hexokinase	triosephosphate isomerase	[INST]Context: [PMID: 958753 Action of growth hormone on erythropoiesis: changes in red blood cell enzyme activities in growth-retarded patients with and without growth hormone deficiency. Fifteen red cell enzyme activities of growth-retarded patients with and without growth hormone deficiency were investigated before and after growth hormone administration. The 15 enzymes were Hexokinase, phosphoglucomutase, glucose phosphate, isomerase, phosphofructokinase, fructose diphosphate aldolase, glyceraldehyde-3-phosphae dehydrogenase, triosephosphate isomerase, 2,3-diphosphoglycerate mutase, 3-phosphoglycerate kinase, 3-phosphoglycerate mutase, enolase, pyruvate kinase, glycose-6-phosphate dehydrogenase, 6-phosphogluconic dehydrogenase, glutathione reducase. Sixty-six subjects were studied: 30 normal control subjects (group N) and 36 patients (aged 5-23 years) with short stature. Complete endocrine evaluation showed 21 (group I) to have growth hormone deficiency (10 patients with isolated growth hormone deficiency) and 15 (group II) to have normal hypothalamic and pituitary function except for two patients with a moderate hypothyroidism. Both had been receiving thyroid hormone treatment for a long time before our studies. All 36 patients were treated with 2 mg human growth hormone intramuscularly for 7 days. Before growth hormone treatment no significant difference was observed between hematologic data in group I (growth hormone deficiency) and group II (no growth hormone deficiency). After growth hormone therapy there was a significant increase in reticulocyte count in both groups of patients with short stature. In group II (no growth hormone deficiency) mean pretreatment erythrocyte enzyme activities were not significantly different from those activities observed in normal control subjects (group N). However, in patients who lacked growth hormone, the pretreatment activities of five red cell enzymes (glucose phosphate isomerase, triosephosphate isomerase, glyceraldehyde-3-phosphate dehydrogenase, 2,3-diphosphoglycerate mutase, 3-phosphoglycerate kinase) were significantly decreased before growth hormone administration compared with the values in normal control subjects...] Question: Based on the provided context, do the terms [Hexokinase protein] and [triosephosphate isomerase protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the effects of growth hormone on various red cell enzyme activities in growth-retarded patients. While it mentions several enzymes, including Hexokinase and triosephosphate isomerase, it does not indicate any direct interaction between these two specific enzymes. The context focuses on the overall changes in enzyme activities before and after growth hormone administration but does not describe any specific interaction between Hexokinase and triosephosphate isomerase.</s>
143331 2A2535594 2A2547361	Fbw7	Cdh1	[INST]Context: [PMID: 23670162 Regulation of APC(Cdh1) E3 ligase activity by the Fbw7/cyclin E signaling axis contributes to the tumor suppressor function of Fbw7. Fbw7 and Cdh1 are substrate-recognition subunits of the SCF- and APC-type E3 ubiquitin ligases, respectively. There is emerging evidence suggesting that both Fbw7 and Cdh1 function as tumor suppressors by targeting oncoproteins for destruction. Loss of Fbw7, but not Cdh1, is frequently observed in various human tumors. However, it remains largely unknown how Fbw7 mechanistically functions as a tumor suppressor and whether there is a signaling crosstalk between Fbw7 and Cdh1. Here, we report that Fbw7-deficient cells not only display elevated expression levels of SCF(Fbw7) substrates, including cyclin E, but also have increased expression of various APC(Cdh1) substrates. We further defined cyclin E as the critical signaling link by which Fbw7 governs APC(Cdh1) activity, as depletion of cyclin E in Fbw7-deficient cells results in decreased expression of APC(Cdh1) substrates to levels comparable to those in wild-type cells. Conversely, ectopic expression of cyclin E recapitulates the aberrant APC(Cdh1) substrate expression observed in Fbw7-deficient cells. More importantly, 4A-Cdh1 that is resistant to Cdk2/cyclin E-mediated phosphorylation, but not WT-Cdh1, reversed the elevated expression of various APC(Cdh1) substrates in Fbw7-deficient cells. Overexpression of 4A-Cdh1 also resulted in retarded cell growth and decreased anchorage-independent colony formation. Altogether, we have identified a novel regulatory mechanism by which Fbw7 governs Cdh1 activity in a cyclin E-dependent manner. As a result, loss of Fbw7 can lead to aberrant increase in the expression of both SCF(Fbw7) and APC(Cdh1) substrates. Our study provides a better understanding of the tumor suppressor function of Fbw7, and suggests that Cdk2/cyclin E inhibitors could serve as effective therapeutic agents for treating Fbw7-deficient tumors. Mice.] Question: Based on the provided context, do the terms [Fbw7 protein] and [Cdh1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that Fbw7 and Cdh1 interact in a regulatory mechanism where Fbw7 governs Cdh1 activity in a cyclin E-dependent manner. Specifically, the study shows that Fbw7-deficient cells have increased expression of APC(Cdh1) substrates, and this is linked to cyclin E levels. The interaction is further supported by the observation that 4A-Cdh1, which is resistant to Cdk2/cyclin E-mediated phosphorylation, can reverse the elevated expression of APC(Cdh1) substrates in Fbw7-deficient cells. This suggests that Fbw7 and Cdh1 are part of a signaling pathway where Fbw7 influences Cdh1 activity through cyclin E, thus indicating an interaction between the two proteins.</s>
593126 2A2875319 2A2764443	STX11	RAB27A	[INST]Context: [PMID: 16278825 Mutation spectrum in children with primary hemophagocytic lymphohistiocytosis: molecular and functional analyses of perforin 1 gene, UNC13D, STX11, and RAB27A. Familial hemophagocytic lymphohistiocytosis is an autosomal-recessive disease that affects young children. It presents as a severe hyperinflammatory syndrome with activated macrophages and T lymphocytes. Mutations in the perforin 1 gene were found in FHL-2 in 15-50% of all cases. Defective granule exocytosis caused by mutations in the hMunc13-4 gene (UNC13D) has been described in FHL-3. FHL-4 patients have mutations in STX11, a t-SNARE involved in intracellular trafficking. We analyzed a large group of 63 unrelated patients with familial hemophagocytic lymphohistiocytosis of different geographic origins (Turkey:32; Germany:23; others:8) for mutations in STX11, perforin 1 gene, and UNC13D. We identified mutations in 38 samples (20 in perforin 1 gene, 12 in UNC13D, and six in STX11). Of 32 patients from Turkey, 14 had mutations in perforin 1 gene, six had mutations in UNC13D, and six had mutations in STX11. The mutation Trp374X in perforin 1 gene was found in 12 patients from Turkey and was associated with a very early onset of the disease below the age of 3 months in all cases. In contrast, three of 23 and four of 23 patients from Germany, and three of eight and two of eight from other origins showed mutations in perforin 1 gene and UNC13D, respectively, but none in STX11. Thus, FHL-2, FHL-3, and FHL-4 account for 80% of the HLH cases of Turkish origin, and for 30% of German patients. Furthermore, we identified mutations in RAB27A in three patients with FHL-related Griscelli syndrome type 2. In functional studies using a mammalian two-hybrid system we found that missense mutations Ala87Pro in Rab27a and Leu403Pro in hMunc13-4 each prevented the formation of a stable hMunc13-4/Rab27a complex in vitro. Our findings demonstrate extensive genetic and allelic heterogeneity in familial hemophagocytic lymphohistiocytosis and delineate an approach for functionally characterizing missense mutations in RAB27A and UNC13D.] Question: Based on the provided context, do the terms [STX11 protein] and [RAB27A protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the STX11 protein and the RAB27A protein. While it discusses mutations in both proteins and their roles in familial hemophagocytic lymphohistiocytosis (FHL), it does not indicate that these proteins interact with each other. Instead, it focuses on the functional characterization of missense mutations in RAB27A and UNC13D, and the formation of a stable hMunc13-4/Rab27a complex in vitro. Therefore, there is no evidence in the context to suggest that STX11 and RAB27A proteins interact directly.</s>
596859 2A2434596 2A2698429	Atp5b	ornithine aminotransferase	[INST]Context: [PMID: 19445961 Proteome response to ochratoxin A-induced apoptotic cell death in mouse hippocampal HT22 cells. Mycotoxins are commonly encountered natural products, and are capable of poisoning animals or humans that inhale mold particles from mycotoxin-contaminated foods. Ochratoxin A is produced by Aspergillu ochracus and Penicillium verrucosum, and is often found in cereals and agricultural products. Although previous studies have focused on the potent nephrotoxicity and renal carcinogenicity of ochratoxin a, more recent studies suggest that it accumulates in the brain and causes oxidative stress and DNA damage in various brain regions and neuronal populations. In the present study, we undertook to investigate the potential harm caused by environmental exposure to ochratoxin a in terms of its effects on neuronal cell viability and proteome profiles. Ochratoxin a was found to significantly reduce the viabilities of human neuroblastoma SH-SY5Y and mouse hippocampal HT22 cells, as assessed by lactic dehydrogenase release into culture media. Generation of reactive oxygen species was detected in OTA-treated SH-SY5Y and HT22 cells, however, caspase activation and increase in p53 phosphorylation were only detected in HT22 cells, and the expressions of several proteins were found to be significantly altered after treating HT22 cells with ochratoxin a. Valosin containing protein, prolyl 4-hydroxylase, Atp5b protein, nucleophosmin 1, eukaryotic translation elongation factor 1 delta isoform, ornithine aminotransferase, prohibitin, and peroxiredoxin 6, which have been suggested to be implicated in the pathogenesis of neurodegenerative disorders, were up-regulated. Our findings suggest that coordinated regulations of molecular networks are involved in the OTA-induced cytotoxicity and that proteome response can be an indicative for neurodegeneration. Mice.] Question: Based on the provided context, do the terms [Atp5b protein] and [ornithine aminotransferase protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between Atp5b protein and ornithine aminotransferase protein. Instead, it lists these proteins as part of a broader set of proteins whose expressions were significantly altered after treating HT22 cells with ochratoxin A. The context focuses on the overall proteome response to ochratoxin A-induced cytotoxicity and neurodegeneration, rather than specific interactions between individual proteins.</s>
419893 2A2536414 2A2548752	FEN1	GADD45A	[INST]Context: [PMID: 23670255 BRCA1 and p53 regulate critical prostate cancer pathways. BACKGROUND: Loss or mutations of the BRCA1 gene are associated with increased risk of breast and ovarian cancers and with prostate cancer aggressiveness. Previously, we identified GADD153 as a target of BRCA1 protein, which increases doxorubicin sensitivity in human p53 -/- prostate cancer cells . Considering that p53 is a crucial target in cancer therapy, in this work we investigated p53 role in the regulation of transcription of GADD153. METHODS: We performed reverse transcription quantitative PCR, western blot and luciferase assays to analyze GADD153 and/or BRCA1 expression in response to ultraviolet or doxorubicin exposure in pca cells p53 stable-transfected cells and LNCaP (p53+/+) cells. BRCA1 protein recruitment to GADD153 promoter was studied by chromatin immunoprecipitation-qPCR. To assess expression of BRCA1 and/or p53 target genes, we used a panel of stable-transfected prostate cancer cell lines. We finally analyzed these genes in vivo using BRCA1-depleted prostate cancer xenograft models. RESULTS: We found that GADD153 was highly induced by doxorubicin in pca cells ; However, this response was totally abolished in LNCaP (p53wt) and in p53-restituted pca cells . Furthermore, BRCA1 protein associates to GADD153 promoter after DNA damage in the presence of p53. Additionally, we demonstrated that BRCA1 and/or p53 modulate genes involved in DNA damage and cell cycle regulation (cyclin D1, BLM, BRCA2, DDB2, p21(WAF1/CIP1), H3F3B, GADD153, GADD45A, FEN1, CCNB2), EMT (E-cadherin, beta-catenin, vimentin, fibronectin, slug, snail) and Hedgehog pathways (SHH, IHH, DHH, Gli1, PATCH1). Furthermore, xenograft studies demonstrated that BRCA1 knockdown in pca cells increased tumor growth and modulated these genes in vivo. CONCLUSIONS: Although BRCA1 induces GADD153 in a p53 independent manner, p53 abolished GADD153 induction in response to DNA damage. In addition, several important prostate cancer targets are modulated by BRCA1 and p53. Altogether, these data might be important to understand the therapy response of prostate cancer patients. Mice.] Question: Based on the provided context, do the terms [FEN1 protein] and [GADD45A protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between FEN1 protein and GADD45A protein. While both proteins are listed among the genes modulated by BRCA1 and p53, there is no specific information or evidence provided that indicates a direct interaction between FEN1 and GADD45A. The context focuses on the roles of BRCA1 and p53 in regulating various pathways and genes, but it does not detail any specific interaction between FEN1 and GADD45A.</s>
419632 2A2536414 2A2507390	flap endonuclease 1	DNA Ligase 1	[INST]Context: [PMID: 32268955 In the first scheme, we introduce a biotin-labeled SUMO-tag to each of human flap endonuclease 1 and Escherichia coli replication termination protein Tus, and elute both proteins by performing on-resin cleavage using SUMO protease. In the second scheme, we immobilize biotin-labeled human proliferating cell nuclear antigen on the avidin-coupled resin and use the resulting resin as a tag-free affinity method to purify the PCNA-binding protein human DNA Ligase 1. Furthermore, we streamlined the protein biotinylation protocol by constructing a single plasmid expression system that ensures high level of expression and solubility for each of the target protein bearing the biotin-tag and the enzyme responsible for the in vivo biotinylation reaction.] Question: Based on the provided context, do the terms [flap endonuclease 1 protein] and [DNA Ligase 1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context describes two separate schemes for protein purification using biotin-labeled proteins and affinity methods. It mentions the purification of human flap endonuclease 1 and Escherichia coli replication termination protein Tus using a SUMO-tag and the purification of human DNA Ligase 1 using a biotin-labeled human proliferating cell nuclear antigen. There is no mention of a direct interaction between flap endonuclease 1 protein and DNA Ligase 1 protein. Instead, they are described as separate entities purified using different methods.</s>
302507 2A2406535 2A2509801	ACTG1	CDC2	[INST]Context: [PMID: 16466844 Gene expression profiles of U937 human macrophages exposed to Chlamydophila pneumoniae and/or low density lipoprotein in five study models using differential display and real-time RT-PCR. Many studies on atherosclerosis have indicated an association with Chlamydophila pneumoniae, a respiratory intracellular pathogen that can infect bronchoalveolar macrophages, and be transported to sites of vascular injury. Furthermore, the connection between low density lipoprotein, macrophages, foam cell formation, and atherosclerosis is well established. Five study models were designed to mimic the early events in plaque formation, i.e. untreated U937 human macrophages as control; Macrophages treated with low density lipoprotein only; Macrophages infected with the AR-39 strain of C. pneumoniae only; And the last two models in which macrophages were exposed to both C. pneumoniae and low density lipoprotein but in different order. Differential display RT-PCR was employed to analyze mRNAs from the five models to elucidate the transcriptional responses arising from macrophage interactions with C. pneumoniae and/or low density lipoprotein. In relation to atherosclerosis, some interesting modified transcripts are involved in cell proliferation (CDC2, CDC27, CDC42EP3, GBDR1, GPR6, RPL27A, Similar to COX2), apoptosis (BCL2A1), ubiquitination (CTSH, HSPC150, NUC2), and structural integrity (ACTG1, FLOT1). Other genes exhibiting altered expression include those that modulate inflammatory and immune responses or signal transduction linking infection to host immunity (ARPP-19, BLAME, HCA58, IK cytokine, IRS2, STAT1P1). The transcriptional alterations of critical human genes in response to C. pneumoniae infection and foam cell development provide insights into certain key molecular pathophysiological mechanisms of atherosclerosis. From MeSH: Chlamydophila pneumoniae.] Question: Based on the provided context, do the terms [ACTG1 protein] and [CDC2 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the transcriptional alterations of various genes in response to Chlamydophila pneumoniae infection and foam cell development. While it mentions the involvement of ACTG1 (encoding actin, a structural protein) and CDC2 (encoding cyclin-dependent kinase 2, involved in cell cycle regulation), there is no direct interaction mentioned between these two proteins. Instead, they are presented as separate entities with altered expression levels in response to the infection and foam cell formation. Therefore, based on the given information, there is no evidence to suggest that ACTG1 protein and CDC2 protein interact with each other.</s>
40879 2A2939612 2A2871057	END1	AGT	[INST]Context: [PMID: 32535289 Polymorphisms in genes involved in inflammation, the NF-kB pathway and the renin-angiotensin-aldosterone system are associated with the risk of osteoporotic fracture. Osteoporosis is the most common bone disorder worldwide and is associated with a reduced quality of life with important clinical and economic consequences. The most widely accepted etiopathogenic hypothesis on the origin of osteoporosis and its complications is that they are a consequence of the synergic action of environmental and genetic factors. Bone is constantly being remodelled through anabolic and catabolic pathways in which inflammation, the NF-kB pathway and the renin-angiotensin-aldosterone system are crucial. The aim of our study was to determine whether polymorphisms in genes implicated in inflammation, the NF-kB pathway and renin-angiotensin-aldosterone system modified the risk of osteoporotic fracture. We analysed 221 patients with osteoporotic fracture and 354 controls without fracture from the HORTEGA sample after 12-14__^years of follow up. In addition, we studied the genotypic distribution of 230 single nucleotide polymorphisms in genes involved in inflammation, NF-kB pathway and renin-angiotensin-aldosterone system. Our results showed that be carrier of the C allele of the rs2228145 IL6R polymorphism was the principal genetic risk factor associated with osteoporotic fracture. The results also showed that variant genotypes of the rs4762 AGT, rs4073 IL8, rs2070699 END1 and rs4291 ACE polymorphisms were important genetic risk factors for fracture. The study provides information about the genetic factors associated with inflammation, the NF-kB pathway and renin-angiotensin-aldosterone system, which are involved in the risk of osteoporotic fracture and reinforces the hypothesis that genetic factors are crucial in the etiopathogenesis of osteoporosis and its complications.] Question: Based on the provided context, do the terms [END1 protein] and [AGT protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the association of polymorphisms in genes involved in inflammation, the NF-kB pathway, and the renin-angiotensin-aldosterone system with the risk of osteoporotic fracture. It mentions specific polymorphisms in genes such as IL6R, IL8, END1, and AGT, but it does not provide any information about a direct interaction between the END1 protein and the AGT protein. The context focuses on the genetic risk factors associated with osteoporotic fracture rather than describing any protein-protein interactions.</s>
514938 2A2922459 2A2922425	UbcH7	UbcH6	[INST]Context: [PMID: 9990509 Human ubiquitin-protein ligase Nedd4: expression, subcellular localization and selective interaction with ubiquitin-conjugating enzymes. BACKGROUND: Nedd4 is a ubiquitin-protein ligase containing a calcium/lipid-binding domain, multiple WW domains and a C-terminal Hect domain, which is required for both the ubiquitin transfer and the association with E2 ubiquitin-conjugating enzymes. Nedd4 has been reported to be involved in the selective ubiquitination of some regulatory proteins in transcription and membrane transport. RESULTS: Three mRNA species for human Nedd4 were found to be 6.4-, 7.8- and 9.5-kb in size, and their expression patterns varied among normal tissues and cancer cell lines, indicating the tissue- and cell-specificities of Nedd4 expression. The Nedd4 protein, approximately 120 kDa in weight, was found in the cytoplasm, mainly in the perinuclear region and cytoplasmic periphery, of human cultured cells. Neural differentiation induced not only the down-regulation of Nedd4 but also the localization of the protein to both the cytoplasm and neurites. To identify the ubiquitination pathway that is linked to Nedd4, we demonstrated that specific E2 enzymes, including human Ubc4, UbcH5B, UbcH5C, UbcH6 and UbcH7, could transfer ubiquitin molecules to Nedd4 at the active cysteine residue, whereas E6AP accepted ubiquitins from Ubc4, UbcH5B, UbcH5C and UbcH7. Furthermore, nuclear localization of N-terminal deletion mutant Nedd4 enabled us to investigate the interaction between Nedd4 and E2 enzyme (Ubc4 or UbcH7) in the cell. The simultaneous expression of the full-length Nedd4 and E2 enzyme revealed the both proteins mostly colocalized in the cytoplasmic periphery, while the N-terminal deleted Nedd4 induced the nuclear and perinuclear colocalization with E2 enzyme. CONCLUSION: Our findings suggested that Nedd4 plays an important role in the cell regulation, including neural differentiation through cooperation with specific E2 ubiquitination pathways.] Question: Based on the provided context, do the terms [UbcH7 protein] and [UbcH6 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the interaction of Nedd4 with various ubiquitin-conjugating enzymes (E2s), including UbcH7 and UbcH6. However, it does not mention any direct interaction between UbcH7 and UbcH6 proteins themselves. Instead, it describes how Nedd4 interacts with specific E2 enzymes, such as UbcH7 and UbcH6, to facilitate ubiquitination processes. Therefore, there is no evidence in the context that UbcH7 and UbcH6 interact with each other.</s>
502365 2A2847424 2A2601220	LBP-type	Il 6	[INST]Context: [PMID: 23125878 Lipopolysaccharide binding protein (L.B.P.)--an inflammatory marker of prognosis in the acute appendicitis. LIPOPOLYSACCHARIDE BINDING PROTEIN is an important mediator of the inflammatory reaction. A multitude of factors can determine the genic transcription activation and the increase of the lipopolysaccharide binding protein in the blood and the human body humours: Il1, Il 6, lipopolysaccharides, Gram-negative bacteria, as well as non-infectious agents. This paper is a prospective study performed on 147 patients admitted for acute appendicitis in 2010-2012 and evaluates the dynamics of lipopolysaccharide binding protein in acute appendicitis, by identifying the correlations between the pre- and post-operatory levels of lipopolysaccharide binding protein (up to 72 hours after surgery) and the anatomopathological type (i.e. catarrhal, phlegmonous and gangrenous). The mean pre-op lipopolysaccharide binding protein values are significantly different as to the histopathological result (p<0,005). Among the biological inflammatory markers measured in this present study, lipopolysaccharide binding protein has a dynamics of its own in the catarrhal and phlegmonous appendicitis. Thus, if after the surgical removal of the infectious source, the leukocites and neutrophiles decrease 72 hrs after surgery, lipopolysaccharide binding protein continues an ascending curve. The importance of this study consists in the introduction of last generation LBP-type inflammatory markers' dosage in the cecal appendix pathology. The good correlation between the lipopolysaccharide binding protein pre-op values and the histopathological diagnosis of the appendicits form that we discovered during the present study opens the way to large-scale use of the biochemical dosage of lipopolysaccharide binding protein in the management of acute appendicitis.] Question: Based on the provided context, do the terms [LBP-type protein] and [Il 6 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that lipopolysaccharide binding protein (LBP) is an important mediator of the inflammatory reaction and that various factors, including Il6, can determine the genic transcription activation and increase of LBP in the blood and human body humours. This suggests that Il6 and LBP interact in the inflammatory process, as Il6 can influence the levels of LBP. Therefore, the terms [LBP-type protein] and [Il 6 protein] interact with each other in the context of inflammation.</s>
197622 2A2430988 2A2522086	Atf3	ELF1	[INST]Context: [PMID: 32581210 Identification of Target Genes and Transcription Factors in Mice with LMNA-Related Dilated Cardiomyopathy by Integrated Bioinformatic Analyses. BACKGROUND Dilated cardiomyopathy, which is characterized by enlarged ventricular dimensions and systolic dysfunction, is the most common type of cardiomyopathy. Mutations in the LMNA gene are reported in approximately 10% of familial dilated cardiomyopathy cases. However, the mechanism of LMNA mutations in human dilated cardiomyopathy remains unclear. MATERIAL AND METHODS We used the GSE36502 and GSE123916 datasets to obtain gene expression profiles from LMNA-related dilated cardiomyopathy mice and to identify differentially expressed genes . Crucial function and pathway enrichment analyses of differentially expressed genes were performed. Weighted gene co-expression network analysis was used to explore the module relevant to external traits of LMNA-related dilated cardiomyopathy mice. The enriched biological functions and pathways were oxidative stress, regulation of apoptosis, regulation of fibrosis, and MAPK pathways. Five target genes (Timp1, Hmox1, Spp1, Atf3, and Adipoq) were verified after reverse transcription-polymerase chain reaction. Three transcription factors (ELF1, ETS1, and NRF1) showed close interactions with the hub genes. CONCLUSIONS Our study used integrated bioinformatic analyses and revealed some important genes in mice with LMNA-related dilated cardiomyopathy, which could provide novel insights into the mechanism underlying human LMNA-related dilated cardiomyopathy. Mice.] Question: Based on the provided context, do the terms [Atf3 protein] and [ELF1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the Atf3 protein and the ELF1 protein. While both proteins are mentioned in the context of LMNA-related dilated cardiomyopathy in mice, there is no specific information indicating that they interact with each other. The context focuses on the roles of these proteins in the disease mechanism but does not describe any direct interaction between them.</s>
260156 2A2632153 2A2401213	LPP	APOBEC3G	[INST]Context: [PMID: 18615101 The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab. Gene expression profiles have been associated with clinical outcome in patients with diffuse large B-cell lymphoma treated with anthracycline-containing chemotherapy. Using Affymetrix HU133A microarrays, we analyzed the lymphoma transcriptional profile of 30 patients treated with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) and 23 patients treated with rituximab (R)-CHOP in the Groupe d'Etude des Lymphomes de l'Adulte clinical centers. We used this data set to select transcripts showing an association with progression-free survival in all patients or showing a differential effect in the two treatment groups. In these 67 patients, the level of expression of 16 genes and the cell-of-origin classification were significantly associated with overall survival, independently of the International Prognostic Index. A multivariate model comprising four genes of the cell-of-origin signature (LMO2, MME, LPP and FOXP1) and two genes related to immune response, identified for their differential effects in R-CHOP patients (APOBEC3G and RAB33A), demonstrated a high predictive efficiency in this set of patients, suggesting that both features affect outcome in diffuse large b-cell lymphoma patients receiving immunochemotherapy.] Question: Based on the provided context, do the terms [LPP protein] and [APOBEC3G protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the expression of various genes, including LPP and APOBEC3G, and their association with overall survival in patients with diffuse large B-cell lymphoma. However, there is no direct mention of an interaction between the LPP protein and the APOBEC3G protein. Instead, they are presented as separate entities whose expression levels are independently associated with clinical outcomes. Therefore, based on the given information, there is no evidence to suggest that LPP and APOBEC3G proteins interact with each other.</s>
37040 2A2936581 2A2903080	Vim	Timp1	[INST]Context: [PMID: 33628784 Analysis of Differentially Expressed Genes in the Dentate Gyrus and Anterior Cingulate Cortex in a Mouse Model of Depression. Major depressive disorder is a prevalent, chronic, and relapse-prone psychiatric disease. To clarify the pathological changes in the dentate gyrus and anterior cingulate cortex regions of the major depressive disorder brain, which are the most closely related to the disease, we investigated the published microarray profile dataset GSE84183 to identify unpredictable chronic mild stress- (UCMS-) induced differentially expressed genes in the dentate gyrus and anterior cingulate cortex regions. The pathways and GO terms enriched by the differentially expressed genes in the dentate gyrus, such as cell adhesion, proteolysis, ion transport, transmembrane transport, chemical synaptic transmission, immune system processes, response to lipopolysaccharide, and nervous system development, may reveal the molecular mechanism of major depressive disorder. However, the differentially expressed genes in the anterior cingulate cortex involved metabolic processes, proteolysis, visual learning, DNA methylation, innate immune responses, cell migration, and circadian rhythm. Sixteen hub genes in the dentate gyrus (Fn1, Col1a1, Anxa1, Penk, Ptgs2, Cdh1, Timp1, Vim, Rpl30, Rps21, Dntt, Ptk2b, Jun, Avp, Slit1, and Sema5a) were identified. Eight hub genes in the anterior cingulate cortex (Prkcg, Grin1, Syngap1, Rrp9, Grwd1, Pik3r1, Hnrnpc, and Prpf40a) were identified. In addition, eleven TFs (Chd2, Zmiz1, Myb, Etv4, Rela, Tcf4, Tcf12, Chd1, Mef2a, Ubtf, and Mxi1) were predicted to regulate more than two of these hub genes. The expression levels of ten randomly selected hub genes that were specifically differentially expressed in the MDD-like animal model were verified in the corresponding regions in the human brain. These hub genes and TFs may be regarded as potential targets for future major depressive disorder treatment strategies, thus aiding in the development of new therapeutic approaches to major depressive disorder. From MeSH: Mice.] Question: Based on the provided context, do the terms [Vim protein] and [Timp1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the Vim protein and the Timp1 protein. While both proteins are listed as hub genes in the dentate gyrus, there is no specific information indicating that they interact with each other. The context focuses on the differentially expressed genes and their roles in the dentate gyrus and anterior cingulate cortex regions in a mouse model of depression, but it does not provide details about the interactions between specific proteins.</s>
103022 2A2704682 2A2984829	P53	ZEB-2	[INST]Context: [PMID: 29371906 Profile of epigenetic mechanisms in lung tumors of patients with underlying chronic respiratory conditions. Background: Chronic lung diseases such as chronic obstructive pulmonary disease and epigenetic events underlie lung cancer development. The study objective was that lung tumor expression levels of specific microRNAs and their downstream biomarkers may be differentially regulated in patients with and without chronic obstructive pulmonary disease. Methods: In lung specimens (tumor and non-tumor), microRNAs known to be involved in lung tumorigenesis (miR-21, miR-200b, miR-126, miR-451, miR-210, miR-let7c, miR-30a-30p, miR-155 and miR-let7a, qRT-PCR), DNA methylation, and downstream biomarkers were determined (qRT-PCR and immunoblotting) in 40 patients with lung cancer (prospective study, subdivided into LC-chronic obstructive pulmonary disease and lung cancer, N___=___20/group). Results: Expression of miR-21, miR-200b, miR-210, and miR-let7c and DNA methylation were greater in lung tumor specimens of LC-chronic obstructive pulmonary disease than of lung cancer patients. Expression of downstream markers PTEN, MARCKs, TPM-1, PDCD4, SPRY-2, ETS-1, ZEB-2, FGFRL-1, EFNA-3, and k-RAS together with P53 were selectively downregulated in tumor samples of LC-chronic obstructive pulmonary disease patients. In these patients, tumor expression of miR-126 and miR-451 and that of the biomarkers PTEN, MARCKs, FGFRL-1, SNAIL-1, P63, and k-RAS were reduced. Conclusions: Biomarkers of mechanisms involved in tumor growth, angiogenesis, migration, and apoptosis were differentially expressed in tumors of patients with underlying respiratory disease. These findings shed light into the underlying biology of the reported greater risk to develop lung cancer seen in patients with chronic respiratory conditions. The presence of an underlying respiratory disease should be identified in all patients with lung cancer as the differential biological profile may help determine tumor progression and the therapeutic response.] Question: Based on the provided context, do the terms [P53 protein] and [ZEB-2 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the P53 protein and the ZEB-2 protein. While both proteins are involved in various cellular processes, including tumorigenesis and metastasis, the context does not indicate that they interact with each other. Instead, it describes their differential expression levels in lung tumor specimens of patients with and without chronic obstructive pulmonary disease.</s>
366159 2A2592211 2A2712591	HSPA8	P4HB	[INST]Context: [PMID: 24413982 Downregulation of proteins involved in the endoplasmic reticulum stress response and Nrf2-ARE signaling in lymphoblastoid cells of spinocerebellar ataxia type 17. Spinocerebellar ataxia type 17 is caused by CAG repeat expansion in the TATA-box binding protein gene. Studies of several polyglutamine expansion diseases have suggested that the expanded polyglutamine proteins misfold and induce oxidative stress to contribute to cell death. Substantial deficits in peripheral tissues including lymphocytes have been shown and these peripheral abnormalities could also be found in neurons possessing polyglutamine disease proteins. In this study, we used a lymphoblastoid cell model to investigate the functional implication of spinocerebellar ataxia type 17 expanded alleles and assess the potential therapeutic strategies that may ameliorate the effects of expanded polyglutamine. A total of 8 proteins with reduced expression changes greater than 1.3-fold were identified, including previously reported HSPA5 and HSPA8. Among 6 proteins further semi-quantified by immunoblotting and real-time PCR, the reduced expression of HYOU1, PDIA3, P4HB, NQO1 and HMOX1 was confirmed. Treatment with resveratrol and genipin up-regulated NQO1 and HMOX1 expression and reduced oxidative stress in patients' lymphoblastoid cells. The results illustrate downregulation of proteins involved in the endoplasmic reticulum stress response (HYOU1, HSPA5, PDIA3, and P4HB) and Nrf2-ARE signaling (NQO1 and HMOX1) in spinocerebellar ataxia type 17 lymphoblastoid cells. Compounds increasing anti-oxidative activity such as resveratrol and genipin may serve as a potential therapeutic strategy for spinocerebellar ataxia type 17.] Question: Based on the provided context, do the terms [HSPA8 protein] and [P4HB protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between HSPA8 protein and P4HB protein. It lists these proteins as part of a group of proteins with reduced expression in spinocerebellar ataxia type 17 lymphoblastoid cells but does not describe any specific interaction between HSPA8 and P4HB. Instead, it focuses on the overall downregulation of proteins involved in the endoplasmic reticulum stress response and Nrf2-ARE signaling.</s>
576877 2A2416086 2A2736893	annexin A5	peroxiredoxin-1	[INST]Context: [PMID: 35454982 Proteomic Analysis of Endometrial Cancer Tissues from Patients with Type 2 Diabetes Mellitus. Endometrial cancer is the most common form of gynecological cancer. Type 2 diabetes mellitus is associated with an increased risk of endometrial cancer. Currently, no proteomic studies have investigated the role of diabetes in endometrial cancers from clinical samples. The present study aims to elucidate the molecular link between diabetes and endometrial cancer using a proteomic approach. Endometrial tissue samples were obtained from age-matched patients (endometrial cancer Diabetic and endometrial cancer Non-Diabetic) during surgery. The significantly upregulated proteins included peroxiredoxin-1, vinculin, endoplasmin, annexin A5, calreticulin, and serotransferrin. The significantly downregulated proteins were myosin regulatory light polypeptide 9, Retinol dehydrogenase 12, protein WWC3, intraflagellar transport protein 88 homolog, superoxide dismutase [Cu-Zn], and retinal dehydrogenase 1. The network pathway was related to connective tissue disorder, developmental disorder, and hereditary disorder, with the identified proteins centered around dysregulation of ERK1/2 and F Actin signaling pathways. Cancer-associated protein alterations such as upregulation of peroxiredoxin-1, annexin 5, and iNOS, and downregulation of RDH12, retinaldehyde dehydrogenase 1, SOD1, and MYL 9, were found in the endometrial cancer tissues of the diabetic group. Differential expression of proteins linked to cancer metastasis, such as the upregulation of vinculin and endoplasmin and downregulation of WWC3 and IFT88, was seen in the patients with diabetes. Calreticulin and alpha-enolase, which might have a role in the interplay between diabetes and endometrial cancer, need further investigation.] Question: Based on the provided context, do the terms [annexin A5 protein] and [peroxiredoxin-1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between annexin A5 protein and peroxiredoxin-1 protein. Instead, it lists these proteins as part of the significantly upregulated proteins in endometrial cancer tissues from patients with type 2 diabetes mellitus. The context focuses on the differential expression of various proteins in endometrial cancer tissues related to diabetes but does not indicate any specific interaction between annexin A5 and peroxiredoxin-1.</s>
396268 2A2736579 2A2875376	PPP1R15A	STX5	[INST]Context: [PMID: 31952466 BACKGROUND: asthma, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis are three serious pulmonary diseases that contain common and unique characteristics. RESULTS: The results confirmed that the asthma lung transcriptome was more similar to chronic obstructive pulmonary disease than idiopathic pulmonary fibrosis. In addition, the biomarkers were found in each disease and thus were proposed for further clinical validations. These genes included RBM42, STX5, and TRIM41 in asthma, CYP27A1, GM2A, LGALS9, SPI1, and NLRC4 in chronic obstructive pulmonary disease, ATF3, PPP1R15A, ZFP36, SOCS3, NAMPT, and GADD45B in idiopathic pulmonary fibrosis, LRRC48 and CETN2 in asthma-COPD, COL15A1, GIMAP6, and JAM2 in asthma-idiopathic pulmonary fibrosis and LMO7, TSPAN13, LAMA3, and ANXA3 in COPD-IPF.] Question: Based on the provided context, do the terms [PPP1R15A protein] and [STX5 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the PPP1R15A protein and the STX5 protein. The context discusses the biomarkers found in each of the three pulmonary diseases (asthma, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis) but does not indicate any specific interaction between these two proteins. Therefore, based on the given information, there is no evidence to suggest that PPP1R15A protein and STX5 protein interact with each other.</s>
411978 2A2481140 2A2525541	CREB	P300	[INST]Context: [PMID: 28903900 To explore the relationship between brain-derived neurotrophic factor gene and bone mineral density in Chinese Han population, we performed association analysis of 14 tag SNPs on brain-derived neurotrophic factor gene with hip/spine bone mineral density in 1300 Han Chinese samples from Shaanxi Province. To further explore the regulatory mechanism of brain-derived neurotrophic factor gene in osteoporosis, we further performed a set of data analyses, including linkage disequilibrium and haplotype analysis, epigenetic annotation, expression quantitative trait locus analysis and metabolic pathway analysis. Further, we have established a mouse pre-osteoblasts differentiation cell model (MC3T3-E1) by recombination human bone morphogenetic protein induction. SiRNA- mediated knock down of brain-derived neurotrophic factor in this cell model showed that all 14 SNPs are in the same haplotype block. Strong signals of active histone H3K4me1, H3K4me3, H3K27ac modifications and P300 binding were observed in osteoblasts, in the region surrounding the most significant SNP rs16917237, suggesting that this SNP might have a regulatory function in osteoblasts. Furthermore, analysis of genotype data of rs16917237 and brain-derived neurotrophic factor expression in multiple tissues from GTEx showed that rs16917237 SNP could significantly affect the expression of brain-derived neurotrophic factor in 11 tissues. Through analysis of the various brain-derived neurotrophic factor pathways, we showed that brain-derived neurotrophic factor participates in the MAPK pathway, which is a vital and well-established pathway affecting osteoblasts proliferation and differentiation. SiRNA knock down of brain-derived neurotrophic factor significantly decreased the mRNA and protein levels of CREB, which is important in the MAPK pathway in osteoblast differentiation. These findings suggest that brain-derived neurotrophic factor might affect osteoblast differentiation via regulation of CREB expression. In conclusion, our results from combined genetic association and functional analyses show that brain-derived neurotrophic factor is a vital osteoporosis susceptibility gene, which can affect bone mineral density not only in Chinese Han but also likely in other populations.] Question: Based on the provided context, do the terms [CREB protein] and [P300 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between CREB protein and P300 protein. While both proteins are involved in pathways related to osteoblast differentiation and bone mineral density, there is no specific interaction described between them. Instead, the context focuses on the role of brain-derived neurotrophic factor (BDNF) in regulating CREB expression and its impact on osteoblast differentiation through the MAPK pathway. P300 is mentioned in the context of epigenetic modifications and histone binding, but not in relation to CREB. Therefore, based on the provided information, there is no evidence of a direct interaction between CREB protein and P300 protein.</s>
149456 2A2740476 2A2747114	PSMC2	PSMG2	[INST]Context: [PMID: 32366381 NFE2L1 and NFE2L3 Complementarily Maintain Basal Proteasome Activity in Cancer Cells through CPEB3-Mediated Translational Repression. Proteasomes are protease complexes essential for cellular homeostasis, and their activity is crucial for cancer cell growth. However, the mechanism of how proteasome activity is maintained in cancer cells has remained unclear. The CNC family transcription factor NFE2L1 induces the expression of almost all proteasome-related genes under proteasome inhibition. Both NFE2L1 and its phylogenetically closest homolog, NFE2L3, are highly expressed in several types of cancer, such as colorectal cancer. Here, we demonstrate that NFE2L1 and NFE2L3 complementarily maintain basal proteasome activity in cancer cells. Double knockdown of NFE2L1 and NFE2L3 impaired basal proteasome activity in cancer cells and cancer cell resistance to a proteasome inhibitor anticancer drug, bortezomib, by significantly reducing the basal expression of seven proteasome-related genes: PSMB3, PSMB7, PSMC2, PSMD3, PSMG2, PSMG3, and POMP Interestingly, the molecular basis behind these cellular consequences was that NFE2L3 repressed NFE2L1 translation by the induction of the gene encoding the translational regulator CPEB3, which binds to the NFE2L1 3' untranslated region and decreases polysome formation on NFE2L1 mRNA. Consistent results were obtained from clinical analysis, wherein patients with cancer having tumors expressing higher levels of CPEB3/NFE2L3 exhibit poor prognosis. These results provide the novel regulatory mechanism of basal proteasome activity in cancer cells through an NFE2L3-CPEB3-NFE2L1 translational repression axis.] Question: Based on the provided context, do the terms [PSMC2 protein] and [PSMG2 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the PSMC2 protein and the PSMG2 protein. Instead, it focuses on the complementary roles of NFE2L1 and NFE2L3 in maintaining basal proteasome activity through the regulation of seven proteasome-related genes, including PSMC2 and PSMG2. The context describes how NFE2L3 represses NFE2L1 translation and how this affects the expression of these genes, but it does not indicate any direct interaction between PSMC2 and PSMG2 proteins.</s>
306233 2A2459929 2A2642346	Cdkn1a	TRPML1	[INST]Context: [PMID: 35095492 Molecular Mechanisms of Epileptic Encephalopathy Caused by KCNMA1 Loss-of-Function Mutations. The gene kcnma1 encodes the alpha-subunit of high-conductance calcium- and voltage-dependent K+ (BK) potassium channel. With the development of generation gene sequencing technology, many KCNMA1 mutants have been identified and are more closely related to generalized epilepsy and paroxysmal dyskinesia. Here, we performed a genetic screen of 26 patients with febrile seizures and identified a novel mutation of KCNMA1 (E155Q). Electrophysiological characterization of different KCNMA1 mutants in HEK 293T cells, the previously-reported R458T and E884K variants (not yet determined), as well as the newly-found E155Q variant, revealed that the current density amplitude of all the above variants was significantly smaller than that of the wild-type channel. Moreover, the beta4 subunit slowed down the activation of the E155Q mutant. Then, we used kcnma1 knockout (BK KO) mice as the overall animal model of loss-of-function mutants. It was found that BK KO mice had spontaneous epilepsy, motor impairment, autophagic dysfunction, abnormal electroencephalogram (EEG) signals, as well as possible anxiety and cognitive impairment. In addition, we performed transcriptomic analysis on the hippocampus and cortex of BK KO and wild-type mice. Eight dysregulated genes [i.e., (Gfap and Grm3 associated with astrocyte activation) (Alpl and Nlrp10 associated with neuroinflammation) (Efna5 and Reln associated with epilepsy) (Cdkn1a and Nr4a1 associated with autophagy)] were validated by RT-PCR, which showed a high concordance with transcriptomic analysis. Calcium imaging results suggested that BK might regulate the autophagy pathway from TRPML1. In conclusion, our study indicated that newly-found point E155Q resulted in a novel loss-of-function variant and the dysregulation of gene expression, especially astrocyte activation, neuroinflammation and autophagy, might be the molecular mechanism of BK-loss-of-function meditated epilepsy.] Question: Based on the provided context, do the terms [Cdkn1a protein] and [TRPML1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention a direct interaction between the Cdkn1a protein and the TRPML1 protein. While both proteins are involved in the autophagy pathway and are dysregulated in BK-loss-of-function mediated epilepsy, there is no specific evidence or statement indicating that they interact with each other. Instead, they are presented as separate entities involved in the broader molecular mechanisms of epilepsy.</s>
148269 2A2548823 2A2548822	GB1	GB2	[INST]Context: [PMID: 32555460 Structural basis of the activation of a metabotropic GABA receptor. Metabotropic gamma-aminobutyric acid receptors (GABAB) are involved in the modulation of synaptic responses in the central nervous system and have been implicated in neuropsychological conditions that range from addiction to psychosis1. GABAB belongs to class C of the G-protein-coupled receptors, and its functional entity comprises an obligate heterodimer that is composed of the GB1 and GB2 subunits2. Here we present four cryo-electron microscopy structures of the human full-length GB1-GB2 heterodimer: one structure of its inactive apo state, two intermediate agonist-bound forms and an active form in which the heterodimer is bound to an agonist and a positive allosteric modulator. Our results show that agonist binding leads to the closure of the Venus flytrap domain of GB1, triggering a series of transitions, first rearranging and bringing the two transmembrane domains into close contact along transmembrane helix 6 and ultimately inducing conformational rearrangements in the GB2 transmembrane domain via a lever-like mechanism to initiate downstream signalling. This active state is stabilized by a positive allosteric modulator binding at the transmembrane dimerization interface.] Question: Based on the provided context, do the terms [GB1 protein] and [GB2 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context clearly indicates that the GB1 and GB2 proteins interact with each other to form a functional heterodimer. The text describes how agonist binding to GB1 triggers a series of conformational changes that involve both GB1 and GB2, ultimately leading to the activation of the receptor. This indicates a direct interaction between the GB1 and GB2 proteins in the formation and activation of the metabotropic GABA receptor.</s>
218856 2A2791395 2A2790558	L22	L21	[INST]Context: [PMID: 11551941 Peptide sequence information was used to search the human EST data bases and complete coding sequences were assembled. The human mitochondrial 39 S subunit has 48 distinct proteins. Twenty eight of these are homologs of the Escherichia coli 50 S ribosomal proteins L1, L2, L3, L4, L7/L12, L9, L10, L11, L13, L14, L15, L16, L17, L18, L19, L20, L21, L22, L23, L24, L27, L28, L30, L32, L33, L34, L35, and L36. Almost all of these proteins have homologs in Drosophila melanogaster, Caenorhabditis elegans, and Saccharomyces cerevisiae mitochondrial ribosomes. No mitochondrial homologs to prokaryotic ribosomal proteins L5, L6, L25, L29, and L31 could be found either in the peptides obtained or by analysis of the available data bases. Ten of the 20 mitochondrial specific 39 S proteins have homologs in S. cerevisiae. Homologs of 2 of these new classes of ribosomal proteins could be identified in the Arabidopsis thaliana genome. From MeSH: Cattle.] Question: Based on the provided context, do the terms [L22 protein] and [L21 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the homologs of various ribosomal proteins in different organisms, including the human mitochondrial 39S subunit. It mentions the presence of homologs for ribosomal proteins L1 to L36, but it does not provide any information about direct interactions between specific ribosomal proteins such as L22 and L21. Therefore, based on the given context, there is no evidence to suggest that L22 protein and L21 protein interact with each other.</s>
701405 2A2462506 2A2592309	HSP10	HSP25	[INST]Context: [PMID: 30114749 Di (2-ethyl hexyl) phthalate (DEHP)-induced kidney injury in quail (Coturnix japonica) via inhibiting HSF1/HSF3-dependent heat shock response. Di (2-ethyl hexyl) phthalate (DEHP) as a plasticizer can leach away from the plastic and hence entrances into the animal food chain which caused serious hazard in organs of animals, but there are few studies on DEHP kidney toxicity. To investigate the influence on kidney toxicity and the modulation of heat-shock response during DEHP exposure, female quail were fed the diet with 0, 250, 500 and 750__^mg/kg DEHP by gavage administration for 45 days. The shrinkages of glomeruli and dilation of kidney tubule epithelia cells were observed in the kidney of DEHP-exposed quail. DEHP treatment could significantly decrease the expressions of HSP25, HSP27, HSP47, HSP60, while the expressions of HSP10, HSP40, HSP70, HSP90, HSP110 were upregulated in the kidney. In addition, the expression levels of HSF1 and HSF3 were significantly increased under DEHP. This is the first study to demonstrate quail exposure to DEHP is in fact detrimental to bird kidney. Besides, DEHP could attack heat-shock response by affecting the synthesis of HSFs to mediate the transcription of the HSPs resulting in kidney damage.] Question: Based on the provided context, do the terms [HSP10 protein] and [HSP25 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not indicate a direct interaction between HSP10 protein and HSP25 protein. Instead, it describes the effects of DEHP exposure on the expression levels of various heat shock proteins (HSPs) in the kidney of quail. While it mentions that the expression levels of HSP10 and HSP25 are affected by DEHP, it does not suggest that these two proteins interact with each other. The context focuses on the overall modulation of the heat-shock response by DEHP rather than specific interactions between individual HSPs.</s>
668902 2A2652496 2A2652473	p38alpha	c-Jun N-terminal kinase 2	[INST]Context: [PMID: 22664133 Differential regulation of mitogen-activated protein kinase signaling pathways in human with different types of mitral valvular disease. BACKGROUND: Mitogen-activated protein kinases are considered to play a prominent role in cardiac development, function, and pathogenesis. The different types of mitral valvular disease, including mitral regurgitation and mitral stenosis, have different underlying pathophysiologic changes, but the precise intracellular signal transduction mechanisms are not clear. Thus, we investigated the differential regulation of MAPK signaling pathways in humans with different types of mitral valvular disease. METHODS: Left atrial appendage tissue samples from 32 patients with mitral valvular disease who were undergoing mitral valve replacement surgery were studied. Serum angiotensin II concentrations were measured using enzyme-linked immunosorbent assay. The expression of MAPK pathway-related genes and proteins was assessed using quantitative polymerase chain reaction, Western blot, and immunohistochemistry. RESULTS: Echocardiography showed that patients with mitral stenosis had a greater left atrial pressure overload than those with mitral regurgitation. The relative amounts of angiotensin II, extracellular signal-regulated kinase 1, p38alpha, c-Jun N-terminal kinase 2, c-Fos, activating transcription factor 2, and c-Jun mRNA were significantly upregulated in those with mitral stenosis compared with those with mitral regurgitation (P < 0.05). The serum angiotensin II concentrations were significantly increased in those with mitral stenosis compared with those with mitral regurgitation (P = 0.017). Substantial changes in the phosphorylated forms of the MAPK proteins were detected. Phosphorylated extracellular signal-regulated kinase 1/2, and phosphorylated p38 were significantly increased in those with mitral stenosis compared with those with mitral regurgitation (P < 0.001), and phosphorylated c-Jun N-terminal kinase in the mitral regurgitation group was significantly greater than that in the mitral stenosis group (P < 0.001). Histologically, more serious myocardial cells losses, myolysis, and interstitial fibrosis were detected in the mitral stenosis group. CONCLUSIONS: The different types of mitral valvular disease have different hemodynamic characteristics, and different MAPK pathways were activated in the mitral regurgitation and mitral stenosis groups, which could lead to diverse left atrial histologic changes.] Question: Based on the provided context, do the terms [p38alpha protein] and [c-Jun N-terminal kinase 2 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the differential regulation of MAPK signaling pathways in humans with different types of mitral valvular disease, including the upregulation of various MAPK pathway-related genes and proteins. While it mentions the increased expression and phosphorylation of p38alpha and c-Jun N-terminal kinase 2 (JNK2) in different groups, it does not indicate a direct interaction between the p38alpha protein and the c-Jun N-terminal kinase 2 protein. Instead, it describes their individual roles in the different types of mitral valvular disease. Therefore, there is no evidence of a direct interaction between these two proteins based on the given context.</s>
537862 2A2613459 2A2543353	KCNQ2	FOXG1	[INST]Context: [PMID: 27734276 An early-onset epileptic encephalopathy gene panel including sixteen genes (ARX, CDKL5, CNTNAP2, FOLR1, FOXG1, LAMC3, MBD5, MECP2, NTNG1, PCDH19, PNKP, SCN1A, SCN1B, SCN2A, STXBP1, KCNQ2) was constituted. Five mutations had been previously detected (SCN1A c.842C > T (p.P281L), SCN1A c.4907G > C (p.A1636P), PCDH19 c.1091dupC (p.Y366LfsX10), CNTNAP2 c.416A > G (p.N139S), MBD5 c.3595G > A(p.Y1199R) while other seven were novel (SCN1A c.4907G > C (p.A1636P), SCN2A c.4633A > G (p.M1545 V), CDKL5 c.197_198delCT (p.L67QfsX23), FOXG1 c.*6C > T, KCNQ2 c.560c > A (p.S187Y), KCNQ2 c.835G > A (p.G279S), STXBP1 c.1105G > T (p.E369X)). While the overall mutation detection rate was found 40 %, this ratio was 55.5 % (10 out of 18) and 16.6 % (2 out of 12) in patients born to nonconsanguineous parents and consanguineous parents, respectively. In conclusion, a selected gene panel approach including mainly de novo and channel-encoding genes will result in the detection of variants in isolated patients and support the channelopathy theory underlying epilepsy, while consanguineous families will remain less diagnosed.] Question: Based on the provided context, do the terms [KCNQ2 protein] and [FOXG1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the KCNQ2 protein and the FOXG1 protein. The context discusses the detection of mutations in various genes, including KCNQ2 and FOXG1, but it does not describe any interaction between the proteins encoded by these genes. Therefore, based on the given information, there is no evidence to suggest that the KCNQ2 protein and the FOXG1 protein interact with each other.</s>
76994 2A2552838 2A2860488	GBP2	SERPINH1	[INST]Context: [PMID: 30153702 Molecular pathogenesis of renal cell carcinoma: Impact of the anti-tumor miR-29 family on gene regulation. OBJECTIVES: To identify key oncogenes and proteins that are controlled by the microRNA miR-29 family (miR-29a, miR-29b and miR-29c) in renal cell carcinoma pathogenesis. The Cancer Genome Atlas database was used to investigate the clinical significance of gene expression data in renal cell carcinoma patients. RESULTS: We identified 47 possible target genes that might be regulated by the miR-29 family in renal cell carcinoma cells. Among the targets of the miR-29 family, high expression of 10 genes (ADAMTS14, TRIB13, SERPINH1, FCGR1B, COL1A1, LAIR2, WISP2, TREM1, TNKS1BP1 and GBP2) significantly predicted poor patient prognosis (P < 0.001). SERPINH1 was directly regulated by the miR-29 family, and its overexpression was detected in renal cell carcinoma surgical specimens and tyrosine kinase inhibitor failure autopsy specimens. High expression of SERPINH1 was significantly associated with tumor stage, pathological grade and poor prognosis (P < 0.0001).] Question: Based on the provided context, do the terms [GBP2 protein] and [SERPINH1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the GBP2 protein and the SERPINH1 protein. Instead, it discusses the roles of these proteins in renal cell carcinoma pathogenesis and their regulation by the miR-29 family. While both proteins are identified as targets of the miR-29 family, there is no indication that they interact with each other directly. The context focuses on their individual roles and their association with patient prognosis rather than any interaction between the two proteins.</s>
390131 2A2532268 2A2400850	heart-type fatty acid-binding protein	fatty acid-binding protein	[INST]Context: [PMID: 24817549 Prognostic impact of the serum heart-type fatty acid-binding protein levels in patients admitted to the non-surgical intensive care unit. BACKGROUND: Biomarkers predicting adverse outcomes in non-surgical intensive care patients have not been reported. METHODS AND RESULTS: Data for 1,006 emergency department patients were prospectively analyzed. The serum heart-type fatty acid-binding protein level was measured within 10 min of admission. The patients were assigned to intensive care (n = 835) or other departments (n = 171). The intensive care patients were divided into survivors (n = 745) and non-survivors (n = 90) according to the in-hospital mortality and assigned to four groups according to the quartiles of s-heart-type fatty acid-binding protein (Q1, Q2, Q3 and Q4). The s-heart-type fatty acid-binding protein levels were significantly higher in the intensive care patients (12.7 [6.1-38.8] ng/ml versus 5.3 [3.1-9.4] ng/ml) and in the non-survivors (44.9 [23.2-87.6] ng/ml versus 11.5 [5.6-32.6] ng/ml). The sensitivity and specificity of heart-type fatty acid-binding protein for in-hospital mortality were 81.1 and 66.0 % (AUC 0.775) at 20.95 ng/ml. The in-hospitality rate was significantly higher in the high s-heart-type fatty acid-binding protein patients than in the low serum heart-type fatty acid-binding protein patients in each etiology group. CONCLUSIONS: The s-heart-type fatty acid-binding protein level is an effective biomarker for risk stratification in non-surgical intensive care patients.] Question: Based on the provided context, do the terms [heart-type fatty acid-binding protein protein] and [fatty acid-binding protein protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The terms heart-type fatty acid-binding protein" and "fatty acid-binding protein" are not interacting with each other in the provided context. The context discusses the role of serum heart-type fatty acid-binding protein as a biomarker for predicting adverse outcomes in non-surgical intensive care patients. There is no mention of an interaction between "heart-type fatty acid-binding protein" and "fatty acid-binding protein" in the text. Instead, the focus is on the specific role of heart-type fatty acid-binding protein in this context.</s>"
365809 2A2592211 2A2546280	heat shock cognate 71 kDa protein	far upstream element-binding protein 1	[INST]Context: [PMID: 17244485 Proteomic analysis of the aging-related proteins in human normal colon epithelial tissue. In order to screen the aging related proteins in human normal colon epithelia, the comparative proteomics analysis was applied to get the two-dimensional electrophoresis (2-DE) profiles with high resolution and reproducibility from normal colon epithelial tissues of young and aged people. Among them there are sixteen proteins which are significantly up-regulated in the colonic mucosal epithelia of young people group, which include ATP synthase beta chain, electron transfer flavoprotein alpha-subunit, catalase, glutathione peroxidase 1, annexin A2 and heat shock cognate 71 kDa protein, etc.; There are nineteen proteins which are significantly up-regulated in the colonic mucosal epithelia of aged people group, which include far upstream element-binding protein 1, nucleoside diphosphate kinase B, protein disulfide-isomerase precursor and VDAC-2, etc.. The identified differential proteins appear to be involved in metabolism, energy generation, chaperone, antioxidation, signal transduction, protein folding and apoptosis. The data will help to understand the molecular mechanisms of human colon epithelial aging.] Question: Based on the provided context, do the terms [heat shock cognate 71 kDa protein protein] and [far upstream element-binding protein 1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between heat shock cognate 71 kDa protein and far upstream element-binding protein 1. Instead, it lists these proteins as part of different groups of proteins that are significantly up-regulated in the colonic mucosal epithelia of young and aged people, respectively. There is no indication that these two proteins interact with each other in the context of the aging process in human colon epithelial tissue.</s>
247193 2A2440486 2A2537221	beta-2-microglobulin	alpha-fetoprotein	[INST]Context: [PMID: 7967894 [Primary testicular lymphoma. The cases of three patients with primary testicular lymphoma, Ann Arbor IAE stage with the ages of 74, 72 and 60 years are presented. Histologic results demonstrated 2 cases of intermediate grade of malignancy and 1 of low grade. Immunohistochemical analysis for epithelial antigens was negative and the measurement of the serum levels of alpha-fetoprotein and beta-HCG was normal. LDH and beta-2-microglobulin were also normal. Chemotherapy was performed and the three patients remain alive and free of disease at 65, 32 and 19 months following diagnosis.] Question: Based on the provided context, do the terms [beta-2-microglobulin protein] and [alpha-fetoprotein protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not indicate any direct interaction between beta-2-microglobulin protein and alpha-fetoprotein protein. Instead, it mentions the measurement of serum levels of both proteins as part of the diagnostic process for primary testicular lymphoma. The context does not suggest that these proteins interact with each other or have a combined effect on the disease. They are presented as separate entities whose levels are measured independently.</s>
669806 2A2439551 2A2677936	Ipl1	Ndc80	[INST]Context: [PMID: 23275890 Suppressors of ipl1-2 in components of a Glc7 phosphatase complex, Cdc48 AAA ATPase, TORC1, and the kinetochore. Ipl1/Aurora B is the catalytic subunit of a protein kinase complex required for chromosome segregation and nuclear division. Before anaphase, Ipl1 is required to establish proper kinetochore-microtubule associations and to regulate the spindle assembly checkpoint . The phosphatase Glc7/PP1 opposes Ipl1 for these activities. To investigate Ipl1 and Glc7 regulation in more detail, we isolated and characterized mutations in the yeast Saccharomyces cerevisiae that raise the restrictive temperature of the ipl-2 mutant. These suppressors include three intragenic, second-site revertants in IPL1; 17 mutations in Glc7 phosphatase components (GLC7, SDS22, YPI1); Two mutations in SHP1, encoding a regulator of the AAA ATPase Cdc48; And a mutation in TCO89, encoding a subunit of the TOR Complex 1. Two revertants contain missense mutations in microtubule binding components of the kinetochore. rev76 contains the missense mutation duo1-S115F, which alters an essential component of the DAM1/DASH complex. The mutant is cold sensitive and arrests in G2/M due to activation of the spindle assembly checkpoint. rev8 contains the missense mutation ndc80-K204E. K204 of Ndc80 corresponds to K166 of human Ndc80 and the human Ndc80 K166E variant was previously shown to be defective for microtubule binding in vitro. In a wild-type IPL1 background, ndc80-K204E cells grow slowly and the spindle assembly checkpoint is activated. The slow growth and cell cycle delay of ndc80-K204E cells are partially alleviated by the ipl1-2 mutation. These data provide biological confirmation of a biochemically based model for the effect of phosphorylation on Ndc80 function. Saccharomyces cerevisiae.] Question: Based on the provided context, do the terms [Ipl1 protein] and [Ndc80 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that Ipl1 and Ndc80 proteins interact with each other. Specifically, it mentions that the Ipl1 protein is required for proper kinetochore-microtubule associations and that mutations in Ndc80 (specifically, the ndc80-K204E mutation) affect microtubule binding and spindle assembly checkpoint activation. This suggests that Ipl1 and Ndc80 are part of the same regulatory pathway and interact to ensure proper chromosome segregation and nuclear division.</s>
362904 2A2520685 2A2459289	Epidermal Growth Factor Receptor	CDC42	[INST]Context: [PMID: 31465839 Downregulation of Epidermal Growth Factor Receptor in hepatocellular carcinoma facilitates Transforming Growth Factor-beta-induced epithelial to amoeboid transition. The Epidermal Growth Factor Receptor and the Transforming Growth Factor-beta are key regulators of hepatocarcinogenesis. Targeting epidermal growth factor receptor was proposed as a promising therapy; However, poor success was obtained in human hepatocellular carcinoma clinical trials. Here, we describe how epidermal growth factor receptor is frequently downregulated in hepatocellular carcinoma patients while transforming growth factor-beta is upregulated. Using 2D/3D cellular models, we show that after epidermal growth factor receptor loss, transforming growth factor-beta is more efficient in its pro-migratory and invasive effects, inducing epithelial to amoeboid transition. Epidermal growth factor receptor knock-down promotes loss of cell-cell and cell-to-matrix adhesion, favouring TGF-beta-induced actomyosin contractility and acquisition of an amoeboid migratory phenotype. Moreover, transforming growth factor-beta upregulates RHOC and CDC42 after epidermal growth factor receptor silencing, promoting Myosin II in amoeboid cells. Importantly, low epidermal growth factor receptor combined with high TGFB1 or RHOC/CDC42 levels confer poor patient prognosis. In conclusion, this work reveals a new tumour suppressor function for epidermal growth factor receptor counteracting TGF-beta-mediated epithelial to amoeboid transitions in hepatocellular carcinoma, supporting a rational for targeting the transforming growth factor-beta pathway in patients with low epidermal growth factor receptor expression. Our work also highlights the relevance of epithelial to amoeboid transition in human tumours and the need to better target this process in the clinic.] Question: Based on the provided context, do the terms [Epidermal Growth Factor Receptor protein] and [CDC42 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not indicate a direct interaction between the Epidermal Growth Factor Receptor protein and the CDC42 protein. Instead, it describes how the downregulation of Epidermal Growth Factor Receptor facilitates the upregulation of CDC42 by Transforming Growth Factor-beta (TGF-beta) in hepatocellular carcinoma. This suggests that the interaction is mediated through TGF-beta, rather than a direct interaction between Epidermal Growth Factor Receptor and CDC42.</s>
639346 2A2817006 2A2485737	HNRNPA0	CUX1	[INST]Context: [PMID: 35341343 (Genome-wide Association Studies) GWAS have identified ___42 late-onset Alzheimer's disease -associated loci, each of which contains multiple single nucleotide polymorphisms in linkage disequilibrium and most of these single nucleotide polymorphisms are in the non-coding region of human genome. As a proof of evidence, we verified the allele-specific binding of GATA2 and GATA3, ELAVL1 and HNRNPA0, ILF2 and ILF3, NFIB and NFIC, as well as CUX1 to these five functional snps, respectively. Moreover, we demonstrate that all these nine proteins regulate the expression of both HLA-DQA1 and HLA-DRB1 in human microglial cells.] Question: Based on the provided context, do the terms [HNRNPA0 protein] and [CUX1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context mentions that GATA2 and GATA3, ELAVL1 and HNRNPA0, ILF2 and ILF3, NFIB and NFIC, as well as CUX1 bind to specific single nucleotide polymorphisms (SNPs). However, there is no direct mention or evidence of an interaction between the HNRNPA0 protein and the CUX1 protein. The context describes the binding of these proteins to different SNPs and their regulatory roles in gene expression, but it does not indicate any interaction between HNRNPA0 and CUX1.</s>
275003 2A2773804 2A2677936	RACGAP1	NDC80	[INST]Context: [PMID: 27022301 Research is beginning to suggest that the presence and/or severity of symptoms reported by breast cancer survivors may be associated with disease-related factors of cancer. Cognitive dysfunction is utilized as a representative breast cancer survivor symptom to elucidate the conceptualization of and justification for our cellular, disease-based approach to address symptom variability in cancer survivors. Initial candidate gene identification was based on genes evaluated as part of multigene expression profiles for breast cancer, which are commonly used in the clinical setting to characterize the biology of cancer cells for the purpose of describing overall tumor aggressiveness, prognostication, and individualization of therapy. A list of genes evaluated within five multigene expression profiles for breast cancer was compiled. Twenty-one genes (BAG1, BCL2, BIRC5, CCNB1, CENPA, CMC2, DIAPH3, ERBB2, ESR1, GRB7, MELK, MKI67, MMP11, MYBL2, NDC80, ORC6, PGR, RACGAP1, RFC4, RRM2, and SCUBE2) are utilized in two or more profiles, including five genes (CCNB1, CENPA, MELK, MYBL2, and ORC6) used in three profiles. To ensure that the parsimonious 21 gene set is representative of the more global biological hallmarks of cancer, an Ingenuity Pathway Analysis was conducted. Evaluation of genes known to impact pathways involved with cancer development and progression provide a means to evaluate the overlap between the biological underpinnings of cancer and symptom development within the context of cancer.] Question: Based on the provided context, do the terms [RACGAP1 protein] and [NDC80 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the RACGAP1 protein and the NDC80 protein. The context discusses the use of genes in multigene expression profiles for breast cancer and their association with symptom development in breast cancer survivors. However, it does not provide any specific information about an interaction between RACGAP1 and NDC80 proteins. Therefore, based on the given information, there is no evidence to suggest that these two proteins interact with each other.</s>
668708 2A2652496 2A2498551	MAPK14	DDX24	[INST]Context: [PMID: 30836997 Inflammatory, regulatory, and autophagy co-expression modules and hub genes underlie the peripheral immune response to human intracerebral hemorrhage. BACKGROUND: Intracerebral hemorrhage has a high morbidity and mortality. Thus, we delineated the gene networks associated with human intracerebral hemorrhage in the peripheral blood transcriptome. We also compared the differentially expressed genes in blood following intracerebral hemorrhage to a prior human study of perihematomal brain tissue. METHODS: We performed peripheral blood whole-transcriptome analysis of intracerebral hemorrhage and matched vascular risk factor control subjects (n___=___66). Gene co-expression network analysis identified groups of co-expressed genes (modules) associated with intracerebral hemorrhage and their most interconnected genes (hubs). Mixed-effects regression identified differentially expressed genes in intracerebral hemorrhage compared to controls. RESULTS: Of seven ICH-associated modules, six were enriched with cell-specific genes: one neutrophil module, one neutrophil plus monocyte module, one T cell module, one Natural Killer cell module, and two erythroblast modules. And the Natural Killer cell module in genes regulating alternative splicing, epigenetic, and post-translational modifications. One erythroblast module was enriched in autophagy pathways implicated in experimental intracerebral hemorrhage, and NRF2 signaling implicated in hematoma clearance. Many hub genes or module members, such as IARS, mTOR, S1PR1, LCK, FYN, SKAP1, ITK, AMBRA1, NLRC4, IL6R, IL17RA, GAB2, MXD1, PIK3CD, NUMB, MAPK14, DDX24, EVL, TDP1, ATG3, WDFY3, GSK3B, STAT3, STX3, CSF3R, PIP4K2A, ANXA3, DGAT2, LRP10, FLOT2, ANK1, CR1, SLC4A1, and DYSF, have been implicated in neuroinflammation, cell death, transcriptional regulation, and some as experimental intracerebral hemorrhage therapeutic targets. Gene-level analysis revealed 1225 genes (FDR p___<___0.05, fold-change > |1.2|) have altered expression in intracerebral hemorrhage in peripheral blood. There was significant overlap of the 1225 genes with dysregulated genes in human perihematomal brain tissue (p___=___7________10-3). Overlapping genes were enriched for neutrophil-specific genes (p___=___6.4________10-08) involved in interleukin, neuroinflammation, apoptosis, and PPAR signaling. CONCLUSIONS: This study delineates key processes underlying intracerebral hemorrhage pathophysiology, complements experimental intracerebral hemorrhage findings, and the hub genes significantly expand the list of novel intracerebral hemorrhage therapeutic targets. The overlap between blood and brain gene responses underscores the importance of examining blood-brain interactions in human intracerebral hemorrhage.] Question: Based on the provided context, do the terms [MAPK14 protein] and [DDX24 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context lists MAPK14 protein and DDX24 protein among the hub genes or module members implicated in neuroinflammation, cell death, transcriptional regulation, and some as experimental intracerebral hemorrhage therapeutic targets. However, there is no direct mention or evidence of an interaction between MAPK14 protein and DDX24 protein. They are listed as part of a broader set of genes involved in various processes related to intracerebral hemorrhage, but no specific interaction between these two proteins is described.</s>
600496 2A2461061 2A2764262	ITGB3BP	RASA4	[INST]Context: [PMID: 22674380 P-glycoprotein (ABCB1) inhibited network of mitochondrion transport along microtubule and BMP signal-induced cell shape in chimpanzee left cerebrum by systems-theoretical analysis. We constructed the significant low-expression P-glycoprotein (ABCB1) inhibited transport and signal network in chimpanzee compared with high-expression (fold change ___2) the human left cerebrum in GEO data set, by using integration of gene regulatory activated and inhibited network inference method with gene ontology analysis. Our result showed that ABCB1 transport and signal upstream network RAB2A inhibited ABCB1, and downstream ABCB1-inhibited SMAD1_2, NCK2, SLC25A46, GDF10, RASGRP1, EGFR, LRPPRC, RASSF2, RASA4, CA2, CBLB, UBR5, SLC25A16, ITGB3BP, DDIT4, PDPN, RAB2A in chimpanzee left cerebrum. We obtained that the different biological processes of ABCB1 inhibited transport and signal network repressed carbon dioxide transport, ER to Golgi vesicle-mediated transport, folic acid transport, mitochondrion transport along microtubule, water transport, BMP signaling pathway, Ras protein signal transduction, transforming growth factor beta receptor signaling pathway in chimpanzee compared with the inhibited network of the human left cerebrum, as a result of inducing inhibition of mitochondrion transport along microtubule and BMP signal-induced cell shape in chimpanzee left cerebrum. Our hypothesis was verified by the same and different biological processes of ABCB1 inhibited transport and signal network of chimpanzee compared with the corresponding activated network of chimpanzee and the human left cerebrum, respectively. Pan troglodytes.] Question: Based on the provided context, do the terms [ITGB3BP protein] and [RASA4 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between ITGB3BP protein and RASA4 protein. Instead, it lists these proteins as part of the ABCB1 inhibited transport and signal network in chimpanzee left cerebrum. The context describes the roles of these proteins within the network but does not indicate any specific interaction between ITGB3BP and RASA4.</s>
83623 2A2699755 2A2443736	dihydrolipoamide S-succinyltransferase	bridging integrator 1	[INST]Context: [PMID: 30983028 Association of multiple candidate genes with mild cognitive impairment in an elderly Chinese Uygur population in Xinjiang. BACKGROUND: Mild cognitive impairment is a high-risk factor for Alzheimer's disease . In the present study, we investigated the association of genetic polymorphisms of five genes (8-oxoguanine DNA glycosylase 1 (OGG1), bridging integrator 1, sortilin-related receptor 1, presenilin 2 and nerve growth factor ) with mild cognitive impairment risk in a Xinjiang Uygur population. We also tested the relationship between the promoter methylation of genes OGG1 and dihydrolipoamide S-succinyltransferase with mild cognitive impairment. METHODS: This study involved 43 mild cognitive impairment patients and 125 controls. DNA methylation assays used quantitative methylation-specific polymerase chain reaction. RESULTS: We found that polymorphisms of five genes and the methylation of dihydrolipoamide s-succinyltransferase and OGG1 genes were not associated with mild cognitive impairment (P___>___0.05). Further subgroup analysis found that dihydrolipoamide s-succinyltransferase hypomethylation was significantly associated with mild cognitive impairment in the carriers of apolipoprotein E epsilon4 (P___=___0.042). In the carriers of non-apolipoprotein e epsilon4, dihydrolipoamide s-succinyltransferase methylation levels were significantly lower in the male control group than in the female control group (p___=___0.04). Meanwhile, among the non-apolipoprotein e epsilon4 carriers younger than 75, OGG1 hypermethylation levels were significantly associated with mild cognitive impairment (P___=___0.049). Dihydrolipoamide s-succinyltransferase methylation in female controls was significantly lower than that in male controls (P___=___0.003). According to gender stratification, there was a significant positive correlation of fasting plasma glucose (FBG) and high-density lipoprotein with OGG1 methylation in the female controls (FBG: P___=___0.024; high-density lipoprotein: P___=___0.033). There was a significant inverse correlation between low-density lipoprotein and dihydrolipoamide s-succinyltransferase methylation in male mild cognitive impairment (P___=___0.033). There was a significant positive correlation between high-density lipoprotein and dihydrolipoamide s-succinyltransferase methylation levels in the female controls (P___=___0.000). CONCLUSIONS: This study was the first to discover that dihydrolipoamide s-succinyltransferase promoter methylation interacted with apolipoprotein e psilon4 and thus affected the pathogenesis of mild cognitive impairment. In addition, OGG1 promoter methylation interacted with several other factors to increase the risk of mild cognitive impairment.] Question: Based on the provided context, do the terms [dihydrolipoamide S-succinyltransferase protein] and [bridging integrator 1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the dihydrolipoamide S-succinyltransferase protein and the bridging integrator 1 protein. The study focuses on the association of genetic polymorphisms and methylation levels of various genes with mild cognitive impairment, but it does not describe any interaction between these two specific proteins. Therefore, based on the given information, there is no evidence to suggest that these two proteins interact with each other.</s>
441459 2A2703005 2A2457399	OPN	MCP3	[INST]Context: [PMID: 23410727 Effect of glucose ingestion in plasma markers of inflammation and oxidative stress: analysis of 16 plasma markers from oral glucose tolerance test samples of normal and diabetic patients. Sixteen plasma markers of inflammation and oxidative stress were measured during OGTT in 54 subjects. Leptin, RBP4, CRP, OPN, ANG, MDC, and MCSF concentrations significantly decreased during OGTT (P<0.05). IL6, IL8, and MCP3 concentrations significantly increased during OGTT (P<0.05). These results provide evidence that glucose ingestion affects systemic inflammation and oxidative stress.] Question: Based on the provided context, do the terms [OPN protein] and [MCP3 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the effects of glucose ingestion on various plasma markers of inflammation and oxidative stress, including OPN and MCP3. However, it does not mention any direct interaction between OPN protein and MCP3 protein. Instead, it describes how the concentrations of these proteins change independently during the oral glucose tolerance test (OGTT). Therefore, there is no evidence to suggest that OPN and MCP3 interact with each other based on the given information.</s>
362132 2A2454391 2A2480419	CTS-B	CRADD	[INST]Context: [PMID: 12218417 Transforming growth factor-beta1 plays a central role in the response of the brain to different types of injury. Increased transforming growth factor-beta1 has been found in the central nervous system of patients with acute or chronic disorders such as stroke or Alzheimer disease. To further define the molecular targets of transforming growth factor-beta1 in cerebral tissues, a selection of high-density cDNA arrays was used to characterize the mRNA expression profile of 7,000 genes in transgenic mice overexpressing transforming growth factor-beta1 from astrocytes as compared with the wild-type line. Selected findings were further evaluated by reverse transcription-polymerase chain reactions from independent transgenic and wild-type mice. Furthermore, the expression pattern of seven selected genes such as Delta-1, CRADD, PRSC-1, PAI-1, Apo-1/Fas, CTS-B, and TbetaR-II were confirmed in either cultured cortical neurons or astrocytes following transforming growth factor-beta1 treatment. Mice.] Question: Based on the provided context, do the terms [CTS-B protein] and [CRADD protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between CTS-B protein and CRADD protein. It lists these proteins as part of a selection of genes whose expression patterns were evaluated in transgenic mice overexpressing transforming growth factor-beta1. However, there is no specific information or evidence provided that indicates a direct interaction between CTS-B and CRADD proteins. Therefore, based on the given context, it can be concluded that these two proteins do not interact with each other.</s>
2429 2A2612324 2A2418243	TIP60	NOXA	[INST]Context: [PMID: 29174981 Acetylation of TIP60 at K104 is essential for metabolic stress-induced apoptosis in cells of hepatocellular cancer. Tumor cells often encounter hypoglycemic microenvironment due to rapid cell expansion. The tumor suppressor TIP60 functions as the catalytic subunit of the human NuA4 histone acetyltransferase multi-subunit complex and is involved in many different cellular processes including DNA damage response, cell growth and apoptosis. Attenuation of TIP60 expression has been detected in various tumor types. The function of TIP60 in tumor development has not been fully understood. Here we found that suppressing TIP60 inhibited p53 K120 acetylation and thus rescued apoptosis induced by glucose deprivation in hepatocellular cancer cells. Excitingly, Lys-104 (K104), a previously identified lysine acetylation site of TIP60 with unknown function, was observed to be indispensable for inducing p53-mediated apoptosis under low glucose condition. Mutation of Lys-104 to Arg (K104R) impeded the binding of TIP60 to human NuA4 complex, suppressed the acetyltransferase activity of TIP60, and inhibited the expression of pro-apoptotic genes including NOXA and PUMA upon glucose starvation. These findings demonstrate the critical regulation of TIP60/p53 pathway in apoptosis upon metabolic stress and provide a novel insight into the down-regulation of TIP60 in tumor cells.] Question: Based on the provided context, do the terms [TIP60 protein] and [NOXA protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context indicates that the acetylation of TIP60 at K104 is essential for metabolic stress-induced apoptosis in hepatocellular cancer cells. Specifically, it mentions that suppressing TIP60 inhibits p53 K120 acetylation and thus rescues apoptosis induced by glucose deprivation. Furthermore, it states that mutation of Lys-104 to Arg (K104R) impeded the binding of TIP60 to the human NuA4 complex, suppressed the acetyltransferase activity of TIP60, and inhibited the expression of pro-apoptotic genes including NOXA and PUMA upon glucose starvation. This suggests that TIP60 plays a role in regulating the expression of NOXA, indicating an interaction between the TIP60 protein and the NOXA protein.</s>
435810 2A2411597 2A2516455	ALDH2	EDN1	[INST]Context: [PMID: 34366936 Risk and Protective Factors of Lifetime Cocaine-Associated Chest Pain. Introduction: Cocaine users often present with repetitive events of cocaine-associated chest pain, clinically resembling acute coronary syndromes. The aim of the study is to describe the specific risk factors for cocaine-associated chest pain. Method: Cocaine users (n = 316) were recruited for a multicenter cross-sectional study. Lifetime cocaine-associated chest pain history, sociodemographic factors, and lifetime use of cocaine and other substances were assessed. Thirty single nucleotide polymorphisms of NOS3, ROCK2, EDN1, GUCY1A3, and ALDH2 genes, suggested by the literature on coronary spasms, were selected. The associations with cocaine-associated chest pain history were tested using the chi-square test, Student's t-test and logistic regression. Results: Among the 316 subjects [78.5% men, mean age 37.5 years, (standard-deviation +-8.7)], 190 (60.1%) were daily cocaine users and 103 (32.6%) reported a lifetime cocaine-associated chest pain history. Among those with a lifetime cocaine-associated chest pain history, the median was 10 events per individual. In multivariate analysis, lifetime cocaine-associated chest pain history was associated with daily cocaine use [odds-ratio (OR) 3.24; 95% confidence intervals (1.29-9.33)], rapid route of cocaine use [OR 2.33 (1.20-4.64) vs. intranasal use], and lifetime amphetamine use [daily amphetamine use: OR 2.80 (1.25-6.32) and non-daily amphetamine use: OR 2.14 (1.15-4.04) vs. never used]. Patients with lifetime opioid maintenance treatment reported significantly less lifetime cocaine-associated chest pain history [OR 0.35 (0.16-0.76)]. None of the selected single nucleotide polymorphisms was associated with cocaine-associated chest pain history after multiple testing corrections. Conclusions: Clinical variables describing the intensity of stimulant use were positively associated with lifetime cocaine-associated chest pain history, while opioid maintenance treatment was negatively associated with it.] Question: Based on the provided context, do the terms [ALDH2 protein] and [EDN1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the ALDH2 protein and the EDN1 protein. The study focuses on the association of various risk factors, including genetic polymorphisms, with cocaine-associated chest pain history. While it discusses the role of several genes, including those encoding ALDH2 and EDN1, it does not describe any direct interaction between the proteins encoded by these genes. Therefore, based on the given information, there is no evidence to suggest that ALDH2 protein and EDN1 protein interact with each other.</s>
386343 2A2907654 2A2856131	TPI	syntenin-1	[INST]Context: [PMID: 24011924 High glucose-induced proteome alterations in hepatocytes and its possible relevance to diabetic liver disease. Hyperglycemia can cause several abnormalities in liver cells, including diabetic liver disease. Previous research has shown that high blood glucose levels can damage liver cells through glycoxidation. However, the detailed molecular mechanisms underlying the effects of high blood glucose on the development of diabetic liver disease have yet to be elucidated. In this study, we cultured a liver cell line (Chang liver cell) in mannitol-balanced 5.5 mM, 25 mM and 100 mM d-glucose media and evaluated protein expression and redox regulation. We identified 141 proteins that showed significant changes in protein expression and 29 proteins that showed significant changes in thiol reactivity, in response to high glucose concentration. Several proteins involved in transcription-control, signal transduction, redox regulation and cytoskeleton regulation showed significant changes in expression, whereas proteins involved in protein folding and gene regulation displayed changes in thiol reactivity. Further analyses of clinical plasma specimens confirmed that the proteins AKAP8L, galectin-3, PGK 1, syntenin-1, Abin 2, aldose reductase, CD63, GRP-78, GST-pi, RXR-gamma, TPI and vimentin showed type 2 diabetic liver disease-dependent alterations. In summary, in this study we used a comprehensive hepatocyte-based proteomic approach to identify changes in protein expression and to identify redox-associated diabetic liver disease markers induced by high glucose concentration. Some of the identified proteins were validated with clinical samples and are presented as potential targets for the prognosis and diagnosis of diabetic liver disease.] Question: Based on the provided context, do the terms [TPI protein] and [syntenin-1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between TPI protein and syntenin-1 protein. It lists these proteins as part of the identified changes in protein expression and redox reactivity in response to high glucose concentration. However, there is no specific information or evidence provided that indicates a direct interaction between TPI protein and syntenin-1 protein. They are presented as separate entities that show changes in response to high glucose, but not as interacting partners.</s>
578904 2A2459951 2A2403882	CDKN2B	tyrosine kinase non-receptor 2	[INST]Context: [PMID: 29500766 Clinical and Genetic Implications of Mutation Burden in Squamous Cell Carcinoma of the Lung. BACKGROUND: Lung squamous cell carcinoma is a major histological subtype of lung cancer. In this study, we investigated genomic alterations in lung squamous cell carcinoma and evaluated the clinical implications of mutation burden in lung squamous cell carcinoma. METHODS: Genomic alterations were determined in Japanese patients with lung squamous cell carcinoma (N = 67) using next-generation sequencing of 415 known cancer genes. Programmed death-ligand 1 protein expression in cancer cells was evaluated by immunohistochemical analysis. RESULTS: TP53 gene mutations were the most common alteration (n = 51/67, 76.1%), followed by gene alterations in cyclin-dependent kinase inhibitor 2B (CDKN2B; 35.8%), CDKN2A (31.3%), phosphatase and tensin homolog (30.0%), and sex-determining region Y-box 2 (SOX2, 28.3%). Moreover, cancers in the upper or middle lobes had significantly higher mutation burden than cancers in the lower lobes (p = 0.0005), and tended to show higher programmed death-ligand 1 protein expression (p = 0.0573). SOX2 and tyrosine kinase non-receptor 2 amplifications were associated with high mutation burden (p = 0.0065 and p = 0.0010, respectively). CONCLUSIONS: The mutation burden level differed according to the tumor location in lung squamous cell carcinoma, suggesting that the location of cancer development may influence the genomic background of the tumor.] Question: Based on the provided context, do the terms [CDKN2B protein] and [tyrosine kinase non-receptor 2 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between CDKN2B protein and tyrosine kinase non-receptor 2 protein. Instead, it discusses the genomic alterations and mutation burden in lung squamous cell carcinoma, including the frequency of mutations in various genes such as TP53, CDKN2B, CDKN2A, phosphatase and tensin homolog (PTEN), and sex-determining region Y-box 2 (SOX2). The context also notes the association of SOX2 and tyrosine kinase non-receptor 2 amplifications with high mutation burden but does not indicate any direct interaction between CDKN2B protein and tyrosine kinase non-receptor 2 protein.</s>
649253 2A2574471 2A2850032	H2AX	Reptin	[INST]Context: [PMID: 25875766 Reptin regulates DNA double strand breaks repair in human hepatocellular carcinoma. Reptin/RUVBL2 is overexpressed in most hepatocellular carcinomas and is required for the growth and viability of HCC cells. Reptin is involved in several chromatin remodeling complexes, some of which are involved in the detection and repair of DNA damage, but data on Reptin involvement in the repair of DNA damage are scarce and contradictory. Our objective was to study the effects of Reptin silencing on the repair of DNA double-strand breaks in HCC cells. Treatment of HuH7 cells with etoposide (25 muM, 30 min) or gamma irradiation (4 Gy) increased the phosphorylation of H2AX by 1.94 _+- 0.13 and 2.0 _+- 0.02 fold, respectively. These values were significantly reduced by 35 and 65 % after Reptin silencing with inducible shRNA. Irradiation increased the number of BRCA1 (3-fold) and 53BP1 foci (7.5 fold). Depletion of Reptin reduced these values by 62 and 48%, respectively. These defects in activation and/or recruitment of repair proteins were not due to a decreased number of DSBs as measured by the COMET assay. All these results were confirmed in the Hep3B cell line. Protein expression of ATM and DNA-PKcs, the major H2AX kinases, was significantly reduced by 52 and 61 % after Reptin depletion whereas their mRNA level remained unchanged. Phosphorylation of Chk2, another ATM target, was not significantly altered. Using co-immunoprecipitation, we showed an interaction between Reptin and DNA-PKcs. The half-life of newly-synthesized DNA-PKcs was reduced when Reptin was silenced. Finally, depletion of Reptin was synergistic with etoposide or gamma irradiation to reduce cell growth and colony formation. In conclusion, Reptin is an important cofactor for the repair of DSBs. Our data, combined with those of the literature suggests that it operates at least in part by regulating the expression of DNA-PKcs by a stabilization mechanism. Overexpression of Reptin in HCC could be a factor of resistance to treatment, consistent with the observed overexpression of Reptin in subgroups of chemo-resistant breast and ovarian cancers.] Question: Based on the provided context, do the terms [H2AX protein] and [Reptin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the roles of Reptin and H2AX proteins in DNA double-strand breaks (DSBs) repair in hepatocellular carcinoma cells. While it mentions that Reptin silencing affects the phosphorylation of H2AX, it does not indicate a direct interaction between the H2AX protein and the Reptin protein. Instead, it describes how Reptin influences the repair process by affecting the phosphorylation of H2AX, which is a marker of DSBs. Therefore, the terms [H2AX protein] and [Reptin protein] are not interacting in a similar way to the interacting examples provided.</s>
296166 2A2679953 2A2459951	B12	CDKN2B	[INST]Context: [PMID: 32803503 Probing the epigenetic signatures in subjects with coronary artery disease. Depletion of S-adenosyl methionine and 5-methyltetrahydrofolate; And elevation of total plasma homocysteine were documented in CAD patients, which might modulate the gene-specific methylation status and alter their expression. ABCG1, LIPC, PLTP, IL-6, TNF-alpha, CDKN2A, CDKN2B, F2RL3, FGF2, P66 and TGFBR3. CAD patients showed the upregulation of IL-6, TNF-alpha, CDKN2A, CDKN2B, F2RL3, FGF2, P66, and TGFBR3. Hypomethylation of CDKN2A loci was shown to increase risk for CAD by 1.79-folds (95% CI 1.22-2.63). Folate and B12 deficiencies were observed in CAD cases, which were shown to contribute to hypomethylation and upregulation of the prime candidate genes i.e. CDKN2A and F2RL3. Early onset diabetes was associated with IL-6 and TNF-alpha hypomethylation and upregulation of CDKN2A. The expression of F2RL3 and IL-6 (or) hypomethylation status at CDKN2A locus are potential biomarkers in CAD risk prediction. Folate and B12 deficiencies are the contributing factors to these changes in CAD-specific epigenetic signatures.] Question: Based on the provided context, do the terms [B12 protein] and [CDKN2B protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the roles of B12 deficiency and CDKN2B protein in coronary artery disease (CAD) but does not indicate a direct interaction between B12 protein and CDKN2B protein. Instead, it describes how B12 deficiency contributes to hypomethylation and upregulation of certain genes, including CDKN2B, in the context of CAD. There is no mention of a direct interaction between B12 protein and CDKN2B protein.</s>
75563 2A2871962 2A2922637	SRSF5	UBB	[INST]Context: [PMID: 33142748 Genome-Wide Analysis of Prognostic Alternative Splicing Signature and Splicing Factors in Lung Adenocarcinoma. Analysis of The Cancer Genome Atlas data revealed that alternative splicing events could serve as prognostic biomarkers in various cancer types. This study examined lung adenocarcinoma tissues for alternative splicing and assessed alternative splicing events as potential indicators of prognosis in our cohort. We used SUPPA2 to analyze the alternative splicing profiles. Using univariate Cox regression analysis, overall survival -related alternative splicing events were identified. Genes relating to the OS-related alternative splicing events were imported into Cytoscape, and the CytoHubba application was run. OS-related splicing factors were explored using the log-rank test. The relationship between the percent spliced-in value of the OS-related alternative splicing events and SF expression was identified by Spearman correlation analysis. We found 1957 OS-related alternative splicing events in 1151 genes, and most were protective factors. Alternative first exon splicing was the most frequent type of splicing event. The hub genes in the gene network of the OS-related alternative splicing events were FBXW11, FBXL5, KCTD7, UBB and CDC27. The area under the curve of the MIX prediction model was 0.847 for 5-year survival based on seven OS-related alternative splicing events. Overexpression of splicing factors CELF2 and SRSF5 was associated with better overall survival. We constructed a correlation network between splicing factors and OS-related alternative splicing events. In conclusion, we identified prognostic predictors using alternative splicing events that stratified lung adenocarcinoma patients into high- and low-risk groups. The discovery of the splicing networks in this study provides an insight into the underlying mechanisms.] Question: Based on the provided context, do the terms [SRSF5 protein] and [UBB protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between SRSF5 protein and UBB protein. The study discusses the roles of various splicing factors and alternative splicing events in lung adenocarcinoma prognosis, but it does not indicate any specific interaction between SRSF5 and UBB proteins. Instead, it focuses on the individual roles of these proteins in the context of alternative splicing and overall survival.</s>
402689 2A2397481 2A2736893	serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform	peroxiredoxin 1	[INST]Context: [PMID: 34076143 Nicotine promotes the development of oral leukoplakia via regulating peroxiredoxin 1 and its binding proteins. Tobacco can induce reactive oxygen species production extensively in cells, which is a major risk factor for oral leukoplakia development. Peroxiredoxin 1 is a key antioxidant protein, upregulated in a variety of malignant tumors. We previously found that nicotine, the main ingredient of tobacco, promotes oral carcinogenesis via regulating peroxiredoxin 1. The aim of the present study was to screen and identify the peroxiredoxin 1 interacting proteins and investigate the mechanisms of nicotine on the development of oral leukoplakia. Through liquid chromatography-tandem mass spectrometry combined with bioinformatics analysis, the candidate peroxiredoxin 1 interacting proteins of cofilin-1, tropomyosin alpha-3 chain (TPM3), and serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform (PPP2R1A) were screened in human dysplastic oral keratinocyte cells treated with nicotine. Cofilin-1, TPM3, and PPP2R1A were highly expressed in human oral leukoplakia tissues. The expression of cofilin-1 increased and the expression of PPP2R1A decreased in oral leukoplakia of smokers compared to that in oral leukoplakia of non-smokers. Nicotine upregulated cofilin-1 and downregulated PPP2R1A in 4-nitro-quinoline-1-oxide -induced oral leukoplakia tissues in mice in part dependent on peroxiredoxin 1. Furthermore, the in-situ interaction of cofilin-1, TPM3, and PPP2R1A with peroxiredoxin 1 were validated in human oral leukoplakia tissues. Our results suggested that tobacco might promote the development of oral leukoplakia via regulating peroxiredoxin 1 and its interacting proteins cofilin-1 and PPP2R1A. From MeSH: Mice.] Question: Based on the provided context, do the terms [serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform protein] and [peroxiredoxin 1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that the serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform (PPP2R1A) was identified as a candidate peroxiredoxin 1 interacting protein through liquid chromatography-tandem mass spectrometry and bioinformatics analysis. Furthermore, the in-situ interaction of PPP2R1A with peroxiredoxin 1 was validated in human oral leukoplakia tissues. This suggests that the two proteins interact with each other.</s>
330604 2A2874891 2A2874893	SCLIP	SCG10	[INST]Context: [PMID: 12676564 Expression of stathmin family genes in human tissues: non-neural-restricted expression for SCLIP. The stathmin family consists of phosphoproteins highly conserved in vertebrates and thought to be implicated in the development and functional regulation of various organs, most notably the nervous system. This family includes stathmin, SCG10, SCLIP, and RB3, phosphoproteins that are related by structural and functional homologies. They all sequester tubulin and interfere with microtubule dynamics, a property due to their shared stathmin-like domain. Little is known about the expression of the stathmin gene family in humans. Herein, we describe for the first time, for a collection of human tissues, the expression of each member of this family, using real-time quantitative RT-PCR. We found that stathmin is ubiquitously expressed, whereas SCG10 and RB3 are neural enriched, expression patterns similar to those reported for other mammals. Surprisingly, SCLIP, whose expression is thought to be neural-specific, exhibits a broader tissue distribution. Analyses of the SCLIP gene (approved symbol STMN3) show that it contains several NRSE-like elements that display low or no affinity for the cognate binding protein NRSF. The substantial expression of SCLIP in most tissues points out a novel function for this protein outside the nervous system and raises the possibility that its coexpression with stathmin could provide some degree of functional redundancy.] Question: Based on the provided context, do the terms [SCLIP protein] and [SCG10 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context describes the expression patterns of various stathmin family genes in human tissues, including stathmin, SCG10, SCLIP, and RB3. It mentions that stathmin is ubiquitously expressed, SCG10 and RB3 are neural-enriched, and SCLIP exhibits a broader tissue distribution. However, there is no direct mention or evidence of an interaction between SCLIP protein and SCG10 protein. The context focuses on their individual expression patterns and does not indicate any functional or physical interaction between these two proteins.</s>
635163 2A2590068 2A2592309	Hsp 90	Hsp 27	[INST]Context: [PMID: 28964286 The expression and correlation of Hsp 70 and Hsp 27 in serous middle ear effusion fluids of pediatric patients-a preliminary study. OBJECTIVES: Several cytokines and innate immune-associated molecules are present in middle ear effusions, but damage-associated molecular patterns in middle ear effusion have not been studied. Therefore, we evaluated the role of heat shock proteins in the development of otitis media with effusion (OME). METHODS: Serous middle ear effusions from 22 pediatric patients who were diagnosed with OME and underwent ventilation tube insertion from June 2015 to March 2017 were evaluated in our study. The levels of Hsp 90, 70, 27, IL-8, and TNF-alpha in effusion fluids were evaluated by enzyme-linked immunosorbent assays. RESULTS: Hsp 70 and Hsp 27 were detected in all middle ear effusions, but Hsp 90 was detected in only five effusion fluid samples. IL-8 was also detected in all middle ear effusions, but TNF-alpha was detected in only four effusion fluid samples. When we compared the degree of tympanic membrane inflammation with the levels of Hsp 70, Hsp 27, and IL-8, which were detected in all effusion fluids, we could not find statistical significance. However, Hsp 70, Hsp 27, and IL-8 were significantly associated with each other (p < 0.05). CONCLUSIONS: Hsp 70 and Hsp 27 were expressed in middle ear effusions. Furthermore, the levels of Hsp 70 and Hsp 27 were positively correlated with each other, and were also positively associated with the neutrophil chemoattractant, IL-8. Our findings suggested that Hsp 70 and Hsp 27 might be involved in the pathophysiology of pediatric OME.] Question: Based on the provided context, do the terms [Hsp 90 protein] and [Hsp 27 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between Hsp 90 protein and Hsp 27 protein. While both proteins are mentioned in the study, there is no indication that they interact with each other. The study focuses on the expression and correlation of Hsp 70 and Hsp 27 with IL-8 and TNF-alpha in middle ear effusions, but it does not discuss any interaction between Hsp 90 and Hsp 27.</s>
261762 2A2577447 2A2577508	HDAC11	HDAC5	[INST]Context: [PMID: 30519361 Prognosis Analysis of Histone Deacetylases mRNA Expression in Ovarian Cancer Patients. Histone deacetylases modulate the dynamic balance of histone acetylation and deacetylation in cells, which participate in epigenetic regulations. Accumulated evidence has demonstrated that histone deacetylases are associated with angiogenesis, cell proliferation and survival in a variety of human cancers. However, the expression and distinct prognostic value of histone deacetylases in ovarian cancer have not been well elucidated. In the present study, we collected the overall survival, progress free survival, and histone deacetylases mRNA expression in ovarian cancer from the Kaplan-Meier plotter online database. We investigated the relationship between histone deacetylases mRNA level and the clinicopathological parameters of the ovarian cancer patients, such as histology subtypes, clinical stages, grades and TP53 mutation. Our analysis data showed that over-expression of HDAC1, HDAC2, HDAC4, HDAC5 and HDAC11 were correlated to poor overall survival and unfavorable progress free survival in all ovarian cancer patients. Notably, the higher level of HDAC11 was associated with the worse overall survival and progress free survival for serous/ stage III+IV/ grade III/ TP53 mutation ovarian cancer patients. In conclusion, HDACs may play a crucial role in the prognosis of ovarian cancer, but it is worth noting that HDAC11 may be a biomarker for poor prognosis in ovarian cancer patients.] Question: Based on the provided context, do the terms [HDAC11 protein] and [HDAC5 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the expression and prognostic value of various histone deacetylases (HDACs) in ovarian cancer, including HDAC11 and HDAC5. However, it does not mention any direct interaction between HDAC11 protein and HDAC5 protein. Instead, it focuses on their individual roles in the prognosis of ovarian cancer patients. Therefore, based on the given information, there is no evidence to suggest that HDAC11 and HDAC5 interact with each other.</s>
117084 2A2516744 2A2522086	elongation factor 1beta	elongation factor 1	[INST]Context: [PMID: 10368288 The solution structure of the guanine nucleotide exchange domain of human elongation factor 1beta reveals a striking resemblance to that of EF-Ts from Escherichia coli. BACKGROUND: In eukaryotic protein synthesis, the multi-subunit elongation factor 1 plays an important role in ensuring the fidelity and regulating the rate of translation. EF-1alpha, which transports the aminoacyl tRNA to the ribosome, is a member of the G-protein superfamily. EF-1beta regulates the activity of EF-1alpha by catalyzing the exchange of GDP for GTP and thereby regenerating the active form of EF-1alpha. The structure of the bacterial analog of EF-1alpha, EF-Tu has been solved in complex with its GDP exchange factor, EF-Ts. Although there is good sequence conservation between EF-1alpha and EF-Tu, there is essentially no sequence similarity between EF-1beta and EF-Ts. We wished to explore whether the prokaryotic exchange mechanism could shed any light on the mechanism of eukaryotic translation elongation. RESULTS: Here, we report the structure of the guanine-nucleotide exchange factor domain of human EF-1beta (hEF-1beta, residues 135-224); Sequence conservation analysis of the guanine-nucleotide exchange factor domains of elongation factor 1 subunits beta and delta from widely divergent organisms indicates that the most highly conserved residues are in two loop regions. Intriguingly, hEF-1beta[135-224] shares structural homology with the guanine-nucleotide exchange factor domain of EF-Ts despite their different primary sequences. CONCLUSIONS: On the basis of both the structural homology between EF-Ts and hEF-1beta[135-224] and the sequence conservation analysis, we propose that the mechanism of guanine-nucleotide exchange in protein synthesis has been conserved in prokaryotes and eukaryotes. In particular, Tyr181 of hEF-1beta[135-224] appears to be analogous to Phe81 of Escherichia coli EF-Ts. From MeSH: Escherichia coli.] Question: Based on the provided context, do the terms [elongation factor 1beta protein] and [elongation factor 1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that elongation factor 1beta (EF-1beta) regulates the activity of elongation factor 1alpha (EF-1alpha) by catalyzing the exchange of GDP for GTP. This exchange regenerates the active form of EF-1alpha, which is essential for protein synthesis. Therefore, EF-1beta and EF-1alpha interact with each other in the process of regulating the activity of EF-1alpha.</s>
214289 2A2864982 2A2635036	small nuclear ribonucleoprotein D2 polypeptide	U6 snRNA-associated Sm-like protein LSm3	[INST]Context: [PMID: 32308643 The Predicted Key Molecules, Functions, and Pathways That Bridge Mild Cognitive Impairment and Alzheimer's Disease . To elucidate the key molecules, functions, and pathways that bridge mild cognitive impairment and Alzheimer's disease, we investigated open gene expression data sets. One module was significantly negatively associated with mild cognitive impairment samples, in which gene ontology function and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis showed that these genes were related to cytosolic ribosome, ribosomal structure, oxidative phosphorylation, alzheimer's disease, and metabolic pathway. The other two modules correlated significantly with alzheimer's disease samples, in which functional and pathway enrichment analysis revealed strong relationships of these genes with cytoplasmic ribosome, protein binding, alzheimer's disease, cancer, and apoptosis. In addition, we regarded the core genes in the module network closely related to mild cognitive impairment and alzheimer's disease as bridge genes and submitted them to protein interaction network analysis to screen for major pathogenic genes according to the connectivity information. Among them, small nuclear ribonucleoprotein D2 polypeptide (SNRPD2), ribosomal protein S3a, S100 calcium binding protein A8 (S100A8), small nuclear ribonucleoprotein polypeptide G, U6 snRNA-associated Sm-like protein LSm3 (LSM3), ribosomal protein S27a, and ATP synthase F1 subunit gamma (ATP5C1) were not only major pathogenic genes of mild cognitive impairment, but also bridge genes. In addition, SNRPD2, ribosomal protein s3a, S100A8, small nuclear ribonucleoprotein polypeptide g, LSM3, thioredoxin, proteasome 20S subunit alpha 4 (PSMA4), annexin A1, DnaJ heat shock protein family member A1 (DNAJA1), and prefoldin subunit 5 were not only major pathogenic genes of alzheimer's disease, but also bridge genes. Next, we screened for differentially expressed microRNAs to predict the micrornas and transcription factors related the mild cognitive impairment and alzheimer's disease modules, respectively. Thirty-four bridge regulators were analyzed, among which hsa-miR-519d-3p was recognized as the bridge regulator between mild cognitive impairment and alzheimer's disease. Our study contributed to a better understanding of the pathogenic mechanisms of mild cognitive impairment and alzheimer's disease, and might lead to the development of a new strategy for clinical diagnosis and treatment.] Question: Based on the provided context, do the terms [small nuclear ribonucleoprotein D2 polypeptide protein] and [U6 snRNA-associated Sm-like protein LSm3 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that both small nuclear ribonucleoprotein D2 polypeptide (SNRPD2) and U6 snRNA-associated Sm-like protein LSm3 (LSM3) are identified as major pathogenic genes related to mild cognitive impairment and Alzheimer's disease. Furthermore, they are mentioned as bridge genes, suggesting a functional connection between them in the context of these diseases. This implies that SNRPD2 and LSM3 interact in a similar way to the interacting examples provided, contributing to the pathogenic mechanisms of mild cognitive impairment and Alzheimer's disease.</s>
490331 2A2895182 2A2715193	SCA17	SCA8	[INST]Context: [PMID: 15148151 Molecular genetics of hereditary spinocerebellar ataxia: mutation analysis of spinocerebellar ataxia genes and CAG/CTG repeat expansion detection in 225 Italian families. BACKGROUND: Autosomal dominant cerebellar ataxias are a clinical and genetically heterogeneous group of progressive neurodegenerative diseases, at present associated with 22 loci (spinocerebellar ataxia [SCA] 1-SCA8, SCA10-SCA19, SCA21, SCA22, fibroblast growth factor 14 -SCA, and dentatorubral-pallidoluysian atrophy ). The relevant gene has been identified in 12 cases (SCA1-3, SCA6-8, SCA10, SCA12, fibroblast growth factor 14, and DRPLA), and in all but the recently identified SCA14, SCA17, PRKCG and fibroblast growth factor 14 genes, the defect consists of the expansion of a short nucleotide repeat. OBJECTIVES: To investigate the relative prevalence of SCA1-3, SCA6-8, SCA10, SCA12, and SCA17 gene expansions in Italian families with hereditary ataxia, specifically to verify the occurrence of SCA10, SCA12, and SCA17 in Italy; And to analyze samples from probands with negative test results at the initial screening by means of the repeat expansion detection technique to identify CAG/CTG expansions in novel loci.Patients Two hundred twenty-five unrelated Italian index cases with hereditary ataxia, most (n = 183) of whom presented with a clear dominantly transmitted trait. RESULTS: We found that SCA1 and SCA2 gene mutations accounted for most cases (21% and 24%, respectively). We found SCA3, SCA6, SCA7, SCA8, and SCA17 to be very rare (approximately 1% each), and no case of SCA10 or SCA12 was identified. Twenty-one of 22 expansions could be attributed to length variation at 2 polymorphic loci (expanded repeat domain CAG/CTG 1 [ERDA1] or CTG repeat on chromosome 18q21.1 [CTG18.1]). In 1 patient, the expansion was assigned to the dentatorubral-pallidoluysian atrophy gene. CONCLUSIONS: The distribution of SCA1-3 and SCA6-7 gene mutations is peculiar in Italy. We found a relatively high frequency of SCA1 and SCA2 gene expansions; SCA3, SCA6, and SCA7 mutations were rare, compared with other European countries. No SCA10 or SCA12 and only a few SCA8 (2/225) and SCA17 (2/225) families were detected. In patients negative for defects in known SCA genes, repeat expansion detection data strongly suggest that, at least in our population, CAG/CTG expansions in novel genes should be considered an unlikely cause of the SCA phenotype.] Question: Based on the provided context, do the terms [SCA17 protein] and [SCA8 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the prevalence of various spinocerebellar ataxia (SCA) gene mutations in Italian families and does not mention any direct interaction between the SCA17 protein and the SCA8 protein. The context focuses on the genetic analysis of different SCA genes and their respective frequencies in the population, but it does not provide any information about the interaction between the proteins encoded by these genes. Therefore, based on the given information, there is no evidence to suggest that the SCA17 protein and the SCA8 protein interact with each other.</s>
23182 2A2516848 2A2871820	Eef1g	Srprb	[INST]Context: [PMID: 14733910 Molecular hierarchy in neurons differentiated from mouse ES cells containing a single human chromosome 21. Defects in neurogenesis and neuronal differentiation in the fetal brain of Down syndrome patients lead to the apparent neuropathological abnormalities and contribute to the phenotypic characters of mental retardation, and premature development of Alzheimer's disease, those being the most common phenotype in down syndrome. In order to understand the molecular mechanism underlying the cause of phenotypic abnormalities in the down syndrome brain, we have utilized an in vitro model of TT2F mouse embryonic stem cells containing a single human chromosome 21 to study neuron development and neuronal differentiation by microarray containing 15K developmentally expressed cDNAs. Defective neuronal differentiation in the presence of extra human chromosome 21 manifested primarily the post-transcriptional and translational modification, such as Mrpl10, SNAPC3, Srprb, SF3a60 in the early neuronal stem cell stage, and Mrps18a, Eef1g, and Ubce8 in the late differentiated stage. Hierarchical clustering patterned specific expression of human chromosome 21 gene dosage effects on neuron outgrowth, migration, and differentiation, such as Syngr2, Dncic2, Eif3sf, and Peg3. Mice.] Question: Based on the provided context, do the terms [Eef1g protein] and [Srprb protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the roles of various proteins, including Eef1g and Srprb, in the neuronal differentiation process in the presence of an extra human chromosome 21. However, there is no direct mention of an interaction between Eef1g protein and Srprb protein. Instead, they are described as part of a broader molecular hierarchy and their roles are discussed separately in the context of neuronal differentiation. Therefore, based on the given information, there is no evidence to suggest that Eef1g protein and Srprb protein interact with each other.</s>
230625 2A2599593 2A2866344	IFIT5	SOCS3	[INST]Context: [PMID: 34733317 Background: Bovine respiratory disease is the most common disease in the beef and dairy cattle industry. Next, two distinct methods of weighted gene coexpression network analysis, i.e., module-trait relationships and module preservation analysis were used to identify significant highly correlated modules with clinical traits of bovine respiratory disease and non-preserved modules between healthy and bovine respiratory disease samples, respectively. Results: Four significant highly correlated modules with clinical traits of bovine respiratory disease as well as 29 non-preserved modules were identified by module-trait relationships and module preservation methods, respectively. Among them, two significant highly correlated modules (identified by MTRs) and six nonpreserved modules (identified by MP) were biologically associated with immune response, pulmonary inflammation, and pathogenesis of bovine respiratory disease. Interestingly, most of these hub-hub genes were reported to play an important role in the immune response and bovine respiratory disease pathogenesis. Moreover, STAT1, STAT2, STAT3, IRF7, and IRF9 transcription factors were suggested to play an important role in the immune system during bovine respiratory disease by regulating the coexpressed genes of these modules. Additionally, a gene set containing several hub-hub genes was identified in the eight candidate modules, such as TLR2, TLR4, IL10, SOCS3, GZMB, ANXA1, ANXA5, PTEN, SGK1, IFI6, ISG15, MX1, MX2, OAS2, IFIH1, DDX58, DHX58, RSAD2, IFI44, IFI44L, EIF2AK2, ISG20, IFIT5, IFITM3, OAS1Y, HERC5, and PRF1, which are potentially critical during infection with agents of bovine respiratory disease complex .] Question: Based on the provided context, do the terms [IFIT5 protein] and [SOCS3 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between the IFIT5 protein and the SOCS3 protein. While both proteins are mentioned in the context of immune response and bovine respiratory disease pathogenesis, there is no specific information indicating that they interact with each other. Instead, they are presented as part of a larger set of genes and proteins involved in the immune system during bovine respiratory disease.</s>
25788 2A2749708 2A2652644	pleiotrophin	midkine	[INST]Context: [PMID: 23267434 Anaplastic lymphoma kinase receptor activation, ligands and therapeutic targeting in glioblastoma and in other cancers. The intracellular anaplastic lymphoma kinase fragment shows striking homology with members of the insulin receptor family and was initially identified as an oncogenic fusion protein resulting from a translocation in lymphoma and more recently in a range of cancers. This tyrosine kinase receptor and its ligands, the growth factors pleiotrophin and midkine are highly expressed during development of the nervous system and other organs. Each of these genes has been implicated in malignant progression of different tumor types and shown to alter phenotypes as well as signal transduction in cultured normal and tumor cells. Beyond its role in cancer, the anaplastic lymphoma kinase receptor pathway is thought to contribute to nervous system development, function, and repair, as well as metabolic homeostasis and the maintenance of tissue regeneration. Anaplastic lymphoma kinase receptor activity in cancer can be up-regulated by amplification, overexpression, ligand binding, mutations in the intracellular domain of the receptor and by activity of the receptor tyrosine phosphatase PTPRz. Here we discuss the evidence for ligand control of anaplastic lymphoma kinase activity as well as the potential prognostic and therapeutic implications from gene expression and functional studies. An analysis of 18 published gene expression data sets from different cancers shows that overexpression of anaplastic lymphoma kinase, its smaller homolog leukocyte tyrosine kinase and the ligands pleiotrophin and midkine in cancer tissues from patients correlate significantly with worse course and outcome of the disease.] Question: Based on the provided context, do the terms [pleiotrophin protein] and [midkine protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the roles of pleiotrophin and midkine as ligands for the anaplastic lymphoma kinase receptor and their involvement in cancer progression. However, there is no mention of a direct interaction between pleiotrophin and midkine proteins themselves. Instead, they are described as separate ligands that bind to the same receptor, anaplastic lymphoma kinase, and contribute to the signaling pathways involved in cancer.</s>
234250 2A2498455 2A2703005	Ddr1	osteopontin	[INST]Context: [PMID: 31978395 Age- and sex-dependent differences in extracellular matrix metabolism associate with cardiac functional and structural changes. Some cardiac pathologies in the elderly population vary between genders revealing that cardiac remodeling during aging may be sex-dependent. Herein, we analyzed the effects of cardiac aging in male and female C57Bl/6 mice in four age groups, 3, 6, 12, and 18 month old (n = 6-12 animals/sex/age), to elucidate which age-related characteristics of left ventricle remodeling are sex-specific. We focused particularly in parameters associated with age-dependent remodeling of the left ventricle extracellular matrix that are involved in collagen metabolism. Complementary to the traditional echocardiography, speckle tracking echocardiography revealed that circumferential strain rate declined in 18 month old females, compared to younger animals, but not in males, suggesting speckle tracking echocardiography as an earlier indicator for changes in cardiac function between sexes. Age-dependent collagen deposition and expression in the endocardium did not differ between sexes; However, other factors involved in collagen metabolism were sex-specific. Specifically, while decorin, osteopontin, Cthrc1, and Ddr1 expression were age-dependent but sex-independent, periostin, lysyl oxidase, and Mrc2 displayed age-dependent and sex-specific differences. Moreover, our data also suggest that with age males and females have distinct TGFbeta signaling pathways. These data highlight the importance of including sex-differences analysis when studying cardiac aging.] Question: Based on the provided context, do the terms [Ddr1 protein] and [osteopontin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the expression of various proteins involved in collagen metabolism and TGFbeta signaling pathways in male and female mice of different ages. While it mentions that decorin, osteopontin, Cthrc1, and Ddr1 expression are age-dependent but sex-independent, it does not indicate any direct interaction between Ddr1 protein and osteopontin protein. Instead, it describes their expression patterns in relation to age and sex, but not their interaction with each other.</s>
126871 2A2590057 2A2836727	HSP90N	RPS27A	[INST]Context: [PMID: 34754042 3-D vascularized breast cancer model to study the role of osteoblast in formation of a pre-metastatic niche. Breast cancer cells preferentially metastasize to bone. It is known that breast cancer cells remotely primes the distant bone site prior to metastasis. However, the reciprocal influence of bone cells on the primary tumor is relatively overlooked. Here, to study the bone-tumor paracrine influence, a tri-cellular 3-D vascularized breast cancer tissue model is engineered which comprised MDA-MB231, a triple-negative breast cancer cells (TNBC), fibroblasts, and endothelial cells. Vascularized breast cancer tissue alone and in conjunction with osteoblasts led to abnormal vasculature and reduced vessel density but enhanced VEGF production. A total of 1476 significantly upregulated and 775 downregulated genes are identified in the vascularized breast cancer tissue exposed to osteoblasts. HSP90N, CYCS, RPS27A, and EGFR are recognized as upregulated hub-genes. Kaplan Meier plot shows HSP90N to have a significant outcome in TNBC patient survivability. Furthermore, compared to cancer tissues without vessels, gene analysis recognized 1278 significantly upregulated and 566 downregulated genes in vascularized breast cancer tissue. DKK1, CXCL13, C3 protein and BMP4 are identified to be downregulated hub genes in vascularized breast cancer tissue. Together, a multi-cellular breast cancer model and culture protocols are established to study pre-metastatic events in the presence of osteoblasts.] Question: Based on the provided context, do the terms [HSP90N protein] and [RPS27A protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between HSP90N protein and RPS27A protein. While both proteins are identified as upregulated hub-genes in the vascularized breast cancer tissue exposed to osteoblasts, there is no specific information indicating that they interact with each other. The context focuses on the overall gene expression changes and the roles of these genes in the tumor microenvironment but does not provide details about direct protein-protein interactions between HSP90N and RPS27A.</s>
114922 2A2582003 2A2737439	Hip1	Parkin	[INST]Context: [PMID: 28396396 Formation of neurodegenerative aggresome and death-inducing signaling complex in maternal diabetes-induced neural tube defects. Diabetes mellitus in early pregnancy increases the risk in infants of birth defects, such as neural tube defects, known as diabetic embryopathy. Neural tube defects are associated with hyperglycemia-induced protein misfolding and Caspase-8-induced programmed cell death. Misfolded proteins form aggregates containing ubiquitin-binding protein p62, suggesting that autophagic-lysosomal clearance is insufficient. Additionally, these aggregates contain the neurodegenerative disease-associated proteins alpha-Synuclein, Parkin, and Huntingtin . Aggregation of huntingtin may lead to formation of a death-inducing signaling complex of Hip1, Hippi, and Caspase-8. Treatment with chemical chaperones, such as sodium 4-phenylbutyrate, reduces protein aggregation in neural stem cells in vitro and in embryos in vivo. Furthermore, treatment with phenylbutyrate in vivo decreases NTD rate in the embryos of diabetic mice, as well as Caspase-8 activation and cell death. Enhancing protein folding could be a potential interventional approach to preventing embryonic malformations in diabetic pregnancies. From MeSH: Mice.] Question: Based on the provided context, do the terms [Hip1 protein] and [Parkin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between Hip1 protein and Parkin protein. While both proteins are mentioned in the context of protein aggregation and the formation of a death-inducing signaling complex, there is no specific indication that Hip1 and Parkin interact with each other. Instead, the context focuses on the aggregation of huntingtin and the formation of a death-inducing signaling complex involving Hip1, Hippi, and Caspase-8. Therefore, based on the given information, there is no evidence to suggest that Hip1 protein and Parkin protein interact with each other.</s>
412378 2A2672327 2A2672209	MYO15A	MYH9	[INST]Context: [PMID: 32451864 Hearing loss is both genetically and clinically heterogeneous, and pathogenic variants of over a hundred different genes are associated with this common neurosensory disorder. A relatively large number of these 'deafness genes' encode myosin super family members. The evidence that pathogenic variants of human MYO3A, MYO6, MYO7A, MYO15A, MYH14 and MYH9 are associated with deafness ranges from moderate to definitive. Additional evidence for the involvement of these six myosins for normal hearing also comes from animal models, usually mouse or zebra fish, where mutations of these genes cause hearing loss and from biochemical, physiological and cell biological studies of their roles in the inner ear. This chapter focuses on these six genes for which evidence of a causative role in deafness is substantial.] Question: Based on the provided context, do the terms [MYO15A protein] and [MYH9 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the roles of various myosin super family members, including MYO15A and MYH9, in hearing loss and deafness. It mentions that pathogenic variants of these genes are associated with deafness and provides evidence from animal models, biochemical studies, and physiological studies. However, there is no direct mention or evidence of an interaction between the MYO15A protein and the MYH9 protein. The context focuses on their individual roles in hearing loss rather than any interaction between them.</s>
170998 2A2718023 2A2587344	phosphoglycerate mutase 1	high-mobility group box1	[INST]Context: [PMID: 24455688 Profiling of hepatocellular carcinoma cell cycle regulating genes targeted by calycosin. We cocultured calycosin with human hepatocellular carcinoma cell line (BEL-7402) to investigate the effect on cell proliferation. Calycosin can markedly block the cell growth in G1 phase (P < 0.01) on the IC50 concentration. There were seventeen genes involved in cell-cycle regulation showing differentially expressed in treated cells detected by gene chip. Downregulated TFDP-1, CDKN2D, and SPK2 and upregulated CDC2 and CCNB1 might affect cell cycle of tumor cells. Furthermore, we checked the transcription pattern using 2D gel method to find different expression of proteins in human hepatocellular carcinoma cells after exposure to calycosin. Twelve proteins expression were increased such as transgelin 2, pyridoxine 5'-phosphate, stress-induced-phosphoprotein 1, peroxiredoxin 1, endoplasmic reticulum protein 29, and phosphoglycerate mutase 1. Only thioredoxin peroxidase and high-mobility group box1 proteins' expression decreased. Both genes and proteins changes might be relate to the mechanism of antitumor effect under treatment of calycosin. In conclusion, calycosin has a potential effect to inhibit the BEL-7402 cell growth by inhibiting some oncogene expression and increasing anticancer genes expression, what is more, by blocking cell cycle.] Question: Based on the provided context, do the terms [phosphoglycerate mutase 1 protein] and [high-mobility group box1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between phosphoglycerate mutase 1 protein and high-mobility group box1 protein. Instead, it lists these proteins as part of a broader set of proteins whose expression was affected by the treatment with calycosin. The context focuses on the overall changes in gene and protein expression rather than specific interactions between individual proteins.</s>
523185 2A2599133 2A2599119	eIF4A	eIF4A1	[INST]Context: [PMID: 32759815 Identification of Cardiac Glycosides as Novel Inhibitors of eIF4A1-Mediated Translation in Triple-Negative Breast Cancer Cells. The eukaryotic translation initiation factor 4F complex (eIF4F) is a potential chemotherapeutic target in triple-negative breast cancer . This complex regulates cap-dependent translational initiation and consists of three core proteins: eIF4E, eIF4G, and eIF4A1. More specifically, a (CGG)4 motif, which confers eIF4A dependency, was incorporated into the 5'-leader region of a luciferase-tdTomato lentiviral reporter construct. The Prestwick Chemical Library was then screened in multiple triple-negative breast cancer cell lines by measuring the tdTomato fluorescent intensity. We identified several cardiac glycosides as potential inhibitors of eIF4A1-mediated translation. Based on our studies, we find that cardiac glycosides inhibit the expression of eIF4A1. Our pursuits led us to the discovery that cardiac glycosides also decrease levels of c-MYC. Quantitative PCR confirmed that decreases in c-MYC and eIF4A were occurring at the transcriptional level. As such, disruption of the eIF4A1-c-MYC axis may be a viable approach in the treatment of triple-negative breast cancer. The novel combination of rocaglamide A and digoxin exhibited synergistic anti-cancer activity against triple-negative breast cancer cells in vitro. The findings in this study and others are important for formulating potential combination chemotherapies against eIF4A1 in vivo. Thus, drug repositioning may be one classical approach to successfully target eIF4A1 in triple-negative breast cancer patients.] Question: Based on the provided context, do the terms [eIF4A protein] and [eIF4A1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The terms [eIF4A protein] and [eIF4A1 protein] are not interacting in the provided context. The context discusses the role of eIF4A1 in cap-dependent translational initiation and its inhibition by cardiac glycosides. However, there is no mention of a direct interaction between eIF4A protein and eIF4A1 protein. Instead, the focus is on the inhibition of eIF4A1-mediated translation by cardiac glycosides, which affects the expression of eIF4A1 and c-MYC.</s>
121360 2A2734595 2A2865279	TRAcP5b	SMN2	[INST]Context: [PMID: 19434631 Bone loss in survival motor neuron (Smn(-/-) SMN2) genetic mouse model of spinal muscular atrophy. Spinal muscular atrophy is characterized by degenerating lower motor neurons and an increased incidence of congenital bone fractures. Survival motor neuron levels are significantly reduced due to deletions/mutations in the telomeric SMN1 gene in these patients. We utilized the Smn(-/-) SMN2 mouse model of spinal muscular atrophy to determine the functional role for survival motor neuron in bone remodelling. MicroCT analysis of lumber vertebrae, tibia and femur bones from spinal muscular atrophy mice revealed an osteoporotic bone phenotype. Histological analysis demonstrated a thin porous cortex of cortical bone and thin trabeculae at the proximal end of the growth plate in the vertebrae of spinal muscular atrophy mice compared to wild-type mice. Histochemical staining of the vertebrae showed the presence of abundant activated osteoclasts on the sparse trabeculae and on the endosteal surface of the thin cortex in spinal muscular atrophy mice. Histomorphometric analysis of vertebrae from spinal muscular atrophy mice showed an increased number of osteoclasts. Serum TRAcP5b and urinary NTx levels were elevated, consistent with increased bone resorption in these mice. Spinal muscular atrophy mice showed a significant decrease in the levels of osteoblast differentiation markers, osteocalcin, osteopontin and osterix mRNA expression; However, there were no change in the levels of alkaline phosphatase expression compared to WT mice. Spinal muscular atrophy mouse bone marrow cultures revealed an increased rate of osteoclast formation (54%) and bone resorption capacity (46%) compared to WT mice. Pre-osteoclast cells from spinal muscular atrophy mice showed constitutive up-regulation of RANK receptor signalling molecules critical for osteoclast differentiation. Our results implicate survival motor neuron function in bone remodelling and skeletal pathogenesis in spinal muscular atrophy. Understanding basic mechanisms of survival motor neuron action in bone remodelling may uncover new therapeutic targets for preventing bone loss/fracture risk in spinal muscular atrophy. From MeSH: Mice.] Question: Based on the provided context, do the terms [TRAcP5b protein] and [SMN2 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the role of survival motor neuron (SMN) in bone remodeling and the increased bone resorption observed in the Smn(-/-) SMN2 mouse model of spinal muscular atrophy. It mentions elevated serum TRAcP5b levels, which indicate increased bone resorption, but does not describe any direct interaction between the TRAcP5b protein and the SMN2 protein. Instead, it highlights the functional role of SMN in bone remodeling and the consequences of its deficiency on bone health. Therefore, there is no evidence of a direct interaction between TRAcP5b and SMN2 proteins in the given context.</s>
307656 2A2445850 2A2399414	bone morphogenetic protein 1	Sgne1	[INST]Context: [PMID: 22886699 Inactivating mutations of the 'phosphate regulating gene with homologies to endopeptidases on the X chromosome' (PHEX/Phex) underlie disease in patients with X-linked hypophosphatemia and the hyp-mouse, a murine homologue of the human disorder. Although increased serum fibroblast growth factor 23 underlies the HYP phenotype, the mechanism(s) by which PHEX mutations inhibit fibroblast growth factor 23 degradation and/or enhance production remains unknown. Here we show that treatment of wild-type mice with the proprotein convertase inhibitor, decanoyl-Arg-Val-Lys-Arg-chloromethyl ketone (Dec), increases serum fibroblast growth factor 23 and produces the HYP phenotype. Because PC2 is uniquely colocalized with PHEX in osteoblasts/bone, we examined if PC2 regulates PHEX-dependent fibroblast growth factor 23 cleavage and production. Transfection of murine osteoblasts with PC2 and its chaperone protein 7B2 cleaved fibroblast growth factor 23, whereas Signe1 (7B2) RNA interference transfection, which limited 7B2 protein production, decreased fibroblast growth factor 23 degradation and increased Fgf-23 mRNA and protein. The mechanism by which decreased 7B2___PC2 activity influences Fgf-23 mRNA was linked to reduced conversion of the precursor to bone morphogenetic protein 1 (proBMP1) to active BMP1, which resulted in limited cleavage of dentin matrix acidic phosphoprotein 1 (DMP1), and consequent increased Fgf-23 mRNA. The significance of decreased 7B2___PC2 activity in x-linked hypophosphatemia was confirmed by studies of hyp-mouse bone, which revealed significantly decreased Sgne1 (7B2) mRNA and 7B2 protein, and limited cleavage of proPC2 to active PC2. The expected downstream effects of these changes included decreased fibroblast growth factor 23 cleavage and increased fibroblast growth factor 23 synthesis, secondary to decreased BMP1-mediated degradation of DMP1. Subsequent Hexa-D-Arginine treatment of hyp-mice enhanced bone 7B2___PC2 activity, normalized fibroblast growth factor 23 degradation and production, and rescued the HYP phenotype. These data suggest that decreased PHEX-dependent 7B2___PC2 activity is central to the pathogenesis of x-linked hypophosphatemia. Mice.] Question: Based on the provided context, do the terms [bone morphogenetic protein 1 protein] and [Sgne1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided indicates that the activity of bone morphogenetic protein 1 (BMP1) is influenced by the levels of Sgne1 (7B2) protein. Specifically, it mentions that decreased 7B2___PC2 activity leads to reduced conversion of the precursor to BMP1, which in turn affects the degradation of DMP1 and subsequently increases Fgf-23 mRNA. This suggests that the Sgne1 protein (7B2) interacts with BMP1 in the context of regulating fibroblast growth factor 23 (Fgf-23) production and degradation.</s>
92511 2A2445992 2A2430988	BNIP3L	ATF3	[INST]Context: [PMID: 23452288 Anticancer activity of olive oil hydroxytyrosyl acetate in human adenocarcinoma Caco-2 cells. Gene expression of proteins involved in cell cycle (p21, p53, cyclin B1, and cyclin G2) and programmed cell death (BNIP3, BNIP3L, PDCD4, and ATF3), as well as phase I and phase II detoxifying enzymes CYPA1 and UGT1A10, were evaluated by reverse transcription polymerase chain reaction after 24 h of exposure of Caco-2/TC7 cells to 5, 10, and 50 muM of hydroxytyrosyl acetate. The results show that hydroxytyrosyl acetate inhibited cell proliferation and arrested cell cycle by enhancing p21 and CCNG2 and lowering CCNB1 protein expression. Hydroxytyrosyl acetate also affected the transcription of genes involved in apoptosis up-regulating of BNIP3, BNIP3L, PDCD4, and ATF3 and activating caspase-3. In addition, hydroxytyrosyl acetate also up-regulated xenobiotic metabolizing enzymes CYP1A1 and UGT1A10, thus enhancing carcinogen detoxification. In conclusion, these results highlight that hydroxytyrosyl acetate has the potential to modulate biomarkers involved in colon cancer.] Question: Based on the provided context, do the terms [BNIP3L protein] and [ATF3 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the effects of hydroxytyrosyl acetate on various proteins involved in cell cycle and programmed cell death, including BNIP3L and ATF3. However, it does not mention any direct interaction between BNIP3L protein and ATF3 protein. Instead, it describes how hydroxytyrosyl acetate up-regulates the transcription of genes involved in apoptosis, including BNIP3L and ATF3, but does not indicate that these two proteins interact with each other.</s>
36157 2A2936581 2A2909421	VIME	TRFE	[INST]Context: [PMID: 26417028 Comparative Proteomics of Tumor and Paired Normal Breast Tissue Highlights Potential Biomarkers in Breast Cancer. BACKGROUND/AIM: Breast cancer is the most common type of cancer among women worldwide, and about 57,000 new cases are expected for the Brazilian population in 2015. Elucidation of protein expression and modification is essential for the biological understanding, early diagnosis and therapeutics of breast cancer. The main objectives of the study are comparison between the proteome of tumor and paired non-tumor breast cancer tissues, describing all identified proteins, highlighting the ones most differentially expressed and comparing the data with existing literature. MATERIALS AND METHODS: The five paired samples from patients with invasive ductal carcinoma were analyzed by 2-DE and MS. Forty-three differentially-expressed spots were common to at least two samples, and the ten proteins with the highest-fold changes were CASPE, ENOG, TPM1, CAPG, VIME, TPM3, TRFE, PDIA6, WDR61 and PDIA3. CONCLUSION: Taking the fold change as a parameter, we point to future targets to be studied by functional methods in a search for biomarkers for initiation and progress of breast cancer.] Question: Based on the provided context, do the terms [VIME protein] and [TRFE protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not mention any direct interaction between VIME protein and TRFE protein. It only lists these proteins as part of a set of differentially expressed proteins in breast cancer tissue. There is no indication that these proteins interact with each other or that they have a combined effect on the disease. Therefore, based on the given information, it can be concluded that VIME protein and TRFE protein do not interact.</s>
519390 2A2510834 2A2936598	Drebrin	vinculin	[INST]Context: [PMID: 10604653 Drebrin is a widespread actin-associating protein enriched at junctional plaques, defining a specific microfilament anchorage system in polar epithelial cells. 120-kDa protein drebrin, originally identified in - and thought to be specific for - neuronal cells, in diverse kinds of human and bovine non-neuronal cells. Drebrin has been found in numerous cell culture lines and in many tissues of epithelial, endothelial, smooth muscle and neural origin but not in, for example, cardiac, skeletal and certain types of smooth muscle cells, in hepatocytes and in the human epithelium-derived cell culture line A-431. By double-label fluorescence microscopy we have found drebrin enriched in actin microfilament bundles associated with plaques of cell-cell contact sites representing adhering junctions. These drebrin-positive, adhering junction-associated bundles, however, are not identical with the vinculin-containing, junction-attached bundles, and in the same cell both subtypes of microfilament-anchoring plaques are readily distinguished by immunolocalization comparing drebrin and vinculin. The intracellular distribution of the drebrin- and the vinculin-based microfilament systems has been studied in detail by confocal fluorescence laser scanning microscopy in monolayers of the polar epithelial cell lines, MCF-7 and PLC, and drebrin has been found to be totally and selectively absent in the notoriously vinculin-rich focal adhesions. The occurrence and the possible functions of drebrin in non-neuronal cells, notably epithelial cells, and the significance of the existence of two different actin-anchoring junctional plaques is discussed.] Question: Based on the provided context, do the terms [Drebrin protein] and [vinculin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context describes the presence and distribution of drebrin and vinculin proteins in different cell types and their association with microfilament-anchoring plaques. While both proteins are involved in anchoring microfilaments at cell-cell contact sites, there is no direct interaction mentioned between drebrin and vinculin. Instead, they are described as being part of distinct microfilament-anchoring systems within the same cell. The context highlights the differences in their localization and function, indicating that they are separate entities rather than interacting with each other.</s>
483946 2A2681555 2A2587482	NFL	HO-2	[INST]Context: [PMID: 32669339 Regional Brain Recovery from Acute Synaptic Injury in Simian Immunodeficiency Virus-Infected Rhesus Macaques Associates with Heme Oxygenase Isoform Expression. Brain injury occurs within days in simian immunodeficiency virus or human immunodeficiency virus infection, and some recovery may occur within weeks. Inflammation and oxidative stress associate with such injury, but what drives recovery is unknown. Chronic human immunodeficiency virus infection associates with reduced brain frontal cortex expression of the antioxidant/anti-inflammatory enzyme heme oxygenase-1 and increased neuroinflammation in individuals with cognitive impairment. We hypothesized that acute regional brain injury and recovery associate with differences in regional brain heme oxygenase-1 expression. Using SIV-infected rhesus macaques, we analyzed multiple brain regions through acute and chronic infection (90___days postinfection [dpi]) and quantified viral (simian immunodeficiency virus gag RNA), synaptic (PSD-95; synaptophysin), axonal (neurofilament/neurofilament light chain [NFL]), inflammatory, and antioxidant (enzymes, including heme oxygenase isoforms [HO-1, HO-2]) markers. PSD-95 was reduced in the brainstem, basal ganglia, neocortex, and cerebellum within 13___dpi, indicating acute synaptic injury throughout the brain. Unchanged NFL was consistent with no acute axonal injury. Simian immunodeficiency virus RNA expression was highest in the brainstem throughout infection, and it associated with neuroinflammation. Surprisingly, during the synaptic injury and recovery phases, HO-2, and not heme oxygenase-1, progressively decreased in the brainstem. Thus, acute simian immunodeficiency virus synaptic injury occurs throughout the brain, with spontaneous recovery in regions other than the brainstem. Within the brainstem, the high simian immunodeficiency virus load and inflammation, along with reduction of HO-2, may impair recovery. In other brain regions, stable HO-2 expression, with or without increasing heme oxygenase-1, may promote recovery. Our data support roles for heme oxygenase isoforms in modulating recovery from synaptic injury in simian immunodeficiency virus infection and suggest their therapeutic targeting for promoting neuronal recovery.IMPORTANCE Brain injury induced by acute simian (or human) immunodeficiency virus infection may persist or spontaneously resolve in different brain regions. The gradual recovery from such injury observed in many, but not all, brain regions in the rhesus macaque model is consistent with the possible existence of a therapeutic window of opportunity for intervening to promote recovery, even in those regions not showing spontaneous recovery. In persons living with human immunodeficiency virus infection, such neuroprotective treatments could ultimately be considered as adjuncts to the initiation of antiretroviral drug therapy. From MeSH: Macaca mulatta. Simian Immunodeficiency Virus.] Question: Based on the provided context, do the terms [NFL protein] and [HO-2 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not indicate any direct interaction between the NFL protein and the HO-2 protein. The context discusses the expression levels of various markers, including NFL and HO-2, in different brain regions during simian immunodeficiency virus infection. However, it does not mention any direct interaction or combined effect between NFL and HO-2 proteins. Instead, it describes their individual roles and changes in expression levels in relation to synaptic injury and recovery.</s>
459499 2A2651446 2A2406779	macrophage migration inhibitory factor	beta-centractin	[INST]Context: [PMID: 24057270 Proteomics analysis of human brain tissue infected by street rabies virus. In order to extend the knowledge of rabies pathogenesis, a two-dimensional electrophoresis/mass spectrometry based postmortem comparative proteomics analysis was carried out on human brain samples. Proteins related to cytoskeleton, metabolism, proteasome and immune regulatory systems showed the most changes in expression levels. Among these groups, the cytoskeleton related proteins (dynein light chain, beta-centractin, tubulin alpha-1C chain and destrin) and metabolism associated proteins (fatty acid-binding protein, macrophage migration inhibitory factor, glutamine synthetase and alpha enolase) were the main altered proteins. These alterations may be considered as an evidence of disturbances in neuronal key processes including axonal transport, synaptic activity, signaling and metabolic pathways in rabies virus infected human brain. Rabies virus.] Question: Based on the provided context, do the terms [macrophage migration inhibitory factor protein] and [beta-centractin protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the changes in expression levels of various proteins in human brain tissue infected by street rabies virus. While it mentions that macrophage migration inhibitory factor and beta-centractin are among the proteins that show altered expression levels, there is no direct interaction mentioned between these two proteins. The context focuses on the overall changes in protein expression related to different cellular processes rather than specific interactions between individual proteins. Therefore, based on the given information, there is no evidence to suggest that macrophage migration inhibitory factor protein and beta-centractin protein interact with each other.</s>
574784 2A2734750 2A2508404	PPARA	DNMT1	[INST]Context: [PMID: 32562712 Developmental programming: Prenatal testosterone-induced changes in epigenetic modulators and gene expression in metabolic tissues of female sheep. Prenatal testosterone (T)-treated female sheep manifest peripheral insulin resistance and tissue-specific changes in insulin sensitivity with liver and muscle manifesting insulin resistance accompanied by inflammatory, oxidative and lipotoxic state. In contrast, visceral and subcutaneous adipose tissues are insulin sensitive in spite of visceral manifesting changes in inflammatory and oxidative state. We hypothesized that prenatal T-induced changes in tissue-specific insulin resistance arise from disrupted lipid storage and metabolism gene expression driven by changes in DNA and histone modifying enzymes. Changes in gene expression were assessed in liver, muscle and 4 adipose (VAT, subcutaneous, epicardiac and perirenal ) depots collected from control and prenatal T-treated female sheep. Prenatal T-treatment increased lipid droplet and metabolism genes PPARA and PLIN1 in liver, SREBF and PLIN1 in muscle and showed a trend for decrease in PLIN2 in perirenal. Among epigenetic modifying enzymes, prenatal T-treatment increased expression of 1) DNMT1 in liver and DNMT3A in visceral, perirenal, muscle and liver; 2) HDAC1 in epicardiac, HDAC2 in muscle with decrease in HDAC3 in visceral; 3) EP300 in visceral and epicardiac; And 4) KDM1A in visceral with increases in liver histone acetylation. Increased lipid storage and metabolism genes in liver and muscle are consistent with lipotoxicity in these tissues with increased histone acetylation likely contributing to increased liver PPARA. These findings are suggestive that metabolic defects in prenatal T-treated sheep may arise from changes in key genes mediated, in part, by tissue-specific changes in epigenetic-modifying enzymes. From MeSH: Sheep.] Question: Based on the provided context, do the terms [PPARA protein] and [DNMT1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the effects of prenatal testosterone on gene expression in various tissues of female sheep, including changes in lipid storage and metabolism genes such as PPARA and epigenetic modifying enzymes such as DNMT1. While it mentions that prenatal testosterone treatment increases the expression of PPARA in the liver and DNMT1 in the liver, it does not indicate a direct interaction between the PPARA protein and the DNMT1 protein. Instead, it describes the effects of prenatal testosterone on the expression of these proteins separately, without suggesting that they interact with each other.</s>
665824 2A2476268 2A2874087	catechol-O-methyltransferase	SULT1E1	[INST]Context: [PMID: 18379081 On the sulfation and methylation of catecholestrogens in human mammary epithelial cells and breast cancer cells. Prolonged exposure to high level of estrogen is a known risk factor for breast carcinogenesis. In cells, estrogens, in particular estrone and 17 beta-estradiol, can be converted to catecholestrogens which may be oxidized to form CE-semiquinones and CE-quinones that are capable of binding to DNA to induce mutations, followed by carcinogenesis. MCF-7 breast cancer cells and MCF 10A human mammary epithelial cells were metabolically labeled with [35S]sulfate in the presence of individual catecholestrogens. Whereas both [35S]sulfated 4-methoxy-estrone and [35S]sulfated 4-OH-E1 were detected in the labeling media of cells labeled in the presence of 4-OH-E1. These results indicated a concerted action of catechol-O-methyltransferase and the cytosolic sulfotransferase enzyme(s) in the metabolism of catecholestrogens. Enzymatic assays revealed that, five (SULT1A1, SULT1A2, SULT1A3, SULT1C4, and SULT1E1) of eleven known human SULTs tested could use catecholestrogens and methoxyestrogens as substrates, with SULT1estrone displaying the strongest sulfating activity.] Question: Based on the provided context, do the terms [catechol-O-methyltransferase protein] and [SULT1E1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the metabolism of catecholestrogens in human mammary epithelial cells and breast cancer cells, mentioning the roles of catechol-O-methyltransferase and SULT1E1 in this process. However, it does not indicate a direct interaction between the catechol-O-methyltransferase protein and the SULT1E1 protein. Instead, it describes their individual roles in the metabolic pathways involving catecholestrogens. Therefore, based on the given information, there is no evidence of a direct interaction between these two proteins.</s>
188001 2A2736666 2A2871385	FNBP3	SRC	[INST]Context: [PMID: 14767582 Identification and characterization of human diaphanous homology 3 gene in silico. Formin homology proteins with FH1 and FH2 domains are signaling effectors for assembly and polarization of actin filaments. FH1 is the binding domain for Profilin, SRC, EMS1/Cortactin, FNBP1, FNBP2, FNBP3, FNBP4 and WBP4/Fbp21, while FH2 is the actin-filament modification domain. Diaphanous homology 3 isoform 1, consisting of exons 1-27, was expressed in lymph node, erythroid progenitor cells as well as in pancreatic cancer. Diaphanous homology 3 gene at human chromosome 13q21.2 was found to encode two isoforms due to alternative splicing of the alternative promoter type. Full-length human diaphanous homology 3 protein, consisting of FDD, FH1 and FH2 domains, showed 51.3% total-amino-acid identity with DIAPH1, and 57.3% total-amino-acid identity with DIAPH2. FMNL1/FMNL, FMNL2/FHOD2, FMNL3/WBP3, DAAM1, DAAM2, DIAPH1, DIAPH2 and diaphanous homology 3 were classified as the FDD-type Formin homology proteins, while GRID2IP/Delphilin, FHOD1, Fmn1 and Fmn2 were classified as the non-FDD-type Formin homology proteins. This is the first report on identification and characterization of human diaphanous homology 3 gene.] Question: Based on the provided context, do the terms [FNBP3 protein] and [SRC protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context lists various proteins that interact with the FH1 domain of formin homology proteins, including FNBP3 and SRC. However, it does not mention any direct interaction between FNBP3 protein and SRC protein. Instead, it describes their individual interactions with the FH1 domain. Therefore, based on the given information, there is no evidence to suggest that FNBP3 protein and SRC protein interact with each other.</s>
542504 2A2709298 2A2874087	PAPSs1	Sult1e1	[INST]Context: [PMID: 16807285 Tissue distribution and ontogeny of sulfotransferase enzymes in mice. Sulfotransferases are phase-II conjugation enzymes that catalyze the transfer of a sulfonate group from 3'-phosphoadenosine 5'-phosphosulfate (PAPS) to target endo and xenobiotics. PAPS is formed from inorganic sulfate by the action of the enzyme PAPS synthase (PAPSs). In the present study, the tissue distribution and developmental changes in the mRNA expression of 11 Sult isozymes and 2 PAPSs isoforms in mice were quantified. Sult1a1, 1b1, 1c1, 1c2, 1d1, 1e1, 2a1/2, 2b1, 3a1, 4a1, 5a1, PAPSs1, and PAPSs2 mRNA expression was quantified in 14 tissues from male and female mice using the branched DNA signal amplification assay. Sult1b1, 2b1, and PAPSs2 in small intestine; Sult1a1 in large intestine; Sult1c2 in stomach; Sult1d1 in kidney; Sult1e1 in placenta; And Sult4a1 in brain. Sult1c1, 5a1, and PAPSs1 were ubiquitously expressed in most tissues. Sult1a1, 1c2, 1d1, 2a1/2, and PAPSs2 hepatic expression gradually increased from birth until about 3 weeks of age and then declined somewhat thereafter, Sult1c1 expression was highest before birth and declined after that, and Sult3a1 mRNA expression was very low in fetal livers and remained low until 30 days of age, when expression in females dramatically increased, whereas it never increased in males. The organ-specific distribution of sulfotransferases as well as the different expression of the sulfotransferases in young animals may affect the pharmacokinetic behavior and organ-specific toxicity of xenobiotics. From MeSH: Mice.] Question: Based on the provided context, do the terms [PAPSs1 protein] and [Sult1e1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context describes the tissue distribution and ontogeny of various sulfotransferase enzymes and PAPS synthase isoforms in mice. It mentions the expression levels of different sulfotransferases and PAPS synthases in various tissues and at different developmental stages. However, there is no direct mention of an interaction between the PAPS1 protein and the Sult1e1 protein. The context focuses on the expression patterns and distribution of these enzymes rather than their interactions. Therefore, based on the provided information, there is no evidence to suggest that PAPS1 and Sult1e1 proteins interact with each other.</s>
281988 2A2513342 2A2635032	UAP56	LSM2	[INST]Context: [PMID: 14667819 Analysis of a high-throughput yeast two-hybrid system and its use to predict the function of intracellular proteins encoded within the human MHC class III region. We performed HTP-Y2H screens that included all standard controls, using the predicted intracellular proteins expressed from the human MHC class III region, a region of the genome associated with many autoimmune diseases. The 91 novel interactions identified provide insight into the potential functions of many MHC genes, including C6orf47, LSM2, NELF-E (RDBP), DOM3Z, STK19, PBX2, RNF5, UAP56 (BAT1), ATP6G2, LST1/f, BAT2, Scythe (BAT3), CSNK2B, BAT5, and CLIC1. Surprisingly, our results predict that 1/3 of the proteins may have a role in mRNA processing, which suggests clustering of functionally related genes within the human genome. Saccharomyces cerevisiae.] Question: Based on the provided context, do the terms [UAP56 protein] and [LSM2 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	YES, high confidence; Explanation: The context provided mentions that the HTP-Y2H screens identified 91 novel interactions, including an interaction between UAP56 (BAT1) and LSM2. This indicates that the UAP56 protein and LSM2 protein interact with each other.</s>
220451 2A2629724 2A2508404	Lipoprotein lipase	DNA Methyltransferase 1	[INST]Context: [PMID: 30232292 MicroRNA-377 Inhibits Atherosclerosis by Regulating Triglyceride Metabolism Through the DNA Methyltransferase 1 in Apolipoprotein E-Knockout Mice. BACKGROUND: Lipoprotein lipase plays an important role in triglyceride metabolism. It is translocated across endothelial cells to reach the luminal surface of capillaries by glycosylphosphatidylinositol-anchored high-density lipoprotein binding protein 1 (GPIHBP1), where it hydrolyzes triglycerides in lipoproteins. MicroRNA 377 is highly associated with lipid levels. However, how microrna 377 regulates triglyceride metabolism and whether it is involved in the development of atherosclerosis remain largely unexplored. Methods___and___Results: The clinical examination displayed that microrna 377 expression was markedly lower in plasma from patients with hypertriglyceridemia compared with non-hypertriglyceridemic subjects. Bioinformatics analyses and a luciferase reporter assay showed that DNA methyltransferase 1 was a target gene of microrna 377. Moreover, microrna 377 increased lipoprotein lipase binding to GPIHBP1 by directly targeting dna methyltransferase 1 in human umbilical vein endothelial cells and apolipoprotein E -knockout mice aorta endothelial cells . In vivo, hematoxylin-eosin, Oil Red O and Masson's trichrome staining showed that ApoE-knockout mice treated with microrna 377 developed less atherosclerotic plaques, accompanied by reduced plasma triglyceride levels. CONCLUSIONS: It is concluded that microrna 377 upregulates GPIHBP1 expression, increases the lipoprotein lipase binding to GPIHBP1, and reduces plasma triglyceride levels, likely through targeting dna methyltransferase 1, inhibiting atherosclerosis in ApoE-knockout mice. Mice.] Question: Based on the provided context, do the terms [Lipoprotein lipase protein] and [DNA Methyltransferase 1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The context provided describes how microRNA-377 regulates triglyceride metabolism by targeting DNA Methyltransferase 1 (DNMT1) and subsequently increasing lipoprotein lipase (LPL) binding to GPIHBP1. However, there is no direct interaction mentioned between lipoprotein lipase protein and DNA Methyltransferase 1 protein. Instead, the interaction is mediated through the regulation of GPIHBP1 expression by microRNA-377, which indirectly affects the binding of LPL to GPIHBP1. Therefore, while the two proteins are part of the same regulatory pathway, they do not directly interact with each other.</s>
58738 2A2876707 2A2595548	SUMO2	IDO-1	[INST]Context: [PMID: 30468988 OKN-007 Increases temozolomide Sensitivity and Suppresses TMZ-Resistant Glioblastoma Tumor Growth. Treatment of glioblastoma remains a challenge using conventional chemotherapy, such as temozolomide, and is often ineffective as a result of drug resistance. We have assessed a novel nitrone-based agent, OKN-007, and found it to be effective in decreasing tumor volumes and increasing survival in orthotopic glioblastoma xenografts by decreasing cell proliferation and angiogenesis and increasing apoptosis. In this study, we assessed combining OKN-007 with temozolomide in vivo in a human G55 glioblastoma orthotopic xenograft model and in vitro in TMZ-resistant and TMZ-sensitive human glioblastoma cell lines. For the in vitro studies, cell growth, IC50 values, RNA-seq, RT-PCR, and ELISA were used to assess growth inhibition, possible mechanism-of actions associated with combined OKN-007__^+__^temozolomide versus temozolomide alone, and gene and protein expression levels, respectively. Microarray analysis of OKN-007-treated rat F98 glioma tumors was also carried out to determine possible mechanism-of actions of OKN-007 in glioma-bearing animals either treated or not treated with OKN-007. OKN-007 seems to elicit its effect on glioblastoma tumors via inhibition of tumorigenic TGF-beta1, which affects the extracellular matrix. When combined with temozolomide, OKN-007 significantly increases percent survival, decreases tumor volumes, and normalizes tumor blood vasculature in vivo compared to untreated tumors and seems to affect TMZ-resistant glioblastoma cells possibly via IDO-1, SUMO2, and PFN1 in vitro. Combined OKN-007__^+__^temozolomide may be a potentially potent treatment strategy for glioblastoma patients.] Question: Based on the provided context, do the terms [SUMO2 protein] and [IDO-1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context does not indicate a direct interaction between SUMO2 protein and IDO-1 protein. Instead, it mentions that OKN-007 may affect TMZ-resistant glioblastoma cells possibly via IDO-1, SUMO2, and PFN1. This suggests that these proteins are involved in the mechanism of action of OKN-007 but does not imply a direct interaction between SUMO2 and IDO-1.</s>
43644 2A2918856 2A2406504	TTN	ACTC1	[INST]Context: [PMID: 33237593 Actin-Associated Gene Expression is Associated with Early Regional Metastasis of Tongue Cancer. OBJECTIVES: We aimed to analyze gene expression profile of tongue cancer associated with early lymph node metastasis using the cancer genome atlas data. METHODS: A total of 515 patients with matched RNAseq data of primary tumor and clinical data from the cancer genome atlas data were extracted. Gene ontology and pathway enrichment analysis were performed using the DAVID online tool. FFPE tissue of 285 patients were evaluated for the validation of relevant genes by imunofluorescence and immunohistochemical stain. Gene ontology and pathway enrichment analysis revealed that most of the upregulated genes were associated with actin cytoskeleton and included following genes: ANKRD23, NO3, PDLIM3, MUSTN1, TNNT3, MYBPC1, MB, MYH3, TTN, ACTA1, and ACTC1. When comparing tongue cancer with cN0pN0 vs. pN0pN+ using the total tongue cancer cohort of the cancer genome atlas, ACTA1 was the only parameter which was associated with hidden lymph node metastasis in T1/2 (P = .019). Perineural invasion was significantly associated with high expression of ACTA1 (P___<___.001). Imunofluorescence and immunohistochemical analysis revealed that actin was overexpressed, while E-cadherin and N-cadherin were not significantly different. CONCLUSIONS: Actin associated genes, especially overexpression of ACTA1 may be associated with early regional metastasis of tongue cancer.] Question: Based on the provided context, do the terms [TTN protein] and [ACTC1 protein] interact with each other? NOTE: Always begin your response with 'YES' or 'NO', indicating if the two terms in the are interacting in a similar way to the interacting or non-interacting examples, along with a confidence level (e.g., low, medium, high). If two names belong to the same entity, do not consider them as interacting. Examples: Interacting: "The combination of MLN4924 and imatinib "triggered a dramatic shift in the expression of MCL1 and NOXA" and that the combination "enhanced" the activation of an intra S-phase checkpoint, which indicates that the two drugs interact to produce a combined effect on the leukemia cells that is different from the effect of either drug alone." [YES, high confidence] Explanation: ...; Non-interacting: "While both drugs are used to induce the accumulation of hypoxia-inducible factor 1alpha and subsequently EBV reactivation, there is no direct interaction mentioned between pevonedistat and Desferal. Instead, they are presented as separate agents that stabilize HIF-1alpha and have effects on the induction of EBV reactivation." [NO, high confidence] Explanation: ...[/INST]	NO, high confidence; Explanation: The provided context discusses the association of various genes, including TTN and ACTC1, with early regional metastasis of tongue cancer. However, it does not mention any direct interaction between the TTN protein and the ACTC1 protein. Instead, it focuses on the overexpression of actin-associated genes and their potential role in metastasis. Therefore, there is no evidence in the context to suggest that TTN protein and ACTC1 protein interact with each other.</s>